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Abstract	  
	  
Chronic	   myeloid	   leukaemia	   (CML)	   was	   one	   of	   the	   first	   cancers	   to	   be	  
linked	   to	   a	   chromosomal	   abnormality,	   the	   Philadelphia	   chromosome.	   This	  
chromosome	  results	  in	  a	  translocation	  between	  chromosomes	  9	  and	  22,	  where	  
the	  ABL	  gene	  on	  chromosome	  9,	  a	  tyrosine	  kinase,	   is	  translocated	  to	  the	  BCR	  
gene	   region	   on	   chromosome	   22	   giving	   rise	   to	   an	   abnormal	   BCR/ABL	   fusion	  
gene.	  The	  resultant	  fusion	  gene	  has	  an	  abnormally	  upregulated	  tyrosine	  kinase	  
activity	  that	  results	  in	  an	  increase	  in	  the	  proliferation	  of	  immature	  white	  blood	  
cells,	   thus	   leading	  to	  the	  development	  of	  CML.	  There	  are	  several	  breakpoints	  
that	   can	  occur	   in	   the	  BCR	  gene	   two	  of	  which	  give	   rise	   to	  95%	  of	  CML	   cases.	  
These	   fusion	   points	   are	   called	   the	   β3α2	   and	   β2α2	   depending	   on	   where	   the	  
chromosomal	  breakages	  occur	  in	  the	  BCR	  gene.	  The	  aim	  of	  the	  project	  was	  to	  
establish	   a	   new	   method	   of	   treatment	   for	   CML	   through	   the	   use	   of	   RNAi	   to	  
abolish	   the	   increase	   in	   tyrosine	   kinase	   activity	   of	   the	   abnormal	   fusion	   gene	  
product.	  
The	  K562	  and	  KCL22	  cell	   lines	  incorporating	  the	  β3α2	  and	  β2α2	  fusion	  
points	   respectively	  were	   used	   in	   this	   project.	   The	   fusion	   points	  were	   cloned	  
and	   sequenced.	   The	   human	   U6	   and	   H1	   promoters,	   were	   selected	   for	   the	  
production	   of	   the	   antisense	   molecules	   and	   were	   obtained	   by	   PCR	   of	   K562	  
cDNA.	   Short	   hairpin	   RNA	  molecules	   were	   designed	   to	   the	   sequences	   of	   the	  
β3α2	   and	   the	   β2α2	   fusion	   points.	   These	   designed	   shRNA	   molecules	   were	  
synthesized	   as	   oligonucleotides	   and	   were	   incorporated	   into	   a	   reverse	   PCR	  
primer.	  Cassettes	  containing	  shRNA	  molecules	  and	  a	  respective	  promoter	  were	  
produced	   by	   means	   of	   PCR	   and	   the	   products	   cloned	   into	   pB12mcs-­‐eGFP	  
vector,	   which	   was	   used	   as	   a	   GFP	   reporter	   system.	   Constructs	   were	   then	  
transfected	   into	   the	   appropriate	   cell	   lines,	   and	   expression	   studies	   including	  
qPCR	  and	  Western	  blot	  analysis	  were	  conducted,	  to	  examine	  the	  effects	  of	  the	  
designed	   shRNA	   constructs	   to	   their	   target	   sites	   on	   both	   mRNA	   and	   protein	  
levels.	   In	   addition,	   these	   experiments	   also	   indicate	   the	   efficiency	   of	   the	  
construct	  and	  also	  their	  specificity	  to	  their	  targets.	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qPCR	  and	  Western	  blot	  analysis,	  show	  that	  both	  the	  shRNA	  molecules	  
designed	  against	  the	  β3α2	  and	  the	  β2α2	  fusion	  points,	  efficiently	  induced	  RNAi	  
based	  gene	  silencing	  to	  their	  target	  sites.	  In	  addition,	  the	  designed	  constructs	  
show	   high	   specificity	   to	   only	   its	   target	   sites	   and	   not	   to	   other	   unrelated	   or	  
related	  genes.	  These	  results	  point	  towards	  the	  use	  of	  molecular	  modulation	  of	  
gene	  expression	  as	  a	  promising	  strategy	  for	  potential	  CML	  therapy.	  	  	  
	  	   4	  
Acknowledgements	  
	  
I	  would	   like	   to	   thank	  my	   supervisors	   Peter	   Eagles	   and	  Mark	   Sanderson	   for	  
their	  guidance,	  help,	  and	  advice	  through	  out	  the	  current	  project.	  Special	  thanks	  
to	   Amer	   Qureshi	   for	   all	   his	   help,	   advice,	   and	   bearing	   with	   my	   continuous	  
questions,	  and	  great	  thanks	  to	  Derek	  knight	  for	  all	  his	  help.	  
Special	   thanks	   to	  my	   friends:	   Kasia	   (always	   getting	  me	   the	   best	   chocolates	  
and	  selection	  of	  teas	  ever),	  Vibah,	  Aseem,	  Oishik,	  Dima,	  Ashvin,	  Mads,	  Martin,	  
Nicola,	   and	   Alina	   for	   helping	   me,	   being	   there	   for	   me,	   giving	   me	   support	  
whether	  I	  need	  it	  or	  not,	  and	  putting	  a	  smile	  on	  my	  face	  all	  the	  time.	  I	  would	  
also	   like	  to	  thank	  Ay	  Lin	  and	  Martina	  for	  their	  help	   in	  my	  Western	  Blots,	  and	  
Anna	  for	  helping	  me	  with	  qPCR	  data.	  	  
Finally,	   I	   would	   like	   to	   thank	  my	   parents	   for	   their	   support	   throughout	  my	  
















	  	   5	  





TABLE	  OF	  CONTENTS ...............................................................................................5	  
TABLE	  OF	  FIGURES ...................................................................................................9	  
TABLE	  OF	  TABLES .................................................................................................. 12	  
LIST	  OF	  ABBREVIATIONS..................................................................................... 13	  
CHAPTER	  1:	  INTRODUCTION.............................................................................. 17	  1.1	  HAEMATOPOIESIS	  AND	  LEUKAEMIA .................................................................................17	  1.2	  CHRONIC	  MYELOID	  LEUKAEMIA	  (CML)..........................................................................18	  1.2.1	  DEFINITION	  OF	  CML .......................................................................................................19	  1.2.2	  CLINICAL	  STAGING	  OF	  CML ...........................................................................................19	  1.3	  THE	  MOLECULAR	  BIOLOGY	  OF	  CML ................................................................................21	  1.3.1	  THE	  ABL	  PROTEIN ..........................................................................................................22	  1.3.2	  THE	  BCR	  PROTEIN ..........................................................................................................24	  1.3.3	  THE	  BCR-­‐ABL	  FUSION	  GENE........................................................................................26	  1.3.4	  THE	  P210BCR-­‐ABL	  FUSION	  PROTEIN ..............................................................................30	  1.3.5	  BCR-­‐ABL	  ACTIVITY	  IN	  CML.........................................................................................32	  1.3.5.1	  The	  RAS	  Pathway……………………………………………………………………………………………...	  33	  1.3.5.2	  The	  Phosphatidylinositol	  3’	  Kinase	  Pathway………………………………………………………	  36	  1.3.5.3	  The	  JAK/STAT	  Pathway…………………………………………………………………………………….	  39	  1.3.5.4	  Other	  Proteins	  Associated	  with	  BCR-­‐ABL	  Activity………………………………………………	  41	  1.3.5.5	  BCR-­‐ABL	  and	  Protein	  Pathways:	  A	  Conclusion……………………………………………………	  41	  1.4	  CML	  AND	  THERAPY.............................................................................................................42	  1.4.1.1	  Current	  Drug	  Treatment	  for	  CML……………………………………………………………………….	  42	  1.4.1.2	  Mechanisms	  of	  Imatinib	  Drug	  Resistance	  in	  CML………………………………………………..	  44	  1.4.1.2.1	  BCR-­‐ABL	  Independent	  Mechanisms	  of	  Drug	  Resistance…………………………………...	  45	  1.4.1.2.2	  BCR-­‐ABL	  Dependent	  Mechanisms	  of	  Drug	  Resistance………………………………………	  46	  1.4.2	  SECOND	  AND	  THIRD	  GENERATION	  TKI ........................................................................46	  1.5	  MODULATION	  OF	  GENE	  EXPRESSION ................................................................................47	  	  
	  	   6	  
1.5.1	  DNA	  TRIPLE	  HELICES ...................................................................................................................... 48	  1.5.2	  ANTISENSE	  OLIGONUCLEOTIDES .................................................................................................... 49	  1.5.3	  RIBOZYMES........................................................................................................................................ 50	  1.5.4	  RNA	  INTERFERENCE ....................................................................................................................... 51	  1.5.4.1	  The	  Mechanism	  of	  RNAi…………………………………………………………………………………….	  51	  1.5.4.2	  MicroRNAs………………………………………………………………………………………………………..	  54	  1.5.4.3	  siRNAs……………………………………………………………………………………………………………...	  54	  1.5.4.4	  shRNAs……………………………………………………………………………………………………………..	  55	  1.5.5	  THE	  USE	  OF	  RNAI	  AS	  A	  THERAPEUTIC	  TOOL................................................................................ 58	  1.5.6	  RNAI	  AND	  CML ............................................................................................................................... 60	  1.6	  CELL	  LINES	  AS	  A	  MODEL	  FOR	  CML................................................................................................... 62	  1.7	  AIM	  OF	  THE	  PROJECT ........................................................................................................................... 63	  
CHAPTER	  2:	  	  MATERIALS	  AND	  METHODS.................................................................... 65	  2.1	  MOLECULAR	  BIOLOGY......................................................................................................................... 65	  
2.1.1	  RNA	  Extraction	  and	  Purification .............................................................................................. 65	  
2.1.2	  DNA	  Extraction	  and	  Precipitation............................................................................................ 65	  
2.1.3	  Quantification	  of	  Nucleic	  Acid	  Concentration..................................................................... 66	  
2.1.4	  cDNA	  Synthesis.................................................................................................................................. 66	  
2.1.5	  Polymerase	  Chain	  Reaction ......................................................................................................... 67	  
2.1.6	  Agarose	  Gel	  Electrophoresis........................................................................................................ 70	  
2.1.7	  Restriction	  Enzyme	  Digest ........................................................................................................... 71	  
2.1.8	  DNA	  Ligation...................................................................................................................................... 72	  
2.1.9	  Transformations............................................................................................................................... 73	  
2.1.10	  Plasmid	  DNA	  Isolation	  and	  Purification ............................................................................. 74	  
2.1.11	  Glycerol	  Stocks................................................................................................................................ 74	  
2.1.12	  DNA	  sequencing ............................................................................................................................. 75	  
2.1.13	  Generation	  of	  Blunt	  Ends ........................................................................................................... 75	  2.2	  AT	  CLONING ......................................................................................................................................... 76	  2.3	  GENERATION	  OF	  PLASMIDS ................................................................................................................ 77	  
2.3.1	  Construction	  of	  the	  shRNA	  Cassettes....................................................................................... 81	  
2.3.2	  Cloning	  of	  Promoter	  Constructs ................................................................................................ 82	  2.4	  TISSUE	  CULTURE.................................................................................................................................. 87	  
2.4.1	  Cell	  line	  Maintenance ..................................................................................................................... 87	  
2.4.2	  Optimisation	  of	  Cell	  Line	  Transfection ................................................................................... 90	  2.4.2.1	  Chemical	  based	  transfections………………...……………………………………………………………...89	  2.4.2.2	  Non-­‐chemical	  based	  transfections……………………………………………………………………….91	  2.5	  FLUORESCENCE-­‐ACTIVATED	  CELL	  SORTER	  (FACS)	  ANALYSIS ................................................... 94	  2.6	  REAL	  TIME	  PCR................................................................................................................................... 97	  2.7	  WESTERN	  BLOT	  ANALYSIS...............................................................................................................103	  
2.7.1	  Cell	  lysis	  and	  protein	  exctraction ............................................................................................104	  
	  	   7	  
2.7.2	  SDS-­Polyacrylamide	  Gel	  Electrophoresis.............................................................................104	  
2.7.3	  Western	  Blotting ............................................................................................................................105	  
CHAPTER	  3:	  GENERATION	  OF	  A	  REPORTER	  GENE	  SYSTEM	  FOR	  EXPRESSION	  OF	  
SHRNAI	  CASSETTES	  TARGETING	  THE	  BCR-­ABL	  FUSION	  POINTS.......................109	  3.1	  INTRODUCTION...................................................................................................................................109	  3.2	  RESULTS ..............................................................................................................................................110	  
3.2.1	  Sequencing	  of	  the	  β3α2	  and	  the	  β2α2	  Fusion	  Points ....................................................110	  3.2.1.1	  PCR	  Amplification	  of	  the	  β3α2	  and	  the	  β2α2	  Fusion	  points………………………………….108	  3.2.1.2	  AT	  Cloning	  of	  the	  β3α2	  and	  the	  β2α2	  Products	  in	  the	  pGEM®T	  Easy	  Vector	  System…………………………………………………………………………………………………………………………111	  3.2.1.3	  Analysis	  of	  the	  β3α2	  and	  the	  β2α2	  Fusion	  Point	  sequences………………………………….112	  
3.2.2	  Preparation	  of	  the	  pEGFP-­N1	  Vector	  for	  Cloning	  of	  the	  shRNA	  Cassettes............115	  3.2.2.1	  Digestion	  and	  Removal	  of	  the	  CMV	  Promoter	  from	  the	  pEGFP-­‐N1	  vector………………113	  3.2.2.2	  Self	  Ligation	  and	  Cloning	  of	  the	  Modified	  pEGFP-­‐N1	  vector…………………………………..115	  
3.2.3	  Preparation	  of	  the	  pB12mcs-­eGFP	  Vector ..........................................................................119	  3.2.3.1	  Sequencing	  of	  the	  pB12mcs-­‐eGFP	  vector……………………………………………………………..117	  3.2.3.2	  Digestion	  and	  Purification	  of	  the	  pB12mcs-­‐eGFP	  Vector………………………………………117	  
3.2.4	  Amplification	  of	  the	  U6	  and	  H1	  Promoters.........................................................................121	  3.2.4.1	  Cloning	  of	  the	  U6	  and	  H1	  Promoters	  in	  the	  pB12mcs-­‐eGFP	  Vector………………………120	  3.2.4.2	  Sequence	  Analysis	  of	  the	  U6	  and	  H1	  Promoters…………………………………………………..122	  
3.2.5	  Construction	  of	  the	  shRNA	  Molecules ...................................................................................127	  3.2.5.1	  Designing	  of	  the	  shRNA	  Molecules………………………………………………………………………125	  3.2.5.2	  Synthesis	  of	  the	  U6	  and	  H1	  shRNA	  Cassettes………………………………………………………..126	  3.2.5.3	  Cloning	  of	  the	  shRNA	  Cassettes	  in	  the	  pB12mcs-­‐eGFP	  Vector……………………………….128	  3.2.5.4	  Conformation	  by	  PCR	  of	  the	  shRNA	  Cassettes	  and	  the	  Sequencing	  of	  the	  Cassettes..129	  3.3	  DISCUSSION.........................................................................................................................................137	  
CHAPTER	  4:	  EXPRESSION	  OF	  THE	  SHRNA	  CONSTRUCTS	  IN	  K562	  AND	  KCL-­22	  
CELL	  LINES............................................................................................................................139	  4.1	  INTRODUCTION...................................................................................................................................139	  4.2	  RESULTS ..............................................................................................................................................139	  
4.2.1	  Transfection	  of	  the	  shRNA	  Constructs	  in	  K562	  and	  KCL-­22	  Cell	  lines. ...................139	  
4.2.2	  Transfection	  by	  Chemical	  Methods	  and	  FACS	  Analysis .................................................140	  
4.2.3	  Transfection	  Through	  Nucleofection ....................................................................................145	  
4.2.4	  Real	  Time	  PCR	  Analysis	  of	  the	  Transfected	  Cell	  Lines....................................................151	  4.2.4.1	  The	  Generation	  of	  Standard	  Curves……………………………………………………………………..153	  4.2.4.2	  Effects	  of	  shRNAβ3α2	  and	  shRNAβ2α2	  in	  K562	  and	  KCL-­‐22	  cells………………………………161	  4.2.4.3	  Effects	  of	  shRNA1β2α2	  in	  KCL-­‐22	  and	  K562	  cell	  lines……………………………………………..164	  4.2.4.4	  Effects	  of	  the	  shRNA	  constructs	  on	  normal	  BCR	  and	  ABL	  mRNA	  levels………………….167	  
4.2.5	  Protein	  analysis	  of	  the	  K562	  transfected	  Cell	  Line	  by	  Western	  Blotting ...............171	  
4.2.6	  Protein	  analysis	  of	  the	  KCL-­22	  transfected	  Cell	  Line	  by	  Western	  Blotting...........174	  4.3	  DISCUSSION.........................................................................................................................................178	  
	  	   8	  
CHAPTER	  5:	  DISCUSSION .................................................................................................180	  5.1	  DISCUSSION .........................................................................................................................................180	  5.1.1	  DEVELOPMENT	  AND	  EXPRESSION	  OF	  SHRNA	  CONSTRUCTS	  TARGETING	  THE	  BCR-­‐ABL	  VARIANTS....................................................................................................................................................181	  5.1.2	  EFFICIENCY	  OF	  SHRNA	  CONSTRUCTS	  TARGETING	  THE	  Β3Α2	  FUSION	  POINT........................185	  5.1.2.1	  Delivery	  and	  production	  of	  the	  shRNA	  β3α2	  Constructs…………………………………………	  186	  5.1.2.2	  Effects	  of	  the	  shRNAβ3α2	  Constructs	  on	  β3α2	  mRNA	  and	  protein	  levels………………...	  187	  5.1.2.3	  Conclusion………………………………………………………………………………………………………...	  188	  5.1.3	  EFFICIENCY	  OF	  SHRNA	  CONSTRUCTS	  TARGETING	  THE	  Β2Α2	  FUSION	  POINT........................189	  5.1.3.1	  Delivery	  and	  production	  of	  the	  shRNAβ2α2	  Construct…………………………………………...	  189	  5.1.3.2	  Effects	  of	  the	  shRNAβ2α2	  Constructs	  on	  β3α2	  mRNA	  and	  protein	  levels………………...	  190	  5.1.3.3	  Conclusion………………………………………………………………………………………………………...	  191	  5.1.4	  SIRNA	  AGAINST	  THE	  BCR-­‐ABL	  VARIANTS...............................................................................191	  5.1.5	  FUTURE	  DEVELOPMENTS ..............................................................................................................193	  
APPENDIX	  1:	  THE	  MOLECULAR	  WEIGHT	  MARKERS	  USED	  IN	  THE	  CURRENT	  
PROJECT ................................................................................................................................196	  
APPENDIX	  2:	  THE	  SECONDARY	  SHRNA	  STRUCTURES ......................................................200	  
APPENDIX	  3:	  THE	  PROTEIN	  MOLECULAR	  WEIGHT	  MARKER	  USED	  IN	  THE	  
CURRENT	  PROJECT ............................................................................................................205	  
APPENDIX	  4:	  THE	  3Α2	  AND	  Β2Α2	  SEQUENCES..............................................................206	  
APPENDIX	  5:	  THE	  RAW	  SEQUENCING	  DATA	  OF	  THE	  Β3Α2	  AND	  Β2Α2	  FUSION	  
POINT	  SEQUENCES	  IN	  THE	  PGEM®-­T	  EASY	  VECTOR..............................................208	  
APPENDIX	  6:	  THE	  HUMAN	  U6	  AND	  H1	  PROMOTER	  SEQUENCES........................210	  
APPENDIX	  7:	  ELECTROPHORETIC	  ANALYSIS	  OF	  REPRESENTATIVE	  COLONY	  
SCREENS	  PCR	  PRODUCTS	  OF	  THE	  U6	  SHRNA	  AND	  H1	  SHRNA	  	  CONSTRUCT ..212	  
APPENDIX	  8:	  THE	  RAW	  SEQUENCING	  DATA	  OF	  THE	  U6	  AND	  H1	  PROMOTERS	  
INSERTED	  INTO	  THE	  PB12MCS-­EGFP	  PLASMID.......................................................218	  
APPENDIX	  9:	  RAW	  DATA	  OF	  SEQUENCING	  OF	  THE	  SHRNA	  CONSTRUCTS ......222	  
APPENDIX	  10:	  FACS	  GENERATED	  DATA	  OF	  TRANSFECTION	  OF	  K562	  AND	  KCL-­




	  	   9	  
Table	  of	  Figures	  
	  FIGURE	  1.1	  	  CLASSIFICATION	  OF	  THE	  WHITE	  BLOOD	  CELLS	  (HOFFBRAND	  ET	  AL.,	  2006)............ 18	  FIGURE	  1.2	  THE	  RECIPROCAL	  TRANSLOCATION	  BETWEEN	  CHROMOSOMES	  9	  AND	  22	  PRODUCING	  	  THE	  PHILADELPHIA	  CHROMOSOME. ........................................................................................................ 22	  FIGURE	  1.3	  THE	  STRUCTURAL	  ORGANIZATION	  OF	  THE	  C-­‐ABL	  PROTEIN. ......................................... 23	  FIGURE	  1.4	  THE	  STRUCTURAL	  ORGANIZATION	  OF	  THE	  BCR	  PROTEIN. ............................................ 24	  FIGURE	  1.5	  	  THE	  BREAKPOINTS	  WITHIN	  THE	  BCR	  GENE	  FOUND	  ON	  CHROMOSOME	  22................. 27	  FIGURE	  1.6	  THE	  BCR	  AND	  ABL	  GENES,	  BREAKPOINTS,	  AND	  TRANSCRIPTS...................................... 28	  FIGURE	  1.7	  SCHEMATIC	  REPRESENTATION	  OF	  THE	  STRUCTURAL	  MOTIFS	  OF	  THE	  NORMAL	  BCR	  	  PROTEIN	  AND	  THEIR	  ASSOCIATION	  WITH	  THE	  BREAKPOINT	  CLUSTER	  REGIONS. ............................... 30	  FIGURE	  1.8	  SCHEMATIC	  REPRESENTATION	  OF	  THE	  STRUCTURAL	  MOTIFS	  OF	  THE	  P210	  BCR-­‐ABL	  	  PROTEIN. ....................................................................................................................................................... 32	  FIGURE	  1.9	  A	  SCHEMATIC	  DIAGRAM	  OF	  THE	  RAS	  PATHWAY	  AND	  THE	  EFFECTS	  OF	  THE	  BCR-­‐ABL	  	  ON	  IT.. ........................................................................................................................................................... 34	  FIGURE	  1.10	  SCHEMATIC	  DIAGRAM	  OF	  THE	  PI3K	  PATHWAY. ............................................................ 38	  FIGURE	  1.11	  A	  SCHEMATIC	  DIAGRAM	  OF	  THE	  JAK/STAT	  PATHWAY............................................... 40	  FIGURE	  1.12	  THE	  MECHANISM	  OF	  BCR-­‐ABL	  INHIBITION	  BY	  IMATINIB. .......................................... 44	  FIGURE	  1.13	  SCHEMATIC	  DIAGRAM	  OF	  RNAI	  MECHANISM. ................................................................ 53	  FIGURE	  1.14	  THE	  MECHANISMS	  OF	  ENDOGENOUS	  AND	  EXOGENOUS	  EXPRESSION	  OF	  MIRNA,	  	  SHRNA,	  AND	  SIRNA................................................................................................................................... 57	  FIGURE	  2.1	  MAP	  OF	  THE	  PGEM®T	  EASY	  VECTOR	  SYSTEM.	  THE	  DIAGRAM	  WAS	  OBTAINED	  FROM	  	  THEPROMEGA	  WEBSITE.............................................................................................................................. 77	  FIGURE	  2.2	  PEGFP-­‐N1	  VECTOR	  MAP.	  THE	  DIAGRAM	  WAS	  OBTAINED	  FROM	  THE	  CLONTECH	  	  WEBSITE........................................................................................................................................................ 79	  FIGURE	  2.3	  THE	  PB12MCS-­‐EGFP	  VECTOR	  MAP.	  THE	  PLASMID	  WAS	  CONSTRUCTED	  AND	  GIVEN	  BY	  	  DR.	  ADAM	  RODAWAY ................................................................................................................................. 80	  FIGURE	  2.4	  SCHEMATIC	  DIAGRAM	  OF	  THE	  SYNTHESIS	  OF	  THE	  SHRNA	  CASSETTES. ....................... 84	  FIGURE	  2.5	  A	  FLOW	  DIAGRAM	  OF	  THE	  OVERALL	  PROCEDURES	  UNDERTAKEN	  TO	  GENERATE	  THE	  	  PLASMIDS	  CONTAINING	  THE	  SHRNA	  CASSETTES. ................................................................................ 86	  FIGURE	  2.6	  THE	  HAEMACYTOMETER.	  (THE	  DIAGRAM	  WAS	  TAKEN	  FROM	  THE	  KLINIK	  ANDROLOGI	  
	  WEBSITE) ....................................................................................................................................................... 89	  FIGURE	  2.7	  THE	  BASIC	  PRINCIPLE	  OF	  THE	  FACS	  SCAN.	  (SOURCE	  WWW.ABCAM.COM) .................. 95	  FIGURE	  2.8	  FACS	  HISTOGRAM	  GRAPH. .................................................................................................. 97	  FIGURE	  2.9	  REAL	  TIME	  PCR	  USING	  SYBR	  GREEN	  I	  METHODOLOGY. ................................................ 99	  FIGURE	  2.10	  REAL	  TIME	  PCR	  IN	  THE	  PRESENCE	  OF	  TAQMAN	  PROBES. ..........................................100	  FIGURE	  3.1	  ELECTROPHORETIC	  ANALYSIS	  OF	  PCR	  REACTION	  USING	  β-­‐ACTIN	  PRIMERS	  ON	  K562	  	  CDNA. .........................................................................................................................................................111	  
	  	   10	  
FIGURE	  3.2	  ELECTROPHORETIC	  ANALYSIS	  OF	  THE	  Β2Α2	  PCR	  PRODUCT	  FROM	  KCL-­‐22	  CDNA.112	  FIGURE	  3.3	  ELECTROPHORETIC	  ANALYSIS	  OF	  THE	  Β3Α2	  PCR	  PRODUCT	  FROM	  K562	  CDNA. ...113	  FIGURE	  3.4	  THE	  K562	  AND	  KCL-­‐22	  FUSION	  POINT	  SEQUENCING	  RESULTS................................114	  FIGURE	  3.5	  ELECTROPHORETIC	  ANALYSIS	  OF	  PEGFP-­‐N1	  DIGESTIONS .........................................116	  FIGURE	  3.6	  ELECTROPHORETIC	  ANALYSIS	  OF	  PCR	  PRODUCTS	  FROM	  THE	  SELF-­‐LIGATED	  	  PEGFP-­‐N1	  VECTOR..................................................................................................................................118	  FIGURE	  3.7	  ELECTROPHORETIC	  ANALYSIS	  OF	  THE	  DIGESTED	  PB12MCS-­‐EGFP	  VECTOR .............120	  FIGURE	  3.8	  ELECTROPHORETIC	  ANALYSIS	  OF	  THE	  PCR	  PRODUCTS	  OF	  THE	  U6	  AND	  H1	  HUMAN	  PROMOTERS................................................................................................................................................122	  FIGURE	  3.9	  ELECTROPHORETIC	  ANALYSIS	  OF	  THE	  PCR	  PRODUCTS	  OF	  THE	  PB12MCS-­‐U6-­‐EGFP	  	  PLASMID	  COLONY	  SCREEN ......................................................................................................................123	  FIGURE	  3.10	  ELECTROPHORETIC	  ANALYSIS	  OF	  THE	  PCR	  PRODUCTS	  OF	  THE	  COLONY	  SCREEN	  OF	  	  THE	  PB12MCS-­‐H1-­‐EGFP	  VECTOR.........................................................................................................124	  FIGURE	  3.11	  ELECTROPHORETIC	  ANALYSIS	  OF	  THE	  PCR	  PRODUCTS	  OF	  THE	  PB12MCS-­‐U6-­‐EGFP	  	  PLASMID	  (COLONY	  11) ............................................................................................................................125	  FIGURE	  3.12	  ELECTROPHORETIC	  ANALYSIS	  OF	  THE	  PCR	  PRODUCTS	  OF	  THE	  EXTRACTED	  PB12MCS-­‐	  H1-­‐EGFP	  PLASMIDS	  (COLONIES	  3,4,	  8,	  AND	  9) ..................................................................................126	  FIGURE	  3.13	  THE	  SECONDARY	  STRUCTURE	  OF	  SHRNA1	  ANTISENSE	  OLIGONUCLEOTIDE	  TARGETING	  	  THE	  Β3Α2	  FUSION	  POINT .........................................................................................................................128	  FIGURE	  3.14	  ELECTROPHORETIC	  ANALYSIS	  OF	  PCR	  PRODUCTS	  FROM	  SHRNA	  CASSETTE	  	  SYNTHESIS..................................................................................................................................................129	  FIGURE	  3.15	  ELECTROPHORETIC	  ANALYSIS	  OF	  THE	  COLONY	  SCREEN	  PCR	  PRODUCTS	  OF	  THE	  U6	  	  SHRNA1	  CONSTRUCT	  WITH	  T7	  FORWARD	  AND	  T3	  REVERSE	  PRIMERS...........................................130	  FIGURE	  3.16	  ELECTROPHORETIC	  ANALYSIS	  OF	  THE	  PB12MCS-­‐EGFP	  EXTRACTED	  PLASMID	  WITH	  	  THE	  U6	  SHRNA1	  CONSTRUCT	  TARGETING	  THE	  Β2Α2	  FUSION	  GENE.............................................132	  FIGURE	  4.1	  HISTOGRAM	  GENERATED	  BY	  FACS	  DEMONSTRATING	  THE	  TRANSFECTION	  EFFICIENCY	  OF	  	  THE	  NIMT	  FEOFECTION/YELLOW	  TRANSFECTION	  REAGENT	  IN	  K562	  CELL	  LINES. ...................141	  FIGURE	  4.2	  HISTOGRAM	  GENERATED	  BY	  FACS	  DEMONSTRATING	  THE	  TRANSFECTION	  EFFICIENCY	  OF	  	  THE	  NIMT	  FEOFECTION/YELLOW	  TRANSFECTION	  REAGENT	  IN	  KCL-­‐22	  CELL	  LINE...................142	  FIGURE	  4.3	  HISTOGRAM	  GENERATED	  BY	  FACS	  DEMONSTRATING	  THE	  TRANSFECTION	  EFFICIENCY	  	  OF	  THE	  NANOFECTIN	  TRANSFECTION	  REAGENT	  IN	  K562	  CELL	  LINE...............................................143	  FIGURE	  4.4	  HISTOGRAM	  GENERATED	  BY	  FACS	  DEMONSTRATING	  THE	  TRANSFECTION	  EFFICIENCY	  	  OF	  THE	  NANOFECTIN	  TRANSFECTION	  REAGENT	  IN	  KCL-­‐22	  CELL	  LINE. ..........................................144	  FIGURE	  4.5	  NUCLEOFECTION	  OF	  THE	  K562	  CELL	  LINES	  WITH	  THE	  PB12MCS	  PLASMIDS............147	  FIGURE	  4.6	  NUCLEOFECTION	  OF	  THE	  KCL-­‐22	  CELL	  LINES	  WITH	  THE	  PB12MCS	  PLASMIDS. ......148	  FIGURE	  4.7	  HISTOGRAM	  GENERATED	  BY	  FACS	  DEMONSTRATING	  THE	  TRANSFECTION	  	  EFFICIENCY	  OF	  NUCLEOFECTION	  IN	  THE	  K562	  CELL	  LINE..................................................................149	  FIGURE	  4.8	  HISTOGRAM	  GENERATED	  BY	  FACS	  DEMONSTRATING	  THE	  TRANSFECTION	  	  EFFICIENCY	  OF	  NUCLEOFECTION	  IN	  THE	  KCL-­‐22	  CELL	  LINE..............................................................150	  
	  	   11	  






	  	   12	  
Table	  of	  Tables	  
	   TABLE	  1.1	  THE	  CHARACTERISTICS	  OF	  CML	  CLINICAL	  PHASES............................................................................20	  TABLE	  2.1	  COMPONENTS	  OF	  THE	  PCR	  MASTER	  MIX. ...........................................................................................67	  TABLE	  2.2	  COMPONENTS	  OF	  THE	  FAST	  START	  HIGH	  FIDELITY	  PCR	  SYSTEM. .................................................68	  
TABLE	  2.3	  PRIMER	  SETS	  USED	  WITHIN	  THE	  PROJECT....................................................................................................69	  TABLE	  2.4	  RESTRICTION	  ENZYMES	  USED	  IN	  THIS	  PROJECT	  AND	  THEIR	  INCUBATION	  BUFFERS. ....................72	  TABLE	  2.5	  THE	  DESIGNED	  SHRNA	  TRANSCRIPTS. ................................................................................................82	  TABLE	  2.6	  PRIMER	  SEQUENCES	  USED	  TO	  CONSTRUCT	  THE	  SHRNA	  CASSETTES...............................................85	  TABLE	  2.7	  TAQMAN	  PRIMERS	  AND	  PROBE	  SETS	  USED	  IN	  THE	  PROJECT. ......................................................... 101	  TABLE	  2.8	  PARAMETERS	  USED	  FOR	  REAL	  TIME	  PCR	  CONDUCTED	  IN	  THIS	  PROJECT.. .................................. 102	  TABLE	  2.9	  COMPONENTS	  OF	  THE	  QPCR	  MASTER	  MIX	  20µL	  REACTION	  MIXTURE. ..................................... 103	  TABLE	  2.10	  COMPONENTS	  OF	  THE	  QPCR	  MASTER	  MIX	  20µL........................................................................ 103	  TABLE	  2.11	  COMPONENTS	  OF	  THE	  LYSIS	  BUFFER	  AND	  THE	  SAMPLE	  LOADING	  BUFFER. ............................. 105	  TABLE	  2.12	  RECIPES	  OF	  THE	  SOLUTIONS	  USED	  IN	  THE	  PROCESS	  OF	  SDS-­‐PAGE	  ELECTROPHORESIS	  AND	  WESTERN	  BLOTTING. .............................................................................................................................................. 107	  TABLE	  2.13	  A	  LIST	  OF	  THE	  PRIMARY	  AND	  SECONDARY	  ANTIBODIES	  USED	  IN	  THE	  WESTERN	  BLOTS	  IN	  THIS	  PROJECT...................................................................................................................................................................... 108	  TABLE	  3.1	  A	  SUMMARY	  OF	  THE	  SYNTHESIS	  AND	  SEQUENCING	  OF	  THE	  SHRNA	  CONSTRUCTS..................... 133	  TABLE	  3.2	  THE	  SHRNA	  SEQUENCING	  RESULTS	  OF	  THE	  PB12MCS-­‐U6-­‐SHRNA-­‐EGFP	  CONSTRUCTS. ..... 134	  TABLE	  3.3	  THE	  U6	  SEQUENCING	  RESULTS	  OF	  THE	  PB12MCS-­‐U6-­‐SHRNA-­‐EGFP	  CONSTRUCTS. ............. 135	  TABLE	  3.4	  THE	  SHRNA	  SEQUENCING	  RESULTS	  OF	  THE	  PB12MCS-­‐H1-­‐SHRNA-­‐EGFP	  CONSTRUCTS. ..... 136	  TABLE	  3.5	  THE	  H1	  SEQUENCING	  RESULTS	  OF	  THE	  PB12MCS-­‐H1-­‐SHRNA-­‐EGFP	  CONSTRUCTS.............. 136	  TABLE	  4.1	  A	  SUMMARY	  OF	  DIFFERENT	  TRANSFECTION	  METHODS	  ON	  THE	  TRANSFECTION	  EFFICIENCY	  OF	  K562	  AND	  KCL-­‐22	  CELL	  LINES. ........................................................................................................................... 145	  TABLE	  4.2	  A	  SUMMARY	  OF	  THE	  TRANSFECTION	  EFFICIENCY	  OBTAINED	  FROM	  FACS	  ANALYSIS	  AND	  CELL	  VIABILITY	  OF	  K562	  AND	  KCL-­‐22	  CELL	  LINES	  BY	  NUCLEOFECTION	  WITH	  THE	  PB12MCS-­‐U6-­‐EGFP	  VECTOR....................................................................................................................................................................... 146	  TABLE	  4.3	  A	  SUMMARY	  OF	  THE	  THREE	  NUCLEOFECTIONS	  CONDUCTED	  ON	  EACH	  OF	  THE	  HUMAN	  LEUKAEMIC	  CELL	  LINES,	  K562	  AND	  KCL-­‐22,	  AND	  THE	  CELL	  VIABILITY	  IN	  EACH	  OF	  THE	  TRANSFECTED	  CELL	  GROUPS.151	  TABLE	  4.4	  THE	  QPCR	  DATA	  OF	  THE	  Β3Α2	  MRNA	  LEVELS	  OF	  THE	  TRANSFECTED	  K562	  CELLS. .............. 164	  TABLE	  4.5	  THE	  QPCR	  DATA	  OF	  THE	  Β2Α2	  MRNA	  LEVELS	  OF	  THE	  TRANSFECTED	  KCL-­‐22	  CELLS. .......... 167	  TABLE	  4.6	  STATISTICALLY	  ANALYSED	  DATA	  FROM	  THE	  WESTERN	  BLOT	  CONDUCTED	  ON	  THE	  Β3Α2	  FUSION	  PROTEIN	  EXTRACTED	  FROM	  K562	  CELLS	  THAT	  WERE	  TRANSFECTED	  WITH	  SHRNA1Β3Α2,	  SHRNA3Β3Α2,	  SHRNA1Β2Α2,	  AND	  THE	  BLOT	  PROBED	  WITH	  C-­‐ABL	  AB,	  AND	  BAND	  INTENSITIES	  MEASURED..................... 173	  TABLE	  4.7	  STATISTICALLY	  ANALYSED	  DATA	  FROM	  WESTERN	  BLOT	  CONDUCTED	  ON	  THE	  Β2Α2	  FUSION	  PROTEIN	  FROM	  KCL-­‐22	  CELLS	  TRANSFECTED	  WITH	  WITH	  SHRNA1Β2Α2,	  SHRNA1Β3Α2,	  SHRNA3Β3Α2,	  AND	  THE	  BLOT	  PROBED	  WITH	  Β2Α2	  AB,	  AND	  BAND	  INTENSITIES	  MEASURED......................................................... 176	  
	  	   13	  
	  
List	  of	  Abbreviations	  	  
	  
A	   	   	   	   Adenine	  
AAV	   	   	   Adeno-­‐associated	  viral	  
A260nm	   	   	   Absorbance	  at	  260nm	  
Ab	  	   	   	   Antibody/s	  
ALL	   	   	   Acute	  lymphoid	  leukaemia	  
AML	   	   	   Acute	  myeloid	  leukaemia	  
ATP	   	   	   Adenosine	  triphosphate	  
bcr	   	   	   Breakpoint	  cluster	  region	  
BM	   	   	   Bone	  marrow	  
BSA	   	   	   Bovine	  serum	  albumin	  
C	   	   	   	   Cytosine	  
cDNA	   	   	   Complimentary	  DNA	  
CLL	   	   	   Chronic	  lymphoid	  leukaemia	  
CML	   	   	   Chronic	  myeloid	  leukaemia	  
CrkL	   	   	   Crk	  Like	  
DEPC	   	   	   Diethylpyrocarbonate	  
cfu	   	   	   Colony	  forming	  Unit	  
CML	   	   	   Chronic	  Myeloid	  Leukaemia	  
CMV	   	   	   Cytomegalovirus	  
DNA	   	   	   Deoxyribonucleic	  acid	  
dNTP	   	   	   Deoxyribonucleotide	  triphosphate	  
DMSO	   	   	   Dimethylsulfoxide	  
dsRNA	   	   	   Double	  stranded	  RNA	  
DTT	   	   	   Dithiothreitol	  
E.Coli	   	   	   Escherichia	  coli	  
ECL	   	   	   Enhanced	  chemiluminescence	  
EDTA	   	   	   Ethylenediaminetetraacetic	  acid	  
eGFP	   	   	   Enhanced	  Green	  Fluorescent	  protein	  
	  	   14	  
FACS	  	   	   	   Fluorescence-­‐Activated	  Cell	  Sorter	  
FBS	   	   	   Foetal	  bovine	  serum	  
G	   	   	   	   Guanine	  
GAP	   	   	   GTPase	  activating	  protein	  
GAPDH	   	   	   Glyceraldehyde-­‐3-­‐phosphate	  dehydrogenase	  
GDP	   	   	   Guanosine	  diphosphate	  
GEFs	   	   	   Guanine	  nucleotide	  exchange	  factors	  
GFP	   	   	   Green	  fluorescent	  protein	  
GMCSFR	   	  Granulocyte	   monocyte	   colony	   stimulating	   factor	  
receptor	  
Grb2	   	   	   Growth	  factor	  receptor-­‐bound	  protein	  2	  
GTP	   	   	   Guanosine	  triphosphate	  
H2O	   	   	   Water	  
HEPES	   	   	   4-­‐(2-­‐hydroxyethyl)-­‐1-­‐piperazineethanesulfonic	  acid	  
hr	   	   	   	   hour/s	  
INF	   	   	   Interferon	  
IPTG	   	   	   Isopropyl-­‐β-­‐D-­‐thio-­‐galactoside	  
IRS1	   	   	   Insulin	  receptor	  substrate	  1	  
JAK	   	   	   Janus	  kinase	  
KDa	   	   	   Kilo-­‐Daltons	  
Kb	  	   	   	   Kilobase	  
LB	  	   	   	   Lysogeny	  broth	  
Max	   	   	   Maximum	  
M-­‐bcr	   	   	   Major	  breakpoint	  cluster	  region	  
m-­‐bcr	   	   	   minor	  breakpoint	  cluster	  region	  
μ-­‐bcr	   	   	   micro	  breakpoint	  cluster	  region	  
MCR	   	   	   Multiple	  Cloning	  Region	  
μg	  	   	   	   Micro-­‐gram	  
miRNA	   	   	   MicroRNA	  
miRNP	   	   	   MicroRNA	  protein	  complex	  
Min	   	   	   Minutes	  
μl	   	   	   	   Micro-­‐Litre	  
	  	   15	  
M-­‐MLV	   	   	   Moloney	  Murine	  Leukaemia	  Virus	  
ng	  	   	   	   Nanograms	  
nt	   	   	   	   Nucleotides	  
OD	   	   	   Optical	  density	  
PBS	   	   	   Phosphate	  buffered	  saline	  
PCR	   	   	   Polymerase	  chain	  reaction	  
PDK	   	   	   Phosphoinositide-­‐dependent	  kinase	  
PFA	   	   	   Paraformaldehyde	  
pg	  	   	   	   Picogram	  
Ph	  	   	   	   Philadelphia	  chromosome	  
Ph+	   	   	   Philadelphia	  chromosome	  positive	  
PIP2	   	   	   Phosphoinositide-­‐4,	  5-­‐triphosphate	  
PIP3	   	   	   Phosphoinositide-­‐3,	  4,	  5-­‐triphosphate	  
PI3K	   	   	   Phosphatidylinositol	  3-­‐kinases	  
Pol	  III	   	   	   Polymerase	  III	  
Pri-­‐miRNA	   	   primary	  miRNA	  
PRL13	   	   	   Ribosomal	  protein	  large	  13	  
PVDF	   	   	   Polyvinylidene	  fluoride	  
qPCR	   	   	   quantitative	  PCR	  
RISC	   	   	   RNA-­‐induced	  silencing	  complex	  
RNA	   	   	   Ribonucleic	  acid	  
RNAi	   	   	   RNA	  interference	  
Rpm	   	   	   Revolutions	  per	  minute	  
RT-­‐PCR	   	   	   Reverse	  transcription	  polymerase	  chain	  reaction	  
SCID	   	   	   Severe	  Combined	  Immunodeficiency	  
SD	  	   	   	   Standard	  deviation	  
SDS	   	   	   Sodium	  dodecyl	  sulfate	  
SDS-­‐PAGE	  	   	   Sodium	  dodecyl	  sulfate	  polyacrylamide	  gel	  
electrophoresis	  
SH3	   	   	   Src-­‐homology	  3	  
SHIP1	   	   	   SH2	  domain-­‐containing	  inositol	  5-­‐phosphatase	  
shRNA	   	   	   Short	  hairpin	  RNA	  
	  	   16	  
siRNA	   	   	   Short	  interfering	  RNA	  
SOS	   	   	   Son	  of	  sevenless	  protein	  
STAT	   	   	   Signal	  transducer	  and	  activator	  of	  transcription	  
T	   	   	   	   Thymine	  
TAE	   	   	   Tris-­‐acetic	  acid	  EDTA	  
TBS	   	   	   Tris	  buffer	  saline	  
TE	  	   	   	   Tris-­‐Ethylenediaminetetraacetic	  acid	  
TFO	   	   	   Triplex	  forming	  oligonucleotides	  
TKI	   	   	   Tyrosine	  kinase	  inhibitor	  
UPL	   	   	   Universal	  probe	  library	  
UV	  	   	   	   Ultra	  violet	  
WBC	   	   	   White	  blood	  cell	  
w/v	   	   	   Weight	  per	  volume	  



















	  	   17	  
Chapter	  1 :	  Introduction	  
	  
	  
1.1 	  Haematopoiesis	  and	  Leukaemia	  
	  
Haematopoiesis	   is	   defined	   as	   the	   process	   of	   white	   blood	   cell	   (WBC)	  
production.	   The	   process	   starts	  with	   the	   haematopoietic	   stem	   cell,	   then	   goes	  
through	   several	   steps	   of	   differentiation	   and	   proliferation,	   involving	   several	  
haemopoietic	  growth	  factors	  and	  cytokines.	  Mature	  WBC	  are	  then	  produced.	  	  
There	  are	   two	  main	   types	  of	  WBC,	   the	  myeloid	  or	   the	  phagocytic	   lineage	  
and	  the	  lymphoid	  or	  the	  immunocytic	  lineage.	  The	  myeloid	  lineage	  gives	  rise	  to	  
the	  monocytes	  and	  granulocytes,	  the	  latter	  includes	  the	  neutrophils,	  basophils	  
and	   eosinophils,	   whereas	   the	   lymphoid	   lineage	   gives	   rise	   to	   the	   B-­‐	   and	   T-­‐
lymphocytes	  (Hoffbrand	  et	  al.,	  2006).	  Figure	  1.1	  	  
Leukaemias	  or	  blood	  cancers	  are	  a	  group	  of	  malignancies	  that	   involve	  the	  
haemopoietic	   system	   (Sobecks	   and	   Theil,	   2003)	   in	   particular	   the	  WBC.	   In	   all	  
leukaemias	   the	   WBC	   proliferation	   dramatically	   increases;	   however,	  
differentiation	   decreases	   to	   a	   point	   where	   the	   bone	  marrow	   (BM)	   becomes	  
hypercellular	  and	  immature	  malignant	  cells	  are	  seen	  in	  the	  peripheral	  blood.	  	  
Four	  types	  of	  leukaemia	  exist	  depending	  on	  the	  cell	   lineages	  affected,	  the	  
types	  of	  malignant	  cells	  seen	  and	  the	  disease	  progression.	  These	  are	  the	  acute	  
myeloid	   leukaemia	   (AML),	   the	   chronic	   myeloid	   leukaemia	   (CML),	   the	   acute	  
lymphoid	   leukaemia	   (ALL)	   and	   the	   chronic	   lymphoid	   leukaemia	   (CLL)	  
(Hoffbrand	  et	  al.,	  2006).	  This	  project	  considers	  CML,	  therefore	  only	  this	  type	  of	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The	  White	  Blood	  Cells	  
(WBC)	  





Phagocytes:	   	   	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  Immunocytes:	  
-­‐	  Monocytes	  (4	  -­‐6%)	   	   	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  -­‐	  Lymphocytes	  (25	  -­‐35%)	  
	  	  	  	  	  	  	  	  	  	  -­‐	  Granulocytes:	   	   	   	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  *	  B-­‐Lymphocytes	  
o Neutrophils	  (50	  -­‐70%)	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  *	  T-­‐Lymphocytes	  
o Eosinophils	  (1	  -­‐3%)	  
o Basophils	  (0.4	  -­‐1%)	  
	  
	  
Figure	  1.1	  	  Classification	  of	  the	  White	  Blood	  Cells	  (Hoffbrand	  et	  al.,	  2006).	  
A	  normal	  adult	  has	  4	  -­‐11x109/L	  WBC	  in	  their	  peripheral	  blood.	  WBC	  can	  be	  mainly	  divided	  into	  
phagocytes	  and	  immunocytes.	  The	  phagocytes	  are	  further	  divided	  into	  the	  monocytes	  and	  the	  
granulocytes.	  Monocytes	  are	  agranulocytic	  cells	  making	  up	  4-­‐6%	  of	  the	  total	  WBC	  count,	  while	  
the	  granulocytes	  consist	  of	  neutrophils,	  eosinophils	  and	  basophils	  that	  make	  up	  50-­‐70%,	  1-­‐3%	  
and	  0.4-­‐1%	  of	  the	  total	  WBC	  count	  respectively.	  The	  immunocytes,	  on	  the	  other	  hand,	  consist	  
of	  the	  T-­‐	  and	  B-­‐	  lymphocytes	  that	  make	  up	  25-­‐35%	  of	  the	  total	  WBC	  count.	  	  	  	  
	  
	  
1.2 Chronic	  Myeloid	  Leukaemia	  (CML)	  
	  
In	   1845	   Chronic	   Myeloid	   leukaemia	   (CML)	   was	   independently	   described	  
and	  recognized	  by	  three	  German	  pathologists	  Virchow,	  Craigie	  and	  Bennett	  in	  
Edinburgh,	  (Chopra	  et	  al.,	  1999).	  However,	  it	  was	  not	  until	  the	  1920s	  that	  the	  
epidemiology	   of	   the	   disease	   was	   recognized	   (Chopra	   et	   al.,	   1999).	   The	  
incidence	  of	  CML	  is	  approximately	  1	  in	  100,000	  (Jemal	  A.	  et	  al.,	  2002)	  with	  the	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disease	   affecting	   both	   sexes.	  However,	   it	   is	   slightly	   higher	   in	  males	   (Sobecks	  
and	  Theil,	  2003)	  and	  increases	  with	  age	  (Michor	  et	  al.,	  2006).	  	  The	  median	  age	  
of	  presentation	  of	  CML	   is	  between	  50	  and	  60	  years,	  nevertheless,	  12-­‐30%	  of	  
cases	  are	  diagnosed	  above	  60	  (Kalidas	  et	  al.,	  2001).	  
	  
	  
1.2.1 Definition	  of	  CML	  
	  
CML	   is	   a	   myeloproliferative	   disorder	   that	   arises	   due	   to	   a	   clonal	   process	  
involving	  the	  haematopoietic	  stem	  cells.	  The	  disease	  primarily	  affects	  the	  cells	  
of	   the	  myeloid	   lineage,	  however,	  as	  the	  disease	  progresses	   it	  also	  affects	   the	  
erythroid,	  megakaryocytic	  and	  lymphoid	  lineages	  (Faderl	  et	  al.,	  1999).	  	  
The	  disease	  is	  characterised	  by	  having	  a	  severe	  increase	  in	  the	  WBC	  count,	  
a	   mild	   to	   moderate	   anaemia	   and	   a	   hypercellular	   BM	   with	   a	   marked	  
proliferation	   of	   all	   the	   granulocytic	   elements.	   The	   latter,	   leads	   to	   BM	   failure	  
and	  cytopenias	  that	  will	  in	  turn	  lead	  to	  haemorrhage,	  recurrent	  infections	  and	  




1.2.2 Clinical	  Staging	  of	  CML	  
	  
CML	   is	  known	  to	  be	  a	   triphasic	  disorder,	  and	  the	  chronic	  phase	   is	   the	  
first	   phase	   of	   the	   disease.	   50%	   of	   Patients	   are	   usually	   asymptomatic	   at	   this	  
stage	  of	  the	  disorder.	  However,	  if	  symptoms	  persist,	  they	  can	  include	  fatigue,	  
weight	   loss,	   abdominal	   fullness,	   bleeding,	   sweats,	   splenomegaly,	  
hepatomegaly	   (Advani	   and	   Pendergast,	   2002),	   anaemia,	   leukocytosis,	   and	  
thrombocytosis	   (Faderl	   et	   al.,	   1999).	   It	   is	   then	   followed	   by	   the	   accelerated	  
phase	  and	  subsequently	  the	  blastic	  phase	  (Sawyers,	  1999).	  The	  last	  two	  phases	  
are	   sometimes	   joined	   together	   and	   considered	   to	   be	   advanced-­‐phase	   CML.	  
The	  duration	  of	  the	  three	  phases	  together,	  if	  untreated,	  has	  a	  median	  span	  of	  2	  
	  	   20	  
to	   5	   years.	   Usually	   the	   chronic	   phase	   lasts	   from	   2-­‐5	   years;	   the	   accelerated	  
phase	   can	   last	   up	   to	   one	   year,	   whereas	   the	   blastic	   phase	  may	   lasts	   for	   3-­‐6	  
months	  (Sessions,	  2007).	  Patients	  may	  be	  diagnosed	  at	  any	  of	  the	  three	  stages.	  
Table	  1.1	  summarizes	  the	  main	  characteristics	  of	  each	  phase.	  85%	  of	  Patients	  
are	   usually	   diagnosed	   in	   the	   chronic	   phase	   and	   50%	   of	   them	   are	   diagnosed	  
from	  routine	  tests	  where	  patients	  are	  asymptomatic	  (Faderl	  et	  al.,	  1999):	  they	  
visit	   their	   physicians	   for	   other	  unrelated	   issues,	   and	  end	  up	  being	  diagnosed	  
through	  an	  abnormally	  elevated	  WBC	  (Sessions,	  2007).	  	  	  	  	  
	  
Name	  of	  CML	  clinical	  phase	   Main	  characteristics	  
Chronic	  phase	   • Usually	  an	  asymptomatic	  phase.	  If	  symptoms	  
persist,	   they	   may	   include	   splenomegaly,	  
anaemia	  and	  hyperviscosity.	  
• This	   phase	   is	   easily	   controlled	   by	  
conventional	  therapy.	  
• Lasts	  for	  an	  average	  of	  3	  years.	  
Accelerated	  phase	   • WBC	  doubling	  every	  five	  days,	  hard	  to	  control	  
by	  conventional	  therapy.	  
• 20%	  of	  blasts	  and	  promyelocytes	  are	  found	  in	  
the	  blood	  and	  BM.	  
• 30%	  basophils	  and	  eosinophils	  are	  seen	  in	  the	  
blood.	  
• Splenomegaly	  in	  consistently	  increasing.	  
• Anaemia	   and	   thrombocytopenia	   are	   non-­‐
respondent.	  
Blastic	  phase	   • 30%	  of	  blasts	  and	  promyelocytes	  are	  found	  in	  
the	  blood	  and	  BM.	  
• Patients	  experience	  splenic	  and	  bone	  pain	   in	  
addition	  to	  lymphoadenopathy.	  
• Median	  survival	  rate	  3-­‐6	  months.	  
Table	  1.1	  The	  characteristics	  of	  CML	  clinical	  phases.	  (Hoffbran	  et	  al.,	  	  2006).	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1.3 	  	  The	  Molecular	  Biology	  of	  CML	  
	  
CML	  was	  one	  of	  the	  first	  cancers	  to	  be	  associated	  with	  a	  chromosomal	  
abnormality	   (Sawyers,	   1999).	   In	   1960	   Nowell	   and	   Hungerford	   noticed	   an	  
abnormally	   small	   chromosome	   in	   patients	   with	   CML	   (Nowell,	   2007).	   Further	  
studies	   by	   Rowley	   J.D	   in	   1973,	   using	   quinacrine	   fluorescent	   and	   Giemsa	  
staining	   band	   technique,	   revealed	   that	   the	   abnormal	   chromosome	   in	   these	  
patients	  was	  produced	  due	  to	  a	  balanced	  translocation	  between	  chromosomes	  
9	   and	   22.	   This	   new	   chromosome	   came	   to	   be	   known	   as	   the	   Philadelphia	  
chromosome	   (Ph):	   named	   after	   the	   city	   where	   it	   was	   first	   discovered.	   The	  
chromosome	  plays	  a	  significant	  role	  in	  the	  development	  of	  the	  disease	  and	  it	  is	  
found	  to	  be	  present	  in	  95%	  of	  all	  CML	  cases	  (Evans	  and	  Sillibourne,	  1996	  and	  
Wertheim	   et	   al.,	   2002).	   Patients	   with	   t(9;22)	   translocation	   are	   termed	   Ph	  
positive	  (Ph+).	  	  	  	  	  	  
In	   1982	   the	   first	   aspects	   of	   the	   molecular	   biology	   of	   CML	   were	  
subsequently	  discovered.	  In	  that	  year	  a	  research	  group	  in	  the	  USA	  showed	  that	  
the	  gene	  on	  chromosome	  9,	  which	  was	  translocated	  to	  chromosome	  22,	  was	  
the	  human	  ABL	  (Heisterkamp	  et	  al.,	  1982	  and	  Heisterkamp	  and	  Groffen,	  2002)	  
proto-­‐oncogene	   (Advani	   and	   Pendergast,	   2002).	   It	   was	   then	   found	   that	   this	  
gene	   was	   translocated	   into	   a	   limited	   region,	   around	   5.8	   kilo	   bases	   (KB),	   on	  
chromosome	   22.	   This	   region	  was	   termed	   the	   breakpoint	   cluster	   region	   (bcr)	  
(Groffen	  et	  al.,	  1984).	  Hence,	  the	  name	  of	  the	  gene	  on	  chromosome	  22	  is	  now	  
known	   as	   the	   BCR	   gene.	   Figure	   1.2	   shows	   the	   translocation	   between	  
chromosomes	  9	  and	  22.	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Figure	   1.2	   The	   Reciprocal	   translocation	   between	   Chromosomes	   9	   and	   22	   producing	   the	  
Philadelphia	  Chromosome.	  	  
The	   ABL	   gene	   located	   in	   chromosome	   9	   is	   translocated	   on	   chromosome	   22,	  where	   the	  BCR	  
gene	  is	  located	  via	  a	  reciprocal	  translocation.	  This	  results	  in	  the	  Philadelphia	  chromosome	  that	  
bears	  the	  abnormal	  ABL-­‐BCR	  fusion	  gene.	  	  	  
	  
	  
1.3.1 The	  ABL	  Protein	  
	  
The	  normal	  ABL	   gene	   is	   composed	  of	  11	  exons	   (Laurent	  et	  al.,	  2001),	  and	  
transcribes	   the	   c-­‐ABL	   protein.	   This	   145	   Kilo-­‐Daltons	   (KDa)	   protein	   is	   a	   non-­‐
receptor	   tyrosine	   kinase.	   c-­‐ABL	   has	   roles	   in	   assembling	   signalling	   proteins,	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growth	   factor	   signalling,	   cytoskeletal	   organization,	   lipid	   metabolism,	   	   and	  
transcriptional	  regulation	  (Chopra	  et	  al.,	  1999).	  Two	  alternative	  first	  exons	  are	  
present	   (1a	   and	   1b)	   and	   depending	   on	   the	   alternative	   splicing	   of	   the	  
transcribed	   RNA	   of	   the	   human	   c-­‐ABL	   gene,	   two	   splice	   variants	   are	   present	  
(Shtivelman	  et	  al.,	  1986).	  Furthermore,	  the	  c-­‐ABL	  type	  1a	  is	  the	  spliced	  form	  of	  
the	  protein	  and	  does	  not	  include	  a	  myristolation	  signal.	  In	  both	  variants,	  at	  the	  
amino-­‐terminus,	   a	   Cap	   region	   is	   present,	   then	   an	   Src-­‐homology	   3	   (SH3)	  
domain,	   followed	  by	   an	   SH2	  domain,	   a	   tyrosine	   kinase	  domain,	   and	   finally	   a	  
long	   carboxyl-­‐terminal	   extension,	   which	   is	   also	   called	   the	   last	   exon	   region	  
(Hantschel,	   2004).	   The	   c-­‐ABL	   protein	   also	   contains	   both	   nuclear	   localization	  
and	   F-­‐actin	   binding	   motifs.	   This	   explains	   the	   observations	   that	   the	   c-­‐ABL	  
protein	   can	   be	   seen	   in	   both	   the	   nucleus	   and	   the	   cytoplasm	   (Laurent	   et	   al.,	  
2001).	  	  	  
In	   addition,	   Pluk	   et	   al.,	   2002,	   showed	   that	   the	   c-­‐ABL	   protein	   is	  
autoregulated,	  and	  the	  Cap,	  SH3,	  SH2	  and	  the	  SH3-­‐SH2	  linker	  catalytic	  domain,	  
play	   a	   role	   in	   autoinhibition	   of	   the	   normal	   c-­‐ABL	   protein.	   The	   structural	  
organization	  of	  this	  protein	  can	  be	  seen	  in	  Figure	  1.3.	  	  	  	  
	  
	  
	  	  	  
	  	  	  	   	  	  	  	  	  
	  
Figure	  1.3	  The	  Structural	  Organization	  of	  the	  c-­‐ABL	  protein.	  	  	  
The	  c-­‐ABL	  protein	   is	  145	  KDa,	  and	  consists	  of	   several	   structural	  motifs.	   These	  motifs	   include	  
the	  Cap,	  the	  SH3,	  the	  SH2,	  and	  the	  tyrosine	  kinase	  domain.	  The	  protein	   is	  autoregulated	  and	  
the	  kinase	  domain	  is	  autoinhibited	  in	  the	  normal	  protein.	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1.3.2 The	  BCR	  Protein	  
	  
The	  BCR	  gene	  spans	  130kb	  and	  is	  composed	  of	  23	  exons.	  	  The	  gene	  is	  found	  
to	  have	  two	  alternative	  exons;	  an	  alternative	  exon	  1	  and	  an	  alternative	  exon	  2,	  
which	  are	  usually	   spliced	  out	   (Laurent	  et	  al.,	   2001).	   The	  gene	  encodes	  a	  160	  
KDa	  protein.	  The	  protein	  has	  several	  structural	  domains	  that	  are	  illustrated	  in	  
Figure	  1.4.	  From	  the	  N-­‐terminus	  of	  the	  BCR	  protein	  the	  following	  domains	  are	  
present;	   an	   oligomerization	   domain	   (Zhao	   et	   al.,	   2002),	   a	   serine/threonine	  
kinase	  domain	  (Maru,	  1991),	  SH2-­‐binding	  domains	  (Laurent	  et	  al.,	  2001),	  and	  a	  
GDP-­‐GTP	  exchange	  domain	  (Chopra	  et	  al.,	  1999).	  At	  the	  C-­‐terminus,	  a	  domain	  
showing	  homology	   to	   the	  GTPase	   activating	   protein,	  GAP	  domain,	   is	   present	  
(Diekmann	  et	  al.,	  1991).	  	  The	  first	  two	  domains	  are	  encoded	  from	  the	  first	  exon	  
of	  the	  gene	  and	  are	  preserved	  in	  all	  BCR-­‐ABL	  variants	  (Laurent	  et	  al.,	  2001),	  as	  






Figure	  1.4	  The	  Structural	  Organization	  of	  the	  BCR	  Protein.	  	  
The	  BCR	  protein	   is	   composed	  of	   several	   structural	  motifs.	   These	   include	   the	  oligomerization	  
domain,	   the	  serine/threonine	  domain	  and	  the	  GDP-­‐GTP	  exchange	  domain	  on	  the	  N-­‐terminus	  
of	  the	  protein.	  At	  the	  C-­‐terminus,	  the	  GAP	  domain	  is	  present.	  
	  
The	   oligomerization	   domain	   (a	   coiled-­‐coil	   motif)	   facilitates	   hetero-­‐
oligomerization	  with	  the	  BCR	  protein.	  In	  the	  abnormal	  CML	  fusion	  protein	  this	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motif	  allows	  homo-­‐dimerization	  of	  the	  fusion	  protein	  that	  is	  necessary	  for	  the	  
activity	  (Faderl	  et	  al.,	  1999)	  and	  localization	  of	  the	  abnormal	  BCR-­‐ABL	  protein.	  
Deletions	  of	  this	  portion	  of	  the	  protein	  were	  found	  to	  decrease	  its	  binding	  to	  F-­‐
actin,	  because	  a	   F-­‐actin	  binding	  motif	   is	   found	  within	   the	  ABL	  portion	  of	   the	  
protein.	   It	   is	   found	   that	   the	   oligomerization	   domain	   is	   responsible	   for	   the	  
cytoplasmic	   localization	  of	   the	   fusion	  protein	   (Laurent	  et	  al.,	  2001)	   to	  one	  of	  
the	  SH2-­‐binding	  domains	  of	  the	  c-­‐ABL	  protein.	  This	  interaction	  is	  thought	  to	  be	  
essential	   for	   the	  oncogenic	   activation	  of	   the	  BCR-­‐ABL	  protein	   (Laurent	  et	  al.,	  
2001).	  The	  GDP-­‐GTP	  exchange	  domain	  serves	  as	  an	  important	  control	  element	  
for	   the	   RAS	   family,	   and	   is	   a	  GDP-­‐GTP	   exchange	   factor	   for	   other	  GTP	   binding	  
proteins,	  whereas	  the	  GAP	  domain	  is	  associated	  with	  the	  RAS-­‐related	  protein	  
family,	  RAC	  and	  RHO.	  The	  GAP	  domain	  controls	   the	  rate	  of	  GTP	  hydrolysis	  of	  
the	   active	   RAS	   proteins	   to	   their	   inactive	   form,	   bound	   to	   GDP	   (Faderl	   et	   al.,	  
1999).	  The	  structure	  of	  the	  BCR	  protein,	  therefore,	  makes	  it	  a	  multifunctional	  
signal	  transducting	  molecule	  (Chopra	  et	  al.,	  1999	  and	  Laurent	  et	  al.,	  2001).	  And	  
because	  of	   the	  presence	  of	   the	  GDP-­‐GTP	  exchange	   factor	   and	  GDP	  domains,	  
see	   Figure	   1.4,	   the	   protein	   seems	   to	   be	   especially	   concerned	   with	  
phosphorylation,	  GTP	  binding	  of	  various	  proteins	  in	  several	  pathways	  that	  are	  
involved	   in	   cytoskeletal	   organization,	   cell	   growth,	   and	   normal	   development	  
(Laurent	  et	  al.,	  2001).	  These	  pathways	  are	  further	  discussed	  in	  sections	  1.3.5.1-­‐	  
1.3.5.4.	  
In	   terms	  of	  BCR	  expression,	   the	  protein	   is	   constantly	  expressed	   in	  various	  
tissues	  and	  cells,	  indicating	  its	  role	  in	  general	  cell	  metabolism	  rather	  than	  being	  
specific	   to	   a	   particular	   tissue	   (Maru,	   1991).	   The	   protein’s	  mRNA	   levels	   were	  
found	   to	   be	   highest	   in	   brain	   and	   hematopoietic	   cells.	   Interestingly,	   the	   BCR	  
protein	  is	  expressed	  in	  the	  first	  stages	  of	  myeloid	  differentiation,	  and	  the	  levels	  
of	  the	  protein	  decreases	  significantly	  with	  leukocyte	  maturation	  (Laurent	  et	  al.,	  
2001).	   	   Finally,	   the	   protein	   is	   usually	   cytoplasmic.	   However,	   it	   has	   also	   been	  




	  	   26	  
1.3.3 The	  BCR-­‐ABL	  Fusion	  Gene	  
	  
When	  the	  c-­‐ABL	  gene	  is	  translocated	  from	  chromosome	  9	  to	  chromosome	  
22,	   the	   gene	  will	   be	   under	   the	   regulation	   of	   the	  BCR	   promoter	   (Shah	   et	   al.,	  
1991	   and	   Zhu	   et	   al.,	   1990).	   This	   translocation	   gives	   rise	   to	   an	   abnormal	  
upregulated	   tyrosine	   kinase	   activity	   of	   the	   BCR/ABL	   fusion	   gene.	   The	  
breakpoint	  within	   the	   c-­‐ABL	  gene	   occurs	  within	   the	   first	   intron	   of	   this	   gene,	  
leading	   to	   the	   fact	   that	   the	   resultant	   fusion	   transcripts	   always	   include	   the	  
portion	  of	   the	  ABL	   gene	   from	  exon	  2	  onwards	   (Shtivelman	  et	  al.,	   1985).	   The	  
BCR	  part	  of	  the	  fusion	  gene	  has	  three	  different	  points	  at	  which	  a	  chromosomal	  
breakage	   can	   occur.	   Three	   breakpoints	   exist,	   and	   are	   called	   the	   Major	  
breakpoint	  cluster	  region	  (M-­‐bcr),	  the	  minor	  breakpoint	  cluster	  region	  (m-­‐bcr)	  
and	  the	  micro	  breakpoint	  cluster	  region	  (μ-­‐bcr)	  (Chopra	  et	  al.,	  1999	  and	  Melo,	  
1997);	   this	   is	  how	  the	  BCR	  gene	  got	   its	  name.	  Figure	  1.5	  demonstrates	   these	  
breakpoints.	  The	  M-­‐bcr	  spans	  a	  5.8kb	  region	  within	  the	  BCR	  gene	  (Groffen	  et	  
al.,	   1984).	   The	  breakpoints	  here	   span	  5	  exons	  historically	  named	  b1-­‐b5,	  now	  
known	  as	  exons	  12	  to	  16	  (Melo,	  1996),	  and	  all	  breakpoints	  within	  this	  region	  





















Figure	  1.5	  	  The	  Breakpoints	  within	  the	  BCR	  gene	  found	  on	  chromosome	  22.	  
The	  position	  of	  the	  BCR	  gene	  is	  indicated	  by	  the	  dark	  transverse	  band	  shown	  on	  the	  long	  arm	  
of	   chromosome	   22.	   The	   gene	   is	   then	   further	   amplified	   to	   show	   the	   three	   points	   at	   which	  
breakages	   may	   occur	   in	   the	   chromosome.	   These	   are	   the	   minor-­‐bcr,	   the	   major-­‐bcr	   and	   the	  
micro-­‐bcr	   breakpoints.	   The	  minor-­‐bcr	   is	   located	   between	   exons	   1	   and	   2,	   fusions	   to	   the	  ABL	  
gene	  at	  this	  point	  give	  rise	  to	  the	  p190	  fusion	  protein	  that	  is	  responsible	  for	  30%	  of	  ALL	  cases.	  
The	  major-­‐bcr	   is	  between	  exons	  13	  and	  15	  and	  when	  fused	  to	  the	  ABL	  gene	  the	  p210	  fusion	  
protein	   results.	   This	   protein	   is	   responsible	   for	   95%	   of	   CML	   cases.	   Finally,	   the	   micro-­‐bcr	   is	  
between	  exons	  19	  and	  20,	  and	  fusions	  to	  the	  ABL	  gene	  at	  this	  point	  give	  rise	  to	  the	  p230	  fusion	  
protein	  that	  is	  associated	  with	  chronic	  neutrophilic	  leukaemia.	  Note	  that	  exons	  13	  and	  14	  are	  
also	  known	  as	  β2	  and	  β3	  respectively.	  	  	  
	  	  
The	  M-­‐bcr	  occurs	  between	  exons	  13	  and	  14	  or	  14	  and	  15	  giving	  rise	  to	  two	  
variants	  of	  the	  p210	  protein	  that	  are	  associated	  with	  95%	  of	  CML	  cases.	  The	  m-­‐
bcr	  occurs	  between	  the	  alternative	  exons	  1	  (1b	  and	  1a)	  and	  exon	  2.	  Breaks	  at	  
this	  point	  give	  rise	  to	  the	  p190	  protein	  that	  is	  associated	  with	  15-­‐30%	  of	  adult	  
ALL	  and	  around	  3-­‐5%	  of	  childhood	  ALL.	  Finally,	  the	  μ-­‐bcr	  occurs	  between	  exons	  
19	  and	  20	  of	  the	  BCR	  gene.	  The	  resultant	  protein	  is	  the	  p230	  (Melo,	  1997	  and	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Van	   Der	   Burg	   et	   al.,	   2004)	   and	   it	   is	   found	   to	   be	   associated	   with	   chronic	  
neutrophilic	  leukaemia	  (Advani	  and	  Pendergast,	  2002	  and	  Quackenbush	  et	  al.,	  
2000).	   Figure	   1.6	   demonstrates	   the	   different	   BCR-­‐ABL	   fusion	   proteins.	   Note	  






Figure	  1.6	  The	  BCR	  and	  ABL	  genes,	  breakpoints,	  and	  transcripts.	  	  
	  
Depending	  on	  where	  the	  chromosomal	  breakage	  occurs	   in	  the	  BCR	  gene,	  four	  transcriptional	  
variants	   can	   result.	   Breakages	   in	   the	   m-­‐bcr	   region	   give	   rise	   to	   the	   e1a2	   variant	   that	   is	  
transcribed	  into	  a	  190	  kDa	  protein,	  p190.	  Breaks	  in	  the	  M-­‐bcr	  region	  may	  give	  rise	  to	  the	  b3a2	  
or	  the	  b2a2	  variants	  both	  of	  which	  transcribe	  a	  210	  kDa	  protein,	  p210.	  Finally,	  breakages	  in	  the	  
μ-­‐bcr	  region	  give	  rise	  to	  the	  e19a2	  variant	  that	  transcribes	  a	  230	  kDa	  protein,	  p230.	  	  	  
	  
Each	  of	  the	  different	  BCR-­‐ABL	  proteins	  is	  associated	  with	  a	  different	  type	  of	  
leukaemia,	   as	   demonstrated	   above.	   This	   strongly	   suggests	   that	   the	   type	   of	  
leukaemia,	   phenotype	   outcome,	   depends	   highly	   on	   the	   domains	   of	   the	  BCR	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gene	   included.	   The	   p190	   is	   the	   smallest	   of	   the	   BCR-­‐ABL	   proteins	   and	   is	  
associated	   with	   cases	   of	   ALL	   whereas	   the	   p230,	   the	   largest	   of	   the	   BCR-­‐ABL	  
proteins,	   is	   associated	   with	   chronic	   neutrophilic	   leukaemia,	   which	   is	  
considered	  to	  be	  a	   less	  aggressive	   form	  of	   leukaemia	   in	  comparison	  with	  ALL	  
and	  CML	  (Melo,	  1996	  and	  Advani	  and	  Pendergast,	  2002).	  Hence,	   the	   less	   the	  
amount	  of	  the	  BCR	  gene	  included,	  the	  more	  aggressive	  the	  leukaemia.	  	  
The	  amount	  of	  the	  BCR	  gene	  being	  encoded	  in	  the	  BCR-­‐ABL	  fusion	  protein	  
correlates	  with	   the	  BCR	  domains	  present	   in	   the	   latter.	   Thus,	   in	  p190	  protein	  
only	   the	   oligomerization	   domain	   and	   the	   serine/threonine	   domains	   are	  
present,	  whereas	  in	  the	  p210	  protein,	  the	  previous	  domains	  in	  addition	  to	  the	  
GDP-­‐GTP	  exchange	  domain	  are	  present.	  Finally,	   the	  p230	  protein	   includes	  all	  
the	   domains	   present	   in	   the	   p210	   protein	   and	   part	   of	   the	   GAP	   domain.	   This	  
suggests	   the	  presence	  of	  a	  correlation	  between	  the	  structure	  of	   the	  BCR-­‐ABL	  
fusion	  protein	  and	   the	  disease	  phenotype	   (Melo,	  1996).	   Figure	  1.7	   illustrates	  
the	   relation	   between	   breakpoint	   cluster	   regions	   and	   the	   BCR	   domains.	   This	  
project	  will	  only	  take	  into	  account	  the	  p210	  BCR/ABL	  fusion	  protein	  due	  to	  its	  






















Figure	  1.7	  Schematic	  representation	  of	  the	  structural	  motifs	  of	  the	  normal	  BCR	  protein	  and	  
their	  association	  with	  the	  breakpoint	  cluster	  regions.	  	  
The	  red	  arrows	  show	  the	  positions	  of	  the	  three	  breakpoints.	  The	  first	  arrow	  represents	  the	  m-­‐
bcr.	   Breakpoints	   at	   this	   position	   results	   in	   a	   p190	   bcr-­‐abl	   fusion	   protein	   that	   retains	   the	  
oligomerization	  domain	  and	  the	  serine/threonine	  domain.	  The	  second	  arrow	  indicates	  the	  M-­‐
bcr.	  Breakpoints	  here	  give	  rise	  to	  the	  p210	  BCR-­‐ABL	  fusion	  proteins.	  These	  proteins	  include	  the	  
domains	   present	   in	   the	   p190	   protein	   and	   the	   GDP-­‐GTP	   exchange	   domain.	   The	   p210	   fusion	  
protein	  is	  associated	  with	  CML	  and	  has	  two	  subsequent	  variants	  (β2α2	  and	  β3α2).	  Finally,	  the	  
third	  arrow	  labelled	  μ-­‐bcr	  points	  to	  the	  last	  breakpoint.	  Breakpoints	  at	  this	  position	  results	  in	  
the	   p230	   BCR-­‐ABL	   protein.	   This	   protein	   has	   all	   the	   domains	   with	   the	   exception	   of	   the	   GAP	  
domain,	  where	  only	  a	  part	  of	  it	  is	  present.	  
	  	  	  	  	  	  	  
	  
1.3.4 The	  p210BCR-­‐ABL	  Fusion	  Protein	  
	  
The	   M-­‐bcr	   is	   around	   5.8	   kb	   in	   size	   (Pane	   et	   al.,	   2002)	   and	   as	   figure	   1.5	  
demonstrated	   the	   breakage	   occurs	   between	   exons	   13/14	   or	   14/15,	   thus	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retaining	  the	  coding	  region	  of	  the	  BCR	  gene	  from	  exon	  1	  to	  exon	  13	  or	  14;	  the	  
last	   two	   are	   also	   known	   as	   exons	   b2	   and	   b3	   respectively	   (Melo,	   1996	   and	  
Chopra	  et	  al.,	  1999).	  Moreover,	  breakages	  on	  the	  ABL	  gene	  occur	  between	  the	  
alternative	  exons	  1b	  and	  1a,	  which	  are	  then	  spliced	  out.	  	  
The	  net	  result	  of	  the	  t(9;22)	  translocation	  is	  that	  the	  second	  exon	  of	  the	  ABL	  
gene	  will	  fuse	  (at	  the	  gene’s	  3’	  end)	  to	  either	  exon	  13	  or	  14	  of	  the	  BCR	  gene	  (at	  
it’s	  5’	  end)	  (Pane	  et	  al.,	  2002	  and	  Laurent	  et	  al.,	  2001).	  Hence,	  giving	  raise	  to	  
the	  two	  BCR-­‐ABL	  alternative	  transcripts,	  the	  β2α2	  and	  the	  β3α2	  variants,	  with	  
the	   second	  variant	  having	  a	   longer	   transcript.	   (Advani	  and	  Pendergast,	  2002)	  
Both	   variants	   encode	   the	   p210	   BCR-­‐ABL	   protein	   in	   which	   the	   ABL	   tyrosine	  
kinase	   is	   constitutively	   active.	   This	   constitutive	   activation	   is	   the	   result	   of	  
oligomerization	  domain	  of	  the	  BCR	  gene	  that	  promotes	  tetramerization	  of	  the	  
fusion	  protein	  (Faderl	  et	  al.,	  1999),	  thus	  allowing	  the	  Serine/threonine	  domain	  
of	   the	  BCR	  protein	   to	   bind	   to	   the	   SH2	  domain	  of	   the	  ABL	  protein	   leading	   to	  
activation	  of	   it’s	   the	   tyrosine	  kinase	  domain	   (Laurent	  et	  al.,	  2001).	  Figure	  1.8	  
demonstrates	  the	  BCR	  and	  ABL	  domains	  included	  in	  the	  p210	  BCR-­‐ABL	  protein.	  	  
On	   the	   basis	   of	   the	  more	  BCR	   sequence	   included	   in	   the	   protein,	   the	   less	  
aggressive	   the	   leukaemia,	   mentioned	   earlier,	   scientists	   were	   interested	   to	  
examine	  if	  this	  was	  true	  for	  the	  p210	  variants	  (Mills	  et	  al.,	  1988,	  Leibowitz	  et	  
al.,	  1991,	  and	  Shepherd	  et	  al.,	  1995).	  The	  β3α2	  being	  initiated	  from	  a	  breakage	  
in	   the	   3’	   end	   of	   the	   M-­‐bcr	   is	   the	   longer	   transcript,	   whereas	   the	   β2α2	   was	  
produced	   due	   to	   breakages	   in	   the	   5’	   end	   of	   the	   M-­‐bcr	   yielding	   shorter	  
transcripts	   (Melo,	  1997).	  Studies	  that	  examined	  the	  presence	  of	  a	  correlation	  
between	  the	  p210	  BCR-­‐ABL	  variants	  and	  CML	  disease	  prognosis	  had	  different	  
results.	   Some	   studies	   found	   that	   a	   correlation	   does	   exists;	   those	   studies	  
implied	   that	   the	   β3α2	   variant	   had	   a	   better	   prognosis	   and	   a	   longer	   chronic	  
phase	  than	  β2α2	  (Mills	  et	  al.,	  1988	  and	  Leibowitz	  et	  al.,	  1991),	  others	  found	  no	  
evidence	  (Shepherd	  et	  al.,	  1995).	  From	  this	  point	  onward	  the	  BCR-­‐ABL	  protein	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Figure	  1.8	  Schematic	  representation	  of	  the	  structural	  motifs	  of	  the	  p210	  BCR-­‐ABL	  protein.	  	  
The	   BCR	   part	   of	   the	   p210	   fusion	   protein	   is	   indicated	   by	   the	   red	   arrows	   and	   include	   the	  
oligomerization,	  the	  serine/threonine,	  and	  the	  GEF	  domains.	  The	  ABL	  part	  of	  the	  fusion	  protein	  
is	  indicated	  by	  the	  black	  arrows	  and	  include	  the	  SH2,	  the	  SH3,	  and	  the	  tyrosine	  kinase	  domains.	  	  
	  
1.3.5 BCR-­‐ABL	  Activity	  in	  CML	  
	  
How	   the	   BCR-­‐ABL	   protein’s	   activity	   leads	   to	   leukaemogenesis	   is	   of	   great	  
interest.	   There	   is	   no	   single	   protein,	   or	   one	   signalling	   pathway	   that	   has	   been	  
identified	   to	   cause	   leukaemogenesis.	   In	   fact	   a	   multi-­‐network	   of	   signalling	  
pathways	  and	  different	  proteins	  are	  involved	  in	  this	  process	  (Heisterkamp	  and	  
Groffen,	  2002).	  Therefore,	  the	  main	  pathways	  involved	  in	  leukaemogenesis	  of	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1.3.5.1 The	  RAS	  Pathway	  
	  
This	  pathway	  is	  a	  central	  signal	  transduction	  pathway	  that	  transmits	  signals	  
from	   several	   cell	   surface	   receptors	   to	   several	   transcription	   factors	   in	   the	  
nucleus.	  Ras	  protein	   is	  a	  small	  protein	  that	   is	  a	  common	  molecule	  for	  several	  
other	  signalling	  pathways.	  The	  protein	  is	  in	  its	  active	  form	  when	  bond	  to	  GTP,	  
and	  is	  inactive	  when	  bound	  to	  GDP.	  Thus,	  the	  regulation	  of	  the	  RAS	  protein	  can	  
be	   achieved	   by	   GTPase	   activating	   proteins	   and	   GEFs	   (guanine	   nucleotide	  
exchange	   factors).	  Mutations	   that	   result	   in	   the	   continuous	   expression	   of	   the	  
active	   RAS	   protein	   are	   observed	   in	   around	   30%	   of	   cancers	   (Steelman	   et	   al.,	  
2004).	  The	  Ras	  pathway	  is	  demonstrated	  in	  Figure	  1.9.	  	  	  




Figure	  1.9	  A	  Schematic	  diagram	  of	  the	  RAS	  pathway	  and	  the	  effects	  of	  the	  BCR-­‐ABL	  on	  it.	  	  
Illustrated	   is	   the	   RAS	   pathway.	   Under	   normal	   conditions	   the	   RAS	   pathway	  will	   be	   activated	  
through	  the	  activation	  of	  Shc	  via	  a	  stimulated	  cell	  surface	  receptor	  (not	  shown	  here).	  The	  Shc+	  
will	   recruit	  Grb2,	  activate	   it,	  and	   in	  turn	  Grb2+	  activates	  the	  downstream	  GDP	  bound	  RAS	  to	  
the	  GTP	  bound	  RAS.	  RAS+	  will	  activate	  RAF	  that	  in	  turns	  activates	  MEK	  that	  will	  activate	  ERK.	  
Finally	   ERK+	   activates	   p90Rsk-­‐1	   that	  will	  make	   its	  way	   to	   the	   nucleus	   and	   cause	   activation	   of	  
various	   transcriptional	   factors.	   It	   should	   also	   be	   noted	   that	   RAF	   can	   translocate	   to	   the	  
mitochondrial	  membrane	  and	  through	  the	  interactions	  with	  Bcl2	  family,	  especially	  BAD,	  cause	  
anti-­‐apoptosis	  effects	  by	  inactivation	  of	  the	  pro-­‐apoptotic	  protein	  BAD.	  Finally,	  the	  red	  arrows	  
from	  the	  fusion	  protein	   itself	  demonstrate	  the	  points	  at	  which	  the	  BCR-­‐ABL	  protein	  activates	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For	  activation	  of	  RAS,	  a	   cell	   surface	   receptor	   that	   can	  be	  a	  growth	   factor,	  
mitogen,	  or	  cytokine	  receptor,	  should	  be	   first	  simulated.	  This	  will	   lead	  to	  the	  
Shc	   adaptor	   protein	   to	   be	   associated	   with	   the	   simulated	   receptor.	   The	   Shc	  
adaptor	  protein	  will	  recruit	  the	  Grb2	  (growth	  factor	  receptor-­‐bound	  protein	  2)	  
and	   SOS	   (son	   of	   sevenless	   protein).	   This	   interaction	   leads	   to	   loading	   the	  
membrane	  bound	  RAS	  with	  a	  GTP,	  hence	  its	  activation	  (Steelman	  et	  al.,	  2011).	  
The	  activated	  RAS	  protein	  undergoes	  conformational	  change	  that	  leads	  to	  the	  
translocation	  of	  the	  RAF	  protein	  to	  the	  cell’s	  membrane	  where	  it	  binds	  to	  the	  
active	   RAS	   and	   will	   be	   activated	   by	   phosphorylation.	   The	   RAF	   protein	   is	  
involved	   in	   proliferation,	   differentiation,	   apoptosis	   induction,	   and	   further	   to	  
cytokine	   stimulation.	   In	   addition,	   over	   expression	   of	   this	   protein	   abolishes	  
cytokine	  dependence	  in	  the	  haematopoietic	  cells.	  	  
Furthermore,	   the	   activated	   RAF	   will	   in	   turn	   activate	   MEK1	   that	   in	   turn	  
activates	  ERK1	  and	  ERK2	  through	  phosphorylation	   (Steelman	  et	  al.,	  2011	  and	  
Steelman	  et	  al.,	  2004).	  This	  results	  in	  phosphorylation	  of	  transcription	  factors,	  
proliferation,	   and	   apoptosis	   inhibition	   (Steelman	   et	   al.,	   2004),	   which	   is	  
achieved	  directly	  through	  the	  activated	  ERK	  where	  it	  translocate	  to	  the	  nucleus	  
phosphorylation	  several	  transcription	  factors	  that	  in	  turn	  bind	  to	  promoters	  of	  
growth	   factors	   and	   cytokines.	   The	   activated	   ERK	   can	   further	   activate	  
downstream	   p90Rsk-­‐1	   that	   will	   influence	   gene	   expression	   (Steelman	   et	   al.,	  
2011).	  	  
Activated	  RAF	  protein	  can	  be	  translocated	  to	  the	  mitochondria	  (Hindley	  and	  
Kolch,	   2002)	   leading	   to	   the	   alteration	   of	   the	   mitochondrial	   distribution	   of	  
another	   downstream	   protein	   called	   BAD	   (Steelman	   et	   al.,	   2004),	   a	   pro-­‐
apoptotic	   protein	   that	   will	   be	   inactivated	   (Henson	   and	   Gibson,	   2006).	   This	  
alteration	  has	  been	  seen	  to	  prevent	  apoptosis	  in	  hematopoietic	  cells	  (Steelman	  
et	  al.,	  2004).	  Thus,	  the	  activation	  of	  this	  pathway	  plays	  a	  role	  in	  neoplasia	  and	  
to	  be	  more	  precise	  in	  leukaemogenesis.	  In	  CML	  the	  BCR-­‐ABL	  protein	  has	  direct	  
effects	   on	  many	   of	   the	   proteins	  within	   the	   RAS	   pathway.	   The	   effects	   of	   the	  
BCR-­‐ABL	  protein	  is	  through	  direct	  activation	  of	  Grb2	  (Puil	  et	  al.,	  1994,	  Chopra	  
et	  al.,	  1999	  and	  Steelman	  et	  al.,	  2011),	  SOS	  (Laurent	  et	  al.,	  2001	  and	  Steelman	  
et	  al.,	  2011),	  RAS	  and	  RAF	   (Steelman	  et	  al.,	  2004	  and	  Steelman	  et	  al.,	  2011).	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See	   Figure	   1.9.	   In	   summary,	   it	   can	   be	   concluded	   that	   the	   BCR-­‐ABL	   fusion	  
protein	  can	  play	  a	  role	  in	  CML	  development	  through	  the	  activation	  of	  the	  RAS	  
pathway.	  	  	  	  	   	   	  	  	  	  	  
	  
1.3.5.2 The	  Phosphatidylinositol	  3’	  Kinase	  Pathway	  
	  
In	  CML,	  BCR-­‐ABL	  protein	   is	   seen	   to	  activate	   the	  PI3K	  pathway	   (Zhu	  et	  al.,	  
2011,	  Naughton	  et	   al.,	   2009,	   Steelman	  et	   al.,	   2004,	   Chopra	  et	   al.,	   1999,	   and	  
Faderl	  et	  al.,	  1999).	  Phosphatidylinositol	  3’	  kinase	  (PI3K)	  is	  a	  protein	  made	  of	  2	  
subunits	  a	   catalytic	   subunit	   (p110)	  and	  a	   regulatory	   subunit	   (p85)	   (Chopra	  et	  
al.,	   1999).	   The	   protein’s	   activity	   is	   involved	   with	   cell	   division,	   cytoskeletal	  
organization,	  and	  inhibition	  of	  apoptosis	  (Steelman	  et	  al.,	  2004).	  The	  catalytic	  
subunit	  of	  the	  protein	  is	  the	  part	  that	  interacts	  with	  receptor	  and	  non-­‐receptor	  
protein	  tyrosine	  kinases	  leading	  to	  the	  activation	  of	  PI3K	  (Chopra	  et	  al.,	  1999).	  
In	   addition	   PI3K	   can	   also	   be	   activated	   through	   RAS	   (Steelman	   el	   al.,	   2004).	  
Once	  activated,	  the	  active	  PI3K	  will	  act	  on	  its	  substrate	  PIP2	  (phosphoinositide-­‐
4,	  5-­‐triphosphate)	  generating	  PIP3	  (phosphoinositide-­‐3,	  4,5-­‐triphosphate)	  that	  
will	   lead	   to	   the	   activation	   of	   PDK	   (Phosphoinositide-­‐dependent	   kinase)	   and	  
Akt.	   In	   addition,	   Akt	   is	   also	   a	   substrate	   for	   the	   active	   PDK,	   hence	   it	   will	   be	  
activated	  by	  that	  protein	  (Georgescu,	  2010).	  
From	  this	  point	  the	  activated	  Akt	  protein	  will	  lead	  to	  the	  phosphorylation	  of	  
several	   target	   sites,	   these	  will	   include	   the	  TSC2	  and	  PRS40,	  GSK3,	  and	  FOXO.	  
TSC2	  and	  PRAS40	  are	  two	  upstream	  inhibitors	  of	  RehB.	  RehB	  is	  a	  protein	  that	  
activates	  mTORC1,	  which	  is	  responsible	  for	  protein	  synthesis	  in	  cells.	  When	  Akt	  
phosphorylates	  TAC2	  and	  PRAS40,	  it	  will	  lead	  to	  their	  inactivation,	  hence	  there	  
will	   be	   no	   negative	   regulation	   of	   RehB	   and	   an	   increase	   in	   the	   activation	   of	  
mTORC1	  is	  established.	  The	  net	  result	  here	  is	  an	  increase	  in	  protein	  synthesis	  
(Georgescu,	   2010).	  Akt	   also	  negatively	   regulates	  GSK3,	   a	  protein	   that	  usually	  
signals	   apoptosis.	   When	   Akt	   phosphorylates	   GSK3,	   the	   latter	   is	   inhibited	  
leading	  to	  cell	  proliferation	  (Henson	  and	  Gibson,	  2006	  and	  Georgescu,	  2010).	  
Finally,	  FOXO	  proteins	  induce	  cell	  cycle	  arrest	  and	  apoptosis.	  They	  achieve	  this	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through	  regulating	  the	  expression	  of	  various	  cell	  cycle	  regulators,	  and	  through	  
up-­‐regulation	   of	   pro-­‐apoptotic	   members	   of	   the	   Bcl2	   family.	   The	   active	   Akt	  
protein	   again	   has	   a	   negative	   inhibitory	   effect	   on	   FOXO,	   thus	   leading	   to	   cell	  
survival,	  proliferation,	  and	  apoptosis	  resistance	  (Georgescu,	  2010).	  Figure	  1.10	  
summarises	  the	  PI3K	  pathway.	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Figure	  1.10	  Schematic	  Diagram	  of	  the	  PI3K	  pathway.	  	  
The	  PI3K	  pathway	  as	  demonstrated	  is	  rather	  a	  complex	  pathway.	  It	  is	  initiated	  by	  the	  activation	  
of	   PI3K	   that	   in	   turn	   leads	   to	   a	   series	   of	   lipid-­‐protein	   and	  protein-­‐protein	   interactions.	   These	  
interactions	   lead	   to	   the	   activation	   of	   the	   protein	   Akt.	   From	   here	   the	   protein	   negatively	  
regulates	   further	   downstream	   substrates	   that	   usually	   inhibit	   cell	   growth,	   proliferation	   and	  
protein	   synthesis.	  Akt	   negatively	   regulates	  downstream	  proteins	   leading	   to	   the	  net	   result	   of	  
cell	  growth	  and	  anti-­‐apoptosis.	  This	  complex	  pathway	  is	  activated	  in	  Philadelphia	  positive	  cells,	  
hence,	  the	  proliferation	  and	  apoptotic	  resistance	  of	  these	  cells.	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1.3.5.3 The	  JAK/STAT	  Pathway	  
	  
CML	  also	  affects	  the	  JAK	  (janus	  kinase)	  family	  of	  kinases	  which	  are	  activated	  
by	   signal	   transduction	   from	   cytokine	   receptors	   such	   IL-­‐3	   and	   GMCSFR	  
(granulocyte	   monocyte	   colony	   stimulating	   factor	   receptor).	   Activated	   JAK	  
protein	  will	   lead	   to	  activation	  of	   the	  STAT	   (signal	   transducer	  and	  activator	  of	  
transcription)	   protein	   through	   phosphorylation.	   In	   turn	   the	   activated	   STAT	  
proteins	  dimerize	  and	  move	   into	   the	  nucleus	  where	   they	  direct	   transcription	  
and	  regulate	  gene	  expression	  (Constantinescu	  et	  al.,	  2008)	  through	  binding	  to	  
specific	  DNA	  elements	  (Henson	  and	  Gibson,	  2006	  and	  Chopra	  et	  al.,	  1999).	  The	  
down-­‐regulation	   of	   the	   JAK/STAT	   pathway	   is	   achieved	   through	   the	   CIS/SOCS	  
proteins.	  Where	  the	  CIS	  proteins	  inhibit	  STATs	  and	  the	  SOCS	  proteins	  bind	  and	  
inhibit	   JAKs	   (Steelman	   et	   al.,	   2004).	   The	   activity	   of	   the	   JAK/STAT	   pathway	   is	  
highly	   increased	   in	   CML	   (Laurent	   et	   al.,	   2001),	   and	   the	   BCR-­‐ABL	   protein	   can	  
directly	  activate	  STAT	  (Steelman	  et	  al.,	  2004,	  Laurent	  et	  al.,	  2001	  and	  Noor	  et	  
al.,	   2011).	   This	   results	   in	   the	   growth	   factor	   independence	   observed	   in	   CML	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Figure	  1.11	  A	  Schematic	  diagram	  of	  the	  JAK/STAT	  pathway.	  	  
The	   JAK/STAT	  pathway	   is	   activated	   in	  CML,	   this	   is	   due	   to	   the	  direct	   activation	  effects	  of	   the	  
BCR-­‐ABL	   fusion	   protein	   on	   STAT.	   giving	   a	   net	   results	   of	   increased	   transcription	   and	   growth	  




The	   JAK/STAT	   pathway	   has	   also	   been	   found	   to	   be	   activated	   in	   BCR-­‐ABL	  
negative	  myeloproliferative	   leukaemias,	   thus	   emphasising	   the	   important	   role	  
of	  this	  pathway	  in	  leukaemogenesis.	  In	  these	  leukaemias,	  the	  activation	  of	  the	  
JAK/STAT	   pathway	   is	   initiated	   through	   a	   mutated	   JAK,	   where	   the	   protein	   is	  
constitutively	  activated	  and	  bypasses	  the	  need	  for	  cytokine	  receptor	  activation	  
(Constantinescu	  et	  al.,	  2008).	  Consequently,	  scientists	  have	  taken	  an	  interest	  in	  
developing	   Anti-­‐cancer	   drugs	   targeting	   this	   mutated	   protein	   (Knoops	   and	  
Constantinescu,	   2011	   and	   Noor	   et	   al.,	   2011).	   In	   summary,	   the	   JAK/STAT	  
pathway	  is	  involved	  in	  leukaemogenesis,	  and	  due	  to	  the	  effects	  of	  the	  BCR-­‐ABL	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1.3.5.4 Other	  Proteins	  Associated	  with	  BCR-­‐ABL	  Activity	  
	  
Other	  proteins	  that	  are	  associated	  with	  the	  activity	  of	  BCR-­‐ABL	  can	  include	  
Crk	   Like	   (CrkL)	   and	   SH2	   domain-­‐containing	   inositol	   5-­‐phosphatase	   (SHIP1)	  
proteins.	   CrkL	  protein	  has	  been	  noted	   to	  be	   associated	  with	   the	   fusion	  BCR-­‐
ABL	  protein,	  however,	  how	  this	  protein	  plays	  a	  role	  in	  haematopoietic	  diseases	  
and	  CML	   is	   still	  not	  understood	   (Sriram	  and	  Birge,	  2010).	   In	  spite	  of	   this,	   the	  
interaction	   between	   CrkL	   and	   the	   BCR-­‐ABL	   protein	   is	   confirmed	   and	   the	  
phosphorylation	   levels	   of	   CrkL	   are	   considered	   as	   a	   prognostic	   parameter	   for	  
CML	  patients	  (La	  Rosee	  et	  al.,	  2008	  and	  Xu	  et	  al,	  2011).	  A	  study	  done	  by	  Siriram	  
et	  al.	   in	  2011	  has	  revealed	  that	  a	  tyrosine	  phosphorylation	  site	  on	  the	  CrkL	   is	  
constitutively	  phosphorylated	  by	  BCR-­‐ABL,	   this	   further	  confirms	  that	   the	  CrkL	  
plays	  a	  role	  in	  CML;	  still	  more	  light	  is	  yet	  to	  be	  shed	  in	  this	  area.	  	  	  
SHIP1	   protein	   has	   been	   shown	   to	   regulate	   haematopoiesis	   in	   mice	   and	  
when	   disrupted	   leads	   to	   the	   development	   of	   myeloproliferative	   disorders	  
(Laurent	   et	   al.,	   2001).	   It	   is	   a	   negative	   regulator	   of	   the	   PI3K	   pathway	   by	  
hydrolysing	  5’	  phosphate	  of	  the	  PI3K	  substrate,	  PIP3,	  to	  its	  inactive	  form	  PIP2	  
(Ruschmann	   et	   al.,	   2010).	   It	   has	   also	   been	   documented	   that	   the	   BCR-­‐ABL	  
protein	  inhibits	  SHIP1	  (Steelman	  et	  al.,	  2004)	  by	  tyrosine	  phosphorylation.	  This	  
phosphorylation	  signals	  the	  proteasomal	  degradation	  of	  SHIP1	  (Ruschmann	  et	  
al.,	  2010),	  thus	  abolishing	  its	  negative	  control	  on	  the	  PI3K	  pathway.	  	  	  
	  
	  
1.3.5.5 BCR-­‐ABL	  and	  Protein	  Pathways:	  A	  Conclusion	  	  
	  
In	  conclusion,	  the	  BCR-­‐ABL	  has	  an	  upregulated	  tyrosine	  kinase	  activity.	  The	  
BCR-­‐ABL	   protein	   interacts	   with	   many	   other	   proteins	   that	   are	   involved	   in	  
different	  pathways	  (Brehme	  et	  al.,	  2009)	  leading	  to	  increased	  gene	  expression,	  
protein	   synthesis,	   cell	   proliferation,	   differentiation,	   growth	   factor	  
independence,	   and	   resistance	   to	   apoptosis.	   These	   effects	   all	   lead	   to	   the	  
developments	  of	  leukaemic	  transformation	  and	  the	  development	  of	  CML.	  	  
	  	   42	  
The	   BCR-­‐ABL	   activated	   pathways	   involve	   the	   RAS	   pathway,	   the	   PI3K	  
pathway,	   the	   JAK/STAT	   pathway	   and	   other	   proteins	   such	   as	   CrkL	   and	   SHIP.	  
These	  pathways	  are	  non-­‐linear	  and	  are	  very	  complex	  as	  discussed	  above.	  The	  
BCR-­‐ABL	  protein	  can	  cause	  activation	  of	  these	  pathways	  at	  different	  levels	  and	  
can	  also	  deactivate	  some	  negative	  regulatory	  events.	  This	  makes	  targeting	  the	  
BCR-­‐ABL	  fusion	  protein	  a	  highly	  appealing	  approach	  for	  CML	  therapy.	  
	  
	  
1.4 CML	  and	  Therapy	  
	  
Like	   all	   cancers,	   the	   treatment	   approach	   in	   CML	   is	   multiple	   sessions	   of	  
chemotherapy	  via	   the	  usage	  of	  drug	  cocktails	   (Hoffbrand	  et	  al.,	   2006).	  Drugs	  
for	  the	  disease	  have	  been	  developed	  over	  the	  years,	  differing	   in	  their	  actions	  
and	   target	   sites.	  Historically,	   drugs	   such	   as	   busulfan	   and	  hydroxyurea,	  which	  
fall	  under	  the	  name	  of	  cytoreductive	  chemotherapy,	  were	  used	  to	  control	  the	  
WBC	  of	  patients	  with	  CML.	  However,	   this	  kind	  of	   treatment	  has	  not	   stopped	  
the	  disease	  progressing	  to	  the	  accelerated	  phase	  and	  the	  blastic	  phase	  (Fausel,	  
2007).	   Then	   interferon	   (IFN)	   was	   developed	   and	   used.	   This	   drug	   showed	   a	  
complete	   haematologic	   response	   in	   50%	  of	   patients.	  However,	   IFN's	   adverse	  
effects,	   toxicity,	   cost	   effectiveness,	   and	   inconvenience	   limited	   its	   benefits.	  
Therefore,	  new	  strategies	  of	  treatment	  were	  required	  (Fausel,	  2007).	  
	  
	  
1.4.1.1 Current	  Drug	  Treatment	  for	  CML	  
	  
With	  further	  understanding	  of	  the	  molecular	  pathology	  of	  CML,	  new	  drugs	  
have	  been	  designed	  and	  developed.	  These	  drugs	  aimed	  at	   inhibiting	   the	  ABL	  
tyrosine	   kinase	   activity	   (Milojkovic	   and	   Apperiey,	   2008,	   Puttini	   et	   al.,	   2008)	  
therefore,	  are	  named	  tyrosine	  kinase	  inhibitors	  (TKI).	  	  Three	  generations	  of	  TKI	  
exist:	   first	  generation	  TKI	   include	   Imatinib,	  which	  to	  date	   is	   the	  most	  popular	  
drug	   for	   CML.	   Second	   generation	   TKI	   include	  Dasatinib	   and	  Nilotinib.	   Finally,	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the	  third	  generation	  TKI	  include	  Ponatinib	  and	  Bosutinib.	  Ponatinib	  is	  in	  clinical	  
phase	  II	  (Vaidya	  et	  al.,	  2011),	  while	  Bosutinib	  has	  just	  finished	  phase	  III	  clinical	  
trials	  (Shieh	  et	  al.,	  2011).	  	  
Imatinib,	   also	   known	   as	   STI571,	   is	   a	   drug	   made	   by	   Novartis	   and	   has	   a	  
commercial	   name	   of	   Gleevec	   or	   Glivec	   (Druker,	   2002).	   The	   drug	   works	   by	  
competing	   with	   adenosine	   triphosphate	   (ATP)	   for	   its	   binding	   site	   to	   the	  
BCR/ABL	  gene	  product.	  This	  inhibits	  the	  tyrosine	  kinase	  activity	  of	  the	  mutated	  
gene,	   hence	   inhibiting	   its	   autophosphorylation,	   and	   subsequent	   activation	  of	  
all	   its	  protein	   substrates	   that	   are	   involved	   in	   the	   various	  pathways	  discussed	  
earlier.	   This	   will	   finally	   lead	   to	   the	   decrease	   in	   WBC	   proliferation	   and	   cell	  
survival	  (Fausel,	  2007	  and	  Stentoft	  et	  al.,	  2001).	  See	  Figure	  1.12.	  Chronic	  phase	  
patients	  on	  imatinib	  showed	  a	  90%	  complete	  haematologic	  response.	  The	  drug	  
initially	  showed	  promising	  outcomes,	  however,	  cases	  of	  drug	  resistance	  quickly	  























Figure	  1.12	  The	  mechanism	  of	  BCR-­‐ABL	  inhibition	  by	  Imatinib.	  	  
In	   CML,	   BCR-­‐ABL	   is	   able	   to	   phosphorylate	   downstream	  proteins	  when	   bound	   to	  ATP,	   and	   is	  
therefore	   termed	  “active”	   in	   this	   state.	  The	  BCR-­‐ABL	  protein	   switches	   from	  being	  active	  and	  
inactive.	  When	  BCR-­‐ABL	  is	  in	  its	  inactive	  state,	  Imatinib	  binds	  to	  the	  protein	  at	  its	  ATP	  binding	  
site,	   locking	   the	   protein	   in	   its	   inactivated	   form,	   consequently,	   inactivating	   the	   protein	  
pathways	  responsible	  for	  leukaemogenesis.	  
	  
	  
1.4.1.2 Mechanisms	  of	  Imatinib	  Drug	  Resistance	  in	  CML	  	  
	  
Drug	   resistance	   to	   Imatinib	   can	   be	   classified	   into	   primary	   and	   secondary	  
resistance.	  Patients	  with	  primary	  resistance	  illustrate	  a	  lack	  of	  effectiveness	  to	  
the	   drug	   from	   the	   start	   of	   treatment.	   Those	   with	   secondary/acquired	  
resistance	   show	  a	   loss	   in	  haematologic,	   cytogenetic	   and	  molecular	   response.	  
The	  mechanisms	  by	  which	   resistance	   to	   Imatinib	  develop	   can	  be	  either	  BCR-­‐
ABL	  dependent	  or	  independent	  (Vaidya	  et	  al.,	  2011).	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1.4.1.2.1 	  BCR-­‐ABL	  Independent	  Mechanisms	  of	  Drug	  Resistance	  	  
	  
BCR-­‐ABL	   independent	   mechanisms	   include	   the	   persistence	   of	   insensitive	  
haematopoietic	  stem	  cells;	  these	  cells	  seem	  to	  be	  persistent	  due	  to	  their	  over	  
expression	   of	   the	   BCR-­‐ABL	   protein	   (Vaidya	   et	   al.,	   2011).	   Plasma	   enzymes	  
inactivate	  Imatinib	  by	  binding	  and	  metabolizing	  it.	  This	  also	  demonstrates	  that	  
the	  drug’s	  plasma	   levels	  do	  not	   reflect	   the	  actual	   concentrations	  of	   the	  drug	  
within	   the	   CML	   cells	   (Gambacorti-­‐Passerini	   et	   al.,	   2003).	   Another	   BCR-­‐ABL	  
independent	   mechanism	   includes	   drug	   efflux.	   Drug	   efflux	   alters	   the	  
intracellular	  availability	  of	  the	  drug.	  It	  has	  been	  shown	  that	  some	  CML	  patients	  
resistant	  to	  Imatinib	  over	  express	  proteins,	  such	  as	  P-­‐glycoprotein,	  responsible	  
for	   imatinib	   efflux.	   When	   those	   patients	   were	   treated	   with	   P-­‐glycoprotein	  
inhibitor	   their	   sensitivity	   to	   Imatinib	   was	   increased	   (Jabbour	   et	   al.,	   2011).	  
Finally,	   Imatinib	  resistance	  independent	  from	  BCR-­‐ABL	  can	  also	  be	  due	  to	  the	  
activation	  of	  the	  pathways	  implicated	  in	  CML	  due	  to	  mutations	  in	  the	  different	  
proteins	   involved	   in	   these	   pathways.	   Many	   studies	   have	   demonstrated	   that	  
mutations	   in	  proteins	   involved	   in	  any	  of	  the	  three	  main	  pathways	   involved	   in	  
leukaemogenesis	   can	   independently	   lead	   to	   CML	   or	   a	   myeloproliferative	  
disorder.	   Nambu	   et	   al.,	   2010,	   showed	   that	   one	   mechanism	   of	   independent	  
resistance	  was	  the	  phosphorylation	  of	  ERK1	  and	  2.	  Scientists	  here	  developed	  a	  
K562R	   cell	   line	   that	   is	   highly	   resistant	   to	   imatinib	   and	   had	   phosphorylated	  
ERK1/2,	   STAT	   5	   and	   Akt	   proteins.	   When	   treated	   with	   Imatinib,	   the	   drug	  
reduced	   the	   phosphorylation	   of	   all	   proteins	  with	   the	   exception	   of	   ERK1	   and	  
ERK2.	   A	   study	   done	   by	   Esposito	   et	   al.,	   2011,	   found	   that	   the	   levels	   of	   SHIP1	  
were	   decreased	   in	   cell	   lines	   resistant	   to	   imatinib,	   suggesting	   it	   as	   another	  
mechanism	   for	   independent	   resistance.	   Another	   study	   showed	   that	   five	   cell	  
lines,	  all	  resistance	  to	  Imatinib,	  had	  an	  increase	  in	  activity	  of	  the	  PI3K	  pathway	  
due	  to	  a	  mutation	  in	  PI3K	  making	  the	  protein	  continuously	  active	  (Quentmeier	  
et	  al.,	  2011).	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1.4.1.2.2 	  BCR-­‐ABL	  Dependent	  Mechanisms	  of	  Drug	  Resistance	  	  
	  
The	  BCR-­‐ABL	  dependent	  resistance	  to	  Imatinib	  can	  be	  classified	  into	  three	  
categories.	   Resistance	   due	   to	   mutations	   within	   the	   tyrosine	   kinase	   domain,	  
outside	  the	  tyrosine	  kinase	  domain,	  and	  resistance	  due	  to	  over	  expression	  of	  
BCR-­‐ABL.	  Mutations	  within	  the	  tyrosine	  kinase	  domain	  all	  result	  in	  the	  inability	  
of	   the	   drug	   to	   bind	   to	   its	   target	   site	   on	   the	   BCR-­‐ABL	   protein	   (Vaidya	   et	   al.,	  
2011).	  An	  example	  is	  the	  T315I	  mutation	  that	  is	  the	  first	  BCR-­‐ABL	  mutation	  to	  
be	   discovered	   leading	   to	   Imatinib	   resistance	   (Gorre	   et	   al.,	   2001).	   Mutations	  
outside	   the	  kinase	  domain	   include	  mutations	   in	   the	  Cap,	  SH3,	  SH2,	  and	  SH3-­‐
SH2	   linker	  domains.	  These	  domains	  are	  usually	   responsible	   for	  autoinhibition	  
of	  the	  c-­‐ABL	  protein;	  therefore,	  when	  mutated	  they	  will	  lead	  to	  the	  activation	  
of	   the	   tyrosine	   kinase	   (Sherbenou	   et	   al.,	   2010	   and	   Vaidya	   et	   al.,	   2011).	  
Resistance	   due	   to	   over-­‐expression	   of	   the	   BCR-­‐ABL	   protein	   develops	   because	  
the	   BCR-­‐ABL	   protein	   is	   over	   expressed	   to	   a	   point	  where	   it	   can	   no	   longer	   be	  
inhibited	  by	  the	  therapeutic	  dosage	  (Vaidya	  et	  al.,	  2011).	  	  
As	   demonstrated	   a	  wide	   range	   of	   resistant	  mechanisms	   exist	   against	   the	  
first	   generation	   TKI	   Imatinib	   leading	   to	   drug	   resistance	   in	   CML.	   Mutations	  
leading	   to	   drug	   resistance	   can	   occur	   at	   any	   stage	   of	   the	   disease	   and	   is	   not	  
limited	   to	   the	  accelerated	  or	  blast	  phase	  of	   the	  disorder	   (Roche-­‐Lestienne	  et	  
al.,	   2002).	   Therefore,	   other	   TKI	   were	   developed.	   These	   include	   second	   and	  
third	  generation	  TKI	  (Vaidya	  et	  al.,	  2011).	  
	  
	  	  	  	  
1.4.2 Second	  and	  third	  generation	  TKI	  
	  
	  New	   second	   generation	   TKIs	   for	   relapsed	  patients,	   resistant	   to	   Imatinib,	  
have	  been	  developed.	  These	   include	  a	  drug	  called	  Dasatinib	   (Steinberg,	  2007	  
and	  Talpaz	  et	  al.,	  2006),	  developed	  by	  Bristol	  Pharmaceuticals	   in	  Switzerland,	  
and	   FDA	   approved	   in	   October	   2010	   (Shieh	   et	   al.,	   2011),	   and	   another	   called	  
Nilotinib.	  The	  latter	   is	  developed	  by	  Novartis	   in	  the	  USA	  (Vaidya	  et	  al.,	  2011),	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and	  was	  FDA	  approved	  in	  June	  2010	  (Eskazan	  et	  al.,	  2011	  and	  Faber	  et	  al.,	  2010	  
and	  Shieh	  et	  al.,	  2011).	  These	  drugs	  were	  developed	  due	  to	  the	  cases	  of	  CML	  
patient	   relapse.	   Nilotinib	   shows	   10-­‐25	   fold	   more	   potency	   then	   the	   drug	  
Imatinib,	  whereas	  Dasatinib	  shows	  between	  100-­‐300	  fold	  greater	  activity.	  	  CML	  
drug	   resistance	   to	   Nilotinib	   has	   also	   developed,	   and	   in	   some	   cases	   can	   be	  
overcome	  by	  treatment	  with	  Dasatinib	  (Okabe	  et	  al.,	  2011).	  Nevertheless,	  the	  
first	   BCR-­‐ABL	   mutation	   to	   give	   rise	   to	   imatinib	   drug	   resistance	   remains	  
resistant	  to	  all	  three	  drugs	  discussed	  above	  (Skaggs	  et	  al.,	  2006).	  
Third	  generation	  drugs,	  Ponatinib	  and	  Bosutinib,	  are	  in	  clinical	  phases	  with	  
Bosutinib	   recently	   just	   completed	   phase	   III	   clinical	   trials	   (Shieh	   et	   al.,	   2011).	  
Data	   from	   the	   third	   generation	   TKI	   are	   yet	   to	   be	   collected	   and	   evaluated.	  
Meanwhile,	  TKI	  available	   for	  CML	  treatment	  can	  be	  used	   for	  CML	  patients	   in	  
any	   phase	   of	   the	   disease,	   with	   always	   a	   better	   prognosis	   when	   used	   in	   the	  
chronic	  phase.	  	  
However,	  these	  drugs	  are	  only	  treatments	  not	  cures	  for	  CML.	  Patients	  tend	  
to	   relapse,	   and	   the	   issue	   of	   drug	   side	   effects	   still	   remain.	   These	  will	   include	  
toxicity,	   fluid	   retention,	   cardiac	   toxicity,	   platelet	   dysfunction	   and	   bleeding,	  
immunosuppression,	  proinflammatory	  effects,	  and	  gastrointestinal	  side	  effects	  
(Shieh	  et	  al.,	  2011).	  The	  only	  cure	  available	  for	  this	  disease	  to	  date	  is	  allogeneic	  
BM	   transplants	   (Fausel,	   2007).	   Nevertheless,	   BM	   transplants	   are	   limited	   to	  
younger	  patients	  (patients	  with	  CML	  are	  usually	  diagnosed	  between	  ages	  50	  –	  
60)	   and	   the	   availability	   of	   an	   appropriate	   HLA	   matching	   donor	   (Advani	   and	  
Pendergast,	   2002).	   Thus,	  making	  modulation	   of	   gene	   expression	   a	   promising	  
strategy	  for	  potential	  CML	  treatment.	  
	  
	  
1.5 Modulation	  of	  gene	  expression	  
	  
Various	  strategies	  exist	  for	  modulating	  gene	  expression,	  and	  expression	  can	  
be	   increased,	   decreased	   or	   even	   abolished	   (Lavrovsky	   et	   al.,	   1997).	   For	   the	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purpose	  of	  this	  study,	  only	  those	  that	  decrease	  or	  abolish	  gene	  expression	  will	  
be	  considered.	  	  
Strategies	  that	  abolish	  gene	  expression	  can	  act	  at	  different	  molecular	  levels.	  
These	  will	   include	   intervention	   at	   pre-­‐transcription	   (DNA),	   post	   transcription	  
(RNA),	   or	   post	   translational	   levels	   (protein).	   In	   past	   years,	   studies	   in	   down-­‐
regulating	   gene	   expression	   have	   focused	   on	   specific	   areas.	   These	   are,	   the	  
formation	   of	   DNA	   triple	   helices,	   antisense,	   ribozyme,	   and	   RNA	   interference	  
(RNAi)	  technologies.	  Each	  approach	  has	  its	  own	  advantages	  and	  disadvantages,	  
depending	   on	   the	   nature	   of	   the	   pathological	   condition	   (Karagiannis	   and	   El-­‐
Osta,	  2005	  and	  Lavrovsky	  et	  al.,	  1997).	  
	  
	  
1.5.1 DNA	  triple	  helices	  	  
	  
DNA	  triple	  helices,	  also	  known	  as	  triplex	  forming	  oligonucleotides	  (TFO),	  are	  
short	  oligonucleotides	  designed	  to	  be	  complementary	  to	  a	  regulatory	  region	  in	  
a	  gene	  (Duca	  et	  al.,	  2008).	  Hence	  the	  binding	  of	  the	  TFO	  to	  their	  specific	  target	  
sites	  in	  the	  major	  grove	  of	  the	  double-­‐stranded	  DNA,	  results	  in	  the	  formation	  
of	  a	  triple	  helix	  (Arya,	  2011).	  The	  resultant	  triple	  helix	  will	  block	  the	  binding	  of	  
various	   DNA	   binding	   proteins,	   such	   as	   endonucleases,	   transcription	   factors,	  
DNA	  methylating	   enzymes	   and	   polymerases,	   resulting	   in	   down	   regulation	   of	  
gene	   expression	   (Lavrovsky	   et	   al.,	   1997).	   One	   example	   of	   the	   use	   of	   TFO	  
technology	  to	  target	  the	  fusion	  gene	  in	  CML	  is	  a	  study	  done	  by	  Rapozzi	  et	  al.	  
2002.	   In	  this	  study	  a	  13-­‐mer	  TFO	  targeting	  the	  BCR-­‐ABL	  promoter	  region	  was	  
designed.	   The	   TFOBCR-­‐ABL	   showed	   down	   regulation	   of	   the	   BCR-­‐ABL	   mRNA	  
expression	  in	  K562	  cell	  lines.	  	  
Although	   TFO	   are	   attractive	   tools	   for	   modulating	   gene	   expression,	  
limitations	   do	   exist.	   These	   include	   the	   dependency	   of	   the	   presence	   of	   an	  
oligopyrimidine/oligopurine	   in	  the	  DNA	  target	  site	  for	  binding,	  stability	  of	  the	  
triple	  helix	   (Duca	  et	  al.,	   2008),	   inefficient	   cellular	  uptake,	   insufficient	  nuclear	  
internalization	  and	  oligonucleotide	  aggregation	  (Rapozzi	  et	  al.,	  2002).	  	  	  
	  	   49	  
1.5.2 Antisense	  oligonucleotides	  
	  
This	   technology	   involves	   molecules	   that	   modulate	   gene	   expression	   by	  
targeting	   mRNA	   sequences,	   and	   uses	   antisense	   oligonucleotides	   of	   single-­‐
stranded	   DNA	   or	   RNA	   molecules.	   These	   sequences	   are	   13-­‐25	   nt	   long,	  
complementary	   to	   a	   specific	   site	   on	   the	   mRNA	   molecule	   of	   the	   gene	   of	  
interest,	  and	  the	  binding	  results	   in	  the	  formation	  of	  sequence	  specific	  double	  
helices.	   The	  use	  of	   synthesized	  phosphodiester	  oligonucleotides	  have	  proven	  
to	  be	  of	  limited	  use.	  This	  is	  because	  these	  oligonucleotides	  are	  easily	  degraded	  
by	   intracellular	   endo-­‐	   and	   exo-­‐nucleases.	   Therefore,	   attempts	   to	   chemically	  
modify	   these	   synthesized	   oligonucleotides	   have	   been	  made	  with	   the	   overall	  
purpose	   to	   gain	   more	   stable,	   nuclease	   resistant,	   high	   mRNA	   target	  
hybridization	  affinity	  oligonucleotides.	  Dias	  and	  Stein	  reviewed	  these	  chemical	  
modifications,	  in	  2002	  (Dias	  and	  Stein,	  2002).	  	  
The	   double-­‐helix	   formation	   may	   then	   down-­‐regulate	   gene	   expression	   in	  
two	  ways:	  one	   is	   by	  blocking	   the	   translation	  of	   the	  bonded	  mRNA	  molecule,	  
and	  the	  other,	   is	  through	  the	  activation	  of	  cellular	  ribonuclease	  called	  RNase-­‐
H.	   This	   ribonuclease	   specifically	   cleaves	   RNA	   that	   is	   in	   a	   RNA-­‐DNA	   hybrid.	  
Theoretically,	  only	  the	  desired	  gene	  will	  be	  affected,	  making	  this	  technology	  an	  
effective	  and	  powerful	  tool	  in	  gene	  expression	  modulation	  of	  various	  diseases	  
and	  disorders	  (Dias	  and	  Stein,	  2002	  and	  Lavrovsky	  et	  al.,	  1997).	  	  
The	  use	  of	  antisense	  oligonucleotides	  has	  been	  applied	  to	  target	  the	  mRNA	  
of	   the	   BCR-­‐ABL	   gene	   in	   CML.	   Though	   it	   was	   reported	   to	   be	   successful	   in	  
reducing	  the	  mRNA	  expression	   in	  SCID	  mouse	  tissue,	  previously	   injected	  with	  
Ph+	  CML	  blast	  crisis	  cell	  line,	  and	  increased	  the	  duration	  of	  survival	  in	  treated	  
mice	  (Agarwal	  and	  Gewirtz,	  1999).	  Its	  clinical	  applications	  have	  been	  held	  back	  
due	   to	   lack	   of	   stability,	   and	   the	   requirements	   of	   high	   dosages	   to	   achieve	   an	  
anti-­‐leukaemic	   effect.	   These	   dosages	   can	   also	   lead	   to	   unspecific	   binding	   and	  
off-­‐target	  toxicity	  (Quintas-­‐Cardama,	  2008).	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1.5.3 Ribozymes	  	  	  	  	  
	  
Ribozymes	   are	   RNA	   structures	   with	   a	   specific	   catalytic	   activity.	   They	   are	  
able	   to	  bind	   to	  other	  RNA	  molecules;	   thus	  breaking	  and/or	   forming	   covalent	  
bonds	   with	   extraordinary	   specificity,	   thereby	   accelerating	   the	   rate	   of	   these	  
reactions	  (Castanotto	  et	  al.,	  2002).	  	  
Naturally	   occurring	   ribozymes	   act	   in	   a	   cis	   manner.	   These	   include	  
hammerhead	   and	   hairpin	   ribozymes,	   that	   are	   derived	   from	   plants,	   RNase	   P	  
(Kijima	   et	   al.,	   1995),	   and	   group	   I	   and	   group	   II	   ribozymes	   that	   are	   found	   as	  
introns	   in	   organelles	   and	   bacteria	   (James	   and	   Gibson,	   1998).	   However,	  
ribozymes	  can	  be	  also	  engineered	  to	  act	  in	  a	  trans-­‐acting	  manner	  (Castanotto	  
et	  al.,	  2002	  and	  Kijima	  et	  al.,	  1995).	  	  
In	   the	   hammerheads,	   hairpins	   and	   group	   I	   introns,	   the	   specificity	   of	   a	  
ribozyme	   to	   a	   particular	   target	   site	   depends	   on	   base-­‐pairing	   between	   the	  
ribozyme	  and	  its	  RNA	  target	  (Kijma	  et	  al.,	  1995).	   In	  the	  RNase	  P	  ribozymes,	   it	  
depends	  on	  the	  pairing	  of	  a	  guide	  RNA	  with	  the	  RNA	  target	  (Castanotto	  et	  al.,	  
2002),	  while	   in	  cases	  of	  group	   II	   introns	   it	   is	  contingent	  on	  the	  pairing	  of	   the	  
ribozyme	  to	  its	  target	  DNA	  (Lewin	  and	  Hauswirth,	  2001).	  
Once	   the	   ribozyme	   is	   attached	   to	   its	   target	   site,	   it	   will	   form	   a	   specific	  
complex	  that	  will	  catalyse	  the	  hydrolysis	  of	   the	  phosphodiester	  bonds,	  hence	  
cleaving	   the	   target	   RNA	   (Lavrovsky	   et	   al.,	   1997).	   These	   properties	   make	  
ribozymes	  useful	   tools	   in	   gene	   therapy	   (Kijma	  et	  al.,	   1995)	   especially	   against	  
HIV	  and	  cancer	  (Mulhbacher	  et	  al.,	  2010).	  Ribozymes	  have	  been	  also	  previously	  
used	  against	  the	  mRNA	  of	  the	  BCR-­‐ABL	  gene.	  A	  reduction	  in	  the	  mRNA	  levels	  
was	   observed	   in	   several	   studies	   (Lange	   et	   al.,	  1994,	  Mendoza-­‐Maldonado	   et	  
al.,	   2002),	   however,	   other	   studies	  didn’t	   replicate	   these	   findings	  but	   showed	  
nonspecific	   cleavage	   of	   the	   normal	   c-­‐ABL	   mRNA	   (James	   et	   al.,	   1996).	  
Limitations	  of	  ribozymes	  exist,	  these	  include	  ribozyme	  stability,	  efficient	  target	  
binding,	   co-­‐localization	   of	   target	   and	   ribozyme,	   and	   specificity	   of	   delivery	  
(Castanotto	  et	  al.,	  2002	  and	  James	  and	  Gibson,	  1998).	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1.5.4 RNA	  interference	  
	  	  
In	  1998,	  Fire	  et	  al.	  observed	  that	  double	  stranded	  RNA	  (dsRNA)	  in	  C.elegans	  
caused	   a	   substantially	  more	   effective	   RNA	   interference	   than	   using	   either	   an	  
individual	   sense	   or	   anti-­‐sense	   strand	   to	   modify	   gene	   expression.	   From	   that	  
point	  on	  the	  process	  of	  RNA	  interference	  (RNAi)	  was	  discovered.	  RNAi	  quickly	  
become	  evident	  as	  an	  ancient	  process.	   It	   is	  now	  known	  to	  be	   the	  oldest	  and	  
most	  ubiquitous	  antiviral	  system	  in	  plants	  and	  animals,	  where	  RNAi	  is	  seen	  to	  
be	   linked	   with	   post-­‐transcriptional	   gene	   silencing	   in	   the	   above	   organisms	  
(Sharp,	  2001	  and	  Elbashir	  et	  al.,	  2001).	  	  
	  
	  
1.5.4.1 The	  Mechanism	  of	  RNAi	  
	  
Basically,	   RNAi	   is	   the	   process	   whereby	   a	   double-­‐stranded	   RNA	   (dsRNA)	  
induces	  sequence	  specific	  post-­‐transcriptional	  gene	  silencing.	  The	  dsRNA	  (>30	  
bp)	  does	  this	  by	  generating	  specific	  21-­‐	  and	  22-­‐	  nucleotide	  (nt)	  RNA	  fragments	  
(Elbashir	  et	  al.,	  2001).	  These	  fragments	  are	  generated	  by	  the	  cleaving	  action	  of	  
a	   RNase-­‐III	   family	   nuclease	   called	   "dicer",	   which	   is	   believed	   to	   be	   the	   first	  
initiating	   step	   in	   RNAi	   (Bernstein	   et	   al.,	   2001)	   and	   the	   fragments	   are	   called	  
short	  interfering	  RNAs	  (siRNAs)	  (Cullen,	  2002,	  and	  Elbashir	  et	  al.,	  2001).	  	  
Dicer	   is	   associated	  with	  another	  protein	   called	  TRBP.	  The	   last	   recruits	   the	  
RNA	  endonuclease	  Ago2	  (Chendrimada	  et	  al.,	  2005).	  Ago2	  is	  also	  the	  catalytic	  
component	   of	   the	   RNA-­‐induced	   silencing	   complex	   (RISC)	   (Matranga	   et	   al.,	  
2005).	   The	   double	   stranded	   siRNA	   gets	   loaded	   onto	   Ago2	   nuclease,	   and	   the	  
passenger	  strand	  (sense	  strand)	  of	  the	  siRNA	  molecule	  is	  cleaved	  by	  the	  action	  
of	   this	  protein.	  This	  cleavage	  occurs	  9-­‐10	  nt	  counting	   from	  the	  5’	  end	  of	   this	  
strand	  (Rand	  et	  al.,	  2005).	  This	  leads	  to	  the	  activation	  of	  the	  RISC	  complex	  that	  
is	  guided	  by	   the	  siRNA	  guide	  strand	   (anti-­‐sense	  strand)	   to	   its	  complementary	  
target	  mRNA	   causing	   its	   degradation	   by	   the	   endonuclease	   activities	   of	   Ago2	  
(Matranga	  et	  al.,	  2005).	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In	   summary,	   the	   Dicer	   generated	   siRNA	   fragments	   are	   the	  mediators	   for	  
RNAi	   and	   they	  do	  not	  exist	   independently.	   They	  are	   found	  associated	  with	  a	  
number	  of	  proteins,	  which	  are	  still	  being	  studied	  in	  order	  to	  shed	  more	  light	  on	  
their	   structure	   and	   how	   they	   contribute	   in	   the	   RNAi	   pathway	   (Wang	   et	   al.,	  
2009).	   Together	   these	  molecules	   form	   complexes	   called	   silencing	   complexes	  
that	  recognize	  their	  single-­‐stranded	  mRNA	  targets	  in	  a	  highly	  sequence	  specific	  
manner.	  The	  silencing	  complexes	  will	  then	  cause	  direct	  cleavage	  of	  their	  target	  
sites,	   thus	   destroying	   any	   mRNAs	   that	   perfectly	   match	   the	   guiding	   siRNA	  
strands.	   This	   will	   prevent	   the	   mRNA	   molecule(s)	   from	   being	   translated	   into	  
protein.	   It	   should	  also	  be	  noted	   that	  even	  with	  a	   single	  nucleotide	  mismatch	  
between	  the	  siRNA	  and	  its	  target,	  the	  effect	  is	  greatly	  diminished	  and	  may	  be	  
even	  eliminated	  entirely	  (Dykxhoorn	  et	  al.,	  2003),	  making	  RNAi	  a	  highly	  precise	  
and	  very	  specific	  tool.	  Figure	  1.13	  illustrates	  this	  process.	  Since	  the	  discovery	  of	  
RNAi,	  this	  process	  has	  been	  used	  for	  various	  loss	  of	  function	  studies	  and	  other	  
therapeutic	   approaches,	   which	   will	   be	   discussed	   later	   on.	   To	   date	   the	  
application	   of	   RNAi	   has	   been	  mediated	   through	   synthetic	   siRNA,	   microRNA,	  
and	  short	  hairpin	  RNA	  (shRNA)	  molecules.	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Figure	  1.13	  Schematic	  diagram	  of	  RNAi	  mechanism.	  
dsRNA	   is	   recognised	  by	   the	  protein	  Dicer	   to	  which	   it	  binds.	  Once	  bound,	   the	  TRBP	  protein	  
associated	  with	  Dicer	   recruits	   the	  RSIC	  complex	  and	   the	  dsRNA	  gets	   loaded	  onto	   the	  Ago2	  
protein	  within	  the	  complex.	  The	  endonuclease	  action	  of	  Ago2	  cleaves	  the	  passenger	  strand,	  
shown	   in	  blue,	   and	   the	  RISC	   is	   then	  activated.	   The	  guide	   strand,	   shown	   in	   red,	  directs	   the	  
activated	   complex	   to	   its	   complementary	   mRNA.	   The	   antisense	   strand	   binds	   to	   its	   target	  
mRNA	  and	  through	  the	  nuclease	  action	  of	  Ago2,	   the	  target	  mRNA	  will	  be	  cleaved	  10-­‐12	  nt	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1.5.4.2 MicroRNAs	  
	  
MicroRNAs	   (miRNAs)	   are	   a	   group	   of	   endogenously	   expressed	   small	   RNA	  
molecules	  that	  are	  encoded	  by	  genes	  present	  in	  the	  host’s	  genome.	  miRNAs	  do	  
not	   lead	   to	   protein	   production,	   instead	   they	   act	   as	   regulators	   for	   mRNA	  
expression.	   miRNAs	   are	   single	   stranded	   21-­‐23	   nt	   long	   molecules	   that	   are	  
produced	  by	   the	  cleavage	  of	  70-­‐90	  nt	  shRNA	  precursor	  by	   the	  enzyme	  Dicer.	  
This	  shRNA	  precursor	  is	  also	  known	  as	  pre-­‐miRNA	  (Terasawa	  et	  al.,	  2011).	  The	  
miRNA	   molecules	   go	   on	   to	   associate	   with	   RISC	   that	   in	   turn	   induces	  
translational	  repression	  by	  blocking	  the	  ribosomal	  translation	  (Karagiannis	  and	  
El-­‐Osta,	  2005),	  and	  leading	  to	  inhibition	  of	  the	  translation	  of	  the	  target	  mRNA.	  
Translational	   inhibition	  occurs	  when	  the	  miRNAs	  are	  partially	  complementary	  
to	  the	  3’	  untranslated	  region	  of	  their	  target	  sites.	  However,	  if	  the	  miRNAs	  are	  
completely	   complementary	   to	   their	   targets,	   they	  will	   act	   in	   a	  way	   similar	   to	  
siRNA	  molecules.	  Hence,	  by	  causing	  cleavage	  and	  degradation	  of	  their	  targets,	  
see	  figure	  1.14.	  	  
miRNA	   molecules	   have	   been	   identified	   in	   many	   multi-­‐cellular	   organisms	  
such	   as	   fruit	   flies,	   plants	   and	   humans	   (Pushparaj	   and	   Melendez,	   2006	   and	  
Karagiannis	  and	  El-­‐Osta,	  2005).	  A	  study	  by	  Terasawa	  et	  al.,	  2011,	  demonstrated	  
that	   synthetic	   pre-­‐miRNA	   based-­‐shRNA	   had	   more	   potent	   RNAi	   activity	   than	  
their	  corresponding	  siRNA	  molecules.	  In	  addition,	  they	  also	  observed	  that	  the	  
guide	  strand	  of	  these	  pre-­‐miRNA	  molecules	  was	  more	  efficiently	  incorporated	  
into	   RISC.	   Thus,	   giving	   scientists	   further	   options	   in	   designing	   RNA	  molecules	  





As	   stated	   earlier,	   siRNA	   molecules	   are	   the	   first	   discovered	   naturally	  
occurring	  mediators	  of	  an	  RNAi	  response.	  	  They	  are	  21-­‐	  22	  nt	  long	  and	  are	  the	  
products	   of	   dsRNA	   precursors.	   Synthetic	   siRNA	   molecules	   have	   been	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developed	   and	   used	   for	   loss	   of	   function	   studies	   or	   as	   therapeutic	   tools	   to	  
modulate	   gene	   expression,	   of	   either	   an	   abnormal	   or	   an	   over	   expressed	  wild	  
type	  gene	   (Dykxhoorn	  et	  al.,	  2003).	  These	  synthetic	   siRNA	  can	  be	   introduced	  
exogenously	  or	  by	   the	  expression	  of	  viral	  or	  non-­‐viral	  vectors	   (Pushparaj	  and	  
Melendez,	  2006),	  see	  figure	  1.14.	   	  The	  classical	  siRNA	  structures	  proposed	  by	  
Elbashir	   et	   al.	   in	   2001	   are	   siRNA	  molecules	   that	   are	   19	   nt	   in	   length	   with	   3’	  
overhang	  of	  2	  nt.	  A	   fixed	   length,	  symmetry	   in	  structure	  and	  the	  3’	  overhang,	  
were	   structural	   design	   rules	   to	   achieve	  optimum	  RNAi.	  However,	   these	   rules	  
were	  observed	  in	  Drosophila	  embryonic	  extract.	  However,	  a	  recent	  review	  by	  
Chang	   et	   al.,	   2011,	   shed	   light	   that	   siRNA	   structures	   used	   in	  mammalian	   cell	  
lines	  can	  undergo	  more	  flexibility	   in	  design	  and	  chemical	  modifications	  based	  
on	   the	   different	   siRNA	   structures	   that	   have	   been	   used	   with	   successful	  
induction	  of	  RNAi	  to	  their	  target	  genes.	  Hence,	  the	  previously	  proposed	  fixed	  
rules	   can	   be	   altered	   in	   mammalian	   cell	   lines,	   giving	   the	   advantage	   of	  
developing	   siRNA	   molecules	   with	   more	   potent	   RNAi,	   reduced	   off	   target	  





These	   RNA	  molecules	   are	   characterized	   by	   base-­‐paired	   stems	   and	   a	   loop	  
region,	  hence	  their	  name	  hairpin.	  shRNA	  is	  also	  processed	  by	  Dicer	  into	  siRNA	  
that	   are	   21	   -­‐	   23	   nt	   duplexes	   with	   a	   two	   base	   overhang	   at	   the	   3’	   ends.	   The	  
processing	   of	   such	  molecules	   yields	  mature	   products	   similar	   to	   the	   naturally	  
occurring	  miRNA.	   Thus,	   competition	   between	   synthetic	   shRNA	   and	   naturally	  
occurring	  miRNA	  for	  the	  endogenous	  RNAi	  machinery	  may	  result.	  However,	  to	  
bypass	  this,	  the	  best	  approach	  is	  to	  select	  potent	  shRNA	  molecules	  capable	  of	  
down-­‐regulation	  of	  target	  gene	  when	  expressed	  in	  low	  levels	  (Rossi,	  2008).	  	  
The	  use	  of	  synthetic	  siRNA	  is	  appropriate	  when	  transient	  inhibition	  of	  gene	  
expression	   is	   satisfactory.	   However,	   in	   cases	   of	   prolonged	   gene	   silencing,	  
several	   or	   continuous	   siRNA	   administrations	   will	   be	   required	   in	   order	   to	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maintain	  a	  long-­‐term	  inhibition	  of	  gene	  expression.	  Expression	  vector	  systems	  
have	  been	  developed	  where	  the	  DNA	  is	  transcribed	  and	  processed	   into	  short	  
RNA	  within	  the	  cells,	  see	  Figure	  1.14.	  In	  these	  systems	  the	  expression	  of	  shRNA	  
molecules	   are	   favourable	   (Karagiannis	   and	   El-­‐Osta,	   2005).	   These	   systems	  
usually	   use	   RNA	   polymerase	   III	   promoters	   (Pol	   III),	   especially	   the	   U6	   small	  
nuclear	  RNA	  and	  the	  H1	  RNase	  P	  RNA	  promoters.	  These	  promoters	  are	  known	  
for	  their	  simplicity,	  and	  strength	  of	  expression	  (Rossi,	  2008).	  They	  do	  not	  add	  
any	  extra	  bases	  that	  might	  affect	  the	  functional	  activity	  of	  the	  transcript,	  and	  
their	  expression	  is	  well	  known	  to	  be	  constitutive	  and	  ubiquitous	  (Ohkawa	  and	  
Taira,	  2000).	  Hence,	  the	  combination	  of	  an	  expression	  vector	  system	  that	  uses	  
a	   Pol	   III	   promoter	   to	   induce	   a	   high	   RNAi	   through	   the	   expression	   of	   shRNA	  

























Figure	   1.14	   The	  Mechanisms	   of	   Endogenous	   and	   Exogenous	   expression	   of	  miRNA,	   shRNA,	  
and	  siRNA.	  
The	   process	   of	   RNAi	   can	   be	   achieved	   from	   either	   endogenous	   or	   exogenous	   triggers.	   The	  
endogenous	  triggers	  of	  RNAi	  are	  the	  miRNA	  molecules.	  These	  are	  expressed	  from	  non-­‐protein	  
genes.	   miRNA	   are	   initially	   expressed	   as	   a	   long	   primary	   miRNA	   (pri-­‐miRNA)	   that	   is	   further	  
processed	   by	   an	   RNase-­‐III	   type	   endonuclease	   enzyme	   called	   Drosha	   and	   its	   cofactor	   DGCR8	  
(Han	  et	  al.,	  2004)	  into	  the	  miRNA	  precursors	  known	  as	  pre-­‐miRNA.	  The	  pre-­‐miRNA	  than	  exits	  
the	  nucleus	  and	  gets	  processed	  by	  Dicer	  to	  imperfect	  21-­‐	  23	  nt	  long	  duplexes.	  These	  duplexes	  
are	   taken	   up	   by	   RISC	   that	   cleaves	   the	   passenger	   strand	   and	   the	  mature	  miRNA	   directs	   the	  
activated	  complex	  to	  its	  target	  mRNA	  where	  translational	  repression	  occurs.	  It	  should	  be	  noted	  
that	   if	   the	  miRNA	  perfectly	  binds	   to	   its	   target	  mRNA	   it	  will	   leads	   to	  nuclease	   cleavage	  of	   its	  
target.	   Exogenous	   RNAi	   is	   induced	   through	   the	   expression	   of	   shRNA	   constructs	   or	   the	  
exogenous	  administration	  of	   synthetic	   siRNA.	  shRNA	  can	  be	  also	  administrated	   into	   the	  cells	  
via	  the	  use	  of	  viral	  vectors.	  Dicer	  processes	  the	  shRNA	  molecules	  into	  siRNA	  duplexes	  that	  are	  
loaded	   into	   RISC.	   Within	   RISC	   the	   passenger	   strand	   is	   cleaved	   and	   the	   active	   complex	   is	  
directed	   to	   the	   target	  mRNA.	   Complementary	   binding	   between	   the	   guide	   strand	   and	   target	  
leads	  to	  the	  cleavage	  of	  the	  latter	  and	  the	  achievement	  of	  RNAi.	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1.5.5 The	  use	  of	  RNAi	  as	  a	  therapeutic	  tool	  
	  
With	   the	   developments	   of	   siRNA	   and	   shRNA	   based	   technologies,	   several	  
research	   groups	   have	   directed	   their	   work	   and	   interests	   in	   using	   the	   RNAi	  
technology	   for	   therapeutic	   applications.	   These	   applications	   included	   viral	  
infections,	   neurodegenerative	   disorders,	   cancer	   (Karagiannis	   and	   El-­‐Osta,	  
2005),	   dominant	   gene	   disorders	   (Seyhan,	   2011)	   and	   targeting	   downstream	  
modulators	  of	  disease	  (Pushparaj	  and	  Melendez,	  2006).	  Nevertheless,	  several	  
limitations	   do	   exist	   for	   the	   use	   of	   RNAi	   as	   a	   therapeutic	   agent.	   These	  
limitations	   include	   the	   stability	   of	   the	   siRNA	   molecules,	   and	   the	   major	  
drawback	  of	  delivery	  into	  tissues	  in	  addition	  to	  the	  specificity	  of	  delivery.	  	  
To	   over	   come	   these	   limitations,	   various	   chemical	   modifications	   to	   the	  
backbone	  of	  the	  siRNA	  molecules	  can	  be	  introduced.	  These	  modifications	  have	  
been	   proven	   to	   increase	   the	   time	   life	   of	   the	   short	   RNA	   molecules.	   For	   the	  
issues	   of	   delivery	   and	   specificity	   of	   siRNA/shRNA	  molecules,	   several	   delivery	  
systems	  have	  been	  developed	  these	  can	  be	  mainly	  divided	  into	  viral	  and	  non-­‐
viral	  systems.	  Non-­‐viral	  systems	  include	  polymer	  and	  lipid	  based	  systems.	  Here	  
the	   short	   RNA	   molecules	   complexes	   with	   the	   transfecting	   reagent	   to	   form	  
lipoplexes,	   dendriplexes,	   and	   polyplexes	   depending	   on	   the	   vector	   used,	  
cationic	   lipids,	   dendrimer,	   or	   cationic	   polymers	   respectively	   (Shegokar	  et	   al.,	  
2011).	  	  
Viral	  vectors,	  on	  the	  other	  hand,	  have	  also	  been	  developed.	  These	  vectors	  
provide	  sustained	  expression	  of	  their	  transcripts	  and	  have	  higher	  transfection	  
efficiencies.	  Many	  vectors	  exist	  and	  the	  choice	  of	  the	  most	  suitable	  vector	  to	  
be	  used	  highly	  depends	  on	  the	  therapeutic	  aim	  and	  tissue	  to	  be	  targeted.	  The	  
most	   frequently	   used	   viral	   vectors	   will	   include	   adenoviral	   vectors,	   adeno-­‐
associated	   viral	   (AAV)	   vectors,	   retroviral	   vectors,	   and	   lentiviral	   vectors	  
(Davidson	   and	   McCary,	   2011).	   These	   vectors	   have	   the	   advantage	   of	  
transducing	   both	   dividing	   and	   non-­‐dividing	   cells.	   	   The	   adenoviral	   vectors	   are	  
usually	  used	  for	  the	  delivery	  of	  shRNA	  or	  miRNA	  in	  vitro.	  However,	  they	  do	  not	  
usually	  integrate	  into	  their	  target	  cell’s	  genome.	  Thus,	  are	  used	  for	  short-­‐term	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and	   single	   gene	   expressions.	   Three	   generations	   of	   adenoviral	   vectors	   exists.	  
AAV	   vectors	   offer	   stable	   and	   high-­‐level	   gene	   expression.	   They	   don’t	   usually	  
integrate	   into	   their	   host	   genome	   but	   exists	   as	   episomal	   forms.	   There	   are	  
several	   stereotypes	   of	   AAV,	   thus	   giving	   a	   choice	   for	   selection	   of	   the	   most	  
appropriate	  type	  depending	  on	  the	  cells	  of	   interest.	  Retroviral	  vectors	  on	  the	  
other	   hand,	   yields	   long-­‐term	   expression	   of	   the	   transcript	   of	   interest.	   This	   is	  
because	   the	  viral	  RNA	   is	   reverse	   transcribed	   into	  double	   stranded	  DNA	  upon	  
entry	   into	   the	   host	   cells.	   The	   transcribed	   DNA	   will	   then	   integrate	   into	   the	  
host’s	  chromosome.	  	  Nevertheless,	  with	  time,	  persistent	  gene	  expression	  may	  
not	   be	   sustained;	   this	  maybe	   due	   the	   occurrence	   of	   silencing	   transcriptional	  
units.	   Another	   drawback	   in	   retroviral	   vectors	   is	   the	   risk	   of	   T-­‐cell	   leukaemia	  
development	   that	  has	  been	  previously	  observed	   in	  patients.	  Finally,	   lentiviral	  
vectors,	   a	   subgroup	   of	   retroviruses,	   can	   produce	   persistent	   transgene	  
expression,	   which	   can	   also	   be	   silenced	   over	   time.	   These	   vectors	   permit	   the	  
integration	   in	   their	   host’s	   genome	   within	   intronic	   regions	   of	   active	  
transcriptional	  units.	  (Liu	  et	  al.,	  2011).	  	  	  	  	  
With	  all	  the	  recent	  developments	  in	  RNAi,	  the	  technology	  has	  been	  rapidly	  
improving	  since	  its	  discovery	  in	  1998.	  Over	  the	  years	  many	  studies	  have	  been	  
now	  approved	  and	  are	  in	  pre-­‐clinical	  and	  clinical	  trials.	  In	  addition	  some	  RNAi	  
therapeutic	  approaches	  have	  already	  completed	  phase	  II.	  These	  studies	  cover	  
a	  wide	  range	  of	  diseases	  and	  disorders.	  Their	  clinical	  setting	  for	  RNAi	  therapy	  
include	  7	  drugs	  for	  ocular	  and	  retinal	  disorders,	  8	  drugs	  for	  different	  types	  of	  
cancers,	  3	  drugs	  for	  kidney	  disorders,	  2	  drugs	  for	  LDL	  lowering,	  and	  5	  drugs	  for	  
antiviral	   infections	   (reviewed	   by	   Davidson	   and	   McCary,	   2011).	   These	   are	  
promising	   developments	   for	   RNAi	   as	   a	   constantly	   evolving	   technology	   to	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1.5.6 RNAi	  and	  CML	  
	  
CML	  was	  characterized	  as	  the	  first	  cancer	  to	  be	  linked	  with	  a	  chromosomal	  
abnormality	   that	   is	  constant	   in	  95%	  of	  CML	  cases.	  The	  disease	  results	  mainly	  
from	  overexpression	  of	  the	  c-­‐ABL	  tyrosine	  kinase	  activity.	  For	  many	  years	  the	  
BCR-­‐ABL	  abnormal	  protein	  have	  been	  an	  attractive	  site	  for	  modulators	  of	  gene	  
expression.	   These	   include	   antisense	   oligonucleotides,	   ribozymes	   and	   RNAi,	  
including	  both	  siRNA	  and	  shRNA	  molecules.	  
In	  this	  project,	  gene	  modulation	  of	  the	  expression	  of	  the	  abnormal	  BCR-­‐ABL	  
gene	  through	  RNAi	  is	  of	  interest.	  Several	  studies	  have	  attempted	  to	  target	  the	  
BCR-­‐ABL	  chimeric	  protein	  through	  RNAi	  by	  the	  use	  of	  either	  synthetic	  siRNA	  or	  
shRNA	  molecules.	  These	   include	  studies	  done	  by	  Mahmodabady	  et	  al.,	  2010,	  
Myssina	   et	   al.,	   2009,	   Li	   et	   al.,	   2003,	   and	   Arthanari	   et	   al.,	   2010	   for	   shRNA	  
molecules,	  and	  Rapozzi	  and	  Xodo,	  2004,	  Wohlbold	  et	  al.,	  2003,	  and	  Bártová	  et	  
al.	  2005	  for	  siRNA	  molecules.	  The	  studies	  using	  shRNA	  molecules	  targeted	  both	  
fusion	  points,	  β3α2	  (Mahmodabady	  et	  al.,	  2010,	  Myssina	  et	  al.,	  2009,	  Li	  et	  al.,	  
2003,	   and	   Arthanari	   et	   al.,	   2010)	   and	   the	   β2α2	   (Li	   et	   al.,	   2003).	   The	   studies	  
used	   chemical	   and	   physical	   methods	   of	   transfection,	   and	   different	   shRNA	  
sequences	   that	  were	   regulated	   and	   expressed	   from	  different	   promoters	   and	  
vector	   systems.	  However,	  all	  publications	   reported	  a	  decrease	   in	  both	  mRNA	  
and	  protein	  levels	  after	  shRNA	  treatment	  of	  only	  the	  β3α2	  variant.	  The	  mRNA	  
and	  protein	   levels	  of	   the	  β2α2	  variant,	  however,	  were	  not	  affected	   (Li	  et	  al.,	  
2003).	  The	  findings	  of	   these	  publications	  will	   further	  be	  discussed	   in	  detail	   in	  
chapter	  5.	  	  
Other	  studies	  have	  also	  considered	  RNAi	  technology	  either	  as	  a	  therapeutic	  
tool	   for	   CML,	   through	   targeting	   proteins	   down	   stream	   BCR-­‐ABL,	   or	   to	  
understand	   the	   many	   pathways	   involved	   in	   leukaemogenesis	   by	   loss	   of	  
function	  analysis.	  Examples	  include	  a	  study	  done	  by	  Machado-­‐Neto	  et	  al.	  2011,	  
that	  used	  an	  shRNA-­‐lentiviral	  delivery	  system	  to	  study	  the	  knockdown	  effects	  
of	   a	   protein	   called	   IRS1	   (insulin	   receptor	   substrate	   1)	   on	   the	   PI3K-­‐Akt/mTOR	  
and	  MAPK	  pathways	   in	  K562	  cell	   lines.	  This	  study	  was	  done	  on	  the	  basis	  that	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IRS1	  is	  continuously	  phosphorylated	  and	  associated	  with	  BCR-­‐ABL	  in	  K562	  cell	  
line	   (Traina	   et	   al.,	   2003).	   Silencing	   of	   IRS1	   did	   down-­‐regulate	   the	   associated	  
pathways,	   causing	   a	   decrease	   in	   cell	   proliferation	   and	   colony	   formation,	   but	  
apoptosis	  was	  not	  affected.	  	  	  
Another	   study	   conducted	   by	   Albers	  et	   al.	   2011,	   demonstrated	   the	   use	   of	  
RNAi	   based	   systems	   for	   loss	   of	   function	   analysis.	   The	   group	   found	   that	   Raf1	  
protein	  is	  a	  crucial	  mediator	  of	  BCR-­‐ABL	  dependent	  CML,	  through	  activation	  of	  
the	   MAPK/ERK	   cascade.	   In	   this	   study	   the	   shRNA	   was	   expressed	   from	   a	  
retroviral	  vector	  in	  a	  coupled	  expression	  system.	  Another	  study	  done	  by	  Scherr	  
et	  al.	  2006,	  have	  also	  demonstrated	  that	  SHP2,	  STAT5	  and	  Grb2	  proteins	  can	  
be	  therapeutic	   targets	   in	  cases	  of	  drug	  resistance.	  They	  have	   identified	  these	  
target	  proteins	   through	   the	  use	  of	  a	   lentiviral	  mediated	  RNAi.	  The	  study	  also	  
demonstrated	   that	   co-­‐expression	   of	   shRNA	   against	   the	   BCR-­‐ABL	   and	   SHP2	  
proteins	   from	   a	   single	   lentiviral	   vector	   induces	   stronger	   colony	   formation	  
inhibition	  when	  compared	  to	  using	  shRNA	  alone.	  Elmaagacli	  et	  al.	  2005,	  found	  
that	   the	  use	  of	   two	   siRNA	  molecules	  had	  additive	  effects	   in	   the	   induction	  of	  
apoptosis	   in	   CML	   cells,	   in	   comparison	   to	   when	   each	   siRNA	   was	   used	  
individually.	  In	  this	  study	  two	  synthetic	  siRNAs	  were	  co-­‐transfected.	  One	  siRNA	  
was	  against	  the	  BCR-­‐ABL,	  while	  the	  other	  targeted	  the	  Wilms’	  tumor	  genes,	  a	  
gene	  found	  to	  be	  abnormally	  over-­‐expressed	  in	  leukemic	  cells.	  	  
Other	  studies	  have	  found	  that	  the	  use	  of	  RNAi	  technology	  can	  sensitize	  the	  
drug	   resistant	   leukaemic	   cells	   to	   TKI,	   such	   as	   Imatinib	   and	   Nilotinib.	   These	  
studies	  include	  those	  done	  by	  Wohlbold	  et	  al.,	  2003,	  Rumpold	  et	  al.,	  2005,	  and	  
Koldehoff	   et	   al.	   2010,	   respectively.	   In	   these	   studies	   the	   RNAi	   mediated	  
knockdown	  was	   against	   the	   BCR-­‐ABL	   transcripts,	   giving	   a	   basis	   to	   combining	  
both	   RNAi	   technology	   and	   TKI,	   thus	   targeting	   the	   BCR-­‐ABL	   fusion	   gene	  
molecularly	  at	  both	  mRNA	  and	  protein	  levels.	  A	  study	  conducted	  by	  Mendonca	  
et	   al.	   2010,	   showed	   that	   siRNA	   against	   the	   BCR-­‐ABL	   gene	   could	   be	   co-­‐
encapsulated	  with	  Imatinib	  giving	  a	  new	  therapeutic	  approach	  for	  CML	  and	  at	  
the	  same	  time	  bypassing	  the	  effects	  of	  drug	  resistance.	  
In	   conclusion,	   since	   the	   discovery	   of	   RNAi	   by	   Fire	   et	   al.	   in	   1998,	   the	  
technology	   has	   been	   advancing	   at	   a	   high	   speed.	   A	   lot	   has	   been	   unravelled	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about	  RNAi	  mediated	  gene	  silencing,	  the	  proteins	  involved	  in	  the	  process,	  and	  
the	  different	  mechanisms	  of	   the	  different	   triggers	  of	  RNAi.	  The	   technology	   is	  
rapidly	  becoming	  a	  standard	  tool	  for	  loss	  of	  function	  studies	  and	  an	  appealing	  
therapeutic	   approach	   for	   a	   wide	   range	   of	   diseases	   and	   disorders	   including	  
cancer	  in	  general	  and	  targeting	  leukemic	  fusion	  proteins	  in	  particular	  (Thomas	  
et	  al.,	  2006).	  	  
	  
	  
1.6 Cell	  Lines	  as	  a	  Model	  for	  CML	  
	  
Since	   the	   establishment	   of	   the	   first	   CML	   cell	   line	   in	   1975	   by	   Lozzio	   and	  
Lozzio,	  many	  other	  CML	  cell	  lines	  have	  been	  established.	  There	  are	  around	  30	  
CML	  cell	   lines	  as	  listed	  in	  a	  review	  by	  Drexler	  in	  1994,	  some	  of	  which	  express	  
the	   β3α2	   BCR-­‐ABL	   variant,	   whereas	   others	   express	   the	   β2α2	   fusion	   protein.	  
This	   wide	   range	   of	   CML	   cell	   lines	   differ	   morphologically	   and	   phenotypically,	  
giving	  scientists	  the	  opportunity	  to	  study	  the	  pathobiology	  of	  CML	  and	  the	  role	  
of	  the	  BCR-­‐ABL	  protein	  in	  the	  development	  of	  leukaemogenesis	  (Drexler	  et	  al.,	  
1999).	  
In	  1975	  the	  first	  CML	  cell	  line,	  the	  K562	  cell	  line,	  was	  established	  (Lozzio	  and	  
Lozzio,	   1975).	   These	   cells	   express	   the	   β3α2	   BCR-­‐ABL	   variant	   that	   is	   a	   free-­‐
floating	  suspension	  cell	  line	  (Lozzio	  and	  Lozzio,	  1975).	  Cytologically,	  K562	  cells	  
are	   composed	  of	  undifferentiated	  myeloid	   cells	   (lozzio	  and	  Lozzio,	  1979)	  and	  
molecularly,	  are	  a	  triploid	  cell	   line	  (Drexler	  et	  al.,	  1999).	  K562	  cells	  were	  used	  
over	  the	  years	  since	  its	  establishment	  for	  various	  studies	   including	  those	  that	  
shed	  light	  on	  the	  nature	  of	  BCR-­‐ABL	  fusion	  gene	  (Heisterkamp	  et	  al.,	  1983),	  or	  
those	  that	  used	  the	  cell	  line	  for	  gene	  modulation	  (Wilda	  et	  al.,	  2002,	  Rapoozi	  et	  
al.,	  2002,	  Mahmodabady	  et	  al.,	  2010,	  and	  Arthanari	  et	  al.,	  2010).	  Because	  the	  
cell	  line	  is	  easy	  to	  grow	  and	  maintain,	  in	  addition,	  molecularly	  they	  express	  the	  
BCR-­‐ABL	  gene	  in	  an	  oncogenic	  amplification	  manner	  (20	  –	  30	  fold),	  this	  cell	  line	  
provides	   a	   suitable	   CML	   model	   for	   gene	   modulation	   studies;	   therefore,	   the	  
K562	  cell	  line	  was	  selected	  for	  the	  purposes	  of	  the	  current	  study.	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The	   KCL-­‐22	   cell	   line,	   on	   the	   other	   hand,	   expresses	   the	   β2α2	   BCR-­‐ABL	  
variant.	   Kubonishi	   and	  Miyoshi,	   1983,	   first	   established	   this	   cell	   line	   in	   1983.	  
KCL-­‐22	   cells	   are	   also	   free-­‐floating	   in	   suspension,	   cytologically	   the	   cells	   are	  
composed	  of	  immature	  undifferentiated	  haematopoietic	  cells;	  and	  molecularly	  
it	   is	   a	   diploid	   cell	   line	  with	   double	   Ph	   chromosome,	   in	   addition	   to	   a	   normal	  
chromosome	   9	   and	   22	   (Kubonishi	   and	   Miyoshi,	   1983).	   The	   double	   Ph	  
chromosomes	   are	   not	   surprising	   as	   this	   cell	   line	   (and	   K562)	  was	   established	  
from	   a	   CML	   patient	   in	   blast	   phase.	   In	   the	   CML	   blast	   phase/crisis	   other	  
chromosomal	   abnormalities	   occur	   including	   trisomy♯8,	   isochromosome	   of	  
the	  long	  arm	  of	  chromosome	  ♯17,	  and	  double	  Ph	  chromosomes	  are	  observed	  
(Kubonishi	  and	  Miyoshi,	  1983,	  Drexler,	  1994,	  and	  Drexler	  et	  al.,	  1999),	  hence,	  
actually	  giving	  evidence	  of	  the	  leukaemic	  origin	  of	  the	  KCL-­‐22	  cells.	  Rapozzi	  and	  
Xodo,	   in	   2004	   used	   the	   KCL-­‐22	   cell	   line	   as	   a	   leukaemic	  model	   in	   attempt	   to	  
down-­‐regulate	   the	  expression	  of	   the	  β2α2	  BCR-­‐ABL	  by	   siRNA	  molecules,	   and	  
Ohmine	  et	  al.,	  2003,	  used	  these	  cells	  to	  establish	  a	  new	  Imatinib-­‐resistant	  cell	  
line,	  KCL-­‐22/SR	   in	  2003.	  A	  publication	  by	  Esposito	  et	  al.,	   in	  2011	  used	  a	  KCL-­‐
22/R	  (imatinib	  resistant)	  cell	  line	  to	  study	  the	  mechanisms	  of	  imatinib	  resistant	  
in	   CML.	   The	   cells	   are	   also	   easy	   to	   grow	   and	   maintain,	   and	   have	   a	   rate	   of	  
doubling	   every	   24hr	   (Kubonishi	   and	  Miyoshi,	   1983),	   thus,	   for	   the	  purpose	  of	  
this	   study,	   this	   cell	   line	  was	   chosen	   as	   it	   serves	   as	   an	   appropriate	  model	   for	  
CML	  expressing	  the	  β2α2	  BCR-­‐ABL	  fusion	  protein.	  	  
	  
	  
1.7 Aim	  of	  the	  project	  	  	  
	  	  
As	   previously	   mentioned,	   RNAi	   is	   becoming	   a	   tool	   for	   therapeutic	  
approaches	  against	  several	  diseases	  and	  disorders,	  including	  cancer.	  CML	  was	  
the	   first	   cancer	   to	   be	   characterized	   by	   the	   presence	   of	   an	   abnormal	  
Philadelphia	  chromosome	  that	  transcribes	  an	  abnormal	  protein	  through	  as	  the	  
BCR-­‐ABL	  oncogene.	  This	  abnormal	  fusion	  gene	  has	  two	  variants;	  the	  β3α2	  and	  
β2α2,	   both	   playing	   an	   important	   role	   in	   leukaemogenesis	   of	   CML.	   TKI	   are	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currently	   the	   first	   line	   of	   treatment	   for	   CML.	   However,	   first	   and	   second	  
generations	  of	  TKI	  have	  failed	  to	  overcome	  the	  development	  of	  leukaemic	  drug	  
resistance	   in	   relapsed	   patients,	   making	  modulation	   of	   the	   expression	   of	   the	  
BCR-­‐ABL	  oncogene	  a	  favourable	  approach.	  Using	  RNAi	  mediated	  gene	  silencing	  
of	  the	  BCR-­‐ABL	  oncogene	  through	  stable	  expression	  of	  shRNABCR-­‐ABL	  would	  be	  
an	  excellent	   therapeutic	  approach	   for	  CML.	  The	  combination	  of	   two	  or	  more	  
shRNA,	  targeted	  against	  one	  fusion	  variant	  or	  both	  together	  (in	  some	  cases	  of	  
CML	   both	   fusion	   variants	   are	   expressed	   simultaneously	   (Adler	   et	   al.,	   2009)),	  
would	   be	   another	   therapeutic	   approach.	   This	   is	   based	   on	   the	   studies	  
mentioned	  earlier	  where	  siRNA	  molecules	  had	  additive	  effects	  on	  CML.	  Finally,	  
shRNA	  molecules	  against	  CML	  can	  also	  be	  used	   to	   sensitize	   leukemic	  cells	   to	  
TKI,	   or	   the	   shRNA	   constructs	   can	   be	   administrated	   with	   TKI	   to	   establish	  
complete	  hematologic	  response	  for	  patients	  with	  CML.	  	  	  
This	  project	  aims	  to	  decrease	  or	  abolish	  the	  expression	  of	  the	  two	  BCR/ABL	  
variants.	  It	  aims	  to	  accomplish	  this	  by	  inducing	  RNAi	  through	  designing	  shRNA	  
molecules	  against	  the	  two	  BCR-­‐ABL	  transcripts.	  The	  designed	  molecules	  were	  
then	  expressed	  and	  delivered	  via	  a	  non-­‐viral	  system	  in	  two	  CML	  cell	  lines;	  one	  
for	  each	  variant.	  The	  shRNA	  molecules	  to	  be	  expressed	  were	  designed	  to	  be	  as	  
symmetrical	  as	  possible,	  with	  an	  8	  nt	  long	  loop,	  and	  were	  under	  the	  regulation	  
of	   the	  human	  Pol	   III	   promoters,	  U6	  or	  H1.	  The	  efficacy	  and	   specificity	  of	   the	  
shRNA	   constructs	   were	   established	   as	   a	   prelude	   to	   these	   molecules	   being	  
incorporated	   in	  a	   lentiviral	   system	  that	  would	  be	   tested	  on	  cell	   lines,	  and	  on	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Chapter	  2 :	  	  Materials	  and	  Methods	  
	  
	  
2.1 Molecular	  Biology	  
	  
2.1.1 	  RNA	  Extraction	  and	  Purification	  
	  
Cell	  lines	  were	  grown	  and	  1	  x	  106	  cells	  were	  used	  for	  RNA	  extraction.	  RNA	  
extraction	  was	   done	   using	   the	   RNeasy	  Mini	   Kit	   (Qiagen,	   UK).	   The	   extraction	  
was	  done	  according	  to	  the	  manufacturer’s	  instructions.	  The	  extracted	  RNA	  was	  
further	   treated	  with	   DNase	   in	   order	   to	   remove	   any	   traces	   of	   contaminating	  
DNA.	   This	   was	   done	   using	   the	   TURBO	   DNA-­‐freeTM	   Kit	   (Ambion	   Applied	  
Biosystems,	   UK),	   following	   the	   manufacturer’s	   protocol.	   The	   amount	   of	   the	  
extracted	  RNA	  and	  the	  purity	  of	  the	  sample	  obtained	  are	  described	  in	  section	  
2.1.3.	  
	  
2.1.2 	  DNA	  Extraction	  and	  Precipitation	  
	  
To	   the	   DNA	   containing	   solution,	   an	   equal	   volume	   of	   phenol/chloroform	  
mixture	  was	  added.	  The	  mixture	  was	  vortexed	  for	  a	  couple	  of	  seconds,	  kept	  at	  
room	  temperature	  for	  15	  minutes,	  then	  centrifuged	  for	  5	  minutes	  at	  14,000g.	  
The	   layer	   containing	   the	   DNA,	   the	   top	   layer,	   was	   transferred	   to	   a	   fresh	  
eppendorf.	   To	   that	  1/10	   the	  volume	  of	  10M	  ammonium	  acetate	  and	  2.5	   the	  
volume	  of	  100%	  ethanol	  was	  added.	  The	  solution	  was	  vortexed	  for	  a	  couple	  of	  
seconds,	  incubated	  on	  ice	  for	  30	  minutes,	  and	  then	  centrifuged	  for	  5	  minutes	  
at	   14,000g.	   The	   supernatant	   was	   removed,	   and	   the	   pellet	   was	  washed	  with	  
70%	   ethanol.	   The	   DNA	   pellet	   was	   air	   dried	   for	   20	   minutes,	   and	   then	  
resuspended	  in	  an	  appropriate	  volume	  of	  TE	  buffer	  or	  DEPC	  H2O.	  The	  amount	  
of	  the	  extracted	  and	  purified	  DNA,	  and	  the	  purity	  of	  the	  sample,	  is	  described	  in	  
section	  2.1.3.	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2.1.3 Quantification	  of	  Nucleic	  Acid	  Concentration	  	  
	  
The	  concentration	  of	  nucleic	  acids	  was	  quantified	  by	  measuring	  the	  diluted	  
sample’s	   absorbance	   at	   260nm.	   This	   was	   done	   by	   the	   use	   of	   a	   GeneQuant	  
spectrophotometric	   measurement	   (Pharmacia	   Biotech,	   Sweden),	   and	  
depending	   on	  what	   the	   nucleic	   acid	   pellet	  was	   resuspended	   in,	   TE	   buffer	   or	  
DEPC	  H2O	  was	  used	  as	  a	  blank.	  The	  following	  formula	  was	  used	  to	  estimate	  the	  
nucleic	  acid	  concentration:	  
1.0 OD260	  =	  44ng/	  μl	  for	  RNA	  
	  1.0	  OD260	  =	  50ng/	  μl	  for	  DNA	  
The	  purity	  of	  the	  samples	  was	  estimated	  through	  the	  OD260/	  OD280	  ratio.	  Ratios	  
of	  1.8	  for	  DNA	  and	  2.0	  for	  RNA	  were	  considered	  to	  be	  highly	  pure.	  	  
	  
2.1.4 cDNA	  Synthesis	  
	  
cDNA	  synthesis	  is	  the	  production	  of	  a	  DNA	  complementary	  strand	  from	  an	  
existing	   RNA	   strand.	   This	   process	   can	   be	   obtained	  by	   a	   reverse	   transcription	  
(RT)	   reaction.	   The	   reaction	   is	   accomplished	   by	   the	   use	   of	   a	   reverse	  
transcriptase	  enzyme	  that	  extends	  an	  RNA	  hybridised	  primer.	  Since,	  eukaryotic	  
mRNA	  is	  3'	  polyadenylated,	  a	  polydeoxythymidine	  oligomer	  (16-­‐18	  bases)	  can	  
be	   used	   as	   a	   primer	   for	   this	   reaction,	   consequently	   giving	   rise	   to	   RNA-­‐DNA	  
hybrids	  (Gerard	  et	  al.,	  1997).	  	  
For	  the	  RT	  reaction	  the	  following	  mix	  was	  prepared:	  a	  volume	  equivalent	  to	  
1-­‐2μg	  of	  RNA,	  1μl	  of	  oligo	  dT16-­‐18	  (2μg/μl,	  Synthesized	  by	  the	  Molecular	  Biology	  
Unit	   at	   Hodgkin	   Building,	   King's	   College	   London),	   and	   RNase	   free	   water	  
(Qiagen,	  UK)	  to	  a	  total	  volume	  of	  45μl	  was	  added.	  The	  mixture	  was	  incubated	  
at	   70°C	   for	   10	   minutes	   (Thermal	   Reactor-­‐	   HYBAID	   Omnigene,	   UK).	   This	   was	  
done	  to	  denature	  the	  RNA	  secondary	  structure.	  
The	   45μl	   mixture	   was	   left	   on	   ice	   for	   5	   minutes	   and	   the	   following	   were	  
added:	  5μl	  of	  10mM	  deoxynucleotide	  triphosphate	  (dNTP)	  (Promega,	  UK),	  20μl	  
of	   first	   strand	  5x	  Buffer	   (250mM	  Tris-­‐HCl:	  pH	  8.3,	  375mM	  KCl,	  15mM	  MgCl2:	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Invitrogen,	  UK),	  10μl	  of	  1M	  DTT	   (Invitrogen,	  UK),	  5μl	  of	  RNasin	  Ribonuclease	  
Inhibitor,	   20-­‐40u/μl	   (Promega,	  UK),	   and	   5μl	   of	  M-­‐MLV	   reverse	   transcriptase,	  
200u/μl	   (Promega,	  UK).	   The	   final	   volume	  of	   the	  RT	  mixture	  was	  100μl	  which	  
was	  incubated	  at	  37°C	  for	  one	  hour	  (Techne	  DB,	  DRI-­‐Block®,	  U.S.A).	  
	  
2.1.5 Polymerase	  Chain	  Reaction	  
	  
PCR	   involves	   the	  amplification	  of	  a	  DNA	  segment	  at	  high	   temperature	  by	  
the	  use	  of	  sequence	  specific	  primers.	  The	  DNA	  template	  is	  initially	  denatured,	  
primers	   then	   anneal	   to	   the	   template	   and	   a	   heat	   stable	   DNA	   polymerase	  
extends	   them.	   This	   temperature	   cycle	   is	   repeated	   for	   a	   number	   of	   times,	  
usually	   30-­‐40	   cycles.	   The	   product	   of	   the	   first	   amplification	   becomes	   the	  
template	  for	  the	  next	  one,	  and	  the	  amount	  of	  product	  increases	  exponentially,	  
theoretically,	  two	  fold	  for	  each	  cycle.	  
All	  PCR	   reactions	  were	  carried	  out	  either	  with	  PCR	  master	  mix	   (Promega,	  
UK)	  or	  Fast	  Start	  High	  Fidelity	  PCR	  system	  (Roche,	  UK).	  Tables	  2.1	  and	  2.2	  list	  all	  
components	  that	  were	  used	  with	  the	  above	  PCR	  polymerases	  respectively.	  
	  
Component	   Volume	  per	  25µ l	  
reaction	  
20ng	  of	  DNA	   xµl	  
10µM	  Forward	  Primer	   1µl	  
10µM	  Reverse	  Primer	   1µl	  
PCR	  Master	  Mix	   12.5µl	  
H2O	   Add	  to	  25µl	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Component	   Volume	  per	  25µ l	  
reaction	  
20ng	  of	  DNA	   xµl	  
10µM	  ForwardPrimer	   1µl	  
10µM	  Reverse	  primer	   1µl	  
10mM	  dNTP	   1.25µl	  
10x	  fast	  start	  high	  
fidelity	  buffer	  	  
2.5µl	  




H2O	   Add	  to	  25µl	  
Table	  2.2	  Components	  of	  the	  Fast	  Start	  High	  Fidelity	  PCR	  system	  (25µ l	  reaction	  mixture).	  	  
The	  preparation	  of	   the	   reaction	  master	  mix	  was	  performed	  on	   ice,	   and	   the	  high	   fidelity	  Taq	  
polymerase	  was	  added	  just	  before	  the	  initiation	  of	  the	  reaction.	  	  
	  
	  
The	  parameters	  set	   for	   the	  PCR	  systems	  are	  shown	  below	  and	  all	   sets	  of	  
primers	  used	  for	  this	  project	  can	  be	  seen	  in	  table	  2.3.	  	  
The	  following	  PCR	  conditions	  were	  applied	  for	  the	  reactions	  done	  by	  the	  use	  of	  
the	  PCR	  Master	  Mix	  and	  the	  Fast	  Start	  high	  Fidelity	  PCR	  system:	  
	  
	  
Initial	  denaturation	  at	  96°C	  for	  5	  minutes	  
Denaturation	  at	  95°C	  for	  1	  minute	  
Annealing	   (temperature	   depending	   on	   the	   primer	   set,	   see	   table	  
2.3)	  for	  50	  seconds	  
	  
	  
30	  cycles	  of	  	  
Elongation	  at	  72°C	  for	  15	  seconds	  x	  length	  of	  the	  amplicon/Kb	  
Final	  extension	  at	  72°C	  for	  5	  minutes	  
	  
The	  PCR	  products	  were	  analysed	  by	  agarose	  gel	  electrophoresis.	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PCR	  Primer	  Set	   	  






Forward	  5'	  d-­‐AGCTTCTCCCTGACATCCGTGGA'3	  
Reverse	  5'	  d-­‐CCCATTGTGATTATAGCCTAAGA'3	  
60°C	  
β2α2	  primers*	   Forward	  5'	  d-­‐GCTACGGAGAGGCTGAAGAA'3	  
Reverse	  5'	  d-­‐CGTGATGTAGTTGCTTGGGA'3	  
60°C	  
U6	  primers	   Forward	  5'	  d-­‐CCCAAGCTTCAAGGTCGGGCAGGAAGAGGGCCTA'3	  
Reverse	  5'	  d-­‐ATGGATCCTAGTATATGTGCTGCCGAAGCGAGCAC'3	  
64°C	  
H1	  primers	   Forward	  5'	  d-­‐CCCAAGCTTCGAACGCTGACGTCATCAAC'3	  
Reverse	  5'	  d-­‐ATGGATCCGAAAGAGTGGTCTCATACAGAACTT'3	  
64°C	  
CMV-­‐340	  	   Forward	  5'	  d-­‐TTCCAAGTCTCCACCCCATTGACG	  T'3	   60°C	  
CMV-­‐207	   Forward	  5'	  d-­‐CCACTTGGCAGTACATCAAG'3	   60°C	  
EGFPN1	   Reverse	  5'	  d-­‐GTCCAGCTCGACCAGGATG'3	   60°C	  
Sp6	   5'	  d-­‐ATTTAGGTGACACTATAG'3	   50°C	  
pEGFP-­‐N1	   Forward	  5'	  d-­‐AACGCCAATAGGGACTTTCC'3	  
Reverse	  5'	  d-­‐AAGTCGTGCTGCTTCATGTG'3	  
57°C	  
Β-­‐actin	  primer	  N	   5'	  d-­‐CTGAGTCTCCTTTGGAACTCTGCAG	  '3	   60°C	  
Β-­‐actin	  primer	  K	   5'	  d-­‐GAGCACAGAGCCTCGCCTTTGC'3	   60°C	  
Β-­‐actin	  primer	  L	   5'	  d-­‐GGATCTTCATGAGGTAGTCAGTCAGG'3	   60°C	  
PRL13	  Primers	   Forward	  5'	  d-­‐TGAAGGAGTACCGCTCCAAA'3	  
Reverse	  5'	  d-­‐GGGTGGCCAGTTTCAGTTC	  '3	  
60°C	  
T3	  reverse	   5'	  d-­‐GCAATTAACCCTCACTAAAGG'3	   50°C	  
T7	  forward	   5'	  d-­‐TAATACGACTCACTATAGGG'3	   50°C	  
Table	  2.3	  Primer	  sets	  used	  within	  the	  project.	  Primers	  were	  aimed	  to	  be	  21-­‐23bp	  with	  a	  GC	  
content	   of	   48-­‐60%.	   SGD	   web	   primer	   design	   software	   was	   used	   to	   design	   the	   primers.	   Red	  
coloured	   sequences	   in	   U6	   and	   H1	   primer	   sets,	   indicate	   added	   restriction	   sites.	   These	   are	  
HindIII	   and	   BamHI	   restriction	   sites	   located	   in	   the	   forward	   and	   reverse	   primers	   respectively.	  
Primers	  indicated	  by	  (*)	  were	  taken	  from	  the	  following	  publications,	  (Campanini	  F	  et	  al.,	  2001)	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2.1.6 Agarose	  Gel	  Electrophoresis	  
	  
DNA	   molecules	   carry	   a	   negative	   charge	   as	   a	   consequence	   of	   their	  
phosphate	  backbone.	   Therefore,	   if	  DNA	  molecules	  are	  placed	   in	  an	  electrical	  
field	   they	  will	  migrate	   towards	   the	   positive	   pole.	   An	   agarose	   gel	   is	   used	   for	  
support,	  and	  comprises	  a	  network	  of	  pores,	  through	  which	  DNA	  molecules	  can	  
travel.	  The	  pore	  size	  of	  a	  gel	   is	  determined	  by	  the	  agarose	  concentration,	  the	  
greater	  the	  concentration	  of	  the	  gel,	  the	  smaller	  its	  pores.	  
To	  make	   a	   1%	   gel,	   0.5g	   of	   agarose	   powder	   (Fisher	   Bioreagents,	   UK)	  was	  
weighed	   (Mettler	   R1210)	   and	   transferred	   into	   a	   clean	   conical	   flask	   that	  was	  
then	   filled	  with	  50ml	  of	  1x	  TAE	  buffer	   (40mM	  Tris-­‐Acetate-­‐EDTA,	  1mM	  EDTA	  
pH	  8.5,	   Sigma,	  Germany).	   The	  mixture	  was	   then	  heated	  on	  maximum	  power	  
for	   2	   minutes	   in	   a	   microwave	   oven	   (Hotline,	   930W	   Bejam,	   Korea).	   10µl	   of	  
ethidium	  bromide	  (1mg/ml,	  MBL	  International,	  USA)	  was	  then	  added	  and	  the	  
solution	  was	  mixed.	  	  
An	   electrophoretic	   boat	   was	   placed	   horizontally	   into	   an	   electrophoretic	  
tank	  (Max	  fill,	  Fisher	  brand,	  UK).	  A	  comb	  with	  the	  desired	  number	  of	  wells,	  was	  
placed	   into	  the	  boat.	  The	  agarose	  was	  then	  poured	  into	  the	  boat	  and	  the	  gel	  
was	  allowed	  to	  set.	  Once	  set,	  the	  comb	  was	  removed	  and	  the	  electrophoretic	  
tank	  was	   then	   filled	  with	   1x	   TAE	   buffer	   to	   a	   point	  where	   all	   the	  wells	   were	  
covered.	  Samples	  were	  then	  mixed	  with	  6x	  loading	  buffer	  (0.25%	  bromophenol	  
blue,	  and	  30%	  glycerol	  in	  1x	  TAE	  buffer,	  BioLabs	  inc,	  England)	  and	  loaded	  into	  
the	   wells.	   300-­‐450ng	   of	   the	   appropriate	   molecular	   weight	   marker	   was	   also	  
loaded	  onto	  the	  gel.	  See	  Appendix	  1	  for	  all	  molecular	  weight	  markers	  used	  in	  
this	  project.	  
The	   tank	   was	   then	   connected	   to	   an	   electrophoresis	   3500	   power	   supply	  
(Pharmacia,	   UK)	   and	   a	   current	   between	   90-­‐100	   volts	   was	   applied.	   Once	   the	  
samples	   had	  migrated	   three-­‐quarters	   of	   the	  way	   through	   the	   gel,	   the	   current	  
was	   stopped	  and	   the	  gel	  was	  viewed	  under	  UV	   light	   (Gene	   flash,	   Syngene	  Bio	  
Imaging,	   USA),	   and	   a	   picture	  was	   taken	   (Video	   graphic	   printer,	   UP-­‐850,	   Sony,	  
Japan).	  The	  DNA	  fragments	  of	  the	  size	  of	  interest	  were	  cut	  out	  of	  the	  agarose	  gel	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and	  were	  purified	  by	  the	  use	  of	  the	  Wizard®	  SV	  Gel	  and	  PCR	  Clean-­‐Up	  System	  
according	  to	  the	  manufacturer’s	   instructions	  (Promega,	  UK).	  The	  concentration	  
of	   the	   purified	   DNA	   fragments	   was	   then	   estimated	   my	   means	   of	   OD260nm	  
measurement.	  
	  	  
2.1.7 Restriction	  Enzyme	  Digest	  
	  
DNA	  digestions	  were	  carried	  out	  on	  PCR	  products	  or	  plasmids.	  According	  to	  
the	  manufacturer’s	  protocol,	  1	  unit	  of	  the	  enzyme	  is	  required	  to	  digest	  1μg	  of	  
DNA	   in	   one	   hour	   under	   the	   optimum	   temperature	   and	   buffer	   conditions	  
(Promega	   and	   New	   England	   Biolabs,	   UK).	   In	   this	   project,	   DNA	   fragments	   of	  
interest	  were	  digested	  for	  a	  duration	  of	  3	  hours	  at	  37°C	  with	  the	  appropriate	  
restriction	  enzyme	  at	  its	  optimum	  10x	  buffer.	  All	  restriction	  enzymes	  and	  their	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Restriction	  Enzyme	   Restriction	  Buffer	  (100%	  suitable)	  	   Manufacturer	  
BamHI	   Buffer	   B:	   6mM	   Tris-­‐Cl	   pH	   7.5,	   6mM	   MgCl2,	   50mM	  
NaCl,	  1mM	  DTT	  
0r	   Multicore	   buffer:	   25mM	   Tris-­‐acetate	   pH	   7.8,	  
100mM	  K(Ac),	  10mM	  Mg(Ac)2,	  1mM	  DTT	  
Promega	  
EcoRI	   Buffer	   H:	   90mM	   Tris-­‐Cl	   pH	   7.9,	   6mM	   MgCl2,	   50mM	  
NaCl	  
0r	  Multicore	  buffer	  
Promega	  
HindIII	   Buffer	   E:	   6mM	   Tris-­‐Cl	   pH	   7.5,	   6mM	   MgCl2,	   100mM	  
NaCl,	  1mM	  DTT	  
Promega	  
SacI	   Buffer	  J:	  10mM	  Tris-­‐Cl	  pH	  7.5,	  7mM	  MgCl2,	  50mM	  KCl,	  
1mM	  DTT	  
Promega	  	  
SnaBI	   Buffer	   4:	   20mM	   Tris-­‐acetate	   pH	   7.9,	   50mM	   K(Ac),	  
10mM	  Mg(Ac)2,	  1mM	  DTT	  
New	  England	  
Biolabs	  	  	  
XhoI	   Buffer	   B:	   6mM	   Tris-­‐Cl	   pH	   7.5,	   6mM	   MgCl2,	   150mM	  
NaCl,	  1mM	  DTT	  
Promega	  
Table	  2.4	  Restriction	  Enzymes	  used	  in	  this	  project	  and	  their	  incubation	  buffers.	  
	  
2.1.8 DNA	  Ligation	  
	  
Purified	  and	  digested	  PCR	  products	  were	  ligated	  into	  the	  vector	  pB12mcs-­‐
eGFP,	   that	   was	   kindly	   given	   by	   Dr	   Adam	   Rodaway	   (King’s	   College	   London,	  
Cardiovascular	   Division).	   The	   plasmid	   was	   also	   digested	   with	   the	   same	  
restriction	  enzymes	  as	  that	  used	  for	  digesting	  the	  PCR	  products	  to	  be	  inserted.	  
Following	  gel	  purification	  of	  DNA	  and	  estimation	  of	  its	  concentration	  by	  means	  
of	  OD260nm,	  a	  molar	  ratio	  10:1	  insert	  to	  vector	  was	  used	  to	  establish	  ligation.	  To	  
do	  so,	  the	  following	  equation	  was	  used:	  
	  
ng	  of	  insert	  =	  (ng	  of	  vector	  x	  kb	  of	  insert	  size	  /	  kb	  of	  vector	  size)	  x	  (molar	  ratio	  
of	  insert	  :	  vector)	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The	  ligation	  reactions	  were	  done	  in	  a	  total	  volume	  of	  10µl,	  where	  200ng	  of	  
the	  vector,	  xng	  of	  the	  insert,	  1µl	  of	  T4	  DNA	  ligase	  enzyme	  (3U/µl),	  1µl	  of	  10x	  
ligase	  buffer	   (Promega,	  UK)	  and	  a	  volume	  of	  xµl	  of	  DEPC	  treated	  water	  were	  
added.	  The	  reaction	  was	  left	  for	  overnight	  ligation	  at	  4°C.	  The	  ligation	  reaction	  
was	  further	  assessed	  by	  means	  of	  PCR,	  where	  the	  ligation	  mixture	  was	  diluted	  
by	   1000	   and	   used	   as	   a	   DNA	   template.	   Primer	   sets	   used	   were	   either	   both	  
located	  within	   the	   plasmid	   or	   at	   least	   one	  was	  within	   the	   plasmid	  while	   the	  
other	  was	  within	  the	  insert.	  In	  addition,	  a	  negative	  control	  was	  established	  by	  
the	  use	  of	  the	  same	  set	  of	  primers	  to	  PCR	  the	  wild	  type	  plasmid.	  	  	  
	  	  	  
2.1.9 Transformations	  
	  
50µl	  of	  JM109	  competent	  cells	  (>107	  cfu/µg,	  Promega,	  UK)	  were	  thawed	  on	  
ice	  for	  5	  minutes.	  5µl	  of	  the	  ligation	  mixture	  was	  added	  and	  the	  cells	  were	  kept	  
in	  a	  1.5ml	  Eppendorf	  tube	  on	  ice	  for	  another	  20	  minutes.	  To	  heat	  shock	  the	  cells,	  
the	   tube	   was	   then	   transferred	   to	   a	   heat	   block	   at	   42°C	   (Grant	   BT1	   Block	  
Thermostat,	   UK)	   for	   45-­‐55	   seconds	   then	   back	   on	   ice	   for	   another	   2	   minutes.	  	  
350µl	  of	  SOC	  medium	  (BioLine	  Ltd,	  UK)	  was	  then	  added	  to	  the	  cells,	  and	  the	  cells	  
were	  incubated	  at	  37°C	  for	  45-­‐90	  minutes.	  	  
200µl	  of	  transformed	  competent	  cells	  were	  then	  spread	  on	  prepared	  LB	  agar	  
plates.	   These	  plates	  were	  prepared	   from	  16g	  of	   LB	   agar	   (Sigma,	  UK)	   that	  was	  
dissolved	   in	   500ml	   of	  Milli	   Q	  H2O	   (ELGA	   LA620,	  UK),	   autoclaved,	   then	   further	  
boiled,	   left	   to	  cool	  down,	  and	  60µg/ml	  of	  ampicillin	  was	  added.	  LB	  agar	  plates	  
were	  stored	  at	  4°C	  for	  a	  month	  from	  the	  date	  of	  preparation.	  The	  plates	  were	  
placed	  overnight	   in	  a	  37°C	   incubator	   (Luckham	  R300),	   and	  were	  examined	   for	  
colony	  growth	  the	  next	  day.	  
By	   the	   use	   of	   the	   appropriate	   set	   of	   primers,	   the	   grown	   colonies	   were	  
screened	   by	   means	   of	   PCR.	   A	   negative	   control,	   wild	   type	   plasmid,	   was	   also	  
included.	  Positive	  colonies	  that	  contain	  the	  inserted	  DNA	  fragment	  were	  picked	  
up	  from	  the	  agar	  plate	  and	  further	  grown	   in	  20ml	  of	  LB	  broth	  medium	  (Fisher	  
Scientific,	  UK).	  The	  LB	  medium	  was	  prepared	  by	  dissolving	  12.5g	  of	  LB	  broth	  in	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500ml	  of	  Milli	  Q	  H2O,	  autoclaved,	  and	  60µg/ml	  of	  ampicillin	  was	  added	  just	  prior	  
to	  bacterial	  colony	  addition.	  The	  50ml	  tubes	  containing	  the	  LB	  medium	  were	  left	  
overnight	  at	  37°C	  in	  a	  shaker	  incubator	  (Gallenkamp	  Orbital	  incubator).	  
	  
2.1.10 	  Plasmid	  DNA	  Isolation	  and	  Purification	  	  
	  
Solutions	  used	  include:	  
	  
-­‐ Cell	  suspension	  solution	  (P1):	  25mM	  Tris-­‐HCL,	  pH	  8,	  10mM	  EDTA	  with	  50mM	  
glucose	  and	  DNase-­‐free	  RNase	  (100µg/µl).	  
-­‐ Cell	  lysis	  solution	  (P2):	  0.2N	  NaOH,	  1%	  SDS.	  
-­‐ Potassium	   acetate	   solution	   (P3):	   20	   Volumes	   of	   5M	   potassium	   acetate,	   3	  
volume	  of	  Glacial	  acetic	  acid	  and	  2	  volumes	  of	  H2O.	  	  	  
	  
Mini	  and	  Maxipreps	  were	  conducted	  on	  transformed	  bacterial	  cells,	  which	  
were	   incubated	   in	   20ml	   or	   500ml	   of	   LB	   media	   respectively	   containing	   the	  
appropriate	  antibiotic.	  The	  cells	  were	  grown	  overnight	   in	  a	  shaking	   incubator	  
at	   37°C	  and	  were	  harvested	  by	   centrifugation	   at	   5000rpm	  at	   4°C	   for	   10	  min	  
(Mini)	  or	  20	  min	  (Maxi).	  The	  supernatant	  was	  discharged	  and	  the	  DNA	  isolation	  
was	   performed	   by	   the	   use	   of	   the	   Qiagen	   Plasmid	  Mini	   or	   Endofree	   Plasmid	  
Maxi	   kit	   that	   was	   conducted	   according	   to	   the	   manufacturer’s	   protocol.	   The	  
purity	   and	   the	   amount	   of	   the	   isolated	   DNA	   were	   determined	   as	   described	  
earlier	  in	  section	  2.1.3.	  
	  
2.1.11 	  Glycerol	  Stocks	  
	  
Upon	  confirmation	  of	  clones	  of	  interest	  by	  means	  of	  PCR	  colony	  screening,	  
each	  clone	  was	  picked	  up	  from	  a	  positive	  single	  colony	  and	  grown	  overnight	  in	  
LB	   media	   containing	   a	   suitable	   antibiotic.	   900µl	   of	   the	   overnight	   grown	  
bacterial	  colony	  was	  pipetted	  into	  a	  1.5ml	  Eppendorf	  tube	  containing	  100µl	  of	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glycerol	   (Sigma,	   UK).	   The	   tube	   was	   inverted	   several	   times	   and	   the	   glycerol	  
stock	  was	  stored	  at	  -­‐80°C.	  
	  
2.1.12 	  DNA	  sequencing	  
	  
5µl	   of	   plasmid	   DNA,	   at	   a	   concentration	   of	   100ng/µl,	   was	   enclosed	   in	   a	  
0.5ml	   Eppendorf	   tube	   and	   sent	   to	   Geneservice	   Ltd	   at	   UCL	   London	   for	  
sequencing.	  Geneservice	  Ltd	  provided	  common	  primers	  for	  sequencing	  such	  as	  
those	   that	   bind	   to	   T7	   or	   Sp6	   regions.	   However,	   for	   sequencing	  with	   custom	  
made	   primers,	   5µl	   at	   3.2pmol/µl	   of	   each	   primer	   per	   reaction	   was	   sent	  
separately	  with	   the	  DNA	   samples	   to	   be	   sequenced.	   Sequencing	   results	  were	  
analysed	  using	  the	  Sequence	  Scanner	  software	  v1.0	  (Applied	  Biosystems,	  UK).	  
	  
2.1.13 	  Generation	  of	  Blunt	  Ends	  
	  
Some	   restriction	   enzymes	   generate	   blunt	   ends	   directly,	   such	   as	   StuI	   and	  
SnaBI.	   However,	   other	   enzymes	   generate	   sticky	   ends	   with	   some	   base	  
overhangs.	   To	   achieve	   blunt	   end	   cloning	   or	   even	   vector	   self-­‐ligation	   through	  
blunt	   ends,	   these	   overhangs	   must	   be	   converted	   to	   blunt	   ends.	   This	   can	   be	  
achieved	   by	   either	   filling	   up	   the	   overhangs	   with	   complimentary	   bases	   or	   by	  
removal	  of	  the	  excess	  bases.	  In	  this	  study,	  the	  Klenow	  fragment	  (3’	  	  5’	  exo-­‐),	  
kindly	  given	  by	  Dr.	  Cathy	   Joyce,	   the	  Department	  of	  Molecular	  Biophysics	  and	  
Biochemistry,	  Yale	  University,	  New	  Haven,	  CT.,	  USA,	  was	  used	  to	  create	  blunt	  
ends	  by	  removal	  of	  the	  3’	  overhangs.	  
To	   do	   so,	   1µg	   of	   digested	   vector,	   was	   incubated	   with	   1µl	   of	   Klenow	  
fragment	   in	  3-­‐4µl	  of	  10x	  buffer	  2	  (1x	  buffer	  2:	  10mM	  Tris-­‐HCL	  pH	  7.9,	  50mM	  
NaCl,	  10mM	  MgCl2,	  1mM	  DTT),	  33µM	  of	  each	  dNTP	  and	  xµl	  of	  DEPC	  H2O	  to	  a	  
total	   of	   30-­‐40µl.	   The	   reaction	  was	   left	   at	   room	   temperature	   for	   15	  minutes	  
then	   stopped	  by	  heating	  at	  75°C	   for	  25	  minutes.	  The	  Klenow	   treated	  vector,	  
was	   then	   run	  on	  an	  agarose	  gel,	  were	   the	  band	   representing	   the	  vector	  was	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purified	  by	  the	  use	  of	  the	  Wizard®	  SV	  Gel	  and	  PCR	  Clean-­‐Up	  System	  according	  
to	   the	   manufacturer’s	   protocol.	   The	   concentration	   of	   the	   purified	   DNA	  
fragments	  was	  then	  estimated	  by	  means	  of	  OD260nm	  measurement.	  
	  
2.2 AT	  Cloning	  	  
	  
PCR	  products	  generated	  by	  the	  use	  of	  Taq	  polymerase	  enzyme	  have	  an	  “A”	  
residue	  overhang	  on	  the	  3’	  ends.	  Therefore,	  unmodified	  PCR	  products	  can	  be	  
cloned	  into	  a	   linearised	  vector	  having	  a	  “T”	  overhang	  of	  the	  3’	  end.	  Based	  on	  
these	   facts,	   unmodified	   PCR	   products	   were	   cloned	   into	   the	   pGEM-­‐T	   vector	  
(Promega,	  UK).	  The	  AT	  cloning	  was	  done	  by	  the	  use	  of	  the	  pGEM-­‐T	  easy	  vector	  
kit	   (Promega,	   UK)	   and	   was	   conducted	   according	   to	   the	   manufacturer’s	  
protocol.	  The	  pGEM®T	  easy	  vector	  system	   is	  shown	   in	  Figure	  2.1.	  This	  vector	  
has	   a	   LacZ	   gene	   within	   its	   multiple	   cloning	   region	   (MCR).	   The	   LacZ	   gene	  
expresses	  β-­‐galactosidase	  enzyme	  upon	   induction	  with	   IPTG.	  This	  means	  that	  
bacterial	   colonies	   containing	   the	  pGEM®T	  vector	  when	  grown	  on	  agar	  plates	  
containing	   both	   IPTG	   and	   X-­‐gal	   will	   produce	   β-­‐galactosidase,	   and	   these	  
bacterial	   colonies	   will	   be	   blue	   in	   colour.	   However,	   when	   a	   DNA	   fragment	   is	  
inserted	   into	   the	   MCR,	   the	   LacZ	   gene	   is	   disrupted	   and	   bacterial	   colonies	  
containing	   the	   vector	   and	   insert	   will	   be	   visible	   as	   white	   colonies,	   hence,	  
allowing	  blue-­‐white	  colony	  screening.	  	  
Pre-­‐prepared	  LB	  agar	  plates	  with	  100µg/ml	  ampicillin,	  were	  further	  plated	  
with	  a	  100µl	  of	  100mM	  IPTG	  (promega,	  UK)	  and	  20µl	  50µg/ml	  X-­‐Gal	  (Promega,	  
UK)	  30	  minutes	  prior	  to	  plating	  the	  transformed	  bacterial	  cells.	  Colonies	  were	  
left	  to	  grow	  overnight	  at	  37°C,	  and	  the	  white	  colonies	  were	  screened	  by	  means	  
of	  PCR.	  	  
Positive	  PCR	   screened	   colonies	  were	   further	   grown	  overnight	   in	   LB	  broth	  
containing	   ampicillin	   and	   the	   plasmids	   were	   then	   extracted.	   The	   purified	  
extracted	  plasmids	  were	  quantified	  and	  were	  then	  sent	  to	  Geneservice	  Ltd	  at	  
UCL	   London	   for	   sequencing.	   The	   primers	   T7	   forward	   and	   Sp6	   reverse	   were	  
used	  to	  conduct	  this	  sequencing.	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Figure	   2.1	  Map	   of	   the	   pGEM®T	   Easy	   Vector	   system.	   The	   diagram	   was	   obtained	   from	   the	  
Promega	  website.	  	  
The	  pGEM®T	  easy	  vector	  system	  was	  used	  in	  this	  study	  for	  the	  purposes	  of	  AT	  cloning.	  As	  the	  
Map	   indicates,	   the	  vector	  has	  a	  “T”	  overhang	  within	   the	  MCR	   in	  which	  the	  DNA	  fragment	  of	  
interest,	  having	  an	  “A”	  overhang,	  can	  be	  inserted.	  	  	  
	  
	  
2.3 Generation	  of	  Plasmids	  
	  
Two	   plasmids	   were	   used	   for	   the	   purpose	   of	   incorporating	   shRNA	  
molecules,	   pEGFP-­‐N1	   plasmid	   and	   pB12mcs-­‐eGFP	   plasmid.	   The	   pEGFP-­‐N1	  
vector	   (Clonetech,	   UK)	   has	   an	   enhanced	   GFP,	   and	   includes	   a	   human	  
cytomegalovirus	   (CMV)	   promoter.	   For	   the	   purposes	   of	   this	   project	   the	   CMV	  
promoter	   was	   not	   used.	   Instead	   either	   the	   human	   U6	   or	   the	   human	   H1	  
promoter	  was	  used.	  The	  pEGFP-­‐N1	  plasmid	  with	  the	  CMV	  promoter	  removed	  
was	  used	  as	  a	  negative	  control	  during	  expression	  experiments.	  The	  pEGFP-­‐N1	  
vector,	  where	  either	  the	  U6	  or	  H1	  promoter	  had	  replaced	  the	  CMV	  promoter,	  
would	  be	  used	  as	  the	  positive	  control.	  The	  pEGFP-­‐N1	  vector	  is	  shown	  in	  figure	  
2.2.	  	  
JM109	   bacterial	   cells	   were	   transformed	   with	   the	   pEGFP-­‐N1	   vector.	   The	  
cells	  were	  then	  grown	  overnight	  in	  500ml	  of	  LB	  with	  the	  appropriate	  antibiotic.	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1ml	  of	   the	   grown	  bacteria	  was	   stored	   at	   -­‐80°C	  as	   glycerol	   stock,	   and	   a	  maxi	  
prep	   was	   then	   conducted	   on	   the	   transformed	   bacterial	   cells.	   The	   extracted	  
pEGFP-­‐N1	  plasmid	  was	  resuspended	  in	  an	  appropriate	  volume	  of	  Milli	  Q	  water,	  
quantified	  and	  stored	  at	  -­‐20°C.	  
The	   pB12mcs-­‐eGFP	   vector	   was	   kindly	   given	   by	   Dr.	   Adam	   Rodaway.	   This	  
vector	   also	   contains	   an	   enhanced	  GFP,	   however,	   it	   has	   no	   promoter.	   This	   is	  
advantageous,	   as	   the	   wild	   type	   vector	   can	   be	   used	   as	   a	   negative	   control.	  
Upstream	  of	  the	  eGFP	  is	  the	  MCR,	  in	  which	  the	  U6,	  the	  H1	  human	  promoters,	  
and	  the	  shRNA	  cassettes	  can	  be	   individually	  cloned.	  The	  vector	  with	  only	  the	  
U6	   or	   the	   H1	   promoter	   can	   then	   serve	   as	   positive	   control.	   A	   map	   of	   the	  
pB12mcs-­‐eGFP	   plasmid	   is	   shown	   in	   Figure	   2.3.	   Before	   deciding	   which	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Figure	  2.2	  pEGFP-­‐N1	  Vector	  Map.	  The	  diagram	  was	  obtained	  from	  the	  Clontech	  website.	  
Top:	  The	  map	  of	  the	  pEGFP-­‐N1	  vector.	  
Bottom:	  The	  sequence	  and	  the	  restriction	  sites	  of	  the	  MCR	  of	  the	  pEGFP-­‐N1	  vector.	  
	  
The	  pEGFP-­‐N1	  vector	  was	  selected	  to	  clone	  the	  shRNA	  cassettes.	  The	  vector	  has	  an	  eGFP	  gene	  
that	  gives	  its	  high	  expression	  and	  bright	  fluorescence	  in	  mammalian	  cells.	  
	  





















Figure	   2.3	   The	   pB12mcs-­‐eGFP	  Vector	  Map.	   The	   plasmid	  was	   constructed	   and	   given	   by	  Dr.	  
Adam	  Rodaway	  
The	  pB12mcs-­‐eGFP	  vector	  is	  3029bp	  in	  size,	  has	  an	  ampicillin	  resisted	  gene,	  and	  an	  eGFP	  gene	  
that	  gives	  a	  higher	  and	  brighter	  expression	  of	   this	  protein	   in	  mammalian	  cells.	  The	  wild	  type	  
vector	   can	   be	   used	   as	   a	   negative	   control.	   Positive	   controls	   can	   be	   constructed	   through	   the	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2.3.1 Construction	  of	  the	  shRNA	  Cassettes	  	  
	  
Short	  hairpin	  RNA	  (shRNA)	  molecules	  were	  designed	  according	  to	  the	  Cold	  
Spring	  Harbor	  Lab	  guidelines.	  shRNA	  molecules	  were	  designed	  to	  be	  of	  50-­‐52	  
nt	  long	  and	  were	  to	  be	  cloned	  with,	  and	  downstream	  of,	  the	  U6	  or	  H1	  human	  
promoters.	   The	   U6-­‐shRNA	   primer	   transcripts	   were	   initialised	   with	   a	   “G”	  
nucleotide,	  of	  the	  U6/H1-­‐small	  nuclear	  RNA	  Pol	  III	  transcript,	  and	  termination	  
was	  mediated	  by	  a	  stretch	  of	  6	  “T”	  nt	  at	  the	  end	  of	  the	  transcript.	  
Each	   of	   the	   designed	   shRNA	  molecules	   can	   be	   divided	   into	   four	   regions.	  
These	  are	  the	  anti-­‐sense	  region,	  the	  loop,	  and	  sense	  and	  termination	  regions.	  
The	  sense	  region	  corresponds	  to	  21-­‐22	  nt	  and	  it’s	  sequence	  is	  the	  same	  as	  the	  
target	  DNA,	  this	  region	  was	  designed	  to	  be	  complementary	  to	  the	  fusion	  points	  
of	  the	  BCR-­‐ABL	  gene.	  Thus,	  aiming	  to	  target	  the	  fusion	  gene	  only	  and	  not	  the	  
normal	  BCR	  or	  ABL	  genes.	  The	  anti-­‐sense	  region	  is	  complimentary	  to	  the	  sense	  
part.	   Both	   the	   sense	   and	   anti-­‐sense	   parts	   of	   the	   shRNA	   transcript	   are	  
separated	  by	  an	  8	  nt	  long	  loop.	  The	  final	  region	  is	  made	  up	  of	  a	  stretch	  of	  “Ts”,	  
because	   the	  U6	  and	  H1	  promoters	   require	  an	  oligo	  T	   termination	   signal.	  The	  
sequences	  of	  the	  designed	  shRNA	  transcripts	  can	  be	  found	  in	  table	  2.5.	  	  
Brummelkamp	  and	  colleagues	   in	  2002	  studies	   the	  effects	  of	   the	   loop	  size	  
on	   the	  RNAi	  potency	  of	   shRNA	  molecules	   that	  had	   the	   same	  sense	  and	  anti-­‐
sense	   sequences,	  but	  either	  had	   five,	   seven,	  or	  nine	   long	  nt	   loop	   sequences.	  
Their	   study	   showed	   that	   the	   differences	   in	   loop	   size	   and	   sequence	   had	  
different	   RNAi	   effects,	   where	   shRNA	   molecules	   with	   a	   five	   nt	   loop	   were	  
inactive,	  those	  with	  seven	  were	  moderately	  active,	  and	  shRNAs	  with	  9	  nt	  long	  
gave	   around	   90%	   knockdown	   of	   the	   gene	   of	   interest	   (Brummelkamp	   et	   al.,	  
2002).	   Furthermore,	   in	   2010,	   Schopman	   and	   colleagues	   demonstrated	   that	  
moderate	   or	   even	   weak	   shRNA	   inhibitors	   could	   be	   transformed	   into	   strong	  
potent	  inhibitors	  by	  simply	  changing	  the	  loop	  size	  and	  structure.	  In	  this	  study	  
scientists	   found	   that	   shRNA	   molecules	   with	   an	   open	   loop	   structure	   (no	  
sequences	  of	  the	  loop	  are	  complementary	  to	  each	  other	  at	  the	  sense	  and	  anti-­‐
sense	   part	   of	   the	   shRNA)	   exhibit	   stronger	   RNAi	   gene	   silencing	   (Schopman	  et	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al.,	   2010).	   On	   this	   basis,	   an	   8	   nt	   long	   open	   loop	   structure	  was	   used	   for	   the	  
shRNA	  molecules	  designed	  in	  the	  current	  work.	  	  	  	  	  	  	  	  	  
Once	  the	  designing	  of	  the	  shRNA	  molecules	  was	  complete,	   the	  secondary	  
structures	   of	   these	   molecules	   were	   predicted	   by	   the	   use	   of	   the	   program	  
‘mfold’.	   These	   secondary	   structures	   can	   be	   seen	   in	   Appendix	   2,	   except	   for	  











Table	  2.5	  The	  designed	  shRNA	  transcripts.	  
The	  above	  table	  demonstrates	   that	   three	  different	  shRNA	  molecules	  were	  designed	   for	  each	  
fusion	  point.	  shRNA1	  and	  2	  are	  of	  21	  nt	  long,	  whereas	  shRNA3	  is	  22	  nt	  long.	  shRNA1	  has	  11	  nt	  
upstream	   the	   fusion	   point	   and	   10	   nt	   downstream,	   	   shRNA2	   had	   10	   nt	   upstream	   the	   fusion	  
point	  and	  11	  nt	  downstream,	  whereas	  shRNA3	  has	  11	  nt	  on	  either	  sides	  of	   the	   fusion	  point.	  
The	   sequences	   shown	   in	   blue	   represent	   the	   anti-­‐sense	   part	   of	   the	  molecule	   and	   the	   fusion	  
points	   within	   this	   part	   are	   underlined	   and	   in	   bold.	   Any	   sequence	   differences	   between	   the	  
three	   shRNA	  molecules	   are	   shown	   in	   green.	   The	   sequences	   in	   red	   represent	   the	   sense	  part.	  
The	   sequences	   in	   black	   and	   underlined	   correspond	   to	   the	   hairpin	   loops,	   and	   the	   oligo	   T	  
termination	  signal	  is	  in	  black.	  	  	  	  
	  	  
2.3.2 Cloning	  of	  Promoter	  Constructs	  
	  
PCR	  was	   used	   to	   produce	   the	  U6/shRNA	   and	  H1/shRNA	   cassettes.	   These	  
were	  established	  by	  incorporating	  the	  shRNA	  sequence	  within	  a	  reverse	  primer	  
Fusion	  
point	  
shRNA	  sequences	  5’3’	  
shRNA1(21nt)	   gcagaguucaaaagcccuucagaagcuugugaagggcuuuugaacucugctttttt	  
shRNA2(21nt)	   cagaguucaaaagcccuucaggaagcuugcugaagggcuuuugaacucugtttttt	  
β3α2	  
shRNA3(22nt)	   gcagaguucaaaagcccuucaggaagcuugcugaagggcuuuugaacucugctttttt	  
shRNA1(21nt)	   caauaaggaagaagcccuucagaagcuugugaagggcuucuuccuuauugtttttt	  
shRNA2(21nt)	   aauaaggaagaagcccuucacgaagcuuggugaagggcuucuuccuuauutttttt	  
β2α2	  
shRNA3(22nt)	   caauaaggaagaagcccuucacgaagcuuggugaagggcuucuuccuuauugtttttt	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that	   had	   28	   nt	   of	   its	   sequence	   complimentary	   to	   the	   U6	   or	   H1	   promoters.	  
HindIII	  and	  BamHI	  restriction	  sites	  were	  also	  incorporated	  into	  the	  forward	  and	  
reverse	  primers	  respectively.	  Finally,	  PCR,	  conducted	  on	  K562	  cDNA,	  was	  used	  
to	  produce	  the	  whole	  cassettes.	  The	  sequences	  for	  these	  primers	  are	  shown	  in	  
table	  2.6.	  
The	  U6/shRNA	  and	  the	  H1/shRNA	  cassettes	  were	  cloned	  into	  the	  pB12mcs-­‐
eGFP	  plasmid.	  The	  plasmids	  were	  then	  sent	  for	  DNA	  sequencing	  to	  confirm	  the	  
correct	  sequence.	  A	  schematic	  diagram	  for	  the	  steps	  involved	  in	  the	  synthesis	  
of	   the	   shRNA	   cassette	   is	   shown	   in	   Figure	   2.4.	   A	   flow	   diagram	   showing	   the	  
overall	  procedures	  undertaken	  to	  generate	  the	  pB12mcs-­‐eGFP	  containing	  the	  
shRNA	  cassettes	  can	  be	  seen	  in	  Figure	  2.5.	  	  




Figure	  2.4	  Schematic	  Diagram	  of	  the	  Synthesis	  of	  the	  shRNA	  cassettes.	  	  
The	  diagram	   illustrates	  how	  a	   shRNA	  cassette	  under	   the	   regulation	  of	   the	  U6	  promoter	  was	  
synthesised.	  cDNA	  extracted	  from	  the	  K562	  cell	  line	  was	  used	  as	  a	  DNA	  template	  to	  amplify	  the	  
human	  U6	  promoter.	  To	  synthesise	   the	  shRNA	  cassette	   (top	  part	  of	   the	  diagram)	   the	  shRNA	  
molecule	   was	   synthesised	   as	   an	   oligonucleotide	   that	   had	   27bp	   complimentary	   to	   the	   U6	  
promoter.	  This	  oligo	  was	  part	  of	  a	  U6	  reverse	  primer,	  which	  could	  be	  used	  together	  with	  the	  
U6	   forward	  primer	   in	  a	  PCR	   reaction.	  The	   resultant	  PCR	  product	  contained	   the	  U6	  promoter	  
linked	   to	   the	   shRNA	   (bottom	   part	   of	   the	   diagram).	   The	   reaction	   was	   conducted	   for	   every	  
designed	   shRNA	   molecule,	   and	   the	   same	   technique	   was	   used	   to	   produce	   shRNA	   cassettes	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Primer	  Name	   Primer	  sequence	   Melting	  
temperature	  
U6	  Forward	   5'	  d-­‐CCCAAGCTTCAAGGTCGGGCAGGAAGAGGGCCTA'3	   64°C	  






































H1	  forward	  	   5'	  d-­‐CCCAAGCTTCGAACGCTGACGTCATCAAC'3	   64°C	  




















Table	  2.6	  Primer	  sequences	  used	  to	  construct	  the	  shRNA	  cassettes.	  This	  table	  represents	  all	  
the	   primers	   used	   to	   produce	   the	   shRNA	   cassettes.	   The	   sequences	  within	   the	   primers	   in	   red	  
show	  the	  incorporated	  restriction	  enzyme	  sites,	  HindIII	  and	  BamHI,	  located	  in	  the	  forward	  and	  
reverse	  primers	  respectively.	  	  
	  
	  






















Figure	  2.5	  A	  Flow	  Diagram	  of	  the	  Overall	  Procedures	  Undertaken	  to	  Generate	  the	  Plasmids	  
Containing	  the	  shRNA	  Cassettes.	  
This	   diagram	   summarises	   the	   steps	   and	   experiments	   conducted	   to	   construct	   the	   shRNA	  
cassettes,	  directed	  against	  the	  BCR-­‐ABL	  fusion	  genes,	  and	  to	  incorporate	  these	  cassettes	  into	  a	  
suitable	  vector.	  
	  
Obtaining	  the	  sequences	  of	  the	  β3α2	  and	  the	  β2α2	  fusion	  points	  from	  the	  EMBL	  
website.	  Accession	  numbers	  AJ131466	  and	  AJ131467	  respectively.	  
3	  different	  shRNA	  molecules	  were	  designed	  for	  each	  fusion	  point	  and	  their	  2°	  
structures	  were	  predicted	  through	  the	  program	  “mfold”.	  
Incorporating	  the	  sequence	  of	  each	  designed	  shRNA	  molecules	  within	  a	  U6	  and	  
an	  H1	  reverse	  primer.	  Thus,	  having	  3	  different	  U6	  reverse	  primers	  for	  both	  the	  
BCR-­‐ABL	  variants	  and	  3	  different	  H1	  reverse	  primers	  for	  only	  β3α2	  variant.	  
Using	  the	  above	  reverse	  primers	  and	  the	  forward	  U6	  or	  H1	  primer.	  A	  PCR	  
reaction	  was	  conducted	  on	  cDNA,	  extracted	  from	  K562	  cell	  lines,	  to	  generate	  the	  
U6/shRNA	  and	  the	  H1/shRNA	  cassettes.	  
Double	  digestion	  of	  both	  the	  pB12mcs-­‐eGFP	  vector	  and	  the	  PCR	  generated	  
shRNA	  cassettes	  with	  BamHI	  and	  HindIII	  restriction	  enzymes.	  The	  digested	  vector	  
and	  PCR	  product	  were	  then	  ligated	  overnight	  at	  4°C.	  
JM109	  bacterial	  cells	  were	  transformed	  with	  half	  the	  volume	  of	  the	  ligation	  
reaction.	  Bacterial	  cell	  were	  plated	  onto	  agar	  plates	  and	  were	  left	  to	  grow	  
overnight.	  
Grown	  bacterial	  colonies	  were	  screened	  via	  PCR,	  positive	  colonies	  were	  grown	  
on	  LB	  and	  a	  mini	  prep	  was	  conducted	  to	  extract	  the	  plasmids.	  
Extracted	  plasmids	  were	  sent	  for	  sequencing.	  Plasmids	  with	  the	  correct	  
sequences	  were	  used	  for	  further	  experiments.	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2.4 Tissue	  Culture	  
	  
Two	  types	  of	  cell	  lines	  were	  used	  for	  the	  purposes	  of	  this	  study.	  These	  are	  
the	   K562	   cell	   line	   (kindly	   given	   by	   Dr.	   David	   Grimwade,	   Guy’s	   tower,	   King’s	  
College	  London)	  and	  the	  KCL-­‐22	  cell	  line	  (DSMZ,	  Germany).	  These	  are	  CML	  cell	  
lines,	  and	  as	  explained	  in	  chapter	  1,	  the	  K562	  cells	  are	  CML	  cells	  with	  the	  β3α2	  
fusion	  point,	  whereas	  the	  KCL-­‐22	  cells	  have	  the	  β2α2	  fusion	  point.	  	  
	  
2.4.1 Cell	  line	  Maintenance	  
	  
2.4.1.1 Thawing	  and	  recovery	  of	  cell	  lines	  
	  
A	  vial	  of	  CML	  cell	   lines	  was	   removed	   from	  the	   liquid	  nitrogen	   freezer	   (RS	  
series,	   Jencons	   pls)	   and	   placed	   immediately	   in	   a	   37°C	   water	   bath	   (Grant	  
Instrument	   Ltd,	   England).	   The	   cells	  were	  washed	  with	   2ml	  warm	  RPMI	   1640	  
medium	  with	  L-­‐glutamine	  (PAA,	  Austria),	  10%	  Foetal	  Bovin	  Serum	  (FBS)	  (Sigma,	  
UK)	  and	  550μl	  of	  penicillin/streptomycin	  antibiotic	  (10,000iu	  PEN/ml,	  10,000ug	  
STREP/ml,	  MP	  Biomedicals,	  France),	  and	  centrifuged	  for	  5	  minutes	  at	  1000	  rpm	  
(Beckman	   CS-­‐R6	   centrifuge,	   UK)	   at	   room	   temperature.	   The	   supernatant	   was	  
discharged	   and	   the	   pellet	   resuspended	   in	   1ml	   of	   medium.	   Cells	   were	   then	  
transferred	   to	   a	   75cm2	   culture	   flask	   that	   contained	   30ml	   of	   medium	   and	  
incubated	  in	  a	  humidified	  37°C,	  5%	  CO2	  incubator	  (Binder,	  USA).	  	  	  	  	  	  	  
	  
	  
2.4.1.2 Feeding	  and	  Passageing	  of	  cell	  lines	  
	  
For	   the	   cells	   to	   be	   passaged	   they	  must	   be	   confluent,	   that	   is	   their	   count	  
should	  be	  about	  2.5	   x	   106	   cells/ml	   in	   a	  250ml	   flask;	   cells	  were	   fed	  every	  2-­‐3	  
days	  till	  confluency	  was	  reached.	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-­‐ Feeding	  of	  Cell	  lines	  
	  
Cells	  were	   counted	  and	   if	   non-­‐confluent,	  one	   third	  of	   the	  medium	   in	   the	  
flask	  was	  aseptically	  removed	  and	  replaced	  by	  an	  equal	  volume	  of	  fresh	  warm	  
media.	  The	  flask	  was	  gently	  swirled	  and	  returned	  to	  the	  incubator.	  On	  the	  days	  
cells	  were	  not	  fed,	  they	  were	  checked	  by	  gently	  swirling	  the	  flask,	  to	  resuspend	  
them,	   and	   by	   observing	   any	   media	   colour	   changes	   which	   reflected	   their	  
metabolic	  growth.	  
	  
-­‐ Passaging	  of	  Cell	  lines	  
	  
When	   cells	   were	   confluent,	   half	   the	   cells	   in	   suspension	   were	   aseptically	  
transferred	   to	   a	   new	   culture	   flask.	   To	   each	   flask	   an	   equal	   amount	   of	   warm	  
medium	  was	  added	  and	  flasks	  were	  returned	  to	  the	  incubator.	  
	  
2.4.1.3 Counting	  of	  cell	  lines	  
	  
The	   process	   of	   cell	   counting	   is	   an	   important	   procedure	   through	   which	  
optimisation	   of	   culture	   conditions	   and	   the	   performance	   of	   accurate	  
quantification	   experiments	   can	   be	   conducted.	   To	   count	   the	   cells	   a	  
haemacytometer	  (Bright-­‐Line,	  Hausser	  Scientific,	  USA)	  was	  used.	  The	  device	  is	  
a	  thick	  glass	  slide	  with	  a	  central	  counting	  chamber.	  The	  chamber	  is	  divided	  into	  
two	  portions	  each	  made	  up	  of	  a	  3	  x	  3	  mm	  etched	  grid	  that	   is	   further	  divided	  
into	  nine	  secondary	  squares,	  1	  x	  1	  mm	  each.	  The	  four	  corner	  squares	  and	  the	  
central	   one	   are	   used	   for	   counting;	   they	   are	   divided	   into	   16	   and	   25	   tertiary	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Figure	  2.6	  The	  Haemacytometer.	  (The	  diagram	  was	  taken	  from	  the	  Klinik	  Andrologi	  website)	  
(Top)	  The	  central	  portion	  of	   the	  haemacytometer,	   the	  counting	  chamber,	   is	  divided	   into	  two	  
portions.	  Each	  portion	  has	  its	  counting	  grid.	  (Bottom)	  One	  of	  the	  grids	  is	  amplified	  showing	  five	  
counting	  boxes.	  The	  outer	  four	  are	  further	  divided	  into	  16	  tertiary	  boxes,	  while	  the	  central	  one	  
comprises	  25	  boxes.	  A	  central	  tertiary	  box	  is	  further	  enlarged	  showing	  two	  cells	  within	  it.	  The	  
bent	   arrows	   on	   the	   top	   show	   where	   the	   cover	   slip	   is	   placed	   prior	   to	   loading	   the	   cell	  




The	  haemacytometer	  and	  the	  cover	  slip	  were	  wiped	  with	  70%	  ethanol	  
and	  the	  cover	  slip	  placed	  on	  the	  counting	  chambers.	  A	  1:1	  dilution	  for	  the	  cells	  
with	  trypan	  blue	  (0.4%,	  Sigma,	  UK)	  was	  prepared	  and	  10μl	  of	  the	  dilution	  was	  
loaded	   into	  each	   counting	   chamber	  by	   a	  pipette.	   The	   suspension	  was	  drawn	  
under	   the	   slip	   by	   capillary	   action,	   and	   cells,	   in	   the	   centre	   and	   in	   two	   of	   the	  
corner	   squares,	  were	   counted	   under	   a	   light	  microscope	   (100x	  magnification,	  
Nikon	  Eclipse	  TS1000,	  Japan)	  and	  with	  the	  aid	  of	  a	  hand-­‐held	  counter.	  Whole	  
blue-­‐stained	  cells	  were	  excluded	  in	  the	  count,	  since	  only	  those	  staining	  yellow	  
are	  viable.	  The	  following	  formula	  was	  used	  to	  calculate	  the	  cell	  number:	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  “Cells/ml	  =	  average	  count	  of	  squares	  x	  dilution	  factor	  x	  104”	  
	  
In	  some	  cases	  the	  Invitrogen	  automated	  cell	  counter,	  Countess®,	  was	  also	  
used	  to	  count	  the	  cells.	  Here	  cells	  were	  again	  prepared	  at	  a	  1:1	  dilution	  factor	  
with	  trypan	  blue	  (0.4%,	  Invitrogen,	  UK)	  and	  were	  loaded	  into	  both	  sides	  of	  the	  
CountessTM	   call	   counting	   chamber	   slide.	   The	   manufacturer’s	   protocol	   was	  
followed	  in	  order	  to	  count	  the	  cells	  and	  predict	  the	  percentage	  of	  cell	  viability.	  	  
	  
2.4.1.4 Freezing	  of	  cell	  lines	  
	  
Cells	  for	  freezing	  were	  first	  transferred	  into	  50ml	  test	  tubes,	  centrifuged	  for	  
5	   minutes	   at	   1000	   rpm	   (GS-­‐6R	   Centrifuge,	   Beckman,	   USA)	   at	   room	  
temperature.	  The	  supernatant	  was	  discharged	  and	  the	  pellet	  was	  resuspended	  
in	  10ml	  of	  warm	  medium.	  Cells	  were	  counted,	   spun	  as	  stated	  previously	  and	  
were	  resuspended	  in	  a	  volume	  of	  freezing	  medium,	  90%	  FBS	  with	  10%	  DSMO,	  
(Sigma,	  UK)	  to	  obtain	  a	  concentration	  of	  2	  x	  106	  cells/ml.	  Cells	  were	  pipetted	  in	  
1ml	   aliquots	   into	   2ml	   cyrovials.	   The	   vials	  were	   placed	   in	   a	   1°C	   cryo	   freezing	  
chamber	   (NalgeneTM,	   USA)	   to	   allow	   a	   gradual	   decrease	   in	   temperatue	   thus	  
reducing	  the	  loss	  of	  cells.	  The	  camber	  containing	  the	  cells	  was	  left	  overnight	  in	  
a	  -­‐80°C	  freezer	  (Revco	  Scientific	  Inc,	  USA).	  The	  following	  day,	  cells	  were	  placed	  
in	  a	  -­‐150°C	  liquid	  nitrogen	  Dewar	  (HC	  series,	  Tayler-­‐Wharton,	  UK).	  
	  
2.4.2 Optimisation	  of	  Cell	  Line	  Transfection	  	  
	  
The	  term	  transfection	  is	  usually	  used	  to	  indicate	  a	  process	  in	  which	  nucleic	  
acids	   are	   intentionally	   introduced	   into	   cells.	   To	   date	   various	   methods	   for	  
transfection	  are	  present	  and	  can	  be	  categorised	  as	  chemical	  and	  non-­‐chemical	  
based	   transfections.	   In	   this	   project,	   the	   K562	   and	   KCL22	   cell	   lines	   were	  
transfected	  with	  the	  U6/shRNA	  or	  H1/shRNA	  pB12mcs-­‐eGFP	  plasmids	  in	  order	  
to	  observe	  and	  study	  the	  effects	  of	  the	  constructed	  shRNA	  cassettes.	  However,	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the	   K562	   and	   KCL22	   cell	   lines	   are	   cells	   in	   suspension	   and	   therefore	   are	  
considered	   to	   be	   hard	   to	   transfect	   (Ovcharenko	   et	   al.,	   2005,	   Oliveira	   and	  
Goodell,	   2003	   and	   Merkerova	   et	   al.,	   2007).	   Hence	   several	   transfection	  
methods	  were	  tested	  to	  establish	  an	  acceptable	  transfection	  protocol	  giving	  a	  
good	  efficiency.	  
	  
2.4.2.1 Chemical	  based	  transfections	  
	  
These	  transfections	  depend	  on	  the	  interactions	  of	  chemical	  materials	  with	  the	  
DNA	  of	   interest	   in	   order	   to	   internalise	   the	   latter	   into	   the	   targeted	   cell	   lines.	  
Several	  transfection	  reagents	  were	  tested,	  these	  included	  the	  followings:	  
	  
-­‐ SuperFect®	  Transfection	  Reagent	  (QIAGEN,	  UK):	  This	  transfecting	  reagent	  has	  a	  
specifically	   designed	   activated	   dendrimer	   that	   possesses	   a	   defined	   spherical	  
core	   with	   radiating	   branches	   that	   are	   positively	   charged	   at	   the	   ends.	   	   The	  
reagent	   assembles	   the	   DNA	   particles	   into	   compact	   positively	   charged	  
structures	  that	   in	  turn	  bind	  to	  the	  negatively	  charged	  receptors	  found	  on	  the	  
surfaces	  of	  eukaryotic	  cells,	  hence	  internalising	  the	  target	  DNA	  molecules	  into	  
the	  cells.	  	  
	  
-­‐ FuGENE®	   HD	   Transfection	   Reagent	   (Roche,	   UK):	   This	   transfecting	   reagent	  
consists	   of	   a	   proprietary	   blend	   of	   lipids	   and	   other	   components	   that	   are	  
supplied	   in	   80%	   ethanol,	   sterile-­‐filtered,	   glass	   packaged	   vials.	   The	   reagent	  
complexes	   with	   the	   target	   DNA	   molecules,	   thus	   transporting	   the	   DNA	  
molecules	  into	  the	  cells	  during	  transfection.	  	  	  
	  
-­‐ LipofectamineTM	  2000	  Transfection	  Reagent	  (Invitrogen,	  UK):	  This	  is	  a	  cationic	  
lipid	  based	  reagent.	  The	  reagent	  is	  a	  mix	  of	  cationic	  and	  neutral	  lipids	  that	  form	  
unilamellar	   positively	   charged	   liposome	   vesicles.	  When	  mixed	  with	  DNA,	   the	  
cationic	   liposomes	   will	   absorb	   the	   DNA	   molecules	   then	   facilitate	   their	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internalisation	   into	   the	   target	   cells	   by	   means	   of	   fusion	   to	   the	   cell’s	   plasma	  
membrane,	  thus	  forming	  an	  endocytic	  vesicle.	  	  
	  
-­‐ TransIT®-­‐2020	   Transfection	   Reagent	   (Mirus	   Bio,	   USA):	   According	   to	   the	  
manufacturer,	   this	   transfecting	   reagent	   is	   lipid	   based,	   however	   it	   is	   not	  
liposomal.	  Therefore,	  the	  reagent	  complexes	  with	  the	  DNA	  and	  causes	  it	  to	  be	  
internalized	  into	  the	  cells	  during	  transfection.	  	  
	  
-­‐ HilyMax	   Transfection	   Reagent	   (Dojindo	   Moleculer	   Technologies,	   USA):	   is	   a	  
highly	  purified	  lipid	  of	  a	  single	  molecule.	  The	  reagent	  forms	  cationic	  liposomes	  
that	  complexes	  with	  the	  negatively	  charged	  DNA	  molecule.	  The	  DNA-­‐HilyMax	  
complexes	   electrostatically	   bind	   to	   the	   cell’s	   membrane	   and	   the	   DNA	  
molecules	  enter	  the	  cells	  by	  endocytosis.	  
	  	  
-­‐ NIMT®FeOfection	   Yellow	   Transfection	   Reagent	   (GENOVIS,	   SWEDEN):	   This	  
transfection	   reagent	   is	   composed	   of	   superparamagnetic	   nanoparticles.	   The	  
nanoparticles	  are	  composed	  of	  an	  iron	  oxide	  core	  and	  a	  positive	  surface.	  This	  
composition	   facilitates	   the	   formation	   of	   non-­‐covalent	   bonds	   between	   the	  
nanoparticles	  and	  the	  DNA,	  and	  the	  resultant	  particle/DNA	  complexes	  are	  then	  
internalized	  into	  the	  target	  cell	  lines.	  
	  
-­‐ CalPhos	  Mammalian	  Transfection	  kit	  (Clontech):	  The	  action	  of	  this	  transfection	  
reagent	   depends	   on	   the	   formation	   of	   calcium	   phosphate	   precipitate.	   In	   this	  
method,	   a	   saline	   buffer	   2x	   HEPES	   containing	   the	   phosphate	   ions,	   negatively	  
charged,	   is	   combined	   with	   the	   DNA	   plasmid	   calcium	   solution,	   positively	  
charged.	  This	  finally	  results	  in	  the	  production	  of	  a	  fine	  precipitate	  that	  is	  taken	  
up	  by	  the	  target	  cell	  lines	  when	  added.	  	  
	  
-­‐ Nanofectin	  Kit	  (PAA):	  This	  transfection	  reagent	  is	  formed	  of	  two	  components,	  a	  
positively	  charged	  polymer	  that	  has	  the	  capacity	  to	  bind	  to	  DNA	  and	  a	  porous	  
nanoparticles.	   The	   unique	   size	   of	   the	  DNA-­‐nanoparticle	   complex	   favours	   the	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uptake	   of	   the	   complex	   by	   the	   target	   cells.	   In	   addition,	   the	   complex	   aids	   to	  
protect	  the	  DNA	  from	  nuclease	  degradation.	  	  
	  
To	  determine	  the	  amount	  of	  reagent	  needed	  for	  DNA	  transfection	  for	  each	  
of	   the	   above	   transfection	   reagents,	   the	   pEGFPN-­‐1	   vector	   was	   initially	   used	  
followed	   by	   the	   pB12mcs-­‐U6-­‐eGFP	   vector.	   The	   optimization	   reactions	   were	  
conducted	  according	  to	  each	  manufacturer’s	  protocol.	  	  
	  
2.4.2.2 Non-­‐chemical	  based	  transfections	  
	  
Several	   non-­‐chemical	   based	   transfection	   methods	   exist,	   however,	   only	  
nucleofection,	   a	   subset	   of	   electroporation,	   was	   considered.	   The	   latter	   is	   a	  
transfection	  method	  that	  depends	  on	  the	  discharge	  of	  electrical	  impulses	  that	  
leads	  to	  the	  creation	  of	  transient	  micro-­‐pores	   in	  the	  membrane	  of	  the	  target	  
cell	   line.	  Nucleofection	   is	  a	   transfection	  method	   first	  developed	  by	  Amaxa	   to	  
target	  cell	  lines	  that	  are	  difficult	  to	  transfect,	  such	  as	  primary	  cell	  lines,	  cells	  in	  
suspension	  and	  non-­‐dividing	  cells.	  	  
In	  nucleofection,	  the	  DNA	  molecules	  are	  directly	  delivered	  into	  the	  nucleus	  
of	   the	   target	   cell.	   This	   requires	   both	   a	   nucleofector	   device	   and	   a	   cell-­‐type	  
specific	   nucleofector	   reagent.	   The	   Amaxa®	   Cell	   Line	  Nucleofector®	   Kit	   V	   and	  
the	  Amaxa	  nucleofector	  device,	  Germany,	  were	  used.	  The	  control	  pmaxGFP®	  
vector,	   supplied	   with	   the	   kit,	   was	   used	   to	   determine	   the	   appropriate	  
nucleofection	   program	   to	   be	   used	   on	   the	   K562	   and	   KCL22	   cell	   lines.	  
Furthermore,	   the	   pEGFPN-­‐1	   was	   initially	   used	   to	   determine	   the	   amount	   of	  
plasmid	   DNA	   needed	   to	   optimize	   the	   nucleofection	   reaction.	   Once	   that	   was	  
achieved,	  the	  constructed	  pB12mcs-­‐U6-­‐eGFP	  vector	  was	  used	  to	  optimize	  the	  
amount	   of	   plasmid	   DNA	   needed	   to	   transfect	   the	   target	   cell	   lines.	   All	  
nucleofection	   reactions	   were	   conducted	   according	   to	   the	   manufacture’s	  
protocol.	  
To	  assess	  the	  efficiency	  of	  nucleofection	  a	  6-­‐well	  plate	  with	  the	  transfected	  
cell	   lines	   was	   observed	   under	   a	   fluorescence	  microscope	   (Nikon,	   UK).	   Once,	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fluorescence	  was	  detected,	  the	  cells	  were	  counted	  and	  3	  x	  105	  cells	  were	  fixed	  
as	   described	   below	   for	   FACS	   analysis.	   1	   x	   106	   cells	   were	   used	   for	   RNA	  
extraction	  and	  1	  x	  106	  cells	  were	  used	  for	  western	  blotting.	  
	  	  	  	  	  
	  	  	  	  
2.5 Fluorescence-­‐Activated	  Cell	  Sorter	  (FACS)	  Analysis	  
	  
	  	  	  	  	  	  FACS	  scan	  is	  a	  type	  of	  flow	  cytometry	  that	  involves	  the	  analysis	  and	  sorting	  of	  
single	  cells	  or	  particles,	  in	  this	  case	  the	  K562	  and	  KCL22	  cell	  lines,	  depending	  of	  
their	  physical	  and	  chemical	  properties.	  The	  cells	  of	   interest	  are	  suspended	  in	  a	  
narrow	  precisely	  defined	  liquid	  stream	  also	  known	  as	  the	  sheath	  buffer.	  When	  
the	   cell	   sample	   is	   passed	   through	   the	   sheath	   buffer,	   the	   cells	   will	   undergo	  
hydrodynamic	  focusing.	  This	  type	  of	  pressure	  causes	  the	  cells	  of	   interest	  to	  be	  
individually	   separated	   as	   single	   droplets	   that	   flow	   through	   the	   machine’s	  
cuvette.	  	  Furthermore,	  a	  laser	  beam	  of	  a	  single	  wavelength	  is	  directed	  on	  each	  
cell	   in	  the	  sample.	  The	  laser	  beam	  passing	  through	  the	  flow	  stream	  causes	  the	  
illuminating	  light	  to	  be	  scattered	  and	  fluorescence	  will	  be	  emitted.	  Two	  types	  of	  
light	  scattering	  exist,	  forward	  scatter	  and	  side	  scatter.	  The	  first	  is	  linked	  with	  the	  
cell’s	  volume,	  whereas	  the	  second	  is	  more	  dependent	  on	  the	  internal	  properties	  
of	   the	   cell.	   All	   light	   and	   fluorescent	   emissions	   are	   collected	   and	   directed	   to	  
several	   special	   detectors.	   The	   detectors	  will	   proportionally	   convert	   these	   light	  
pulses	   into	   electrical	   pulses,	   which	   can	   then	   be	   amplified	   by	   a	   linear	   or	  
logarithmic	   amplifier.	   The	   electrical	   pulses	   can	   also	   be	   digitized	   for	   further	  
computer	   processing	   and	   storage	   (Robinson,	   2004).	   In	   the	   current	   work	   the	  
cytometer	  used	  was	  a	  FACScan	  from	  Becton	  Dickinson,	  UK.	  Figure	  2.7	  illustrates	  
the	  basic	  principles	  of	  the	  FACS	  scan.	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Figure	  2.7	  The	  basic	  principle	  of	  the	  FACS	  scan.	  (Source	  www.abcam.com)	  
This	  figure	  illustrates	  the	  principles	  of	  the	  FACS	  scan.	  The	  cells	  of	  interest	  can	  be	  stained	  with	  a	  
specific	  dye	  or	  express	  a	   fluorescent	  protein,	   for	  example	  eGFP.	  The	  sample	  cells	  are	  passed	  
through	   a	   stream	   of	   liquid	   called	   the	   sheath	   fluid/buffer	   and	   through	   the	   process	   of	  
hydrodynamic	  focusing,	  the	  cells	  will	  be	  separated	  into	  individual	  droplets	  that	  pass	  through	  a	  
thin	  narrow	  glass	  cuvette.	  Once	  in	  the	  cuvette,	  a	  laser	  beam	  is	  directed	  in	  each	  individual	  cell,	  
this	   causes	   the	   beam	   to	   separate	   into	   scattered	   light,	   in	   forward	   and	   side	   scattered,	   and	  
emitted	   fluorescence.	   The	   emission	   is	   collected	   through	   a	   detector	   that	   will	   proportionally	  
convert	  the	  collected	  light	  pluses	  into	  digitalized	  electrical	  pulses	  that	  can	  be	  further	  analysed	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As	  discussed	  previously,	  the	  K562	  and	  KCL22	  cell	  lines	  were	  transfected	  with	  
the	  pB12mcs-­‐U6-­‐eGFP	  vector.	  The	  plasmid	  expresses	  eGFP	  that	  can	  be	  detected	  
by	  FACS.	  The	  cell	  lines	  where	  centrifuged	  at	  1,000	  rpm	  (Beckman	  TJ-­‐6	  centrifuge,	  
Ireland),	  the	  supernatant	  discharged	  and	  the	  pellet	  was	  washed	  with	  phosphate	  
buffer	  saline	  (PBS)	  (Invitrogen,	  UK).	  The	  pellet	  was	  then	  resuspended	  in	  500µl	  of	  
PBS	  and	  the	  cells	  fixed	  by	  the	  addition	  of	  500µl	  of	  4%	  paraformaldehyde	  (4g	  PFA,	  
(Sigma,	  UK)	  dissolved	  in	  100ml	  of	  PBS,	  heated	  up	  to	  60°C	  with	  moderate	  stirring,	  
and	  the	  pH	  was	  adjusted	  between	  7.2-­‐8.	  Once	  the	  solution	  was	  clear,	  the	  heat	  
was	  turned	  off,	  the	  solution	  was	  cooled	  down,	  filtered,	  and	  aliquoted	  into	  15ml	  
tubes.	  The	  solution	  was	  then	  stored	  at	  	  -­‐20°C).	  The	  parameters	  were	  set	  for	  the	  
type	  of	  cells	  used	  in	  this	  project,	  the	  K562	  and	  KCL-­‐22,	  and	  the	  cell	  suspensions	  
were	  analysed	  using	  the	  FACS	  machine.	  The	  obtained	  data	  was	  analysed	  by	  the	  
use	  of	  the	  computer	  software	  “CellQuest	  Pro”	  (Becton	  Dickinson,	  UK),	  and	  the	  
collected	  data	  was	  plotted	  in	  a	  single	  dimension	  to	  produce	  a	  histogram.	  A	  two-­‐
dimension	   plot	   in	   the	   form	   of	   a	   dot	   plot	  was	   also	   used,	   this	  was	   done	  when	  
acquiring	  the	  data	  to	  ensure	  that	  the	  initial	  control	  sample	  fell	   in	  one	  group	  of	  
cells.	  Figure	  2.8	  shows	  a	  graph	  generated	  from	  the	  CellQuest	  Pro	  software	  in	  the	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Figure	  2.8	  FACS	  Histogram	  Graph.	  	  
This	   figure	   shows	   a	   Histogram	   graph	   that	  was	   generated	   through	   the	   use	   of	   the	   “CellQuest	  
Pro”	   software.	   The	   Histogram	   shows	   two	   samples,	   a	   control	   sample,	   in	   purple	   (this	   sample	  
represents	  cells	  that	  have	  not	  been	  treated	  by	  any	  means),	  and	  a	  test	  sample	  overlaid	  in	  green.	  
Both	   samples	   contain	   the	   same	   number	   of	   cells	   (10,000).	   The	  M1	   Line	   corresponds	   to	   the	  
gated	   cells.	   The	   histogram	   above	   shows	   that	   above	   52%	   of	   cells	   have	   been	   transfected	  
successfully.	  	  	  	  	  
	  
2.6 Real	  Time	  PCR	  	  
	  
Real	   time	   PCR	   or	   quantitative	   PCR	   (qPCR)	   is	   a	   highly	   sensitive	   technique	  
that	  allows	  simultaneous	  amplification	  and	  accurate	  quantification	  of	  a	  specific	  
nucleic	   acid	   sequence	   from	   DNA	   or	   cDNA	   targets.	   PCR	   products	   in	   this	  
technique	   are	  detected	   through	  using	   either	   fluorescent	   dyes,	  which	  bind	   to	  
double	   stranded	   DNA,	   or	   by	   using	   fluorescently	   labelled	   probes	   that	   are	  
sequence	  specific.	  Consequently,	  quantification	  is	  achieved	  by	  a	  determination	  
of	  the	  cycle	  number	  at	  which	  the	  sequence	  of	  interest	  is	  first	  detectable.	  	  
In	   this	   study,	   real	   time	   PCR	   was	   used	   for	   gene	   expression	   analysis,	   the	  
Roche	  Light	  Cycler	  480	   (Roche,	  UK)	  was	  used	  and	  PCR	  product	  quantification	  
was	  done	  through	  the	  use	  of	  SYBR	  Green	  I	  and	  Taqman	  probes.	  SYBR	  Green	  I	  is	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a	   dye	   that	   binds	   to	   any	   double	   stranded	   DNA	   molecule,	   and	   emits	   a	  
fluorescent	  signal	  of	  a	  particular	  wavelength.	  The	  detection	  of	  its	  fluorescence	  
is	  achieved	  at	  the	  extension	  phase	  of	  the	  qPCR.	  Then	  with	  the	  accumulation	  of	  
the	  double	  stranded	  PCR	  products,	  an	  increase	  of	  the	  fluorescent	  signal	  is	  also	  
detected	  at	   the	  end	  of	  each	  cycle.	  This	   is	  due	  to	  the	   fact	   that	   the	  amount	  of	  
fluorescence/signal	   is	   proportional	   to	   the	   amount	   of	   the	   accumulating	   PCR	  
product.	   Figure	   2.9	   illustrates	   the	   basic	   principles	   of	   real	   time	   PCR	   when	  
conducted	  using	  SYBR	  Green	  I.	  	  
Taqman	   probes	   also	   called	   hydrolysis	   probes	   are	   sequence	   specific	  
oligonucleotides	  that	  carry	  a	  fluorophore	  moiety	  at	  the	  5’	  end	  and	  a	  quencher	  
moiety	  at	   the	  3’	   end.	  Once	   the	  probe	   is	   cleaved	  by	   the	  5’	  	   3’	   exonuclease	  
activity	  of	  Taq	  polymerase	  (Holland	  P.M	  et	  al.,	  1991),	  the	  fluorophore	  and	  the	  
quencher	  moiety	  will	  be	   separated	  and	  a	   fluorescent	   signal	  will	  be	  detected.	  
Again	   the	   signal	   is	   proportional	   to	   the	   amount	   of	   PCR	   product	   being	  
accumulated.	  This	  process	  occurs	  during	  the	  annealing/extension	  phase	  of	  the	  
qPCR.	   Figure	   2.10	   illustrates	   the	   basic	   principles	   of	   real	   time	   PCR	   using	   the	  
Taqman	   probes.	   Taqman	   primers	   and	   probes	   were	   designed	   by	   the	   use	   of	  
Roche	  Universal	  probe	  library	  (UPL)	  software	  and	  Primer3	  software.	  Table	  2.7	  
shows	  all	  Taqman	  primers	  and	  probes	  used	   in	  this	  project.	  The	  same	  primers	  
were	   used	   without	   the	   probes	   when	   conducting	   real	   time	   PCR	   using	   SYBR	  
Green	  I.	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Figure	  2.9	  Real	  time	  PCR	  using	  SYBR	  Green	  I	  methodology.	  	  
SYBR	  Green	  dye	  binds	  to	  any	  double	  stranded	  DNA	  regardless	  its	  sequence.	  The	  dye	  will	  only	  
fluoresce	  once	  bound	  to	  DNA	  and	  is	  excited	  via	  blue	  light.	  In	  (A)	  the	  DNA	  is	  denatured	  and	  the	  
synthesis	   of	   double	   stranded	   DNA	   starts	   in	   (B).	   Once	   the	   double	   stranded	   DNA	   is	   being	  
synthesised	  the	  SYBR	  Green	  dye	  starts	   to	  bind	  to	  the	  newly	  synthesised	  DNA	  molecules.	  The	  
fluorescent	   signal	   increases	   to	   its	   maximum	   when	   the	   DNA	   synthesis	   is	   complete	   and	   the	  
maximum	  amount	  of	  dye	  is	  bound	  (C).	  Hence,	  the	  fluorescent	  signals	  in	  this	  type	  of	  qPCR	  are	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Figure	  2.10	  Real	  time	  PCR	  in	  the	  presence	  of	  Taqman	  probes.	  	  
Taqman	   probes	   or	   hydrolysis	   probes	   are	   sequence	   specific	   that	   bind	   to	   DNA	   at	   a	   specific	  
sequence,	  the	  probe	  has	  both	  a	  dye	  at	  its	  5’	  end	  and	  a	  fluorescence	  quencher	  on	  its	  3’	  end.	  In	  
(A)	   the	   DNA	   is	   being	   denatured	   and	   the	   probe	   binds	   to	   its	   target	   site	   in	   (B)	   while	   DNA	  
amplification	  begins.	  As	   the	  primer	   is	  being	  extended	  and	   the	  double	   stranded	  DNA	   is	  being	  
synthesised	   to	   a	   point	   where	   it	   reaches	   the	   Taqman	   probe,	   the	   5’	   nuclease	   activity	   of	   the	  
polymerase	  enzyme	  will	  cleave	  the	  probe,	  this	  releases	  the	  dye	  and	  a	  fluorescent	  signal	  can	  be	  
detected.	  This	   is	  demonstrated	   in	  part	   (C).	  Finally,	   in	   (D)	   the	  DNA	  synthesis	   is	   complete.	  The	  
fluorescence	  in	  this	  type	  of	  qPCR	  is	  measured	  at	  the	  end	  of	  the	  elongation	  phase.	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5'	  d-­‐GAAGGTGAAGGTCGGAGTC'3	  (NM_002046.3)	  
5'	  d-­‐GAAGATGGTGATGGGATTTC'3	  (NM_002046.3)	  
5'	  d-­‐[6FAM]CAAGCTTCCCGTTCTCAGCC[BHQ1]'3	  






5'	  d-­‐GGGCTGCAAATCCAAGAAG'3	  (NM_005157.3)	  
5'	  d-­‐ATGCTACTGGCCGCTGAA'3	  (NM_005157.3)	  







5'	  d-­‐TCAGCCACTGGATTTAAGCAG'3	  (NM_021574.2)	  
5'	  d-­‐CGCGCGTCTTTGCTTTAT'3	  (NM_021574.2)	  







5'	  d-­‐GTCCACTCAGCCACTGGATT'3	  (AJ131466)	  








5'	  d-­‐GATGCTGACCAACTCGTGTG'3	  (AJ131467)	  
5'	  d-­‐GTTGGGGTCATTTTCACTGG'3	  	  (AJ131467)	  
5'	  d-­‐[TxRd]TCGTTGGAACTCCAAGGAAAACCTTCTCGCT[BHQ2]'3	  
Table	   2.7	   Taqman	   primers	   and	   probe	   sets	   used	   in	   the	   project.	   This	   table	   summarises	   all	  
Taqman	   primer	   sets	   and	   their	   appropriate	   probes	   that	   have	   been	   used	   in	   this	   study.	   The	  
sequence	  of	  each	  set	   is	  shown.	  Primer	  sets	  marked	  with	  (*)	  were	  designed	  by	  the	  use	  of	  the	  
UPL	   software	   (http://www.roche-­‐applied-­‐science.com/sis/rtpcr/upl/ezhome.html),	   while	  
unmarked	  sets	  were	  designed	  using	  primer3	  output	  software.	  The	  PCR	  product	  band	  sizes	  are	  
shown	  in	  column	  1	  and	  the	  accession	  numbers	  of	  the	  transcripts	  are	  shown	  between	  brackets	  
in	  column	  3.	  
	  
For	   qPCR	   reactions	   the	  Roche	   LightCycler®	   480	   SYBR	  Green	   I	  Master	   and	  
the	   Roche	   LightCycler®	   480	   Probe	  Master	  mixes	   were	   used.	   Reactions	   were	  
conducted	  on	  a	  96	  well	  plate	  (Roche,	  UK),	  with	  each	  qPCR	  reaction	  repeated	  in	  
duplicate.	   The	   96	   well	   plate	   was	   covered	   with	   an	   adhesive	   seal	   and	   the	  
reactions	  were	  conducted	  under	  the	  selection	  of	  the	  SYBR	  Green	  I	  or	  the	  multi-­‐
hydrolysis	   probe	   program	   with	   the	   SYBR	   Green	   or	   the	   Taqman	   template	  
respectively.	  The	  parameters	   for	   the	   real	   time	  PCR	  are	  shown	  below	   in	   table	  
2.8	  and	  the	  contents	  of	  each	  qPCR	  reaction	  can	  be	  found	  in	  table	  2.9	  and	  2.10.	  
Genes	  analysed	  by	  qPCR	  post	  transfection	  included	  the	  GAPDH	  gene,	  a	  house	  
keeping	  gene,	  the	  normal	  ABL	  and	  BCR	  genes,	  to	  see	  whether	  or	  not	  the	  shRNA	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constructs	  have	  an	  effect	  on	  the	  normal	  genes,	  and	  the	  abnormal	  fusion	  genes.	  
To	  achieve	  this,	  the	  first	  step	  was	  to	  generate	  standard	  curves	  for	  each	  gene.	  
These	   curves	   are	   then	   used	   to	   determine	   the	   cross	   point	   value	   of	   the	   cDNA	  
levels	  of	  the	  genes	  of	  interest	  in	  the	  transfected	  cell	  lines.	  The	  concentrations	  
of	  each	  gene	  in	  ng	  were	  obtained	  from	  the	  Roche	  Lightcycler	  480	  software	  its	  
self.	   The	   resultant	   concentrations	   where	   normalized	   with	   GAPDH.	   Statistical	  
analysis	  was	   then	   conducted	  on	   the	  normalized	  data.	   The	   student	   t-­‐test	  was	  
used	  to	  calculate	  significance.	  Finally,	  the	  percentage	  of	  mRNA	  expression	  and	  
depletion	   was	   calculated.	   “Microsoft	   Excel”	   was	   used	   to	   conduct	   all	  
calculations.	  	  	  
	  
(A)	  Parameters	  for	  the	  Multi-­‐hydrolysis	  probe	  program:	  	  
One	  cycle	  of	  initial	  denaturation	  at	  95°C	  for	  5	  minutes	  Denaturation	  at	  95°C	  for	  45	  seconds	  Annealing	  temperature	  at	  60°C	  for	  1	  minute	   40 cycles of amplification  
(Quantification) Extension	  at	  72°C	  for	  1	  second	  One	  cycle	  of	  cooling	  at	  40°C	  
	  
(B)	  Parameters	  for	  the	  SYBR	  Green	  I	  program:	  
One	  cycle	  of	  initial	  denaturation	  at	  95°C	  for	  5	  minutes	  Denaturation	  at	  95°C	  for	  15	  seconds	  Annealing	  temperature	  at	  60°C	  for	  10	  seconds	  
Extension	  at	  72°C	  for	  30	  seconds	  
 
40 cycles of amplification  
(Quantification)	  
A	  single	  acquisition	  mode	  at	  80°C	  for	  1	  second	  	  
One	  cycle	  of	  Melting	  that	  goes	  up	  to	  95°C	  for	  1	  second	  then	  down	  to	  60°C	  for	  another	  1	  second	  	  
One	  cycle	  of	  cooling	  at	  40°C	  
Table	   2.8	   Parameters	   used	   for	   real	   time	   PCR	   conducted	   in	   this	   project.	   (A)	   Shows	   the	  
parameters	  used	  for	  real	  time	  PCR	  using	  the	  multi-­‐hydrolysis	  probe	  program,	  while	  (B)	  shows	  
the	  real	  time	  PCR	  parameters	  used	  when	  the	  SYBR	  Green	  I	  program	  was	  conducted.	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Component	   Volume	  per	  20µ l	  reaction	  
cDNA	   2-­‐4µl	  
10µM	  of	  Forward	  primer	  	   1µl	  
10µM	  of	  Reverse	  primer	   1µl	  
0.2µM	  of	  probe	   1µl	  
Roche	   LightCycler®	   480	  
Probe	  Master	  mix	  
10µl	  
Nuclease	  free	  H2O	   xµl	  
Table	  2.9	  Components	  of	   the	  qPCR	  Master	  Mix	   (20µ l	   reaction	  mixture).	  The	  preparation	  of	  
master	  mix	  solution	  was	  done	  on	  ice.	  	  
	  
Component	   Volume	  per	  20µ l	  reaction	  
cDNA	   2-­‐4µl	  
10µM	  of	  Forward	  primer	  	   1µl	  
10µM	  of	  Reverse	  primer	   1µl	  
Roche	  LightCycler®	  480	  
SYBR	  Green	  I	  Master	  mix	  
10µl	  
Nuclease	  free	  H2O	   xµl	  	  
Table	  2.10	  Components	  of	  the	  qPCR	  Master	  Mix	  (20µ l	  reaction	  mixture).	  The	  preparation	  of	  
master	  mix	  solution	  was	  done	  on	  ice.	  	  
	  
2.7 Western	  Blot	  Analysis	  
	  
Western	  blots	  are	  an	   immunoanalytical	  method	  used	   for	   the	  purposes	  of	  
protein	   analysis.	   The	   technique	   depends	   on	   antigen-­‐antibody	   interactions	   in	  
order	   to	   detect	   certain	   proteins	   of	   interest.	   The	   above	   technique	   allows	   a	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2.7.1 Cell	  lysis	  and	  protein	  extraction	  
	  
1	  x	  106	  cells	  (K562	  or	  KCL-­‐22)	  were	  pipetted	  into	  a	  1.5ml	  Eppendorf	  tube,	  
washed	   once	   with	   PBS,	   then	   a	   pellet	   was	   obtained	   by	   centrifugation	   of	   the	  
cells	  for	  5	  minutes	  at	  14,000	  g	  at	  4°C.	  The	  supernatant	  was	  removed	  and	  100µl	  
of	   cell	   lysis	   buffer	   (Table	   2.11)	   was	   added	   and	   the	   cells	   lysed	   by	   pipetting	  
vigorously	   several	   times.	   The	   lysed	   samples	   were	   then	   kept	   on	   ice	   for	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  
30	  minutes,	  centrifuged	  for	  5	  minutes	  at	  14,000	  g	  at	  4°C	  and	  the	  supernatant,	  
containing	  the	  extracted	  proteins,	  was	  pipetted	  to	  a	  new	  Eppendorf.	  The	  lysate	  
was	  then	  mixed	  with	  1x	  sample	  Loading	  buffer	  (Table	  2.11)	   in	  a	  1:1	  ratio	  and	  
the	  samples	  were	  stored	  at	  -­‐20°C.	  	  
	  
2.7.2 SDS-­‐Polyacrylamide	  Gel	  Electrophoresis	  
	  
A	  ready	  prepared	  12%	  polyacrylamide	  gel	  (Serva	  Electrophpresis,	  Germany)	  
was	  placed	  in	  d	  was	  filled	  with	  1	  x	  Running	  buffer,	  Table	  2.11	  demonstrates	  the	  
components	  of	  all	  buffers	  and	  solutions	  that	  are	  used	  during	  the	  running	  of	  the	  
polyacrylamide	   gel	   and	   the	   Western	   blotting	   protocol.	   To	   denature	   the	  
extracted	  proteins,	  previously	  described	   in	  section	  2.7.1,	   the	  protein	  samples	  
were	   placed	   in	   a	   heating	   block	   at	   100°C	   and	   were	   allowed	   to	   boil	   for	   3-­‐4	  
minutes.	   The	   samples	  were	   left	   to	   cool	   down,	   and	   then	   20-­‐30µl	  was	   loaded	  
onto	   the	   gel.	   10µl	   of	   high	   range	   Rainbow	   marker	   (GE	   Healthcare,	   UK),	   see	  
Appendix	  3,	  was	  also	  loaded.	  The	  gel	  was	  then	  run	  at	  100V	  for	  90	  minutes	  or	  







	  	   105	  
Solution	  Name	   Components	   Storage	  Conditions	  
Lysis	  Buffer	   50mM	  Tris-­‐HCL	  (Sigma,	  UK)	  
1%	  Triton	  
150	  NaCL	  (Sigma,	  UK)	  
1mM	  EDTA	  (Sigma,	  UK)	  
-­‐	  For	  every	  10ml	  of	  buffer	  one	  
tablet	  of	  complete,	  mini,	  EDTA-­‐free	  
protease	  inhibitor	  cocktail	  tablets	  
(Roche,	  UK)	  was	  added.	  	  
Once	  the	  protease	  
inhibitor	  tablet	  was	  
added	  the	  solution	  was	  
stored	  at	  -­‐20°C	  for	  12	  




62.5mM	  Tris-­‐HCL	  pH	  6.8	  
25%	  Glycerol	  	  
2%	  SDS	  	  
0.01%	  Bromophenol	  Blue(Bio-­‐RAD)	  
5%	  β-­‐mercaptoethanol	  	  
4°C	  	  
Table	  2.11	  Components	  of	  the	  Lysis	  buffer	  and	  the	  Sample	  loading	  buffer.	  The	  Sample	  loading	  
buffer	  is	  also	  known	  as	  the	  Laemmli	  loading	  buffer.	  	  
	  
2.7.3 Western	  Blotting	  
	  
	   The	  cassette	  containing	  the	  polyacrylamide	  gel	  was	  cracked	  open,	  the	  wells	  
removed	  and	   the	  gel	  washed	  once	  with	  Milli	  Q	  water	   for	  5	  minutes.	   The	  gel	  
was	   then	   covered	  with	   1x	   Transfer	   buffer	   and	   placed	   on	   a	   rotary	   shaker	   for	  	  	  	  	  
20	   minutes.	   The	   PVDF	   transfer	   membrane	   was	   treated	   according	   to	   the	  
manufacturer’s	  instructions	  (Thermo	  Scientific,	  UK),	  and	  the	  transfer	  cassettes,	  
sponge	  pads,	  6	  pieces	  of	  Whatman	  paper	  were	  placed	  in	  a	  large	  container	  and	  
equilibrated	  in	  500ml	  of	  1x	  transfer	  buffer	  for	  a	  few	  minutes.	  
	   The	   transfer	   sandwich	  was	   assembled,	   placed	   in	   the	   transfer	   tank	  with	   a	  
block	   of	   ice	   and	   a	  magnetic	   stirring	   pin.	   The	   tank	  was	   placed	   on	   a	  magnetic	  
stirrer,	  the	  whole	  apparatus	  was	  placed	  in	  a	  cold	  room	  at	  4°C,	  and	  the	  transfer	  
was	  conducted	  overnight	  at	  20-­‐30V.	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   Once	   the	   transfer	  was	   completed,	   the	  membrane	  was	  washed	   once	  with	  
Milli	  Q	  water.	  The	  membrane	  was	  then	  dipped	  for	  a	  couple	  of	  seconds	  in	  50ml	  
of	  1%	  (w/v)	  Ponceau	  S	  solution	  in	  5%	  acetic	  acid	  (Sigma,UK).	  Once	  the	  proteins	  
were	  observed,	  the	  membrane	  was	  scanned	  and	  the	  image	  was	  kept	  to	  assist	  
the	   loading	   of	   the	   samples.	   The	   membrane	   was	   washed	   with	   TBS-­‐Tween,	  
washing	  buffer,	  for	  10	  minutes.	  Then	  the	  membrane	  was	  blocked	  with	  blocking	  
buffer	  (see	  Table	  2.12	  for	  the	  composition	  of	  all	  solutions	  used	  in	  the	  processes	  
of	   SDS-­‐PAGE	   electrophoresis	   and	   Western	   Blotting)	   for	   1	   hour	   at	   room	  
temperature.	  	  
	   The	  blocking	  buffer	  was	  then	  discharged	  and	  the	  membrane	  was	  incubated	  
with	  the	  primary	  antibody,	  diluted	  in	  15ml	  of	  blocking	  buffer,	  overnight	  at	  4°C	  
on	  a	   rotary	   shaker	   (Table	  2.13	   illustrates	  all	   antibodies	  used	   for	   the	  Western	  
blots	   conducted	   in	   this	   study).	   The	   following	   day,	   the	   primary	   antibody	  was	  
discharged	   and	   the	   transfer	   membrane	   was	   washed	   3	   times	   with	   washing	  
buffer,	   5	  minutes	   each	   time	   at	   room	   temperature.	   The	  membrane	  was	   then	  
incubated	   with	   the	   secondary	   antibody,	   again	   diluted	   in	   15ml	   of	   blocking	  
buffer,	   for	   1	   hour	   at	   room	   temperature.	   The	   secondary	   antibody	   was	   then	  
removed	   and	   the	   membrane	   was	   washed	   for	   another	   3	   times	   in	   washing	  
buffer,	   5	   minutes	   each	   time	   at	   room	   temperature.	   Finally,	   the	   blots	   were	  
developed	   using	   the	   Pierce®	   ECL	   Western	   Blotting	   Substrate	   Kit	   (Thermo	  
Scientific,	   UK).	   This	  was	   done	   according	   to	   the	  manufacturer’s	   protocol.	   The	  
membrane	  was	  then	  placed	   in	  a	  film	  cassette,	   in	  such	  a	  way	  that	  the	  treated	  
protein	  side	  of	  the	  PVDF	  membrane	  can	  be	  exposed	  to	  the	  X-­‐ray	  film	  (Fujifilm,	  
UK).	  In	  the	  dark	  room	  and	  under	  a	  red	  safe	  light,	  the	  X-­‐ray	  film	  was	  cut,	  to	  the	  
appropriate	   size	   of	   the	   membrane,	   placed	   on	   the	   treated	   side	   of	   the	  
membrane	  and	  the	  cassette	  was	  closed.	  The	  time	  of	  exposure	  varied	  from	  1-­‐60	  
minutes,	   depending	   on	   the	   intensity	   of	   the	   signal.	   Band	   intensities	   were	  
analysed	  through	  the	  program	  “ImageJ”,	  and	  all	  calculations	  were	  done	  by	  the	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Solution	  name	   Components	   Additional	  
Information	  
10x	  Running	  Buffer	  
(Laemmli	  Buffer)	  
-­‐ 25mM	  Tris-­‐HCL	  
-­‐ 200mM	  Glycine	  	  
-­‐ 0.1%	  (wt/v)	  SDS	  
-­‐ -­‐	  dH2O	  as	  required	  
The	  buffer	  was	  
diluted	  to	  1x	  before	  
use	  
1x	  Transfer	  Buffer	  
(1L)	  
-­‐ 100ml	  of:	  
1.92M	  Glycine	  	  	  
0.25M	  Tris-­‐HCL	  
-­‐ 200ml	  of:	  MetOH	  




-­‐ 1M	  Tris-­‐HCL	  pH6.8	  
-­‐ 5M	  NaCL	  
-­‐ 1%	  Tween	  
-­‐ dH2O	  as	  required	  
	  
Blocking	  Buffer	   -­‐ 5%	  (wt/v)	  Non	  Fat	  Milk	  (Marvel)	  in	  
1x	  TBS-­‐Tween	  
-­‐ 5%	  (wt/v)	  BSA	  (Sigma)	  in	  1x	  TBS-­‐
Tween	  
	  
Table	   2.12	   Recipes	   of	   the	   solutions	   used	   in	   the	   process	   of	   SDS-­‐PAGE	   electrophoresis	   and	  
Western	  Blotting.	  The	  above	  table	  shows	  the	  composition	  of	  all	   the	  buffers	  used	  for	  of	  SDS-­‐















Secondary	  Antibody	   Dilution	  
used	  




1:1000	   Anti-­‐Rabbit	   Secondary	  
Antibody	  
1:1000	   5%	  (wt/v)	  BSA	  in	  
1x	  TBS-­‐Tween	  
β2α2	   junction	  
specific	  	  
(Cell	  Signalling)	  
1:1000	   Anti-­‐Mouse	   Secondary	  
Antibody	  
1:1000	   5%(wt/v)	   Non	  




1:1000	   Anti-­‐Rabbit	   Secondary	  
Antibody	  
1:1000	   5%	  (wt/v)	  BSA	  in	  
1x	  TBS-­‐Tween	  
Table	  2.13	  A	  list	  of	  the	  primary	  and	  secondary	  antibodies	  used	  in	  the	  Western	  Blots	   in	  this	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Chapter	  3 :	   Generation	   of	   a	   Reporter	   gene	   system	   for	  






The	  BCR-­‐ABL	   fusion	  genes	   result	   from	  a	   reciprocal	   translocation	  between	  
chromosomes	   9	   and	   22.	   The	   two	   most	   common	   resultant	   fusion	   points	  
associated	  with	  CML	  are	   the	  β3α2	  and	   the	  β2α2	  variants.	  These	  variants	  are	  
characterised	   by	   an	   abnormally	   up-­‐regulated	   Tyrosine	   kinase	   activity	   that	  
causes	  the	  development	  of	  CML	  (Advani	  and	  Pendergast,	  2002).	  Consequently,	  
targeting	   of	   these	   fusion	  points	   as	   a	   therapeutic	   approach	   for	   CML	   could	   be	  
rewarding.	  	  
In	  this	  project,	  short	  hairpin	  RNA	  molecules	  have	  been	  designed	  to	  target	  
the	  two	  BCR-­‐ABL	  variants.	  To	  achieve	  this,	  a	  reporter	  gene	  system	  was	  needed	  
to	  monitor	  the	  synthesis	  and	  expression	  of	  the	  shRNA	  constructs.	  The	  shRNA	  
oligonucleotides	  were	   designed	   and	   constructed	   in	   such	   a	  manner	   that	   they	  
were	   under	   the	   regulation	   of	   either	   the	   human	   U6	   or	   H1	   promoters.	   The	  
constructed	  cassettes	  were	  further	  incorporated	  into	  an	  expression	  vector	  that	  
had	   the	   gene	   for	   the	   enhanced	   green	   fluorescent	   protein	   (eGFP).	   eGFP	   is	   a	  
mutated	  form	  of	  GFP	  that	  has	  been	  optimised	  to	  have	  a	  brighter	  fluorescence	  
and	   a	   higher	   expression	   in	  mammalian	   cells	   than	  GFP	   (Siemering	   K.	   R	  et	   al.,	  
1996),	  and	  for	  the	  purposes	  of	  this	  project	  eGFP	  acted	  as	  a	  reporter	  gene	  for	  
the	  shRNA	  constructs.	  Two	  plasmids	  were	  considered	  in	  order	  to	  generate	  the	  
reporter	  gene	  system.	  The	  first	  was	  the	  pEGFP-­‐N1	  plasmid;	  however	  by	  using	  
this	   plasmid	   it	   proved	   difficult	   to	   construct	   the	   system.	   The	   second	   plasmid	  
was	  the	  pB12mcs-­‐eGFP	  plasmid	  and	  constructing	  the	  reporter	  gene	  system	  in	  
this	   plasmid	   was	   successful.	   This	   chapter	   shows	   the	   results	   obtained	   from	  
attempts	  to	  construct	  such	  a	  system.	  	  
	  	   110	  
3.2 Results	  
	  
3.2.1 Sequencing	  of	  the	  β3α2	  and	  the	  β2α2	  Fusion	  Points	  	  
	  
The	  β3α2	  and	  the	  β2α2	  fusion	  genes	  present	   in	  the	  K562	  and	  KCL-­‐22	  cell	  
lines	  used	  in	  this	  study	  were	  sequenced.	  This	  step	  was	  done	  to	  verify	  that	  the	  
sequences	   of	   the	   fusion	   points	   matched	   the	   sequences	   found	   in	   the	   EMBL	  
website,	   accession	   numbers	   AJ131466	   and	   AJ131467	   respectively	   (Appendix	  
4).	  
	  
3.2.1.1 PCR	  Amplification	  of	   the	  β3α2	  and	   the	  β2α2	  Fusion	  
Points	  
	  
Total	   RNA	   was	   extracted	   from	   K562	   and	   KCL-­‐22	   cell	   lines.	   The	   RNA	   was	  
quantified	  and	  a	  reverse	  transcriptase	  reaction	  was	  conducted.	  To	  determine	  
whether	  the	  reaction	  worked,	  a	  PCR	  reaction	  using	  β-­‐actin	  primers	  K,	  L	  and	  N,	  
sequences	  found	  in	  Table	  2.2,	  was	  conducted	  on	  the	  synthesised	  cDNA	  of	  both	  
cell	   lines.	  When	  using	   the	  β-­‐actin	  primers	  K	  and	  L	  as	  a	  pair,	   the	  β-­‐actin	  gene	  
PCR	   product	   is	   635bp,	   whereas	   pairing	   primers	   N	   and	   L	   gives	   rise	   to	   a	   PCR	  
product	  of	  512bp.	  The	  last	  set	  of	  primers	  only	  works	  if	  genomic	  DNA	  is	  present	  
in	  the	  sample;	  this	  is	  due	  to	  the	  fact	  that	  primer	  N	  is	  intronic.	  Figure	  3.1	  shows	  
the	  results	  of	   the	  PCR	  reaction	  conducted	  on	  the	  synthesised	  cDNA	  from	  the	  
K562	  cell	   lines	  and	   shows	   that	   cDNA	  synthesis	   is	   successful	  with	  no	  genomic	  
DNA	  contamination.	  Similar	  results	  were	  obtained	  with	  the	  KCL-­‐22	  cell	  line.	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Figure	  3.1	  Electrophoretic	  Analysis	  of	  PCR	  reaction	  using	  β -­‐actin	  primers	  on	  K562	  cDNA.	  
Lane	  1:	  λ/EcoRI/HindIII	  marker	  
Lane	  2:	  PCR	  products	  of	  the	  β-­‐actin	  primers	  K	  and	  L	  	  
Lane	  3:	  PCR	  products	  of	  the	  β-­‐actin	  primers	  N	  and	  L	  (negative	  control)	  
	  
β-­‐actin	   PCR	   products	   were	   analysed	   via	   electrophoresis	   using	   a	   1%	   agarose	   gel	   .The	   635bp	  
band	   in	   lane	   2	   indicates	   that	   the	   RNA	  purification	   and	  K562	   cDNA	   synthesis	  was	   successful.	  
Lane	  3	  is	  the	  negative	  control	  and	  indicates	  the	  absence	  of	  any	  genomic	  DNA	  contamination.	  	  
	  
Once	   the	   synthesis	   of	   cDNA	  was	   confirmed	   for	   the	   K562	   and	   KCL-­‐22	   cell	  
lines,	   a	   PCR	   reaction	   using	   primer	   set	   β3α2	   and	   β2α2,	   sequences	   found	   in	  
Table	  2.2,	  was	  conducted.	  This	  PCR	  was	  done	  to	  amplify	  the	  region	  around	  the	  
β3α2	  and	  β2α2	  fusion	  points,	  and	  PCR	  products	  of	  381bp	  and	  522bp	  in	  size	  are	  
expected	  to	  be	  produced,	  respectively.	  The	  PCR	  products	  are	  shown	  in	  Figures	  
3.2	  and	  3.3.	  The	  β3α2	  and	  β2α2	  PCR	  products	  were	  then	  purified,	  quantified,	  
and	   500ng	   was	   used	   for	   AT	   cloning.	   The	   remaining	   β3α2	   and	   β2α2	   PCR	  
products	  were	  stored	  at	  -­‐20°C.	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Figure	  3.2	  Electrophoretic	  Analysis	  of	  the	  β2α2	  PCR	  product	  from	  KCL-­‐22	  cDNA.	  
Lane	  1:	  pBluescript	  Hpa	  II	  marker	  
Lane	  2:	  PCR	  products	  
Lane	  3:	  repeat	  of	  lane	  2	  
	  
β2α2	  PCR	  products	  were	  analysed	  via	  electrophoresis	  on	  a	  2%	  agarose	  gel.	  The	  bands	  present	  
in	  lanes	  2	  and	  3	  fall	   in	  the	  size	  range	  of	  interest,	  that	  is	  522bp.	  This	  indicates	  that	  the	  KCL-­‐22	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Figure	  3.3	  Electrophoretic	  Analysis	  of	  the	  β3α2	  PCR	  product	  from	  K562	  cDNA.	  
Lane	  1:	  pBluescript	  Hpa	  II	  marker	  
Lane	  2:	  PCR	  products	  
Lanes	  3	  and	  4:	  repeat	  reactions	  
	  
β3α2	  PCR	  products	  were	  analysed	  via	  electrophoresis	  on	  a	  2%	  agarose	  gel.	  The	  bands	  present	  
in	  lanes	  2-­‐4	  fall	  in	  the	  size	  range	  of	  interest,	  that	  is	  381bp.	  This	  indicates	  that	  the	  K562	  cell	  line	  
contains	  the	  β3α2	  fusion	  point.	  
	  
	  
3.2.1.2 AT	  Cloning	  of	  the	  β3α2	  and	  the	  β2α2	  PCR	  Products	  in	  
the	  pGEM®T	  Easy	  Vector	  System	  
	  
The	   amplified	   and	   purified	  β3α2	   and	  β2α2	   PCR	   products	  were	   cloned	   in	  
the	   pGEM®T	   easy	   vector	   system.	   This	   was	   done	   through	   the	   process	   of	   AT	  
cloning.	  The	  PCR	  products	  have	  an	  ‘A’	  overhang,	  and	  the	  pGEM®T	  easy	  vector	  
has	  a	  complimentary	  ‘T’	  overhang	  in	  its	  multiple	  cloning	  region	  (MCR)	  for	  easy	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3.2.1.3 Analysis	   of	   the	   β3α2	   and	   the	   β2α2	   Fusion	   Point	  
Sequences	  
	  
The	  sequences	  of	  the	  cloned	  β3α2	  and	  β2α2	  fusion	  points	  were	  analysed	  
and	   compared	   to	   those	   sequences	   found	   in	   the	   EMBL	   website,	   accession	  
numbers	   AJ131466	   and	   AJ131467	   respectively,	   Figure	   3.4.	   The	   results	  
confirmed	  that	  the	  sequences	  of	  the	  fusion	  points	  found	  in	  the	  K562	  and	  KCL-­‐
22	   cell	   lines	   used	   in	   this	   study	  matched	   their	   sequences	   found	   in	   the	   EMBL	  
website.	   The	   full	   sequences	   of	   β3α2	   and	   β2α2	   fusion	   points	   are	   shown	   in	  
Appendix	  4,	  and	  the	  raw	  sequencing	  data	  are	  shown	  in	  Appendix	  5.	  
	  
	  
Figure	  3.4	  The	  K562	  and	  KCL-­‐22	  Fusion	  Point	  Sequencing	  Results	  
(a) Top:	  Boxed	  and	  underlined	  is	  the	  β3α2	  fusion	  point	  sequence	  found	  in	  the	  EMBL	  website	  
(EMBL/AJ131466)	  
Bottom:	   Boxed	   and	   underlined	   is	   the	   sequencing	   result	   of	   the	   β3α2	   fusion	   point	   sequence	  
found	  in	  the	  K562	  cell	  line	  used	  in	  this	  study.	  	  	  
(b) Top:	  Boxed	  and	  underlined	  is	  the	  β2α2	  fusion	  point	  sequence	  found	  in	  the	  EMBL	  website	  
(EMBL/AJ131467)	  
Bottom:	   Boxed	   and	   underlined	   is	   the	   sequencing	   result	   of	   the	   β2α2	   fusion	   point	   sequence	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3.2.2 Preparation	  of	  the	  pEGFP-­‐N1	  Vector	  for	  Cloning	  of	  the	  
shRNA	  Cassettes	  
	  
The	   first	   step	  was	   to	   remove	   the	  CMV	  promoter.	  Once	   the	  promoter	  was	  
removed	  the	  prepared	  vector	  was	  self-­‐ligated,	  creating	  a	  negative	  control.	  The	  
vector	   was	   subsequently	   used	   for	   cloning	   the	   human	   U6	   promoter	   (positive	  
control),	  the	  human	  H1	  promoter	  (positive	  control),	  and	  the	  shRNA	  cassettes.	  	  
	  
3.2.2.1 Digestion	   and	   Removal	   of	   the	   CMV	   Promoter	   from	  
the	  pEGFP-­‐N1	  Vector	  
	  
For	  total	  removal	  of	  the	  CMV	  promoter,	  the	  restriction	  enzyme	  AseI	  could	  
be	   used	   with	   any	   other	   restriction	   site	   found	   in	   the	   MCR.	   However	   the	  
restriction	  site	  of	  the	  AseI	  enzyme	  is	  also	  found	  within	  the	  shRNA	  cassettes.	  So,	  
instead	  the	  enzyme	  SnaBI,	  which	  has	  a	  site	  within	  the	  CMV	  promoter,	  and	  does	  
not	  cut	  within	  the	  shRNA	  cassettes,	  was	  used.	  	  
2µg	   of	   the	   pEGFP-­‐N1	   vector	   was	   diluted	   and	   then	   digested	   with	   SnaBI	  
enzyme	  for	  3	  hours	  at	  37°C	  with	  the	  appropriate	  buffer,	  Figure	  3.5	  gel	  (a)	  lane	  
2.	  The	  vector	  was	  then	  precipitated,	  resuspended	  in	  Milli	  Q	  water	  and	  further	  
digested	  with	  HindIII	  for	  another	  3	  hours	  at	  37°C	  with	  the	  appropriate	  buffer.	  
The	  digested	  vector	  was	   then	  precipitated,	   resuspended	   in	  Milli	  Q	  water	  and	  
was	  run	  on	  a	  1%	  agarose	  gel,	  Figure	  3.5	  gel	  (b)	  lane	  3.	  The	  double	  digestion	  of	  
the	   SnaBI	   and	   HindIII	   sites	   should	   give	   products	   of	   283bp	   and	   ~4.4Kb.	   The	  
presence	   of	   the	   283bp	   band	   is	   clearly	   seen	   confirming	   that	   the	   double	  
digestion	  has	  worked.	  The	  digested	  vector,	  band	  size	  of	  ~4.417Kb,	  was	  cut	  out	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Figure	  3.5	  Electrophoretic	  Analysis	  of	  pEGFP-­‐N1	  Digestions	  
Gel	  (a)	  	  
Lane	  1:	  λ/EcoRI/HindIII	  marker	  
Lane	  2:	  pEGFP-­‐N1	  vector	  digested	  with	  SnaBI	  
Lane	  3:	  Wild	  type	  pEGFP-­‐N1	  vector	  
Gel	  (b)	  
Lane	  1:	  λ/EcoRI/HindIII	  marker	  
Lane	  2:	  Wild	  type	  pEGFP-­‐N1	  vector	  
Lane	  3:	  pEGFP-­‐N1	  vector	  digested	  with	  SnaB1	  and	  HindIII	  
	  
To	  determine	   the	   success	  of	   the	  pEGFP-­‐N1	  digestion	  by	   the	   restriction	  enzyme	  SnaBI,	  1μl	  of	  
the	   digested	   vector	   was	   run	   on	   a	   1%	   agarose	   gel.	   Gel	   (a)	   lane	   2.	   A	   single	   band,	   of	   a	   size	  
approximately	  4.7Kb	  is	  seen	  compared	  with	  the	  undigested	  wild	  type	  vector	  in	  lane	  3.	  Gel	  (b),	  
lane	  3,	   two	  bands	  of	  approximately	  283bp	  and	  4.4KB	  are	  present,	   thus	  confirming	   that	  both	  
digestions	  have	  worked.	  Lane	  2	  is	  the	  wild	  type	  vector	  that	  was	  run	  as	  a	  negative	  control.	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3.2.2.2 Self	   Ligation	   and	   Cloning	   of	   the	  Modified	   pEGFP-­‐N1	  
Vector	  	  
	  
The	   ends	   generated	   from	   the	   SnaBI	   restriction	   enzyme	   are	   blunt	   ends,	  
whereas	  the	  ends	  generated	  from	  the	  HindIII	  restriction	  enzyme	  are	  sticky	  with	  
a	   couple	   of	   bases	   overhang,	   therefore	   the	   ends	   are	   incompatible	   for	   joining	  
together.	  To	  resolve	  this	  issue	  the	  sticky	  ends	  were	  converted	  to	  blunt	  ones.	  A	  
number	  of	  strategies	  were	  tried	  in	  order	  to	  achieve	  this	  self	  ligation.	  
The	   sticky	   ends	   of	   a	   vector	   can	   be	   either	   filled	   in	   with	   complementary	  
bases	  or	  the	  overhang	  bases	  can	  be	  digested.	   	  To	  fill	   in	  the	  overhang	  created	  
was	  considered	  including	  strategies	  such	  as	  filling	  the	  gap	  with	  Taq	  polymerase	  
or	  treating	  the	  ends	  with	  the	  large	  Klenow	  fragment,	  and	  the	  Klenow	  fragment	  
(3’	   5’	   exo-­‐).	  Taq	   polymerase	  was	   first	   used	   to	   try	   to	   fill	   in	   the	   sticky	   ends.	  
Several	  attempts	  were	  conducted	  but	  the	  vector	  failed	  to	  self	  ligate,	  indicating	  
that	   the	   reaction	   was	   not	   successful.	   The	   large	   Klenow	   fragment	   retains	   its	  
5’	   3’	   polymerase	   activity,	   and	   its	   3’	   5’	   exonuclease	   activity,	   but	   lacks	   its	  
5’3’	   exonuclease	   activity.	   The	   pEGFP-­‐N1	   plasmid	   was	   treated	   with	   this	  
enzyme	  several	  times	  under	  different	  time	  and	  temperature	  conditions.	  Again	  
the	   treated	   vector	   failed	   to	   self	   ligate.	   Finally,	   the	   Klenow	   fragment	   (3’	   5’	  
exo-­‐)	  that	  retains	  its	  5’	  3’	  polymerase	  activity,	  and	  lacks	  both	  its	  3’	  5’	  and	  
its	  5’3’	  exonuclease	  activities	  was	  used	  and	  proved	  successful.	  	  
After	   treatment	   with	   the	   Klenow	   fragment	   (3’	   5’	   exo-­‐),	   the	   treated	  
pEGFP-­‐N1	  plasmid	  was	  purified	  and	  500ng	  were	  used	  for	  self	  ligation.	  The	  self	  
ligation	  reaction	  was	  done	  for	  an	  hour	  at	  room	  temperature,	  and	  overnight	  at	  
16°C	  and	  4°C.	  The	  reaction	  was	  analysed	  by	  PCR	  using	  CMV-­‐207	  forward	  and	  
EGFPN1	  reverse	  primers.	  PCR	  of	  the	  wild	  type	  vector	  was	  included	  as	  a	  control.	  
When	  using	   this	   set	  of	  primers	  a	  band	  of	  530bp	   is	  expected	   in	   the	  wild	   type	  
vector,	   whereas	   a	   band	   of	   219bp	   is	   expected	   in	   the	   double	   digested,	   self-­‐
ligated	  vector.	  The	  results	  of	  this	  PCR	  can	  be	  seen	  below	  in	  Figure	  3.6.	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Figure	  3.6	  Electrophoretic	  Analysis	  of	  PCR	  products	  from	  the	  Self-­‐ligated	  pEGFP-­‐N1	  vector	  
Lane	  1:	  100bp	  DNA	  Ladder	  from	  NEB	  
Lane	  2:	  PCR	  of	  wild	  type	  pEGFP-­‐N1	  vector	  using	  CMV-­‐207	  forward	  and	  EGFPN-­‐1	  reverse	  
Lane	  3:	  PCR	  of	  self-­‐ligated	  pEGFP-­‐N1.	  The	  reaction	  was	  done	  at	  16°C	  
Lane	  4:	  PCR	  of	  self-­‐ligated	  pEGFP-­‐N1.	  The	  reaction	  was	  done	  at	  4°C	  
	  
A	   2%	   agarose	   gel	   was	   used	   to	   analyse	   the	   PCR	   products	   of	   the	   wild	   type	   and	   self-­‐ligated	  
pEGFP-­‐N1	   vectors.	   Lane	  2	  has	   shown	   the	  PCR	  product	  of	   the	  wild	   type	   vector,	  with	   a	   single	  
band	   of	   ~530bp.	   Whereas,	   lane	   4,	   shows	   a	   band	   ~219bp	   that	   corresponds	   to	   the	   double	  
digested,	  self-­‐ligated	  pEGFP-­‐N1	  vector.	  
	  
	  
	   Half	   the	  amount	  of	   the	   ligation	  mix	  was	  used	   to	   transform	  50μl	  of	   JM109	  
bacterial	  cells.	  The	  cells	  were	  then	  plated	  on	  agar	  plates	  with	  the	  appropriate	  
antibiotic	  and	  were	  kept	  overnight	  in	  an	  incubator	  at	  37°C.	  The	  colonies	  on	  the	  
plates	  were	   screened	   by	  means	   of	   PCR.	   The	   PCR	  was	   done	   using	   the	   set	   of	  
primers	  CMV-­‐207	  forward	  and	  EGFPN1	  reverse.	  However,	  all	  screened	  colonies	  
were	  of	  wild	  type	  vector.	  Therefore,	  a	  higher	  concentration	  of	  ligation	  mix	  was	  
used	  to	  transform	  bacterial	  cells.	  This	  also	  resulted	  in	  the	  growth	  of	  wild	  type	  
colonies	  only,	  so	  the	  ligation	  reaction	  was	  digested	  with	  the	  enzyme	  XhoI.	  This	  
was	  done	  to	  decrease	  the	  chances	  that	  a	  wild	  type	  vector	  would	  be	  taken	  into	  
the	  bacterial	  cells,	  as	  an	  XhoI	  site	   is	  only	  present	   in	   the	  wild	   type	  vector	  and	  
not	   in	  the	  self-­‐ligated	  one.	  This	  experiment	  was	  repeated	  three	  times,	  and	   in	  
all	  three	  no	  bacterial	  colonies	  grew	  on	  the	  agar	  plates.	  Consequently,	  work	  on	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this	   vector	   was	   stopped	   and	   another	   vector	   was	   selected	   to	   generate	   a	  
reporter	  system	  
	  
3.2.3 Preparation	  of	  the	  pB12mcs-­‐eGFP	  Vector	  
	  
This	   vector	   was	   selected	   to	   construct	   the	   reporter	   gene	   system	   for	   the	  
shRNA	   cassettes	   after	   work	   on	   the	   pEGFP-­‐N1	   vector	   has	   been	   stopped.	   The	  
vector	  has	  an	  eGFP	  gene	  and	  no	  promoter.	  Therefore,	  the	  wild	  type	  vector	  was	  
used	  as	  the	  negative	  control.	  	  
	  
3.2.3.1 Sequencing	  of	  the	  pB12mcs-­‐eGFP	  Vector	  
	  
The	  plasmid	  was	  sent	  for	  sequencing	  using	  the	  T7	  forward	  primer	  and	  the	  
T3	   reverse	   primer	   and	   a	   new	   primer	   called	   GFPneo.	   The	   sequencing	   results	  
confirmed	  that	  the	  plasmid	  matched	  its	  map	  shown	  in	  materials	  and	  methods	  
chapter.	   However,	   some	   variation	   existed	   in	   the	   MCR;	   there	   was	   no	   EcoRI	  
restriction	   site	   but	   an	   EcoRV	   instead.	   Based	   on	   the	   sequence	   analysis,	   the	  
restriction	  sites	  for	  the	  enzymes	  HindIII	  and	  BamHI	  were	  selected,	  and	  the	  next	  
step	  was	  to	  start	  preparing	  the	  pB12mcs-­‐eGFP	  plasmid	  for	  insert	  intake.	  	  
	  
3.2.3.2 Digestion	   and	   Purification	   of	   the	   pB12mcs-­‐eGFP	  
Vector	  
	  
50μl	  of	  JM109	  bacterial	  cells	  were	  transformed	  with	  50ng	  pB12mcs-­‐eGFP.	  
The	  transformed	  bacterial	  cells	  were	  grown	  overnight	  in	  500ml	  of	  LB	  with	  the	  
appropriate	   antibiotic.	   1ml	   of	   the	   grown	   bacteria	   was	   stored	   at	   -­‐80°C	   as	  
glycerol	  stock	  and	  then	  a	  maxi	  prep	  took	  place	  and	  the	  extracted	  plasmid	  was	  
quantified.	   2μg	   of	   the	   pB12mcs-­‐eGFP	   vector	   was	   diluted	   and	   digested	   with	  
BamHI	  enzyme.	  To	  confirm	  digestion,	  the	  digested	  plasmid	  was	  then	  analysed	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through	  gel	  electrophoresis,	  Figure	  3.7.	  The	  digested	  vector	  was	  then	  purified,	  
further	  digested	  with	  the	  enzyme	  HindIII,	  purified	  and	  quantified.	  	  
The	  double	  digestion	  of	  the	  BamHI	  and	  HindIII	  sites	  should	  give	  products	  of	  
62bp	  and	  3.887Kb.	  The	  presence	  of	  the	  62bp	  band	  cannot	  be	  seen	  when	  the	  
digestion	   reaction	   is	  analysed	  on	   the	  1%	  agarose	  gel.	  Only	   the	  3.887Kb	  band	  
can	  be	   seen.	   Therefore,	   to	  ensure	   that	   the	   restriction	  enzyme	  HindIII	   digests	  
the	   pB12mcs-­‐eGFP	   plasmid	   efficiently,	   2μg	   of	   the	   wild	   type	   pB12mcs-­‐eGFP	  
vector	  was	   freshly	  diluted,	  and	  was	   then	  digested	  separately	  with	   the	  HindIII	  
enzyme.	  5μl	  of	  this	  digestion	  was	  then	  analysed	  through	  electrophoresis.	  The	  
digested	  pB12mcs-­‐eGFP	  plasmid	  appeared	  as	  a	  single	  band,	   in	  comparison	  to	  
the	   supercoiled	   wild	   type	   plasmid,	   hence	   confirming	   that	   the	   digestion	  
conditions	  were	  correct	  (results	  are	  not	  shown).	  	  
	  
	  
Figure	  3.7	  Electrophoretic	  Analysis	  of	  the	  digested	  pB12mcs-­‐eGFP	  vector	  
Lane	  1:	  GeneRulerTM	  1Kb	  DNA	  Ladder	  
Lane	  2:	  Wild	  type	  pB12mcs-­‐eGFP	  vector	  
Lane	  3:	  BamHI	  digested	  pB12mcs-­‐eGFP	  vector	  	  
	  
A	   clear	   single	   band	   of	   ~3.9Kb	   in	   size	   can	   be	   seen	   in	   lane	   3,	   upon	   comparison	   with	   the	  
multiband	  wild	  type	  vector	  observed	  in	  lane	  2.	  The	  multiband	  appearance	  is	  the	  result	  of	  the	  
wild	   type	  vector	  being	   supercoiled.	  Overall,	   the	  gel	   indicates	  digestion	  of	   the	  pB12mcs-­‐eGFP	  
vector	  with	  the	  enzyme	  BamHI.	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3.2.4 Amplification	  of	  the	  U6	  and	  H1	  Promoters	  
	  
Once	  the	  pB12mcs-­‐eGFP	  plasmid	  was	  digested	  and	  purified,	  the	  next	  step	  
was	   to	   construct	   the	   positive	   controls	   by	   incorporating	   the	   U6	   human	  
promoter	   or	   the	   H1	   human	   promoter	   in	   the	  MCR	   of	   the	   digested	   pB12mcs-­‐
eGFP	   plasmid.	   The	   sequences	   of	   both	   promoters	   were	   found	   through	   the	  
EMBL	  website	   and	   the	   sequences	  had	  accession	  number	  M14486	   for	   the	  U6	  
promoter,	  and	  accession	  number	  X16612	  for	  the	  H1	  promoter.	  The	  complete	  
sequences	  of	  these	  promoters	  can	  be	  found	  in	  Appendix	  6.	  	  
From	   the	   sequences	   found	   in	   the	   website,	   a	   U6	   primer	   set	   and	   an	   H1	  
primer	   set	   were	   designed.	   The	   primer	   sequences	   were	   shown	   in	   Table	   2.2.	  
These	   primers	   were	   designed	   in	   such	   a	   way	   that	   a	   restriction	   site	   for	   the	  
enzyme	  HindIII	  was	  incorporated	  in	  the	  forward	  primers,	  and	  a	  restriction	  site	  
for	   the	   BamHI	   enzyme	   was	   incorporated	   in	   the	   reverse	   primers.	   PCR	   using	  
these	   sets	   of	   primers	   was	   conducted	   on	   cDNA	   from	   K562	   cell	   lines	   as	   a	  
template.	  The	  size	  of	  the	  PCR	  products	  for	  these	  reactions	  was	  expected	  to	  be	  
292bp	   for	   the	   U6	   promoter,	   and	   219bp	   for	   the	   H1	   promoter.	   Figure	   3.8	  
demonstrates	  the	  electrophoretic	  analysis	  of	  the	  PCR	  products	  of	  the	  U6	  and	  
H1	  human	  promoters	  respectively.	  	  
The	   PCR	   products	   of	   the	   U6	   and	   H1	   human	   promoters	   were	   purified,	  
digested	   with	   the	   enzyme	   BamHI	   for	   3	   hours	   at	   37°C	   with	   the	   appropriate	  
buffer.	  The	  digested	  promoters	  were	  then	  precipitated	  and	  digested	  again	  for	  
another	   3	   hours	   at	   37°C	  with	   the	  HindIII	   enzyme	   and	   its	   appropriate	   buffer.	  
Once,	   this	   digestion	   was	   achieved,	   the	   promoters	   were	   precipitated,	  
resuspended	  in	  10μl	  of	  Milli	  Q	  water,	  and	  were	  then	  quantified.	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Figure	  3.8	  Electrophoretic	  Analysis	  of	  the	  PCR	  products	  of	  the	  U6	  and	  H1	  human	  promoters	  
(a) Top:	  	  
Lane	  1:	  100bp	  DNA	  Ladder	  from	  NEB	  
Lanes	  2-­‐5:	  U6	  promoter	  PCR	  products	  from	  four	  reactions	  
(b) Bottom:	  
Lane	  1:	  100bp	  DNA	  Ladder	  from	  NEB	  
Lanes	  2-­‐5:	  H1	  promoter	  PCR	  products	  from	  four	  reactions	  
	  
The	  U6	  promoter	   is	  292bp	  in	  size,	  whereas	  the	  H1	  promoter	   is	  220bp.	   In	   lanes	  2-­‐5	   in	  gel	   (a),	  
bands	   of	   ~300bp	   are	   present,	   whereas	   in	   lanes	   2-­‐5	   in	   gel	   (b),	   bands	   just	   above	   200bp	   are	  
present.	  These	  findings	  confirm	  that	  the	  PCR	  products	  are	  of	  the	  size	  expected.	  	  	  
	  	  	  	  	  	  
	  
3.2.4.1 Cloning	  of	  the	  U6	  and	  H1	  Promoters	  in	  the	  pB12mcs-­‐
eGFP	  Vector	  
	  
A	  1:10	  vector	  to	  insert	  ratio	  was	  used	  to	  clone	  the	  prepared	  promoters	  into	  
the	   double	   digested	   pB12mcs-­‐eGFP	   vector.	   The	   ligation	   reaction	   was	   done	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overnight	   at	   4°C	   in	   a	   total	   volume	   of	   10μl.	   Half	   the	   volume	   of	   the	   ligation	  
reaction	  was	  used	   to	   transform	  35μl	  of	   JM109	  bacterial	   cells.	   The	   cells	  were	  
heat	  shocked	  and	  were	   left	   in	  a	  shaking	   incubator	  at	  37°C	  for	  2	  hours	  before	  
being	  plated	  on	  agar	  plates	  with	  the	  appropriate	  antibiotic.	  	  
The	  plate	  was	  examined	  for	  the	  growth	  of	  bacterial	  colonies	  and	  colonies	  
were	  screened	  by	  means	  of	  PCR	  T7	  forward	  and	  T3	  reverse	  primers.	  The	  wild	  
type	   pB12mcs-­‐eGFP	   vector	   was	   also	   included	   as	   a	   negative	   control.	   PCR	  
products	  were	   analysed	  by	   electrophoresis,	   and	   are	   illustrated	   in	   Figures	   3.9	  
and	   3.10.	   Positive	   colonies	   were	   grown	   overnight	   in	   20ml	   of	   LB	   with	   the	  




Figure	   3.9	   Electrophoretic	   Analysis	   of	   the	   PCR	   products	   of	   the	   pB12mcs-­‐U6-­‐eGFP	   plasmid	  
Colony	  Screen	  
Lane	  1:	  GeneRulerTM	  1Kb	  DNA	  Ladder	  
Lane	  2:	  Wild	  type	  pB12mcs-­‐eGFP	  vector	  PCR	  product	  	  
Lanes	  3-­‐13:	  Colony	  screen	  PCR	  products	  
Lane	  11:	  Positive	  Colony	  
	  
The	   primer	   set	   T7	   forward	   and	   T3	   reverse	   was	   used	   for	   the	   above	   colony	   screen	   and	   the	  
expected	  PCR	  product	   for	   the	  wild	   type	  vector	   is	  ~1050bp,	   lane	  2.	  The	  wild	   type	  vector	  was	  
included	  as	  a	  negative	  control.	  Lanes	  3-­‐10	  and	  12-­‐13	  all	  have	  PCR	  products	  matching	  the	  size	  
of	   the	   wild	   type	   vector,	   and	  were	   considered	   to	   be	   negative	   screens.	   However,	   in	   lane	   11,	  
highlighted	   in	   red,	  a	  band	  of	   size	  ~1310bp	   (~1050bp	   for	   the	  wild	   type	  and	  292bp	   for	   the	  U6	  
promoter)	   is	  present.	  This	  colony	  was	  considered	  to	  be	  a	  positive	  colony,	  and	  was	  picked	  up	  
from	  the	  agar	  plate	  and	  grown	  in	  20ml	  of	  LB,	  with	  the	  appropriate	  antibiotic.	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Figure	   3.10	   Electrophoretic	   Analysis	   of	   the	   PCR	   products	   of	   the	   Colony	   Screen	   of	   the	  
pB12mcs-­‐H1-­‐eGFP	  vector	  	  
Lane	  1:	  GeneRulerTM	  1Kb	  DNA	  Ladder	  
Lane	  2:	  Wild	  type	  pB12mcs-­‐eGFP	  vector	  PCR	  product	  	  
Lanes	  3,4,6,8,	  and	  9:	  PCR	  products	  of	  a	  positive	  colony	  screen	  
Lanes	  5	  and	  10-­‐12:	  PCR	  products	  of	  a	  negative	  colony	  screen	  
Lanes	  7	  and	  13:	  PCR	  did	  not	  work	  
	  
Lane	  2	  illustrates	  the	  PCR	  product	  of	  the	  wild	  type	  pB12mcs-­‐eGFP	  vector.	  The	  band	  size	  of	  this	  
PCR	  product	  is	  of	  around	  1050bp	  when	  using	  the	  primer	  set	  T7	  forward	  with	  T3	  reverse.	  The	  
band	  size	  for	  the	  positive	  colonies	  were	  around	  1270bp,	  which	  is	  the	  standard	  size	  of	  the	  wild	  
type	  PCR	  product	  (~1050)	  plus	  the	  size	  of	  the	  H1	  human	  promoter	  (220bp).	  When	  comparing	  
the	  PCR	  products	  of	   the	  colonies	  screened,	   the	  colonies	   in	   lanes	  5	  and	  10-­‐12	  were	  negative,	  
whereas	   colonies	   in	   all	   other	   lanes	   were	   positive	   (lanes	   7	   and	   13	   are	   excluded	   as	   the	   PCR	  
reaction	  did	  not	  work	  here).	  The	   lanes	  highlighted	   in	  red	  are	  the	  colonies	  that	  were	  selected	  
and	  grown	  in	  20ml	  of	  LB	  with	  the	  appropriate	  antibiotic.	  	  
	  
	  
3.2.4.2 Sequence	  Analysis	  of	  the	  U6	  and	  H1	  Promoters	  
	  
Plasmid	  extraction	   took	  place	  by	  means	  of	  mini	  preps,	   and	  plasmids	  were	  
analysed	   by	   PCR	   first.	   Three	   sets	   of	   primers	   were	   used;	   for	   U6	   analysis	   T7	  
forward	  with	  T3	  reverse,	  T7	  forward	  with	  U6	  reverse,	  and	  U6	  forward	  with	  T3	  
reverse.	  While	  the	  set	  of	  primers	  that	  were	  used	  for	  the	  plasmids	  positive	  for	  
the	  H1	  promoter	  were	  T7	  forward	  with	  T3	  reverse,	  T7	  forward	  with	  H1	  reverse,	  
and	   H1	   forward	   with	   T3	   reverse.	   The	   PCR	   products	   of	   the	   reactions	   were	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analysed	  by	  gel	  electrophoresis,	  and	  are	  shown	  in	  Figures	  3.11	  and	  3.12.	  Once,	  
positive	   colonies	   were	   confirmed	   by	   PCR	   the	   plasmids	   were	   sent	   to	  
Geneservice	  LTD	  for	  sequencing.	  	  
	  
	  
	   	  
Figure	   3.11	   Electrophoretic	  Analysis	   of	   the	  PCR	  products	   of	   the	  pB12mcs-­‐U6-­‐eGFP	  plasmid	  
(colony	  11)	  
Lane	  1:	  GeneRulerTM	  1Kb	  DNA	  Ladder	  
Lane	  2:	  PCR	  product	  of	  the	  wild	  type	  pB12mcs-­‐eGFP	  vector	  using	  primer	  set	  T7	  forward	  and	  T3	  
reverse	  (negative	  control)	  
Lane	   3:	   PCR	   product	   of	   the	   pB12mcs-­‐U6-­‐eGFP	   vector	   using	   primer	   set	   T7	   forward	   with	   T3	  
reverse	  
Lane	   4:	   PCR	   product	   of	   the	   pB12mcs-­‐U6-­‐eGFP	   vector	   using	   primer	   set	   T7	   forward	   with	   U6	  
reverse	  
Lane	   5:	   PCR	   product	   of	   the	   pB12mcs-­‐U6-­‐eGFP	   vector	   using	   primer	   set	   U6	   forward	   with	   T3	  
reverse	  
Lane	  6:	  GeneRulerTM	  100bp	  DNA	  Ladder	  
	  
To	  confirm	  that	   the	  plasmid	  had	  the	  right	   insert	   in	   the	  right	  orientation,	   three	  PCR	  reactions	  
were	  conducted	  on	  that	  plasmid.	  The	  three	  different	  sets	  of	  primers	  that	  were	  used	  were	  T7	  
forward	  with	  T3	  reverse,	  T7	  forward	  with	  U6	  reverse	  and	  U6	  forward	  and	  T3	  reverse.	   If	  a	  U6	  
promoter	   has	   been	   inserted	   the	   sizes	   of	   the	   PCR	   products	   expected	   for	   the	   primer	   sets	   are	  
1320bp,	  310bp,	  and	  1350bp	   respectively.	  The	  negative	  control	   lane	  2,	  was	  a	  PCR	  product	  of	  
the	   wild	   type	   vector	   with	   the	   first	   set	   of	   primers,	   giving	   rise	   to	   a	   ~1050bp	   band.	   The	  
electrophoretic	  analysis	   illustrates	   that	   the	   resultant	  PCR	  products	  are	  of	   the	  sizes	  expected,	  
thus	  confirming	  that	  the	  plasmid	  in	  colony	  11	  had	  the	  correct	  insert.	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Figure	  3.12	  Electrophoretic	  Analysis	  of	  the	  PCR	  products	  of	  the	  extracted	  pB12mcs-­‐H1-­‐eGFP	  
plasmids	  (colonies	  3,4,	  8,	  and	  9)	  
Lane	  1:	  GeneRulerTM	  1Kb	  DNA	  Ladder	  
Lane	   2:	   PCR	   product	   of	   the	  wild	   type	   pB12mcs-­‐eGFP	   vector,	   ~1050bp	   in	   size,	   primer	   set	   T7	  
forward	  with	  T3	  reverse	  (negative	  control)	  
Lanes	   3,	   6,	   9,	   and	   12:	   PCR	  product	   of	   the	   pB12mcs-­‐H1-­‐eGFP	   vectors,	   primer	   set	   T7	   forward	  
with	  T3	  reverse.	  Colonies	  3,	  4,	  8	  and	  9	  respectively	  
Lanes	  4,	  7,	  10	  and	  13:	  PCR	  product	  of	   the	  pB12mcs-­‐H1-­‐eGFP	  vectors,	  primer	   set	  T7	   forward	  
with	  H1	  reverse.	  Colonies	  3,	  4,	  8	  and	  9	  respectively	  
Lanes	  5,	  8,	  11,	  and	  14:	  PCR	  product	  of	  the	  pB12mcs-­‐H1-­‐eGFP	  vectors,	  primer	  set	  H1	  forward	  
with	  T3	  reverse.	  Colonies	  3,	  4,	  8	  and	  9	  respectively	  
Lane	  15:	  GeneRulerTM	  100bp	  DNA	  Ladder	  
	  
To	  confirm	  that	  the	  plasmids	  had	  the	  right	  insert	  in	  the	  right	  orientation,	  three	  PCR	  reactions	  
were	   conducted	  on	   each	  plasmid.	   The	   three	  different	   sets	   of	   primers	   that	  were	  used	   in	   the	  
reactions	  were	  T7	  forward	  with	  T3	  reverse,	  T7	  forward	  with	  H1	  reverse	  and	  H1	  forward	  and	  T3	  
reverse.	  The	  sizes	  of	  the	  PCR	  products	  expected	  for	  the	  primer	  sets	  were	  1270bp,	  260bp,	  and	  
1300bp	   respectively.	   The	  analysis	   illustrates	   that	   the	   resultant	  PCR	  products	   are	  of	   the	   sizes	  
expected,	  thus	  confirming	  that	  the	  extracted	  plasmids	  had	  the	  correct	  insert.	  	  
	  
	  
The	  sequencing	  results	  were	  analysed	  and	  the	  results	  for	  the	  pB12mcs-­‐U6-­‐
eGFP	  and	  pB12mcs-­‐H1-­‐eGFP	  used	   in	   this	   study	  are	   found	   in	  Appendix	  8.	  The	  
sequences	   of	   the	   U6	   and	   H1	   human	   promoters	   were	   compared	   to	   their	  
sequences	  found	  in	  EMBL.	  Those	  plasmids	  with	  a	  100%	  sequence	  match	  were	  
	   1	  	  	  	  	  	  2	  	  	  	  3	  	  	  	  4	  	  	  	  5	  	  	  	  	  6	  	  	  	  	  7	  	  	  	  8	  	  	  	  9	  	  	  	  10	  	  11	  	  12	  	  13	  	  14	  	  15	  	  	  
	   bp	  
	  	   127	  
grown	  in	  500ml	  of	  LB	  medium,	  and	  a	  maxi	  prep	  was	  conducted.	  The	  extracted	  
plasmids	  were	  purified,	  quantified	  and	  stored	  at	  -­‐20°C.	  	  
	  
3.2.5 Construction	  of	  the	  shRNA	  Molecules	  
	  
Following	   preparation	   of	   the	   pB12mcs-­‐eGFP	   vector	   for	   insert	   uptake	   and	  
the	  construction	  of	   the	  positive	   control	   vectors.	   The	  next	   step	  was	   to	  design	  
the	   shRNA	   molecules	   targeting	   the	   two	   different	   fusion	   genes,	   followed	   by	  
construction	  of	  the	  shRNA	  cassettes.	  	  
	  	  
3.2.5.1 Designing	  of	  the	  shRNA	  Molecules	  
	  
The	   sequences	   of	   the	   β3α2	   and	   the	   β2α2	   fusion	   points	   found	   in	   EMBL	  
website,	  accession	  numbers	  AJ131466	  and	  AJ131467,	  were	  used	  as	  a	  basis	  for	  
designing	  the	  shRNA	  molecules.	  The	  full	  sequences	  are	  shown	  in	  Appendix	  4.	  
For	   each	   fusion	   point	   three	   different	   shRNA	   molecules	   were	   designed,	   two	  
molecules	  were	  21nt	  long,	  whereas	  the	  third	  molecule	  was	  22nt	  long.	  	  
The	  21nt	   long	  shRNA	  molecule,	  shRNA1,	  had	  11nt	  upstream	  of	  the	  fusion	  
point	  and	  10nt	  downstream,	  whereas	  shRNA2	  had	  10nt	  upstream	  of	  the	  fusion	  
point	  and	  11nt	  downstream.	   In	   the	   case	  of	   the	  22nt	   long	  molecule,	   shRNA3,	  
11nt	  were	   on	   either	   side	   of	   the	   fusion	   points.	   Figure	   3.13	   demonstrates	   the	  
predicted	   secondary	   structure	   of	   the	   shRNA1	   molecule	   targeting	   the	   β3α2	  
fusion	  point.	  The	  predicted	  secondary	   structures	   for	  all	   the	   remaining	  shRNA	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Figure	   3.13	   The	   Secondary	   Structure	   of	   shRNA1	   Antisense	   Oligonucleotide	   targeting	   the	  
β3α2	  fusion	  point	  
The	  figure	  shows	  the	  predicted	  secondary	  hairpin	  structure	  of	  the	  designed	  shRNA1	  molecule	  
targeting	  the	  β3α2	  fusion	  point.	  The	  nucleotide	  sequence	  from	  1-­‐21,	  in	  green,	  represents	  the	  
antisense	  strand,	  whereas	  the	  sense	  strand	  corresponds	  to	  the	  nucleotide	  sequence	  from	  30-­‐
50,	  in	  red.	  The	  8nt	  loop	  is	  in	  blue.	  
	  
	  
3.2.5.2 Synthesis	  of	  the	  U6	  and	  H1	  shRNA	  Cassettes	  
	  
Once	  the	  secondary	  structures	  of	  the	  shRNA	  molecules	  were	  checked,	  U6	  
and	   H1	   human	   promoter	   reverse	   primers,	   which	   contained	   the	   designed	  
shRNA	  molecule	  sequences,	  were	  constructed	  and	  produced.	  The	  sequences	  of	  
these	  primers	  are	  given	  in	  chapter	  2	  in	  Table	  2.6.	  	  
To	   synthesise	   the	   shRNA	   cassettes,	   the	   U6	   forward	   or	   the	   H1	   forward	  
primer	   was	   used	   together	   with	   the	   U6	   or	   the	   H1	   shRNA	   reverse	   primer	   to	  
conduct	  a	  PCR	  reaction.	  K562	  cDNA	  was	  used	  as	  a	  template,	  and	  the	  resultant	  
PCR	  products	  were	  analysed	  through	  agarose	  gel	  electrophoresis.	  Figure	  3.14	  
shows	  the	  analysis	  of	  these	  PCR	  products.	  The	  bands	  of	  the	  correct	  size	  were	  
cut	  out	  of	  the	  gel,	  and	  the	  shRNA	  cassettes	  were	  purified.	  The	  shRNA	  cassettes	  
were	   then	   quantified	   and	   digested	  with	   the	   restriction	   enzymes,	   BamHI	   and	  
	  	   129	  
HindIII	   respectively.	   The	   shRNA	   cassettes	   were	   purified	   and	   quantified	   after	  
each	  digestion.	  The	  final	  shRNA	  cassettes	  were	  then	  stored	  at	  -­‐20°C.	  
	  
	  
Figure	  3.14	  Electrophoretic	  analysis	  of	  PCR	  products	  from	  shRNA	  cassette	  synthesis	  
Lane	  1:	  PCR	  product	  of	  the	  U6	  β3α2	  shRNA1	  cassette	  
Lane	  2:	  PCR	  product	  of	  the	  U6	  β3α2	  shRNA2	  cassette	  
Lane	  3:	  PCR	  product	  of	  the	  U6	  β3α2	  shRNA3	  cassette	  
Lane	  4:	  PCR	  product	  of	  the	  U6	  β2α2	  shRNA1	  cassette	  
Lane	  5:	  PCR	  product	  of	  the	  U6	  β2α2	  shRNA2	  cassette	  	  
Lane	  6:	  PCR	  product	  of	  the	  U6	  β2α2	  shRNA3	  cassette	  
Lane	  7:	  GeneRulerTM	  100bp	  DNA	  Ladder	  
Lane	  8:	  PCR	  product	  of	  the	  H1	  β2α2	  shRNA1	  cassette	  
Lane	  9:	  PCR	  product	  of	  the	  H1	  β2α2	  shRNA2	  cassette	  
Lane	  10:	  PCR	  product	  of	  the	  H1	  β2α2	  shRNA3	  cassette	  
	  
The	  PCR	  products	  of	   the	  shRNA	  cassettes	  were	  analysed	  by	  electrophoresis	  on	  a	  2%	  agarose	  
gel.	   Lanes	   1-­‐3	   show	   the	   PCR	   products	   of	   the	   shRNA	   cassettes	   designed	   to	   target	   the	   β3α2	  
fusion	  point	  under	  the	  regulation	  of	  the	  U6	  promoter.	  Lanes	  4-­‐6	  show	  the	  PCR	  products	  of	  the	  
shRNA	   cassettes	   designed	   to	   target	   the	   β2α2	   fusion	   point	   under	   the	   regulation	   of	   the	   U6	  
promoter.	  The	  PCR	  products	   should	  be	  around	  340bp	   in	  size,	  and	  when	  analysed	  above,	   the	  
visualized	   bands	   are	   of	   the	   correct	   size.	   Lanes	   8-­‐10	   show	   the	   PCR	   products	   of	   the	   shRNA	  
cassettes	   designed	   to	   target	   the	   β3α2	   fusion	   point	   that	   are	   under	   the	   regulation	   of	   the	   H1	  
promoter.	  The	  expected	  size	  of	  these	  PCR	  products	  is	  around	  290bp.	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3.2.5.3 Cloning	  of	  the	  shRNA	  Cassettes	  in	  the	  pB12mcs-­‐eGFP	  
Vector	  
	  
The	   digested,	   purified	   shRNA	   cassettes	   were	   ligated	   into	   the	   pB12mcs-­‐
eGFP	  vector.	  The	  reaction	  was	  conducted	  overnight	  at	  4°C	  with	  a	  1:10	  vector	  
to	  insert	  ratio.	  Colony	  screening	  by	  means	  of	  PCR,	  using	  the	  T7	  forward	  and	  the	  
T3	  reverse	  primer	  set,	  was	  conducted	  and	  the	  wild	  type	  pB12mcs-­‐eGFP	  vector	  
was	  included	  as	  a	  negative	  control.	  An	  example	  of	  the	  colony	  screen	  conducted	  
on	   one	   of	   the	   U6	   shRNA	   constructs	   is	   shown	   in	   Figure	   3.15.	   Representative	  
electrophoretic	  analysis	  for	  all	  the	  remaining	  shRNA	  cassettes	  can	  be	  found	  in	  
Appendix	  7.	  	  
	  
	  
Figure	   3.15	   Electrophoretic	   Analysis	   of	   the	   colony	   screen	   PCR	   products	   of	   the	   U6	   shRNA1	  
construct	  with	  T7	  forward	  and	  T3	  reverse	  primers	  	  
Lane	  1:	  GeneRulerTM	  1Kb	  DNA	  Ladder	  
Lane	  2:	  PCR	  product	  of	  the	  wild	  type	  pB12mcs-­‐eGFP	  vector	  
Lanes	  3-­‐15:	  PCR	  products	  of	  the	  colony	  screen	  	  
Lanes	  7	  and	  10:	  Positive	  colonies	  
	  
This	  electrophoretic	  analysis	  was	  conducted	  on	  a	  2%	  agarose	  gel.	  The	  above	  analysis	  is	  of	  the	  
PCR	  products	  of	  the	  colony	  screen	  conducted	  on	  the	  U6	  shRNA2	  cassette	  that	  targets	  the	  β2α2	  
fusion	  point.	  The	  wild	  type	  vector	  gives	  a	  PCR	  product	  of	  ~1050bp.	  Any	  colony	  with	  the	  same	  
band	  size	  indicates	  that	  the	  insert	  was	  not	  taken	  up	  by	  the	  vector.	  However,	  colonies	  7	  and	  10,	  
which	  are	  highlighted	  in	  red,	  show	  bands	  of	  ~1390bp,	  indicating	  that	  the	  vector	  has	  an	  insert	  
of	  340bp.	  These	  colonies	  were	  therefore	  picked	  up	  further	  analysis.	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3.2.5.4 Confirmation	  by	  PCR	  of	  the	  shRNA	  Cassettes	  and	  the	  
Sequencing	  of	  the	  Cassettes	  	  
	  
The	   positive	   pB12mcs-­‐eGFP-­‐shRNA	   colonies	   were	   grown	   and	   purified	  
plasmids	  were	  screened	  by	  three	  sets	  of	  primers	  prior	  to	  sequencing	  them.	  The	  
sets	  of	  primers	  were	  the	  T7	  forward	  with	  the	  T3	  reserve	  primer,	  the	  T7	  forward	  
with	   the	   appropriate	   U6	   or	   H1	   shRNA	   reverse	   primer,	   and	   the	   U6	   or	   H1	  
forward	   with	   the	   T3	   reverse	   primer.	   PCR	   products	   were	   analysed	   by	  
electrophoresis,	   and	   colonies	   positive	   in	   all	   three	   screens,	   with	   the	   correct	  
band	   sizes,	   were	   sent	   for	   sequencing.	   Figure	   3.16	   shows	   an	   example	   of	   the	  
analysis	   for	   one	   of	   the	   positive	   colonies.	   Representative	   analyses	   of	   the	  
remaining	  colonies	  can	  be	  seen	  in	  Appendix	  7.	  
The	  sequencing	  results	  were	  analysed	  and	  the	  sequences	  of	  both	  the	  U6	  or	  
H1	   promoter	   and	   the	   shRNA	   molecules	   were	   checked.	   The	   raw	   sequencing	  
data	  of	  all	  shRNA	  cassettes	  in	  Appendix	  9	  and	  Table	  3.1	  gives	  a	  brief	  summary	  
and	   overview	   about	   all	   the	   shRNA	   cassettes	   that	   have	   been	   sequenced.	   A	  
summary	  of	  the	  sequencing	  results	  of	  the	  shRNA	  constructs	  that	  were	  tested,	  
and	  used	  for	  further	  expression	  studies	  can	  be	  found	  in	  Tables	  3.2	  –	  3.5.	  Tables	  
3.2	  and	  3.4	  show	  the	  sequencing	  results	  of	  the	  shRNA	  part	  of	  the	  constructs.	  
Table	  3.3	  shows	  the	  sequencing	  results	  of	  the	  U6	  part	  of	  the	  constructs	  and	  3.5	  
the	  H1	  part.	  The	  shRNA	  cassettes	  that	  were	  successfully	  synthesised	  included	  
the	  U6	   shRNA1;	   the	  U6	   shRNA3	   that	   targeted	   the	  β3α2	   fusion	  point;	   the	  U6	  
shRNA1	   that	   targeted	   the	   β2α2	   fusion	   point,	   the	   H1	   shRNA2;	   and	   the	   H1	  
shRNA3	   that	   targeted	   the	   β2α2	   fusion	   point.	   Due	   to	   time	   limitations,	   the	  
synthesis	  of	  further	  shRNA	  cassettes	  was	  stopped	  at	  this	  point.	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Figure	   3.16	   Electrophoretic	   Analysis	   of	   the	   pB12mcs-­‐eGFP	   Extracted	   Plasmid	   with	   the	   U6	  
shRNA1	  Construct	  Targeting	  the	  β2α2	  Fusion	  Gene	  
Lane	  1:	  GeneRulerTM	  1Kb	  DNA	  Ladder	  
Lane	  2:	  PCR	  product	  of	  the	  wild	  type	  pB12mcs-­‐eGFP	  vector	  with	  the	  primer	  set	  T7	  forward	  and	  
T3	  reverse	  (negative	  control)	  
Lane	  3:	  PCR	  product	  of	  the	  primer	  set	  T7	  forward	  with	  the	  T3	  reverse	  
Lane	  4:	  PCR	  product	  of	  the	  primer	  set	  T7	  forward	  with	  the	  U6	  shRNA1β2α2	  reverse	  
Lane	  5:	  PCR	  product	  of	  the	  primer	  set	  U6	  forward	  with	  the	  T3	  reverse	  
Lane	  6:	  GeneRulerTM	  100bp	  DNA	  Ladder	  
	  
The	   electrophoretic	   analysis	   on	   a	   2%	   agarose	   gel	   shows	   three	   PCR	   products	   from	   three	  
different	  sets	  of	  primers.	  A	  negative	  control	  Lane	  2	  is	  included,	  which	  is	  the	  PCR	  product	  of	  the	  
wild	  type	  plasmid	  with	  the	  primer	  set	  T7	  forward	  and	  T3	  reverse	  and	  a	  band	  size	  of	  ~1050bp	  is	  
seen.	  In	  the	  case	  of	  a	  positive	  colony	  a	  band	  size	  of	  ~1390bp	  is	  expected,	  when	  using	  the	  same	  
primer	  set.	  This	  is	  illustrated	  in	  lane	  3.	  Lane	  4	  is	  the	  PCR	  product	  of	  the	  primer	  set	  T7	  forward	  
with	  the	  U6	  shRNA1β2α2	  reverse.	  Here	  a	  band	  size	  of	  380bp	  is	  expected	  and	  seen.	  For	  the	  last	  






















β3α2	  shRNA1	   U6	   Yes	   2	  mismatches	   Yes	   4	  
β3α2	  shRNA2	   U6	   Yes	   Inconclusive	   No	   3	  
β3α2	  shRNA3	   U6	   Yes	   3	  mismatches	   Yes	   3	  
β2α2	  shRNA1	   U6	   Yes	   1	  mismatch	   Yes	   4	  
β2α2	  shRNA2	   U6	   No	   -­‐	   -­‐	   -­‐	  
β2α2	  shRNA3	   U6	   No	   -­‐	   -­‐	   -­‐	  
β2α2	  shRNA1	   H1	   Yes	   ShRNA	  sequence	  
	  was	  missing	  
No	   13	  
β2α2	  shRNA2	   H1	   Yes	   2	  mismatches	   No	  due	  to	  time	  
limitations	  
3	  
β2α2	  shRNA3	   H1	   Yes	   3	  mismatches	   No	  due	  to	  	  time	  
limitations	  
5	  
Table	  3.1	  A	  summary	  of	  the	  synthesis	  and	  sequencing	  of	  the	  shRNA	  constructs.	  	  	  
Nine	  constructs	  were	  designed	  in	  total,	  six	  regulated	  by	  the	  U6	  promoter,	  and	  three	  by	  the	  H1	  
promoter.	   The	   U6-­‐shRNA	   constructs	   targeted	   both	   fusion	   points,	   however,	   the	   H1-­‐shRNA	  
constructs	   only	   targeted	   the	   β2α2	   fusion	   point.	   Several	   colonies	   for	   each	   construct	   were	  
sequenced	  and	  only	   those	  with	   the	   correct	   shRNA	  sequence,	   and	   least	  number	  of	  promoter	  
mismatches,	   were	   selected	   for	   further	   studies.	   *	   All	   mismatches	   indicated	   are	   within	   the	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  DNA	  Fragment	   Sequence	  
1	   β3α2	  shRNA121nt	   AAAAAAGCAG AGTTCAAAAG CCCTTCACAA GCTTCTGAAG 
GGCTTTTGAA CTCTGC  
2	   β3α2	  shRNA322nt	   AAAAAAGCAG AGTTCAAAAG CCCTTCAGCA AGCTTCCTGA 
AGGGCTTTTG AACTCTGC  
3	   β2α2	  shRNA121nt	   AAAAAACAAT AAGGAAGAAG CCCTTCACAA GCTTCTGAAG 
GGCTTCTTCC TTATTG 
Sequencing	  results	  
4	   U6	  β3α2	  shRNA1	   AAAAAAGCAG AGTTCAAAAG CCCTTCACAA GCTTCTGAAG 
GGCTTTTGAA CTCTGC 
5	   U6	  β3α2	  shRNA3	   AAAAAAGCAG AGTTCAAAAG CCCTTCAGCA AGCTTCCTGA 
AGGGCTTTTG AACTCTGC 
6	   U6	  β2α2	  shRNA1	   AAAAAACAAT AAGGAAGAAG CCCTTCACAA GCTTCTGAAG 
GGCTTCTTCC TTATTG 
Table	  3.2	  The	  shRNA	  sequencing	  results	  of	  the	  pB12mcs-­‐U6-­‐shRNA-­‐eGFP	  constructs.	  	  
The	   sequences	  of	   the	  originally	  designed	   shRNA	  molecules	  are	   shown	   in	   rows	  1-­‐3.	  Rows	  4-­‐6	  
show	  the	  consensus	  results	  of	  the	  shRNA	  molecules	  that	  were	  inserted	  into	  the	  pB12mcs-­‐eGFP	  
vector.	   The	   sequencing	   results	   confirm	   that	   the	   shRNA	  molecules	   found	   in	   the	   synthesised	  
constructs	  completely	  match	  their	  original	  designed	  sequence.	  The	  sequences	  are	  given	  as	  the	  

















	  	   135	  
	  




CAAGGTCGGG CAGGAAGAGG GCCTATTTCC CATGATTCCT TCATATTTGC 
ATATACGATA CAAGGCTGTT AGAGAGATAA TTAGAATTAA TTTGACTGTA 
AACACAAAGA TATTAGTACA AAATACGTGA CGTAGAAAGT AATAATTTCT 
TGGGTAGTTT GCAGTTTTAA AATTATGTTT TAAAATGGAC TATCATATGC 
TTACCGTAAC TTGAAAGTAT TTCGATTTCT TGGCTTTATA TATCTTGTGG 
AAAGGACGAA ACACCGTGCT CGCTTCGGCA GCACATATAC TA 
	  
Sequencing	  Results	  
U6	  β3α2	  shRNA1	  
	  
CAAGGTCGGG CAGGAAGAGG GCCTATTTCC CATGATTCCT TCATATTTGC 
ATATACGATA CAAGGCTGTT AGAGAGACAA TTAGAATTAA TTTGACTGTA 
AACACAAAGA TATTAGTACA AAATACGTGA CGTAGAAAGT AATAATTTCT 
TGGGTAGTTT GCAGTTTTAA AATTATGTTT TAAAATGGAC TATCATATGC 
TTACCGTAAC TTGAAAGTAT TTCGATTTCT TGGCTTTATA TATCTTGTGG 
AAAGGACGAA GCACCGTGCT CGCTTCGGCA GCACATATAC TA 
 
U6	  β3α2	  shRNA3	  
	  
CAAGGTCGGG CAGGAAGAGG GCCTATTTCC CATGATTCCT TCATATTTGC 
ATATACGATA CAAGGCTGTT AGAGAGATAA TTAGAATTAA TTTGACTGTA 
AGCACAAAGA TATTAGTACA AAATACGTGA CGTAGAAAGT AATAATTTCT 
TGGGTAGTTT GCAGTTTTAA AATTATGTTT TAAAATGGAC TATCATATGC 
TTACCGTAAC TTGAAAGTAT TTCGATTTCT TGGCTTTATA TATCTTGTGG 
AAAGGACGAA GCACCGTGCT CGTTTCGGCA GCACATATAC TA 
 
U6	  β2α2	  shRNA1	  
	  
CAAGGTCGGG CAGGAAGAGG GCCTATTTCC CATGATTCCT TCATATTTGC 
ATATACGATA CAAGGCTGTT AGAGAGATAA TTAGAATTAA TTTGACTGTA 
AACACAAAGA TATTAGTACA AAATACGTGA CGTAGAAAGT AATAATTTCT 
TGGGTAGTTT GCAGTTTTAA AATTATGTTT TAAAATGGAC TATCATATGC 
TTACCGTAAC TTGAAAGTAT TTCGATTTCT TGGCTTTATA TATCTTGTGG 
AAAGGACGAA GCACCGTGCT CGCTTCGGCA GCACATATAC TA 
 
Table	  3.3	  The	  U6	  sequencing	  results	  of	  the	  pB12mcs-­‐U6-­‐shRNA-­‐eGFP	  Constructs.	  	  
This	   table	   summarises	   the	   sequencing	   results	   from	   the	   pB12mcs-­‐U6-­‐eGFP	   constructs.	   The	  
sequences	  shown	  above	  are	  of	  only	  the	  constructs	  that	  have	  been	  further	  used	  in	  expression	  
studies	   described	   in	   the	   following	   chapter.	   The	   top	   of	   the	   table	   illustrates	   the	   human	   U6	  
promoter	   sequence	   found	   in	   the	   EMBL	  website.	   Below	   are	   the	   consensus	   results	   of	   the	   U6	  
promoter	  from	  each	  construct.	  Any	  mismatches	  in	  the	  sequenced	  data	  are	  highlighted	  in	  red.	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  DNA	  Fragment	   Sequence	  
1	   β2α2	  shRNA221nt	   AAAAAAAATA AGGAAGAAGC CCTTCACCAA GCTTCGTGAA 
GGGCTTCTTC CTTATTG 
2	   β2α2	  shRNA322nt	   AAAAAACAAT AAGGAAGAAG CCCTTCACCA AGCTTCGTGA 
AGGGCTTCTT CCTTATTGG 
Sequencing	  results	  
3	   H1	  β2α2	  shRNA2	  
	  
AAAAAAAATA AGGAAGAAGC CCTTCACCAA GCTTCGTGAA 
GGGCTTCTTC CTTATTG  
4	   H1	  β2α2	  shRNA3	  
	  
AAAAAACAAT AAGGAAGAAG CCCTTCACCA AGCTTCGTGA 
AGGGCTTCTT CCTTATTGG 
Table	  3.4	  The	  shRNA	  sequencing	  results	  of	  the	  pB12mcs-­‐H1-­‐shRNA-­‐eGFP	  constructs.	  	  
The	  sequences	  of	  the	  originally	  designed	  shRNA	  molecules	  are	  shown	  in	  rows	  1	  and	  2.	  Rows	  3	  
and	   4	   show	   the	   consensus	   results	   of	   the	   shRNA	   molecules	   that	   were	   inserted	   into	   the	  
pB12mcs-­‐eGFP	   vector.	   The	   sequencing	   confirms	   that	   the	   shRNA	   molecules	   found	   in	   the	  
synthesised	  constructs	  completely	  match	  their	  original	  designed	  sequence.	  The	  sequences	  are	  
given	  as	  the	  reverse	  sequence	  3’	  	  5’.	  	  	  
	  




GAACGCTGAC GTCATCAACC CGCTCCAAGG AATCGCGGGC CCAGTGTCAC 
TAGGCGGGAA CACCCAGCGC GCGTGCGCCC TGGCAGGAAG ATGGCTGTGA 
GGGACAGGGG AGTGGCGCCC TGCAATATTT GCATGTCGCT ATGTGTTCTG 
GGAAATCACC ATAAACGTGA AATGTCTTTG GATTTGGGAA TCTTATAAGT 
TCTGTATGAG ACCACTCTTT 
Sequencing	  Results	  
H1	  β2α2	  shRNA2	   GAACGCTGAC GTCATCAACC CGCTCCAAGG AATCGCGGGC CCAGTGTCAC 
TAGGCGGGAA CACCCAGCGC GCGTGCGCCC TGGCAGGAAG ATGGCTGTGA 
GGGACAGGGG AGTGGCGCCC TGCAATATCT GCATGTCGCT ATGTGTTCTG 
GGAAATCACC GTAAACGTGA AATGTCTTTG GATTTGGGAA TCTTATAAGT 
TCTGTATGAG ACCACTCTTT 
H1	  β2α2	  shRNA3	  
	  
GAACGCTGAC GTCATCAACC CGCTCCAAGG AATCGCGGGC CCAGTGTCAC 
TAGGCGGGAA CACCCAGCGC GCGTGCGCCC TGGCAGGAAG ATGGCTGTGA 
GGGACAGGGG AGTGGCGCCC TGCAATATCT GCATGTCGCT ATGTGTTCTG 
GGAAATCACC GTAAACGTGA AATGTCTTTG GATTTGGGGA TCTTATAAGT 
TCTGTATGAG ACCACTCTTT 
Table	  3.5	  The	  H1	  sequencing	  results	  of	  the	  pB12mcs-­‐H1-­‐shRNA-­‐eGFP	  Constructs.	  	  
This	  table	  summarises	  the	  sequencing	  results	  obtained	  from	  the	  pB12mcs-­‐H1-­‐eGFP	  constructs.	  
The	   sequences	   shown	   above	   are	   of	   only	   the	   constructs	   that	   have	   been	   further	   used	   in	  
expression	   studies	   described	   in	   the	   following	   chapter.	   The	   top	   of	   the	   table	   illustrates	   the	  
human	  H1	  promoter	  sequence	  found	  in	  the	  EMBL	  website.	  Below	  shows	  the	  consensus	  results	  
of	   the	   H1	   promoter	   from	   each	   construct.	   Any	   mismatches	   in	   the	   sequenced	   data	   are	  
highlighted	  in	  red.	  	  The	  sequences	  are	  given	  as	  the	  forward	  sequence	  5’	  	  3’.	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3.3 Discussion	  
	  
This	   chapter	   describes	   how	   a	   reporter	   gene	   system	   was	   generated.	   The	  
pB12mcs-­‐eGFP	  vector	  was	  used	  for	  this	  purpose.	  The	  vector	  had	  an	  enhanced	  
GFP	   that	   is	   considered	   to	   be	   advantageous	   when	   using	   the	   system	   in	  
mammalian	   cell	   lines.	   The	   plasmid	   was	   used	   to	   clone	   several	   synthesised	  
shRNA	  cassettes.	   These	   shRNA	  molecules	  were	  designed	   to	   target	   the	   fusion	  
points,	  β3α2	  and	  β2α2,	  of	  the	  Philadelphia	  chromosome.	  	  
Cell	  lines	  chosen	  for	  use	  in	  this	  project	  were	  the	  human	  K562	  cell	  line	  that	  
bears	  the	  β3α2	  fusion	  point,	  and	  the	  KCL-­‐22	  cell	  line	  that	  has	  the	  β2α2	  fusion	  
point.	  It	  was	  confirmed	  that	  both	  these	  cell	  lines	  contained	  the	  fusion	  point	  of	  
interest	   by	  means	   of	   PCR	   and	   it	  was	   further	   confirmed	   that	   their	   sequences	  
matched	  the	  β3α2	  and	  the	  β2α2	  sequences,	  that	  are	  found	  in	  EMBL	  website.	  
Upon	   this	   confirmation,	   three	   short	   hairpin	   RNA	   molecules	   for	   each	   fusion	  
point	   were	   designed.	   The	   secondary	   structures	   of	   the	   designed	   antisense	  
oligonucleotides	   were	   predicted	   and	   upon	   confirmation	   that	   the	   designed	  
shRNA	  molecules	   do	   have	   a	   hairpin	   like	   secondary	   structure,	   the	   molecules	  
were	  synthesised.	  Synthesis	  was	  achieved	  by	  PCR,	  where	  the	  sequence	  of	  the	  
designed	  antisense	  molecule	  was	  linked	  to	  a	  reverse	  primer	  for	  the	  U6	  or	  the	  
H1	  human	  promoters.	   The	   shRNA	   cassettes	  were	   therefore,	   synthesised	   in	   a	  
manner	   where	   the	   molecules	   were	   downstream	   to	   the	   human	   U6	   or	   H1	  
promoters.	  	  
The	   U6	   and	   H1	   promoters	   were	   selected	   due	   to	   the	   advantage	   of	   their	  
natural	   presence	   in	   human	   cell	   lines	   and	   the	   ease	   of	   signalling	   their	  
termination,	  where	  a	  stretch	  of	  4	  to	  6	  ‘T’	  nucleotides	  causes	  the	  promoter	  to	  
terminate.	  The	  synthesised	  shRNA	  cassettes	  were	  then	  cloned	  into	  the	  double	  
digested	  pB12mcs-­‐eGFP	  vector.	  Positive	  colonies	  including	  both	  the	  vector	  and	  
inserted	   shRNA	   cassettes	   were	   sequenced	   and	   those	   that	   have	   the	   U6	  
promoter	   and	   the	   correct	   shRNA	   sequence	   were	   selected	   for	   further	  
expression	  studies.	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The	   next	   step	   was	   to	   examine	   and	   test	   how	   efficient	   and	   specific	   the	  
designed	   shRNA	  molecules	   were	   to	   their	   target	   sites.	   The	   following	   chapter	  
deals	   with	   this	   issue,	   where	   expression	   studies	   were	   conducted	   on	   the	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Chapter	  4 :	  Expression	  of	  the	  shRNA	  Constructs	  in	  K562	  





To	   examine	   the	   inhibitory	   effects	   that	   the	   synthesised	   shRNA	   constructs	  
might	   have	   on	   their	   target	   sites,	   these	   constructs	   were	   expressed	   in	   two	  
human	  cell	  lines	  K562	  and	  KCL-­‐22.	  The	  K562	  cell	  line	  expresses	  the	  β3α2	  fusion	  
protein,	   whereas	   the	   KCL-­‐22	   cell	   line	   expresses	   the	   β2α2	   fusion	   protein	  
(Drexler	  et	  al.,	  1999).	  The	  expression	  of	  the	  shRNA	  constructs	  was	  monitored	  
through	  the	  reporter	  gene	  system,	  which	  has	  been	  described	  previously.	  	  
The	  effects	  of	  the	  synthesised	  constructs	  were	  then	  examined	  at	  both	  the	  
RNA	  and	  protein	   levels,	  and	  the	  specificity	  of	  the	  shRNA	  molecules	  were	  also	  
examined.	  In	  this	  part	  of	  the	  study,	  various	  chemical	  methods	  to	  transfect	  the	  
synthesised	   shRNA	   constructs	   were	   undertaken;	   in	   addition,	   one	   type	   of	  
physical	   transfection	   was	   also	   examined:	   nucleofection,	   which	   is	   a	   form	   of	  
electroporation.	  In	  summary,	  this	  chapter	  deals	  with	  examining	  the	  expression	  
of	  the	  generated	  shRNA	  constructs	  and	  their	   inhibitory	  effects	  on	  their	  target	  
BCR-­‐ABL	  fusion	  gene.	  	  	  	  
	  
	  
4.2 Results	  	  	  
	  
	  
4.2.1 Transfection	  of	  the	  shRNA	  Constructs	  in	  K562	  and	  KCL-­‐
22	  Cell	  lines.	  	  
	  
The	  K562	  and	  KCL-­‐22	  cell	  lines	  are	  CML	  cell	  lines	  bearing	  the	  β3α2	  and	  β2α2	  
BCR-­‐ABL	  variants	  respectively.	  Leukaemic	  cell	  lines	  are	  characterised	  by	  having	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a	  growth	  advantage	  over	  normal	  cells,	  due	  to	  their	  rapid	  range	  of	  proliferation.	  
These	  cells	  are	  unable	  to	  mature	  to	  functional	  non-­‐dividing	  cells,	  hence	  leading	  
to	  their	  accumulation	  (Koeffler	  and	  Golde,	  1980).	  Lozzio	  and	  Lozzio,	  1975,	  first	  
reported	   the	  K562	   cell	   line	   that	  was	  established	   from	  a	  pleural	   effusion	  of	   a	  
terminal	   patient	   with	   CML	   in	   blast	   phase.	   The	   KCL-­‐22	   cell	   lines	   were	  
established	   in	   the	   same	  manner	   as	   K562.	   Kubonishi	   and	  Miyoshi,	   1983,	   first	  
reported	  KCL-­‐22	  cell	  line	  in	  1983.	  
These	   cell	   lines	   grow	  as	   single-­‐cell	   suspension	   cultures	   (Lozzio	  and	   Lozzio,	  
1975	   and	   Kubonishi	   and	   Miyoshi,	   1983)	   and	   primary	   cells	   and	   cells	   in	  
suspensions	   are	   hard	   to	   transfect	   (Ovcharenko	   et	   al.,	   2005	   and	  Oliveira	   and	  
Goodell,	  2003).	  Therefore,	   in	  order	  to	  select	  the	  best	  method	  of	  transfection,	  
with	   the	  highest	   transfection	  efficiency,	  both	   chemical	   and	  physical	  methods	  
were	  considered.	  	  
In	   this	   project,	   two	  of	   the	   three	   shRNA	   constructs	   designed	   to	   target	   the	  
mRNA	  sequence	  of	  the	  β3α2	  fusion	  variant	  were	  studied.	  While,	  one	  construct	  
that	  targets	  the	  β2α2	  fusion	  variant	  was	  examined.	  	  
	  
	  
4.2.2 Transfection	  by	  Chemical	  Methods	  and	  FACS	  Analysis	  
	  
A	  range	  of	  chemical	  reagents	  was	  used	  to	  assess	  transfection	  efficiency	  into	  
cell	  lines,	  and	  FACS	  analysis	  was	  performed	  after	  transfection.	  For	  FACS,	  3	  x	  105	  
cells	   were	   counted	   and	   the	   “Cell	   Quest”	   software	   used	   for	   analysis.	   The	  
parameters	   were	   adjusted	   according	   to	   the	   cell	   line	   type	   when	   the	   FACS	  
analysis	   was	   conducted.	   Examples	   of	   the	   generated	   data	   for	   the	   different	  
transfection	  reagents	  tested	  are	  shown	  in	  Figures	  4.1	  -­‐	  4.4.	  Figures	  4.1	  and	  4.2	  
demonstrate	   the	   highest	   transfection	   efficiencies	   achieved	   when	   using	   a	  
chemical	   transfection	   reagent,	   while	   Figures	   4.3	   and	   4.4	   demonstrate	  
transfection	  reactions	  that	  did	  not	  work.	  Table	  4.1	  summarises	  the	  transfection	  
data	   obtained	   when	   using	   the	   different	   types	   of	   chemical	   transfection	  
reagents.	  The	  highest	  levels	  of	  transfection	  in	  both	  K562	  and	  KCL-­‐22	  cells	  were	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seen	  when	  using	   feOfection/Yellow	  as	   a	   transfection	   reagent	   (K562	  48%	  and	  




Figure	   4.1	   Histogram	   generated	   by	   FACS	   demonstrating	   the	   transfection	   efficiency	   of	   the	  
NIMT	  FeOfection/Yellow	  transfection	  reagent	  in	  K562	  cell	  lines.	  	  
A	   histogram	   generated	   by	   the	   program	   CellQuest	   by	   the	   use	   of	   FACS	   for	   the	   K562	   cell	   line	  
transfected	  with	   the	   pEGFP-­‐N1	   vector	   by	  NIMT	   FeOfection/Yellow	   transfection	   reagent.	   The	  
control,	   non-­‐transfected	   cells,	   is	   shown	   in	   purple	   followed	   by	   the	   readings	   of	   the	   different	  
dilutions	  of	   the	  transfection	  reagent,	  green,	  pink,	  blue,	  and	  yellow.	  These	  have	  the	  following	  
dilutions	  of	  the	  transfection	  reagent	  100,	  120,	  140,	  and	  160μl,	  respectively,	  mixed	  with	  5μl	  of	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Figure	   4.2	   Histogram	   generated	   by	   FACS	   demonstrating	   the	   transfection	   efficiency	   of	   the	  
NIMT	  FeOfection/Yellow	  transfection	  reagent	  in	  KCL-­‐22	  cell	  line.	  	  
A	   histogram	   generated	   by	   the	   program	   CellQuest	   by	   the	   use	   of	   FACS	   for	   the	   K562	   cell	   line	  
transfected	  with	   the	   pEGFP-­‐N1	   vector	   by	  NIMT	   FeOfection/Yellow	   transfection	   reagent.	   The	  
control,	   non-­‐transfected	   cells,	   is	   shown	   in	   purple	   followed	   by	   the	   readings	   of	   the	   different	  
dilutions	   of	   the	   transfection	   reagent,	   green,	   pink,	   blue,	   and	   red.	   These	   have	   the	   following	  
dilutions	  of	  the	  transfection	  reagent	  100,	  120,	  140,	  and	  160μl,	  respectively,	  mixed	  with	  5μl	  of	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Figure	   4.3	   Histogram	   generated	   by	   FACS	   demonstrating	   the	   transfection	   efficiency	   of	   the	  
Nanofectin	  transfection	  reagent	  in	  K562	  cell	  line.	  	  
A	   histogram	   generated	   by	   the	   program	   CellQuest	   by	   the	   use	   of	   FACS	   for	   the	   K562	   cell	   line	  
transfected	  with	   the	  pEGFP-­‐N1	   vector	   by	  Nanofectin	   transfection	   reagent.	   The	   control,	   non-­‐
transfected	  cells,	  is	  shown	  in	  purple	  followed	  by	  the	  readings	  of	  the	  different	  nanofectin	  ratios	  
2	   (8μl),	  3	   (12.8μl),	  and	  4	   (16μl)	   that	  were	  mixed	  with	  4μl	  of	  DNA.	  These	  are	  shown	   in	  green,	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Figure	   4.4	   Histogram	   generated	   by	   FACS	   demonstrating	   the	   transfection	   efficiency	   of	   the	  
Nanofectin	  transfection	  reagent	  in	  KCL-­‐22	  cell	  line.	  	  
A	  histogram	  generated	  by	   the	  program	  CellQuest	  by	   the	  use	  of	  FACS	   for	   the	  KCL-­‐22	  cell	   line	  
transfected	  with	   the	  pEGFP-­‐N1	   vector	   by	  Nanofectin	   transfection	   reagent.	   The	   control,	   non-­‐
transfected	  cells,	  is	  shown	  in	  purple	  followed	  by	  the	  readings	  of	  the	  different	  nanofectin	  ratios	  
2	   (8μl),	  3	   (12.8μl),	  and	  4	   (16μl)	   that	  were	  mixed	  with	  4μl	  of	  DNA.	  These	  are	  shown	   in	  green,	  
























Table	  4.1	  A	  summary	  of	  different	  transfection	  methods	  on	  the	  transfection	  efficiency	  of	  K562	  
and	  KCL-­‐22	  cell	  lines.	  	  
Several	   transfection	   kits	   were	   tested	   in	   order	   to	   transfect	   a	   control	   vector,	   the	   pEGFP-­‐N1	  
vector,	   into	   the	   K562	   and	   KCL-­‐22	   cell	   lines.	   The	   above	   table	   shows	   a	   list	   with	   all	   the	  
transfection	  reagents	  that	  have	  been	  tested	  and	  the	  range	  of	  resultant	  transfection	  efficiency	  
obtained	   from	  each	  kit.	   Some	  kits	  didn’t	  work	  at	   all,	  where	  no	   fluorescent	   cells	  were	  visible	  
under	   the	   fluorescent	   microscope	   nor	   any	   difference	   between	   the	   control	   and	   transfected	  
sample	   using	   FACS.	   *The	   highest	   transfection	   efficiency	   was	   by	   using	   the	   NIMT	  
FeOfection/Yellow	  kit	  that	  gave	  an	  efficiency	  of	  up	  to	  48.7%	  in	  the	  K562	  cell	  lines.	  	  
	  
4.2.3 Transfection	  Through	  Nucleofection	  
	  
Chemical	  methods	  of	   transfecting	  K562	  and	  KCL-­‐22	  cells	  did	  not	  give	  high	  
efficiencies	   so	   nucleofection	   was	   tried.	   Nucleofection	   is	   a	   form	   of	  
electroporation,	   where	   specific	   electrical	   impulses	   are	   used	   to	   weaken	   the	  
target	   cell’s	   membrane.	   Pores	   in	   the	   cell’s	   membrane	   are	   created,	   through	  
which	  DNA	  fragments	  can	  be	  internalized.	  In	  nucleofection,	  the	  DNA	  of	  interest	  
is	   mixed	   with	   a	   special	   reagent	   (its	   composition	   is	   unknown	   as	   the	  
manufacturer	   does	   not	   supply	   this	   information),	  which	   is	   then	   added	   to	   the	  
cell	   line,	   and	   a	   wave	   of	   electrical	   impulses	   is	   introduced.	   The	   Amaxa	  
Transfection	  efficiency	  Name	  of	  Kit	   Supplier	  
K562	   KCL-­‐22	  
Superfect	   Qiagen	   21-­‐31%	   Didn’t	  work	  
Lipofectamin	  2000	  	   Invitrogen	   17.7-­‐27%	   14.8-­‐18.5%	  
Hilymax	   Dojindo	   10-­‐15%	   Didn’t	  work	  
TransIT-­‐2020	   Mirus	   21.8-­‐40.5%	   25.5-­‐26.5%	  
NIMT	  FeOfection/Yellow*	   Genovis	   43-­‐48.7%	   29-­‐38%	  
FuGENE	  HD	   Roche	   16-­‐32%	   25-­‐30%	  
Nanofectin	   PAA	   Didn’t	  work	   Didn’t	  work	  
Lentiphos	  HT	   Clontech	   Didn’t	  work	   Didn’t	  work	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nucleofector	   system	   was	   used	   in	   this	   study.	   It	   should	   be	   noted	   that	   the	  
company	   supplies	   different	   transfecting	   reagent	   kits	   and	   nucleofector	  
programs	  depending	  on	  the	  cell	  line	  type.	  	  
For	   the	   K562	   cell	   line	   a	   commercially	   available	   reagent	   and	   two	  
nucleofection	   programs	   were	   available.	   Both	   programs	   were	   used	   with	   the	  
K562	  cells	  and	  control	  vector	  supplied	  with	  the	  nucleofection	  Kit	  to	  determine	  
which	  program	  was	  best	  for	  this	  cell	   line.	  However,	   in	  the	  case	  of	  the	  KCL-­‐22	  
cells,	   neither	   reagent	   nor	   programs	   were	   available.	   Therefore,	   the	   same	  
reagent	  and	  programs,	  previously	  tested	  for	  the	  K562	  cells,	  were	  used	  for	  the	  
KCL-­‐22	   cell	   line.	   The	   program	   T-­‐016	   was	   found	   to	   give	   best	   transfection	  
efficiencies	  and	  cell	  viability	  for	  both	  cell	  lines.	  The	  transfection	  efficiency	  and	  
cell	   viability	   results	   obtained	   from	   both	   nucleofection	   programs	   are	  
summarized	  in	  Table	  4.2	  below.	  	  
	  
	  
	   K562	  cell	  line	   T-­‐003	   T-­‐016	  
1	   Transfection	  efficiency	  	   40.4%	   54.7%	  
2	   Viability	  	   76%	   90%	  
	   KCL-­‐22	  cell	  line	   T-­‐003	   T-­‐016	  
3	   Transfection	  efficiency	   35%	   40%	  
4	   Viability	  	   78%	   90%	  
Table	   4.2	   A	   Summary	   of	   the	   transfection	   efficiency	   obtained	   from	   FACS	   analysis	   and	   cell	  
viability	  of	  K562	  and	  KCL-­‐22	  cell	  lines	  by	  Nucleofection	  with	  the	  pB12mcs-­‐U6-­‐eGFP	  vector.	  	  
K562	  and	  KCL-­‐22	  cell	   lines	  were	  transfected	  using	  the	  Amaxa	  cell	   line	  nucleofector®	  kit	  V	  and	  
two	  nucleofection	  programs,	  T-­‐003	  and	  T-­‐016.	  Each	  program	  was	  for	  nucleofecting	  a	  different	  
K562	  clone.	  The	  two	  programs	  were	  tested	  because	  the	  clone	  of	  the	  given	  K562	  cell	   line	  was	  
unknown.	  Transfection	  and	  viability	  results	  for	  both	  cell	  lines	  showed	  that	  the	  T-­‐016	  program	  
had	  higher	  transfection	  efficiency	  and	  viability	  than	  the	  T-­‐003.	  This	  was	  observed	  in	  both	  cell	  
lines,	  consequently,	  the	  T-­‐016	  program	  was	  used	  for	  all	  following	  nucleofections.	  	  
	  
The	  T-­‐016	  program	  was	  used	   in	  all	   subsequent	   studies.	  To	   investigate	   the	  
transfection	   efficiency	   with	   pB12mcs-­‐eGFP	   vectors,	   groups	   of	   2.5	   x106	   cells	  
were	   transfected	   with	   the	   following:	   negative	   control	   (pB12mcs-­‐eGFP	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wildtype),	   positive	   control	   (pB12mcs-­‐U6-­‐eGFP),	   shRNA1β3α2,	   and	   shRNA3β3α2	  
constructs	   for	   the	   K562	   cell	   line,	   and	   negative	   control	   (pB12mcs-­‐eGFP	  
wildtype),	  positive	  control	  (pB12mcs-­‐U6-­‐eGFP),	  and	  shRNA1β2α2	  construct,	  for	  
the	  KCL-­‐22	  cell	  line.	  Successful	  transfection	  was	  confirmed	  by	  detection	  of	  GFP	  
fluorescence	   of	   the	   target	   cell	   lines	   under	   the	   fluorescent	   microscope,	   see	  
Figures	   4.5	   and	   4.6.	   Once	   the	   fluorescence	   of	   the	   eGFP	   was	   detected,	   the	  
percentage	  of	   cell	   viability	  was	   calculated,	   through	   the	  use	  of	   an	   automated	  




Figure	  4.5	  Nucleofection	  of	  the	  K562	  cell	  line	  with	  the	  pB12mcs	  plasmids.	  	  
	  (A)	   Shows	   the	  K562	   cell	   line	  under	   the	   fluorescent	  microscope	  24	  hours	   after	  nucleofection	  
with	  the	  pB12mcs-­‐U6-­‐eGFP	  plasmid	  (positive	  control,	  U6	  promoter),	  in	  bright	  field.	  (B)	  Shows	  
the	   cells	   when	   excited	   with	   blue	   light,	   fluorescing	   in	   green.	   (C)	   Shows	   the	   K562	   cells	  
transfected	   with	   wild	   type	   pB12mcs-­‐eGFP	   vector	   (negative	   control,	   no	   promoter)	   in	   bright	  
field.	  The	  same	  cells	  are	  shown	  in	  (D)	  after	  excitation	  with	  blue	  light.	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Figure	  4.6	  Nucleofection	  of	  the	  KCL-­‐22	  cell	  line	  with	  the	  pB12mcs	  plasmids.	  	  
(A)	  Shows	  the	  KCL-­‐22	  cell	   line	  under	  the	  fluorescent	  microscope	  24	  hours	  after	  nucleofection	  
with	  the	  pB12mcs-­‐U6-­‐eGFP	  plasmid	  (positive	  control,	  U6	  promoter),	  in	  bright	  field.	  (B)	  Shows	  
the	   cells	   when	   excited	   with	   blue	   light,	   fluorescing	   in	   green.	   (C)	   Shows	   the	   KCL-­‐22	   cells	  
transfected	   with	   wild	   type	   pB12mcs-­‐eGFP	   vector	   (negative	   control,	   no	   promoter)	   in	   bright	  
field.	  The	  same	  cells	  are	  shown	  in	  (D)	  after	  excitation	  with	  blue	  light.	  
	  
Once	  successful	  transformation	  was	  achieved,	  cell	  viability	  was	  determined	  
and	  3	  x	  105	  cells	   from	  an	  original	  number	  of	  2.5	  x	  106	   transfected	  cells	  were	  
counted	   and	   fixed	   and	   the	   transfection	   efficiency	   was	   determined	   by	   FACS	  
analysis.	   Five	   groups	   of	   K562	   cell	   were	   tested:	   non-­‐transfected	   cells,	   cells	  
transfected	   with	   the	   negative	   control	   vector	   (wild	   type	   pB12mcs-­‐eGFP	   no	  
promoter),	   cells	   transfected	   with	   the	   positive	   control	   vector	   (pB12mcs-­‐U6-­‐
eGFP),	   cells	   transfected	   with	   pB12mcs-­‐U6-­‐shRNA1β3α2-­‐eGFP,	   and	   cells	  
transfected	   with	   pB12mcs-­‐U6-­‐shRNA3β3α2-­‐eGFP.	   Four	   groups	   of	   KCL-­‐22	   cell	  
lines	   were	   tested:	   non-­‐transfected	   cells,	   cells	   transfected	   with	   the	   negative	  
control	   vector	   (wild	   type	   pB12mcs-­‐eGFP),	   cells	   transfected	  with	   the	   positive	  
control	   vector	   (pB12mcs-­‐U6-­‐eGFP),	   and	   cells	   transfected	   with	   pB12mcs-­‐U6-­‐
shRNA1β2α2-­‐eGFP.	   Figures	   4.7	   and	   4.8	   are	   examples	   of	   the	   FACS	   results	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generated	  from	  the	  nucleofections	  of	  K562	  and	  KCL-­‐22	  groups,	  and	  Table	  4.3	  
summarises	   the	   transfection	   efficiency	   results	   of	   three	   successful	  
nucleofections	  conducted	  on	  each	  of	  the	  cell	  lines.	  All	  the	  other	  data	  is	  given	  in	  
Appendix	  10.	  	  
It	   was	   interesting	   to	   observe	   that	   the	   shRNA	   constructs	   also	   generated	  
fluorescent	  signals	  indicating	  that	  the	  stop	  signal	  did	  not	  cause	  termination	  of	  
the	  U6	  promoter.	  Advantage	  of	  the	  observed	  GFP	  fluorescence	  generated	  was	  




Figure	   4.7	   Histogram	   generated	   by	   FACS	   demonstrating	   the	   transfection	   efficiency	   of	  
nucleofection	  in	  the	  K562	  cell	  line.	  	  
The	  histogram	  is	  a	  representation	  of	  one	  of	  three	  nucleofections	  conducted	  on	  the	  K562	  cell	  
lines,	  transfection	  number	  2	  in	  Table	  4.3.	  In	  purple	  are	  the	  non-­‐transfected	  K562	  cells.	  In	  pink	  
are	   the	  K562	   cells	   transfected	  with	   the	  positive	   control	   vector	   (pB12mcs-­‐U6-­‐eGFP).	   In	   green	  
are	   the	  K562	   cells	   transfected	  with	   the	  negative	   control,	   pB12mcs-­‐eGFP	  wild	   type	   vector.	   In	  
blue	   are	   the	   cells	   transfected	   with	   the	   shRNA1β3α2	   construct,	   and	   in	   orange	   are	   the	   cells	  
transfected	  with	  the	  shRNA3β3α2	  construct.	  The	  transfection	  efficiencies	  for	  each	  with	  regards	  
to	   the	   non-­‐transfected	   cells	   are	   57%,	   11.63%,	   35%,	   and	   23%	   respectively.	   The	   transfection	  
efficiencies	  with	  regards	  to	  the	  cells	  transfected	  with	  the	  negative	  control	  are	  45.08%	  for	  the	  
positive	  control	  and	  23.29%	  for	  shRNA1β3α2	  construct	  and	  11.39%	  for	  shRNA3β3α2	  construct.	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Figure	   4.8	   Histogram	   generated	   by	   FACS	   demonstrating	   the	   transfection	   efficiency	   of	  
nucleofection	  in	  the	  KCL-­‐22	  cell	  line.	  	  
The	   histogram	   is	   a	   representation	   of	   one	   of	   three	   nucleofections	   conducted	   on	   the	   KCL-­‐22	  
cells,	  transfection	  number	  2	  in	  Table	  4.3.	  In	  purple	  are	  the	  non-­‐transfected	  KCL-­‐22	  cells;	  in	  pink	  
are	  the	  cells	  transfected	  with	  the	  positive	  control	  vector	  (pB12mcs-­‐U6-­‐eGFP);	  in	  green	  are	  cells	  
transfected	  with	  the	  negative	  control	  (pB12mcs-­‐eGFP	  wild	  type	  vector),	  and	  in	  yellow	  are	  the	  
cells	   transfected	   with	   the	   shRNA1β2α2	   construct.	   The	   transfection	   efficiencies	   for	   each	   with	  
regards	  to	  the	  non-­‐transfected	  cells	  are	  64%,	  19.08%,	  and	  29.1%	  respectively.	  The	  transfection	  
efficiencies	  with	   regards	   to	   the	  cells	   transfected	  with	   the	  negative	   control	  are	  44.9%	   for	   the	  
positive	  control	  and	  10.02%	  for	  shRNA1β2α2	  construct.	  
	  
	  
	   Clearly	  the	  negative	  control	  in	  this	  transfection	  exhibiting	  GFP	  fluorescence	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(B)	  Cell	  viability	  of	  cells	  transfected	  with:	  K562	  Cell	  Line	   (A)	  Transfection	  
















Transfection	  1	   28%	   99%	   89%	   90%	   86%	   80%	  
Transfection	  2	   57%	   98%	   90%	   92%	   84%	   82%	  
Transfection	  3	   72%	   99%	   90%	   90%	   87%	   84%	  
(D)	  Cell	  viability	  of	  cells	  transfected	  with:	  KCL-­‐22	  cell	  line	   (C)	  Transfection	  














Transfection	  1	   53%	   98%	   90%	   89%	   87%	  
Transfection	  2	   64%	   98%	   88%	   91%	   86%	  
Transfection	  3	   67%	   99%	   90%	   88%	   87%	  
Table	  4.3	  A	  Summary	  of	  the	  three	  nucleofections	  conducted	  on	  each	  of	  the	  human	  leukaemic	  
cell	  lines,	  K562	  and	  KCL-­‐22,	  and	  the	  cell	  viability	  in	  each	  of	  the	  transfected	  cell	  groups.	  	  
Each	  K562	  cell	  transfection	  consisted	  of	  5	  groups;	  non-­‐transfected	  cells,	  cells	  transfected	  with	  
the	  wild	  type	  pB12mcs-­‐eGFP	  vector	  (negative	  control),	  cells	  transfected	  with	  the	  pB12mcs-­‐U6-­‐
eGFP	   vector	   (positive	   control),	   cells	   transfected	   with	   the	   shRNA1β3α2	   construct,	   and	   cells	  
transfected	   with	   the	   shRNA3β3α2	   construct.	   The	   transfection	   efficiency	   (positive	   control	  
plasmid)	  obtained	   from	  FACS	  analysis	   for	  each	   transfection	   is	   shown	   in	  part	   (A)	  of	   the	   table.	  
The	  cell	  viability	  for	  each	  group	  of	  transfected	  cells	  is	  indicated	  in	  part	  (B).	  The	  bottom	  parts	  of	  
the	  table	  (C)	  and	  (D)	  illustrate	  a	  similar	  table	  but	  for	  the	  KCL-­‐22	  cell	  line	  with	  cells	  transfected	  
with	   the	   wild	   type	   pB12mcs-­‐eGFP	   vector	   (negative	   control),	   cells	   transfected	   with	   the	  
pB12mcs-­‐U6-­‐eGFP	  vector	  (positive	  control),	  cells	  transfected	  with	  the	  shRNA1β2α2	  construct.	  
	   	  
4.2.4 Real	  Time	  PCR	  Analysis	  of	  the	  Transfected	  Cell	  Lines	  
	  
qPCR	  was	  used	   to	  study	   the	  effects	  of	   the	  generated	  shRNA	  constructs	  at	  
the	  mRNA	  levels	  of	  the	  fusion	  gene	  of	  interest.	  To	  do	  so,	  several	  qPCR	  primers	  
were	   designed.	   Primers	   that	   spanned	   the	   fusion	   points,	   β3α2	   and	   the	   β2α2,	  
and	  their	  appropriate	  probes	  were	  designed	  by	  the	  program	  `primer3’.	  Primers	  
that	  amplified	  the	  normal	  BCR	  and	  ABL	  genes	  and	  the	  GAPDH	  reference	  gene	  
were	  generated	  through	  the	  Roche	  UPL	  library	  software,	  which	  has	  a	  set	  of	  250	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probes.	  All	  primers	  gave	  rise	  to	  PCR	  products	  that	  were	  no	  more	  than	  230bp	  in	  
size.	   Primers	  were	   tested	   for	   their	   specificity	   to	   their	   target	   sequences.	   This	  
was	  achieved	  through	  conducting	  a	  PCR	  reaction	  on	  cDNA	  extracted	  from	  K562	  
and	  KCL-­‐22	  cell	  lines.	  The	  electrophoretic	  analysis	  of	  the	  products	  of	  these	  PCR	  
reactions	  can	  be	  seen	  in	  figures	  4.9	  -­‐	  4.11.	  Figure	  4.9	  shows	  an	  electrophoretic	  
analysis	  of	  PCR	  products	  with	  GAPDH	  primers	  using	  K562	  cDNA	  as	  a	  template.	  
Figure	  4.10	  shows	   the	  electrophoretic	  analysis	  of	  PCR	  products	  with	  ABL	  and	  
BCR	   primers.	   The	   electrophoretic	   analysis	   with	   β3α2	   and	   β2α2	   primers	   are	  
shown	  in	  Figure	  4.11.	  	  	  
	  
	  
Figure	  4.9	  Electrophoretic	  analysis	  of	  PCR	  products	  of	  GAPDH	  primers	  using	  K562	  cDNA	  
Lane	  1:	  pBluescript	  Hpa	  II	  marker	  
Lane	  2:	  PCR	  product	  of	  GAPDH	  primers	  using	  K562	  cDNA	  
Lane	  3:	  PCR	  product	  of	  GAPDH	  primers	  using	  MilliQ	  H2O	  	  
	  
GAPDH	  PCR	  products	  were	   analysed	  by	   the	  use	  of	   a	   2%	  agarose	   gel.	   Lane	  2	   shows	   a	   226bp	  
band,	  which	  is	  the	  size	  of	  the	  GAPDH	  PCR	  product.	  PCR	  in	  lane	  3	  is	  a	  negative	  control.	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Figure	  4.10	  Electrophoretic	  analysis	  of	  PCR	  reactions	  using	  the	  ABL	  and	  BCR	  primers	  on	  K562	  
cDNA	  
Lane	  1:	  GeneRulerTM	  100bp	  DNA	  ladder	  
Lane	  2:	  PCR	  product	  of	  MilliQ	  H2O	  using	  the	  ABL	  primers	  (negative	  control)	  
Lane	  3:	  PCR	  product	  of	  K562	  cDNA	  using	  the	  ABL	  primers	  
Lane	  4:	  PCR	  product	  of	  K562	  cDNA	  using	  the	  BCR	  primers	  	  
Lane	  5:	  PCR	  product	  of	  MilliQ	  H2O	  using	  the	  BCR	  primers	  (negative	  control)	  
	  
The	  PCR	  products	  of	  ABL	  and	  BCR	  primers	  were	  analysed	  through	  electrophoresis	  using	  a	  2%	  
agarose	  gel.	  In	  Lane	  3,	  the	  ABL	  PCR	  product	  of	  77bp	  is	  present,	  in	  lane	  4,	  a	  BCR	  PCR	  product	  of	  
91bp	  is	  shown.	  PCR	  in	  lanes	  2	  and	  5	  didn’t	  give	  a	  product.	  
	  
	  	   154	  
	  
Figure	  4.11	  Electrophoretic	  analysis	  of	  PCR	  reaction	  using	  β3α2	  and	  β2α2	  primers	  with	  K562	  
and	  KCL-­‐22	  cDNA,	  respectively.	  
Lane	  1:	  GeneRulerTM	  100bp	  DNA	  ladder	  
Lane	  2:	  PCR	  product	  of	  MilliQ	  H2O	  using	  the	  β3α2	  primers	  (negative	  control)	  
Lane	  3:	  PCR	  product	  of	  K562	  cDNA	  using	  the	  β3α2	  primers	  
Lane	  4:	  PCR	  product	  of	  MilliQ	  H2O	  using	  the	  β2α2	  primers	  (negative	  control)	  	  
Lane	  5:	  PCR	  product	  of	  KCL-­‐22	  cDNA	  using	  the	  β2α2	  primers	  
	  
The	  PCR	  products	  with	  β3α2	  and	  β2α2	  primers	  were	  analysed	  through	  electrophoresis	  using	  a	  
2%	   agarose	   gel.	   In	   Lane	   3,	   a	   β3α2	   PCR	   product	   of	   190bp	   is	   present,	   in	   lane	   5,	   a	   β2α2	   PCR	  
product	  of	  183bp	  is	  shown.	  PCR	  in	  lanes	  2	  and	  4	  didn’t	  give	  a	  product.	  
	  
	  	  
Electrophoretic	  analysis	  of	  all	  hydrolysis	  primers	  confirmed	  the	  specificity	  of	  
the	  primers,	  as	  only	  one	  band	  of	  the	  right	  size	  is	  present	  in	  each	  PCR	  reaction.	  
In	  addition,	  no	  bands	  were	  observed	  in	  the	  negative	  controls	  when	  MilliQ	  H2O	  
was	  used	  as	  a	  template.	  	  
A	   reference	   gene,	   GAPDH,	   is	   included	   in	   this	   analysis	   as	   a	   control.	   The	  
normal	  BCR	  and	  ABL	   levels	  were	  also	  examined;	   this	  was	  done	  to	   investigate	  
whether	  the	  shRNA	  constructs	  had	  an	  inhibitory	  effect	  on	  mRNA	  production	  of	  
the	  normal	  genes	  as	  well	  as	  the	  fusion	  genes.	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4.2.4.1 The	  Generation	  of	  Standard	  Curves	  	  
	  
	  
Preliminary	   experiments	   used	   SYBR	   green	   I	   methodology	   to	   validate	   the	  
primers.	   Once	   validated	   standard	   curves	   for	   each	   gene	   product	   were	  
generated	   by	   the	   use	   of	   Taqman	   and	   UPL	   probes	   and	   primers.	   This	   was	  
achieved	  by	  conducting	  a	  qPCR	  on	  several	  dilutions	  of	  plasmids	  in	  the	  case	  of	  
the	  β3α2	  and	  the	  β2α2	  fusion	  points	  or	  on	  several	  dilutions	  of	  a	  PCR	  product,	  
in	  case	  of	  the	  GAPDH,	  normal	  BCR,	  and	  normal	  ABL	  genes.	  The	  starting	  point	  
for	  the	  concentration	  of	  each	  gene	  ranged	  from	  10-­‐30ng	  (per	  100μl),	  then	  each	  
sample	  was	  diluted	  100x	  to	  give	  rise	  to	  a	  total	  of	  5	  samples.	  The	  qPCR	  results	  
were	  analysed	  through	  the	  Roche	  LightCycler	  480	  software.	  Figures	  4.12-­‐4.16	  















Figure	  4.12	  The	  qPCR	  of	  GAPDH	  standards	  and	  the	  generated	  Standard	  Curve.	  	  
The	  qPCR	  results	  of	  the	  GAPDH	  standards	  are	  shown	  in	  (A).	  The	  qPCR	  was	  conducted	  on	  five	  
dilutions	   of	   a	   GAPDH	   PCR	   product.	   The	   starting	   concentration,	   of	   0.15ng/μl	   of	   a	   purified	  
GAPDH	   PCR	   product,	   and	   the	   dilutions	   used	   are	   also	   shown	   here.	   The	   qPCR	   reactions	  were	  
performed	  in	  duplicate,	  and	  the	  results	  analysed	  by	  the	  Light	  Cycler	  480	  software	  to	  determine	  
the	   values	   of	   the	  GAPDH	   standard	   curve	   in	   (B).	   The	   standard	   curve	   is	   a	   least	   square	   fit	   line	  
drawn	   through	  all	  dilutions,	  which	   is	   the	  mean	  as	   the	   reactions	  were	  done	   in	  duplicate.	  The	  
calculated	   amplification	   efficiency	   was	   91.3%.	   This	   curve	   was	   further	   used	   to	   calculate	   the	  
concentration	  of	  the	  GAPDH	  gene	  product	  in	  the	  cell	  lines	  of	  interest.	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Figure	  4.13	  The	  qPCR	  of	  BCR	  standards	  and	  the	  generated	  Standard	  Curve.	  
The	   qPCR	   results	   of	   the	   BCR	   standards	   are	   shown	   in	   (A).	   The	   qPCR	   was	   conducted	   on	   five	  
dilutions	  of	  a	  BCR	  PCR	  product.	  The	  starting	  concentration,	  of	  0.12ng/μl	  of	  a	  purified	  BCR	  PCR	  
product,	  and	  the	  dilutions	  used	  are	  also	  shown	  here.	  The	  qPCR	  reactions	  were	  performed	   in	  
duplicate,	  and	  the	  results	  analysed	  by	  the	  Light	  Cycler	  480	  software	  to	  determine	  the	  values	  of	  
the	  BCR	  standard	  curve	   in	   (B).	  The	  standard	  curve	   is	  a	   least	  square	  fit	   line	  drawn	  through	  all	  
dilutions,	   which	   is	   the	   mean	   as	   the	   reactions	   were	   done	   in	   duplicate.	   The	   calculated	  
amplification	  efficiency	  was	  96.4%.	  This	  curve	  was	  further	  used	  to	  calculate	  the	  concentration	  
of	  the	  BCR	  gene	  product	  in	  the	  cell	  lines	  of	  interest.	  	  
	  











	  Concentration	  (ng/μl)	  
BCR	  Standard	  Curve	  
(A)	  
(B)	  




Figure	  4.14	  The	  qPCR	  of	  ABL	  standards	  and	  the	  generated	  Standard	  Curve.	  	  
The	   qPCR	   results	   of	   the	   ABL	   standards	   are	   shown	   in	   (A).	   The	   qPCR	   was	   conducted	   on	   five	  
dilutions	  of	  a	  ABL	  PCR	  product.	  The	  starting	  concentration,	  of	  0.195ng/μl	  of	  a	  purified	  ABL	  PCR	  
product,	  and	  the	  dilutions	  used	  are	  also	  shown	  here.	  The	  qPCR	  reactions	  were	  performed	   in	  
duplicate,	  and	  the	  results	  analysed	  by	  the	  Light	  Cycler	  480	  software	  to	  determine	  the	  values	  of	  
the	  ABL	  standard	  curve	   in	   (B).	  The	  standard	  curve	   is	  a	   least	  square	   fit	   line	  drawn	  through	  all	  
dilutions,	  which	  is	  the	  mean	  as	  the	  reaction	  was	  done	  in	  duplicate.	  The	  calculated	  amplification	  
efficiency	  was	   96.6%.	   This	   curve	  was	   further	   used	   to	   calculate	   the	   concentration	  of	   the	  ABL	  
gene	  product	  in	  the	  cell	  lines	  of	  interest.	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Figure	  4.15	  The	  qPCR	  of	  β3α2	  standards	  and	  the	  generated	  Standard	  Curve.	  
The	   qPCR	   results	   of	   the	   β3α2	   standards	   are	   shown	   in	   (A).	   The	   qPCR	  was	   conducted	   on	   five	  
dilutions	   of	   a	   β3α2	   containing	   plasmids.	   The	   starting	   concentration,	   of	   0.2ng/μl	   of	   a	   β3α2	  
construct,	  and	  the	  dilutions	  used	  are	  also	  shown	  here.	  The	  qPCR	  reactions	  were	  performed	  in	  
duplicate,	  and	  the	  results	  analysed	  by	  the	  Light	  Cycler	  480	  software	  to	  determine	  the	  values	  of	  
the	  β3α2	  standard	  curve	  in	  (B).	  The	  standard	  curve	  is	  a	  least	  square	  fit	  line	  drawn	  through	  all	  
dilutions,	  which	  is	  the	  mean	  as	  the	  reaction	  was	  done	  in	  duplicate.	  The	  calculated	  amplification	  
efficiency	  was	   95%.	   This	   curve	  was	   further	   used	   to	   calculate	   the	   concentration	   of	   the	   β3α2	  
fusion	  gene	  product	  in	  the	  cell	  lines	  of	  interest.	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Figure	  4.16	  The	  qPCR	  of	  β2α2	  standards	  and	  the	  generated	  Standard	  Curve.	  	  	  
The	   qPCR	   results	   of	   the	   β2α2	   standards	   are	   shown	   in	   (A).	   The	   qPCR	  was	   conducted	   on	   five	  
dilutions	   of	   a	   β2α2	   containing	   plasmid.	   The	   starting	   concentration,	   of	   0.3ng/μl	   of	   a	   purified	  
β2α2	   construct,	   and	   the	   dilutions	   used	   are	   also	   shown	   here.	   The	   qPCR	   reactions	   were	  
performed	  in	  duplicate,	  and	  the	  results	  analysed	  by	  the	  Light	  Cycler	  480	  software	  to	  determine	  
the	  values	  of	  the	  β2α2	  standard	  curve	  in	  (B).	  The	  standard	  curve	  is	  a	  least	  square	  fit	  line	  drawn	  
through	  all	  dilutions,	  which	  is	  the	  mean	  as	  the	  reaction	  was	  done	  in	  duplicate.	  The	  calculated	  
amplification	  efficiency	  was	  89.7%.	  This	  curve	  was	  further	  used	  to	  calculate	  the	  concentration	  
of	  the	  β2α2	  fusion	  gene	  product	  in	  the	  cell	  lines	  of	  interest.	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Once	  the	  standard	  curves	  were	  established,	  2.5	  x	  106	  cells,	  K562	  or	  KCL-­‐22,	  
were	  nucleofected,	  and	  3	  x	  105	  cells	  were	  used	  for	  FACS	  analysis,	  and	  1	  x	  106	  
cells	  were	  used	  for	  total	  RNA	  extraction,	  followed	  by	  cDNA	  synthesis.	  Another	  
sample	  of	  1	  x	  106	  of	   transfected	  cells	  was	  used	   for	  protein	  extraction.	  A	  PCR	  
reaction	   on	   the	   newly	   synthesised	   cDNA,	   to	   confirm	   that	   the	   RT-­‐PCR	   had	  
worked,	   was	   routinely	   done.	   Primers	   for	   the	   RPL13	   gene	   (ribosomal	   protein	  
L13	  gene),	  a	  housekeeping	  gene,	  were	  also	  used	   in	   this	   reaction,	  and	  a	  band	  
size	   of	   96bp	   was	   expected;	   Figure	   4.17	   shows	   an	   example	   of	   the	  
electrophoretic	  analysis.	  Normal	  ABL	  and	  BCR	  levels	  were	  also	  examined;	  this	  
was	   done	   to	   investigate	   whether	   the	   shRNA	   constructs	   reduced	   the	   mRNA	  
levels	  of	   the	  normal	  genes.	  Five	  qPCR	  reactions	   (for	  GAPDH,	  ABL,	  BCR,	  β3α2,	  
and	  β2α2)	  were	  done	  in	  duplicate	  for	  each	  sample.	  The	  standard	  curves	  were	  
used	   for	   each	   transfection	   to	   determine	   the	   concentrations	   of	   genes	   of	  
interest,	  the	  results	  were	  analysed	  by	  the	  Roche	  LightCycler	  480	  software.	  The	  
software	  calculates	   the	  mRNA	  concentration	   levels.	  The	   levels	  were	  analysed	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Figure	   4.17	   An	   example	   of	   an	   electrophoretic	   Analysis	   of	   the	   PCR	   reaction	   using	   RPL13	  
primers	  on	  transfected	  K562	  cells	  cDNA.	  	  
Lane	  1:	  GeneRulerTM	  100bp	  DNA	  Ladder	  
Lane	  2:	  PCR	  product	  of	  the	  non-­‐transfected	  K562	  cDNA	  
Lane	  3:	  PCR	  product	  of	  the	  K562	  transfected	  cDNA	  wild	  type	  pB12mcs-­‐eGFP	  
Lane	  4:	  PCR	  product	  of	  the	  K562	  transfected	  cDNA	  wild	  type	  pB12mcs-­‐U6-­‐eGFP	  
Lane	  5:	  PCR	  product	  of	  the	  K562	  transfected	  cDNA	  wild	  type	  pB12mcs-­‐U6-­‐shRNA1β3α2-­‐eGFP	  
Lane	  6:	  PCR	  product	  of	  the	  K562	  transfected	  cDNA	  wild	  type	  pB12mcs-­‐U6-­‐shRNA3β3α2-­‐eGFP	  
	  
RPL13	  PCR	  products	  were	  analysed	  via	  electrophoresis	  using	  a	  2%	  agarose	  gel	  .The	  96bp	  band	  
in	  lanes	  2-­‐6	  indicates	  that	  the	  RNA	  purification	  and	  K562	  cDNA	  synthesis	  were	  successful	  in	  all	  
the	  transfections	  including	  the	  non-­‐transfected	  K562	  control.	  
	  
	  
GAPDH	  was	  used	  as	  a	  reference	  gene,	  and	  the	  qPCR	  data	  generated	  in	  this	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4.2.4.2 Effects	   of	   shRNA1β3α2	   and	   shRNA3β3α2	   in	   K562	   and	  
KCL-­‐22	  cells	  	  
	  
To	  study	  the	  effects	  of	  the	  shRNAβ3α2	  constructs,	  the	  RNAi	  molecules	  were	  
transfected	   into	   K562	   cells	   that	   express	   the	   target	   site,	   the	   β3α2	   BCR-­‐ABL	  
variant.	  To	  examine	  the	  specificity	  of	  the	  constructs	  KCL-­‐22	  cells	  expressing	  the	  
β2α2	  variant	  that	  has	  the	  same	  ABL	  sequence	  as	  β3α2	  were	  used.	  To	  measure	  
the	  β3α2	  mRNA	  levels,	  qPCR	  was	  conducted	  using	  primers	  specific	  only	  to	  the	  
β3α2	  fusion	  gene.	  The	  forward	  primer	  binds	  to	  exon	  14	  of	  the	  BCR	  part	  of	  the	  
gene,	   while	   the	   reverse	   primer	   binds	   to	   the	   ABL	   part.	   Similarly,	   the	   β2α2	  
variant	   was	   measured	   using	   primers	   specific	   only	   for	   this	   fusion	   gene.	   The	  
forward	   primer	   binds	   to	   exon	   13	   of	   the	   BCR	   part,	   while	   the	   reverse	   primer	  
binds	  to	  the	  ABL	  part	  of	  the	  fusion	  gene.	  	  
Table	  4.4	  demonstrates	  the	  normalized	  qPCR	  data	  generated	  from	  the	  K562	  
cell	   lines	   transfected	   with	   the	   shRNA1β3α2	   and	   shRNA3β3α2	   constructs.	   The	  
data	   were	   then	   converted	   to	   percentage	   of	   expression	   with	   regards	   to	   the	  
positive	  control	  and	  a	  bar	   chart	   is	   shown	   in	  Figure	  4.18.	  Note,	   the	   `negative’	  
control	   are	   the	   cells	   transfected	   with	   the	   wildtype	   vector	   pB12mcs-­‐eGFP,	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Table	  4.4	  The	  qPCR	  data	  of	  the	  β3α2	  mRNA	  levels	  of	  the	  transfected	  K562	  cells.	  	  
The	  RNA	  extraction	  was	  conducted	  24hr	  after	  each	  transfection.	  The	  generated	  data	  from	  the	  
qPCR	  reactions	  of	  the	  β3α2	  gene	  is	  presented	  as	  concentrations	  in	  pg.	  The	  results	  from	  three	  
transfections	  (Exp.	  1-­‐3)	  with	  their	  corresponding	  transfection	  efficiencies	  are	  shown.	  The	  data	  
are	  normalized	  with	   regards	   to	   the	   reference	  gene,	  GAPDH.	   The	   `negative’	   controls	  are	   cells	  
transfected	  with	  pB12-­‐eGFP	  and	  the	  `positive’	  controls	  are	  cells	  transfected	  with	  pB12mcs-­‐U6-­‐
eGFP.	  Similar	  values	  are	  seen	  with	  the	  `negative’	  control	  and	  `positive’	  control	  because	  qPCR	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Figure	  4.18	  The	  percentage	  of	  expression	  of	  β3α2	  mRNA	  levels	  in	  K562	  cell	   line	  transfected	  
with	  shRNA	  molecules	  targeting	  the	  β3α2	  fusion	  point.	  	  	  
The	   figure	   shows	   the	   results	   for	   three	   transfection	   experiments.	   The	   `positive’	   controls	   are	  
K562	   cells	   transfected	   with	   the	   pB12mcs-­‐U6-­‐eGFP	   vector	   and	   are	   arbitrarily	   chosen	   to	   be	  
100%.	  The	  percentages	  of	  expression	  of	  all	  other	  samples	  were	  calculated	  with	  regards	  to	  the	  
positive	   control.	   The	   `negative’	   controls	  are	   the	  K562	  cells	   treated	  with	   the	  wild	   type	  vector	  
(pB12mcs-­‐eGFP).	  K562	  cells	  transfected	  with	  shRNA1β3α2	  and	  shRNA3β3α2	  showed	  β3α2	  mRNA	  
expression	  levels	  of	  33.6-­‐68%	  (p<0.034)	  and	  68-­‐81.5%	  (p<0.023),	  respectively.	  	  
	  
The	   data	   show	   a	   reduction	   in	   the	   β3α2	   mRNA	   levels	   when	   using	   both	  
constructs.	   However,	   shRNA1β3α2	   constantly	   showed	   a	   higher	   level	   of	  
depletion	  in	  comparison	  with	  shRNA3β3α2.	  The	  third	  transfection	  reaction	  had	  
the	  highest	  transfection	  efficiency	  of	  72%,	  and	  shRNA1β3α2	  decreased	  the	  β3α2	  
mRNA	   levels	   to	   33.6%	   in	   comparison	   with	   shRNA3β3α2	   that	   had	   68%	  
expression.	  	  
To	  test	  the	  specificity	  of	  the	  β3α2	  shRNA	  molecules,	  the	  KCL-­‐22	  cell	  line	  was	  
treated	   with	   the	   constructs	   and	   the	   normalized	   data	   were	   converted	   into	  
percentage	  of	  expression	  with	  regards	  to	  the	  positive	  control,	  the	  KCL-­‐22	  cells	  
transfected	  with	  the	  pB12mcs-­‐U6-­‐eGFP.	  This	  is	  shown	  in	  Figure	  4.19.	  The	  levels	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of	   the	  β2α2	  mRNA	  expression	  were	  on	  average	  99.2%	  of	   the	  controls,	  which	  




Figure	   4.19	   Percentage	   of	   expression	   of	   β2α2	  mRNA	   levels	   in	   KCL-­‐22	   cells	   after	   treatment	  
with	  β3α2	  shRNA	  constructs.	  	  
The	   figure	   shows	   the	   results	   of	   three	   transfection	   experiments.	   The	   controls	   are	   the	   KCL-­‐22	  
cells	   treated	  with	   the	   pB12mcs-­‐U6-­‐eGFP	   vector	   and	   are	   arbitrarily	   chosen	   to	   be	   100%.	   The	  
data	   obtained	   from	   the	   cells	   treated	   with	   shRNA1β3α2	   and	   shRNA3β3α2	   were	   converted	   to	  
percentages	  in	  regards	  to	  the	  `positive’	  control.	  The	  expression	  levels	  of	  the	  β2α2	  mRNA	  was	  
of	  99-­‐99.6%	  (±2	  SD)	  for	  shRNA1β3α2	  and	  of	  98.4-­‐99.6	  (±	  0.5	  SD)	  for	  shRNA3β3α2.	  
	  
4.2.4.3 Effects	  of	  shRNA1β2α2	  in	  KCL-­‐22	  and	  K562	  cell	  lines	  
	  
shRNA1β2α2	  constructs	  were	  transfected	  into	  KCL-­‐22	  cells	  in	  order	  to	  study	  
their	  effects	  on	  their	  target	  site;	  KCL-­‐22	  cells	  express	  the	  β2α2	  gene.	  To	  study	  
the	  specificity	  of	  the	  shRNA	  molecule,	  K562	  cells,	  which	  express	  the	  other	  BCR-­‐
ABL	   variant	   (β3α2),	  were	   used	   for	   transfection.	   The	   β2α2	  mRNA	   levels	  were	  
measured	   by	   qPCR	   with	   the	   use	   of	   primers	   specific	   to	   only	   the	   β2α2	   gene.	  
Table	  4.5	  demonstrates	  the	  normalized	  qPCR	  data	  of	  the	  effects	  of	  shRNA1β2α2	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on	   β2α2	   fusion	   point	   in	   the	   KCL-­‐22	   cell	   line.	   These	   data	   were	   calculated	   as	  
percentages	  of	  expression	  with	  regards	  to	  the	  `positive’	  control.	  The	  `positive’	  
control	  was	  transfected	  with	  the	  pB12mcs-­‐U6-­‐eGFP	  vector	  and	  the	  `negative’	  
control	  was	  transfected	  with	  the	  pB12mcs-­‐eGFP	  vector.	  These	  data	  were	  used	  
to	  generate	  the	  bar	  chart	  shown	  in	  Figure	  4.20.	  The	  data	  showed	  a	  reduction	  
of	   the	   β2α2	   mRNA	   expression.	   The	   expression	   levels	   of	   the	   β2α2	   mRNA	  
treated	  with	  shRNA1β2α2	  reduced	  to	  a	  maximum	  of	  66%	  when	  the	  transfection	  
efficiency	  of	  nucleofection	  was	  67%.	  	  
	  
	  







1	   53%	   5.072	   2.3719	   4.8399	  
2	   64%	   17.7292	   6.6635	   16.6261	  
3	   67%	   14.6786	   4.816	   14.2657	  
	  
Table	  4.5	  The	  qPCR	  data	  of	  the	  β2α2	  mRNA	  levels	  of	  the	  transfected	  KCL-­‐22	  cells.	  	  
The	  RNA	  extraction	  was	  conducted	  24hr	  after	  each	  transfection.	  The	  generated	  data	  from	  the	  
qPCR	  reactions	  of	  the	  β2α2	  gene	  is	  presented	  as	  concentrations	  in	  pg.	  The	  results	  from	  three	  
transfections	  (Exp.	  1-­‐3)	  with	  their	  corresponding	  transfection	  efficiencies	  are	  shown.	  The	  data	  
are	   normalized	   in	   regards	   to	   the	   reference	   gene,	   GAPDH.	   The	   `negative’	   controls	   are	   cells	  
transfected	   with	   pB12-­‐eGFP	   and	   the	   `positive’	   controls	   are	   transfected	   with	   pB12mcs-­‐U6-­‐
eGFP.	  Similar	  values	  are	  seen	  with	  the	  `negative’	  control	  and	  `positive’	  control	  because	  qPCR	  
was	  measuring	  only	  the	  β2α2	  fusion	  point.	  *	  Per	  pg	  of	  GAPDH.	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Figure	  4.20	  The	  percentage	  of	  expression	  of	  β2α2	  mRNA	  levels	  in	  KCL-­‐22	  cell	  line	  transfected	  
with	  shRNA1β2α2	  construct.	  	  
The	   figure	   shows	   the	   results	   of	   three	   transfection	   experiments	   on	   KCL-­‐22	   cell	   line.	   The	  
`positive’	  and	  `negative’	  controls	  were	  transfected	  with	  pB12mcs-­‐U6-­‐eGFP	  and	  pB12mcs-­‐eGFP	  
vectors	   respectively.	   The	  positive	   control	  was	   chosen	  arbitrarily	   to	  be	  100%.	  The	  normalized	  
data	  were	   then	   calculated	   into	   percentages	   of	   expression	   in	   regards	   to	   the	   positive	   control.	  
KCL-­‐22	  cells	  treated	  with	  shRNAβ2α2	  showed	  expression	  levels	  of	  34-­‐49%.	  (p<0.005)	  
	  
The	  specificity	  of	  the	  shRNA1β2α2	  construct	  was	  also	  tested	  in	  the	  K562	  cell	  
line,	  Figure	  4.21,	  where	  the	  β3α2	  mRNA	  levels	  of	  expression	  were	  on	  average	  
98.9%	  of	  the	  controls.	  The	  results	  demonstrate	  that	  the	  shRNA1β2α2	  is	  specific	  
for	  the	  β2α2	  target	  site.	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Figure	  4.21	  Percentage	  of	  β3α2	  mRNA	  levels	  in	  K562	  cells	  after	  treatment	  with	  β2α2	  shRNA	  
constructs.	  	  
The	   figure	   shows	   the	   results	  of	   three	   transfection	  experiments.	  The	  control	   is	   the	  K562	  cells	  
treated	  with	   the	   pB12mcs-­‐U6-­‐eGFP	   vector	   and	   are	   arbitrarily	   chosen	   to	   be	   100%.	   The	   data	  
obtained	  from	  the	  cells	  treated	  with	  shRNA1β2α2	  were	  converted	  to	  percentages	  in	  regards	  to	  
the	  `positive’	  control.	  The	  expression	  levels	  of	  the	  β3α2	  mRNA	  were	  of	  98.2-­‐99.5%	  (±	  0.66	  SD).	  
	  
4.2.4.4 Effects	   of	   the	   shRNA	   constructs	   on	   normal	   BCR	   and	  
ABL	  mRNA	  levels	  
	  
To	   further	   confirm	   the	   specificity	   of	   the	   shRNA	   constructs	   to	   their	   target	  
sites,	  the	  levels	  of	  the	  normal	  ABL	  and	  BCR	  genes	  were	  examined	  in	  K562	  cells	  
when	  transfected	  with	  shRNA1β3α2	  and	  shRNA3β3α2,	  and	  in	  KCL-­‐22	  cells	  when	  
transfected	   with	   shRNA1β2α2.	   This	   was	   done	   by	   qPCR	   with	   primers	   that	   are	  
specific	  only	  for	  the	  normal	  BCR	  and	  ABL	  genes.	  In	  each	  primer	  set,	  at	  least	  one	  
primer	  was	  binding	  to	  an	  exon	  not	  present	  in	  the	  BCR-­‐ABL	  fusion	  genes.	  	  
GAPDH	   was	   used	   as	   a	   reference	   gene,	   and	   the	   data	   generated	   were	  
normalized.	   The	   mRNA	   levels	   of	   the	   normal	   ABL	   and	   BCR	   genes	   were	   not	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affected	   by	   any	   of	   the	   shRNA	   constructs.	   This	   is	   shown	   in	   Figures	   4.22	   and	  
4.23.	  Figure	  4.22	  shows	  the	  levels	  of	  the	  BCR	  and	  ABL	  genes	  in	  relation	  to	  the	  
positive	  control	  in	  transfected	  K562	  cells.	  Figure	  4.23	  shows	  results	  for	  KCL-­‐22	  
cells.	  The	  `negative’	  controls	  are	  the	  cells	  transfected	  with	  the	  wildtype	  vector	  





Figure	  4.22	  The	  percentage	  of	  expression	  of	  the	  normal	  BCR	  and	  ABL	  genes	  in	  K562	  cell	  line	  
transfected	  with	  shRNA	  constructs	  targeting	  the	  β3α2	  fusion	  gene.	  
This	   figure	   shows	   the	   results	   of	   three	   transfection	   reaction	   experiments	   (Exp	   1-­‐3).	   The	  
`positive’	   and	   `negative’	   controls	   are	   K562	   cells	   transfected	   with	   pB12mcs-­‐U6-­‐eGFP	   and	  
pB12mcs-­‐eGFP	  vectors,	  respectively.	  The	  `positive’	  control	  was	  selected	  arbitrarily	  to	  be	  100%;	  
the	   remaining	   data	   generated	   for	   all	   others	   samples	   were	   converted	   to	   percentages	   with	  
regards	   to	   the	  positive	  control.	  BCR	  and	  ABL	  mRNA	  expression	   levels	   for	  shRNA1β3α2	   ranged	  
from	  103.3-­‐106%	   (±	  1.5	   SD),	   and	  98.5-­‐102.8%	   (±	  1.88	  SD),	   respectively.	   For	   shRNA3β3α2	  BCR	  
and	  ABL	  mRNA	  expressions	  ranged	  from	  102.5-­‐106.2%	  (±	  2.4	  SD),	  and	  for	  98.7-­‐102.9%	  (±	  2.1	  
SD),	  respectively.	  	  The	  percentage	  of	  expression	  is	  shown	  in	  the	  bar	  chart,	  red	  for	  shRNA1β3α2	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Figure	  4.23	  The	  percentage	  of	  expression	  of	  the	  normal	  BCR	  and	  ABL	  genes	  in	  KCL-­‐22	  cell	  line	  
transfected	  with	  the	  shRNA1β2α2	  construct.	  
This	   figure	   shows	   the	   results	   of	   three	   transfection	   reaction	   experiments	   (Exp	   1-­‐3).	   The	  
`positive’	   and	   `negative’	   controls	   are	   KCL-­‐22	   cells	   transfected	   with	   pB12mcs-­‐U6-­‐eGFP	   and	  
pB12mcs-­‐eGFP	  vectors,	  respectively.	  The	  `positive’	  control	  was	  selected	  arbitrarily	  to	  be	  100%;	  
the	   remaining	   data	   generated	   for	   all	   others	   samples	   were	   converted	   to	   percentages	   with	  
regards	  to	  the	  `positive’	  control.	  BCR	  and	  ABL	  mRNA	  expression	  levels	  for	  shRNA1β2α2	  ranged	  
from	  99.4-­‐103.8%	  (±	  2.37	  SD),	  and	  96.4-­‐105.3%	  (±	  4.46	  SD),	  respectively.	  
	  
4.2.5 Protein	   analysis	   of	   the	   K562	   transfected	   Cell	   Line	   by	  
Western	  Blotting	  	  
	  
To	  observe	  the	  effects	  of	  the	  constructed	  shRNA	  molecules	  on	  their	  target	  
genes	  at	  the	  protein	   level,	  Western	  blots	  were	  conducted.	  Proteins	  extracted	  
from	   the	  K562	   cell	   line	   transfected	  with	  pB12mcs-­‐U6-­‐eGFP	  and	  all	   pB12mcs-­‐
U6-­‐shRNA-­‐eGFP	  vectors,	  targeting	  both	  BCR-­‐ABL	  genes,	  were	  examined.	  Figure	  
4.24	  shows	  the	  Western	  blot	  analysis	  conducted	  on	  the	  K562	  cell	  lines.	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Figure	  4.24	  Western	  blot	  analysis	  of	  the	  β3α2	  fusion	  protein	  from	  K562	  transfected	  cell	  line.	  
The	   figure	   shows	   a	   representative	   Western	   blot	   analysis	   of	   the	   β3α2	   protein	   from	   the	  
transfected	   K562	   cell	   line.	   The	   first	   band	   in	   Row	   1	   is	   the	   β3α2	   protein	   from	   K562	   cells	  
transfected	  with	  pB12mcs-­‐U6-­‐shRNA1β2α2-­‐eGFP	  plasmid.	  The	  control	  band	  row	  1	  refers	  to	  the	  
β3α2	  protein	  from	  cells	  that	  were	  transfected	  with	  the	  `positive’	  control	  plasmid,	  pB12mcs-­‐U6-­‐
eGFP.	  The	  last	  two	  bands	  in	  Row	  1	  show	  the	  β3α2	  proteins	  from	  the	  K562	  cell	  line	  treated	  with	  
shRNA1β3α2	  and	  shRNA3β3α2	  constructs.	  Row	  2	  shows	  the	  GAPDH	  housekeeping	  gene	  that	  was	  
included	  as	  a	  control	  for	   loading	  and	  was	  further	  used	  to	  normalise	  the	  results.	  The	  blot	  was	  
probed	  with	  an	  anti	  c-­‐ABL	  antibody	  (row	  1)	  and	  anti	  GAPDH	  antibody	  (row2).	  	  
	  	  
The	  band	   intensities	   for	   all	   samples	  were	  measured	   and	  normalized	  with	  
regards	  to	  the	  GAPDH	  housekeeping	  gene.	  The	  data	  generated	  were	  converted	  
to	  percentage	  of	  expression	  with	  regards	  to	  the	   `positive’	  control,	  which	  was	  
chosen	   to	  be	   100%.	  Upon	   analysis	   of	   the	  band	   intensities	   a	   reduction	   in	   the	  
β3α2	   fusion	   protein	   was	   observed.	   Each	   western	   blot	   was	   repeated	   three	  
times.	   Table	   4.6	   shows	   the	   statistical	   analysis	   done	   on	   the	   results	   obtained	  
from	  this	  Western	  blot.	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  SD	  (±)	  
Student	  	  
t-­‐test	  
	  P	  value	  
shRNA1	  β3α2	   1.90	   3.16	   40%	   0.105	   <0.002	  
shRNA3	  β3α2	   2.10	   3.16	   33.5%	   0.232	   <0.014	  
shRNA1	  β2α2	   3.00	   3.16	   5.1%	   0.148	   <0.163	  
Table	   4.6	   Statistically	  Analysed	  data	   from	   the	  Western	  blot	   conducted	  on	   the	   β3α2	   fusion	  
protein	   extracted	   from	   K562	   cells	   that	   were	   transfected	   with	   shRNA1β3α2,	   shRNA3β3α2,	  
shRNA1β2α2,	  and	  the	  blot	  probed	  with	  c-­‐ABL	  Ab,	  and	  band	  intensities	  measured.	  	  	  
The	  arithmetic	  means	  for	  the	  results	  obtained	  from	  three	  Western	  blots	  were	  first	  calculated.	  
A	  reduction	  in	  the	  β3α2	  protein	  treated	  with	  shRNA	  molecules	  specific	  for	  the	  gene	  showed	  a	  
reduction	   in	   comparison	  with	   the	   control.	   The	  percentage	  of	   reduction	  was	   then	   calculated,	  
column	  4.	  The	  results	  showed	  40%	  reduction	  in	  protein	  levels	  when	  treated	  with	  shRNA1β3α2	  
and	   33.5%	   with	   shRNA3β3α2.	   No	   significant	   reduction	   is	   observed	   when	   treated	   with	  
shRNA1β2α2,	  column	  4	  row	  3.	  The	  SD	  and	  the	  student	  t-­‐test	  are	  shown	  in	  columns	  5	  and	  6.	  	  	  	  	  	  	  
	  
Both	   the	  shRNAβ3α2	  molecules	   reduced	   the	   levels	  of	  β3α2	  protein.	   It	  was	  
found	   that	   a	   higher	   reduction	   in	   the	   protein	   level	   was	   observed	   with	  
shRNA1β3α2	   construct	   in	   comparison	   with	   shRNA3β3α2.	   In	   addition,	   the	  
shRNA1β2α2	  molecule	  targeting	  the	  β2α2	  fusion	  gene	  showed	  no	  effects	  on	  the	  
levels	   of	   the	   β3α2	   fusion	   protein.	   These	   results	   support	   the	   previous	   qPCR	  
findings	   (previous	   section)	   and	  demonstrate	   that	   shRNA1β3α2and	   shRNA3β3α2	  
are	   specific	   for	   their	   target	   sites.	   Figure	   4.25	   demonstrates	   the	   generated	  
Western	  blot	  data	  in	  the	  form	  of	  a	  bar	  chart.	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Figure	  4.25	  Western	  blot	  analysis	  of	  the	  β3α2	  fusion	  protein	  from	  K562	  transfected	  cell	  line.	  	  	  
The	  figure	  shows	  Western	  blot	  results	  from	  three	  different	  transfection	  experiments.	  Each	  bar	  
is	   generated	   from	   the	   average	   of	   three	   Western	   blot	   repeats.	   The	   `positive’	   control,	   cells	  
transfected	  with	  the	  pB12mcs-­‐U6-­‐eGFP	  vector,	  was	  selected	  to	  be	  1	  and	  the	  data	  from	  other	  
transfected	  cells	  were	  calculated	  with	  regards	  to	  the	  `positive’	  control.	  The	  chart	  demonstrates	  
that	  shRNA1β3α2	  and	  shRNA3β3α2	  constructs	  reduced	  β3α2	  protein	  levels	  by	  40	  and	  by	  33.5%	  
respectively.	  The	  data	  also	   show	  that	   the	   shRNA1β2α2	  molecule	  has	   little	  effect	  on	   the	  β3α2	  
fusion	  gene	  product.	  **p	  <	  0.002	  and	  *p	  <	  0.01	  	  	  	  	  	  	  
	  
4.2.6 Protein	  analysis	  of	   the	  KCL-­‐22	  transfected	  Cell	   Line	  by	  
Western	  Blotting	  	  
	  
To	  observe	  the	  effects	  of	  shRNA1β2α2	  on	  its	  target	  gene	  at	  the	  protein	  level,	  
three	  Western	  blots	  were	  conducted.	  Proteins	  extracted	  from	  the	  KCL-­‐22	  cell	  
line	   transfected	   with	   pB12mcs-­‐U6-­‐eGFP	   and	   pB12mcs-­‐U6-­‐shRNA1β2α2-­‐eGFP	  
vectors,	   were	   examined.	   Figure	   4.26	   is	   a	   representation	   of	   a	   Western	   blot	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Figure	  4.26	  Western	  blot	  analysis	  of	  the	  β2α2	  fusion	  protein	  from	  the	  KCL-­‐22	  transfected	  cell	  
line.	  
The	   figure	   shows	   a	   representative	   Western	   blot	   analysis	   of	   the	   β2α2	   protein	   from	   the	  
transfected	  KCL-­‐22	  cell	  line.	  The	  first	  band	  in	  Row	  1	  refers	  to	  the	  control	  band	  that	  is	  the	  β2α2	  
protein	   from	   cells	   transfected	   with	   the	   `positive’	   control	   plasmid,	   pB12mcs-­‐U6-­‐eGFP.	   The	  
remaining	  bands	  in	  row	  1	  show	  the	  fusion	  protein	  from	  KCL-­‐22	  cells	  transfected	  with	  pB12mcs-­‐
U6-­‐shRNA-­‐eGFP	  plasmids.	  Row	  2	  shows	  the	  GAPDH	  housekeeping	  gene	  that	  was	  included	  as	  a	  
control	   for	   loading	  and	  was	   further	  used	   to	  normalise	   the	   results.	  The	  blot	  was	  probed	  with	  
anti	  β2α2	  junction	  specific	  antibody	  (row	  1)	  and	  anti	  GAPDH	  antibody	  (row	  2).	  
	  
Band	   intensities	   for	   all	   samples	   were	   measured	   and	   normalized	   with	  
regards	  to	  the	  GAPDH	  housekeeping	  gene.	  The	  data	  generated	  were	  converted	  
to	  percentages	  of	  expression	  with	  regards	  to	  the	  `positive’	  control,	  which	  was	  
chosen	  to	  be	  100%.	  Table	  4.7	  shows	  the	  statistical	  analysis	  done	  on	  the	  results	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shRNA1	  β2α2	   1.7	   3.1	   45%	   0.0248	   0.0001	  
shRNA1	  β3α2	   3.0	   3.1	   4.5%	   0.0984	   0.1335	  
shRNA3	  β3α2	   2.9	   3.1	   6.2%	   0.1299	   0.1240	  
Table	   4.7	   Statistically	   analysed	   data	   from	   Western	   blot	   conducted	   on	   the	   β2α2	   fusion	  
protein	   from	  KCL-­‐22	   cells	   transfected	  with	   shRNA1β2α2,	   shRNA1β3α2,	   shRNA3β3α2,	   and	   the	  
blot	  probed	  with	  β2α2	  Ab,	  and	  band	  intensities	  measured.	  
The	  arithmetic	  means	   for	   the	   results	  obtained	   from	   the	  Western	  blots	  were	   first	   calculated.	  
The	   percentage	   of	   reduction	   was	   then	   calculated,	   column	   4.	   The	   results	   showed	   a	   45%	  
reduction	  in	  protein	  levels	  when	  treated	  with	  shRNA1β2α2.	  No	  significant	  reduction	  is	  observed	  
with	   cells	   treated	  with	   shRNA1β3α2	   or	   shRNA3β3α2,	   column	  4	   rows	   3	   and	   4.	   The	   SD	   and	   the	  
student	  t-­‐test	  are	  shown	  in	  columns	  5	  and	  6.	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Figure	  4.27	  Western	  blot	  analysis	  of	  the	  β2α2	  fusion	  protein	  from	  KCL-­‐22	  transfected	  cells.	  	  	  
The	  bar	  chart	  shows	  Western	  blot	  results	  from	  three	  different	  transfection	  experiments.	  Each	  
bar	   is	  generated	  from	  the	  average	  of	  three	  Western	  blot	  repeats.	  The	  `positive’	  control,	  cells	  
transfected	  with	  the	  pB12mcs-­‐U6-­‐eGFP	  vector,	  was	  selected	  to	  be	  1	  and	  the	  data	  from	  other	  
transfected	  cells	  were	  calculated	  with	  regards	  to	  the	  positive	  control.	  The	  chart	  demonstrates	  
that	   the	   shRNA1β2α2	   construct	   is	   specific	   for	   its	   fusion	   point	   and	   has	   reduced	   its	   target’s	  
protein	   levels	   to	  55%.	   In	  the	  case	  of	   the	  shRNA1β3α2	  and	  shRNA3β3α2	  constructs,	   little	  effect	  
on	  the	  β2α2	  protein	  levels	  was	  seen.	  ***p	  <	  0.0001.	  	  	  	  	  	  	  
	  
The	  data	  generated	  from	  measuring	  band	  intensities	  of	  the	  Western	  blots,	  
show	  a	  reduction	  in	  β2α2	  BCR-­‐ABL	  fusion	  protein	  only	  when	  cells	  are	  treated	  
with	  shRNA1β2α2,	  and	  not	  with	  shRNA1β3α2	  and	  shRNA3β3α2.	  Hence,	  confirming	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In	   this	   chapter	   the	   effects	   of	   some	   of	   the	   constructed	   shRNA	  molecules	  
were	  tested	  and	  studied.	  This	  was	  conducted	  through	  in	  vitro	  studies.	  Three	  of	  
the	  constructed	  shRNA	  molecules	  were	  transfected	  by	  nucleofection	  into	  K562	  
and	   KCL-­‐22	   cell	   lines.	   Following	   confirmation	   of	   successful	   transfection	   by	  
fluorescence	   microscopy,	   FACS	   analysis	   was	   performed	   to	   quantify	  
transfection	   and	   the	   transfection	   efficiencies	   were	   calculated.	   mRNA	   and	  
protein	   extractions	  were	   conducted	   and	   the	   effects	   of	   the	   shRNA	   constructs	  
were	   examined	   at	   the	   mRNA	   levels	   using	   qPCR	   and	   protein	   levels	   using	  
Western	  blotting.	  
FACS	  results	  have	  indicated	  that	  the	  negative	  control,	  pB12mcs-­‐eGFP	  with	  
no	   promoter,	   gave	   GFP	   fluorescent	   signals.	   This	   background	   fluorescence	  
maybe	  due	  to	  cell	  damage	  by	  the	  physical	  process	  of	  nucleofection,	  or	  due	  to	  
intrinsic	   fluorescence	   that	   are	   present	   in	   all	   cells	   due	   to	   mitochondria,	  
lysosomes,	  aromatic	  amino	  acids,	  and	  other	  endogenous	  fluorophores	  such	  as	  
NADPH	  (Srivastava	  et	  al.,	  2011	  and	  Mosiman	  et	  al.,	  1997).	  	  
The	  qPCR	  results	  showed	  that	  the	  mRNA	  levels	  of	  the	  targeted	  genes	  were	  
reduced.	  This	  was	  true	  for	  both	  cell	  lines.	  In	  the	  K562	  cell	  line	  the	  shRNA1β3α2	  
construct	   was	   more	   efficient	   in	   reducing	   its	   target’s	   mRNA	   levels	   than	   the	  
shRNA3β3α2	   construct.	   The	   first	   exhibited	   a	   66.4%	   depletion	   in	   the	  
concentration	   of	   the	   β3α2	  mRNA	   levels,	   whereas	   the	   second	   only	   exhibited	  	  	  	  	  
a	  32%	  depletion.	  The	  specificity	  of	  both	  constructs	  was	  also	  tested,	  and	  it	  was	  
found	   that	   both	   construct	   were	   specific	   to	   their	   target	   gene.	   This	   was	  
concluded	  because	  the	  shRNAβ3α2	  constructs	  did	  not	  reduce	  the	  mRNA	  levels	  
of	   the	   β2α2	   variant	   when	   transfected	   into	   KCL-­‐22	   cell	   line.	   In	   addition,	   the	  
shRNAβ3α2	  construct	  did	  not	  affect	  the	  normal	  levels	  of	  the	  BCR	  and	  ABL	  genes.	  	  
In	   the	   case	   of	   the	   second	   BCR-­‐ABL	   variant	   β2α2,	   the	   KCL-­‐22	   cell	   line	  
showed	   a	   reduction	   in	   the	   mRNA	   levels	   of	   the	   β2α2	   fusion	   point,	   when	  
transfected	  with	  the	  shRNA1β2α2	  construct.	  The	  construct	  caused	  a	  maximum	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of	  66%	  depletion	  in	  the	  mRNA	  levels.	  The	  specificity	  of	  this	  construct	  was	  also	  
tested,	   where	   the	   construct	   was	   used	   to	   transfect	   the	   K562	   cell	   line.	   qPCR	  
results	   of	   this	   transfection	   demonstrated	   that	   there	   was	   no	   significant	  
reduction	   in	   the	   mRNA	   levels	   of	   the	   β3α2	   fusion	   point.	   In	   addition,	   the	  
shRNA1β2α2	   construct	   did	  not	   affect	   the	  normal	   expression	   levels	   of	   the	  BCR	  
and	  ABL	  genes	  when	  transfected	   into	  the	  KCL-­‐22	  cells,	  only	  reductions	   in	  the	  
β2α2	  gene	  were	  observed.	  Hence,	  confirming	  the	  specificity	  of	  the	  synthesised	  
shRNA1β2α2	  molecule	  to	  its	  target	  site.	  	  	  	  	  	  	  
Studies	   conducted	   at	   the	   protein	   level	   were	   performed	   by	   Western	  
blotting.	   The	   results	   obtained	   from	   the	   Western	   blots	   with	   shRNAβ3α2	   and	  
shRNAβ2α2	   constructs	   confirmed	   those	   from	   the	   qPCR,	   where	   reductions	   of	  
both	  BCR-­‐ABL	   fusion	  proteins	  were	  observed.	   In	   the	   case	  of	   the	  β3α2	   fusion	  
protein,	   shRNA1β3α2	   showed	   a	   higher	   reduction	   in	   the	   protein	   levels	   in	  
comparison	   with	   shRNA3β3α2.	   Statistical	   analysis	   showed	   that	   the	   reduction	  
levels	   were	   significant.	   The	  Western	   blots	   also	   confirmed	   the	   qPCR	   findings	  
that	  the	  synthesised	  shRNA	  molecules	  were	  specific	  to	  their	  target	  sequence.	  	  
In	   conclusion,	   the	   results	   shown	   in	   this	   chapter	   give	   evidence	   that	   the	  
constructed	   shRNA	   molecules	   do	   indeed	   specifically	   target	   their	   mRNA	  
sequences	  causing	  a	  reduction	  in	  both	  mRNA	  and	  protein	  levels.	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Chapter	  5 :	  Discussion	  
	  
	  
5.1 	  Discussion	  
	  
Chronic	  myeloid	  leukaemia	  (CML)	  was	  one	  of	  the	  first	  cancers	  to	  be	  linked	  
to	  a	  chromosomal	  abnormality	  (Sawyers,	  1999),	  the	  Philadelphia	  chromosome.	  
This	   chromosome	   results	   from	   a	   translocation	   between	   chromosomes	   9	   and	  
22,	  where	  the	  ABL	  gene	  on	  chromosome	  9,	  a	  tyrosine	  kinase,	  is	  translocated	  to	  
the	  BCR	   gene	   region	  on	   chromosome	  22	  giving	   rise	   to	  an	  abnormal	  BCR-­‐ABL	  
fusion	   gene	   (Rowley,	   1973).	   The	   resultant	   fusion	   gene	   has	   an	   abnormally	  
upregulated	  tyrosine	  kinase	  activity	  (Weisberg	  and	  Griffin,	  2000)	  that	  results	  in	  
an	  increase	  in	  the	  proliferation	  of	  immature	  white	  blood	  cells,	  thus	  leading	  to	  
the	  development	  of	  CML.	  There	  are	  several	  breakpoints	  that	  can	  occur	  in	  the	  
BCR	  gene	  two	  of	  which	  give	  rise	  to	  95%	  of	  CML	  cases	   (Evans	  and	  Sillibourne,	  
1996).	  These	  fusion	  points	  are	  called	  the	  β3α2	  and	  β2α2	  depending	  on	  where	  
the	  chromosomal	  breakages	  occur	  in	  the	  BCR	  gene	  (Van	  Der	  Burg	  et	  al.,	  2004).	  
Like	   all	   cancers,	   the	   treatment	   approach	   in	   CML	   is	   multiple	   sessions	   of	  
chemotherapy	  via	   the	  usage	  of	  drug	  cocktails	   (Hoffbrand	  et	  al.,	   2006).	  Drugs	  
for	  the	  disease	  have	  been	  developed	  over	  the	  years,	  differing	   in	  their	  actions	  
and	   target	   sites.	   With	   further	   understanding	   of	   the	   molecular	   pathology	   of	  
CML,	  new	  drugs	  have	  been	  designed	  and	  developed.	  These	  drugs	  have	  aimed	  
at	   inhibiting	   the	  ABL	   tyrosine	   Kinase	   activity	   (Milojkovic	   and	  Apperiey,	   2008,	  
Puttini	  et	  al.,	  2008)	  and,	  are	  named	  tyrosine	  kinase	  inhibitors	  (TKI).	  However,	  
these	  drugs	  are	  only	  treatments,	  not	  cures,	  for	  CML;	  patients	  tend	  to	  relapse,	  
and	   the	   issue	   of	   drug	   toxicity	   still	   remains.	   The	   only	   cure	   available	   for	   this	  
disease	  is	  allogeneic	  bone	  marrow	  (BM)	  transplants	  (Fausel,	  2007),	  	  
Various	   drugs	   exist	   for	   CML	   and	   the	   TKI	   Imatinib	   is	   considered	   to	   be	   the	  
first	  line	  of	  treatment	  for	  patients	  with	  the	  disorder.	  Imatinib	  (Gleevec®),	  a	  TKI	  
that	   was	   developed	   by	   Novartis,	   USA,	   has	   shown	   promising	   outcomes	   with	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patients	   establishing	   a	   90%	   complete	   hematologic	   response	   upon	   treatment	  
with	   the	   drug.	   However,	   cases	   of	   drug	   resistance	   have	   occurred	   leading	   to	  
patient	   relapse,	   which	   led	   to	   the	   development	   of	   other	   tyrosine	   kinase	  
inhibitors	  such	  as	  Nilotinib	  (Tasigna®),	  produced	  by	  Novaris,	  USA	  (Shieh	  et	  al.,	  
2011),	  and	  Dasatinib	  (Sprycel®)	  (Steinberg,	  2007,	  Talpaz	  et	  al.,	  2006,	  and	  Shieh	  
et	  al.,	  2011),	  produced	  by	  Bristol	  Pharmaceuticals,	  Switzerland.	  Unfortunately,	  
both	   drugs	   display	   toxic	   side	   effects	   and	   the	   issue	   of	   drug	   resistance	   still	  
remains,	   favouring	   the	   need	   for	   development	   of	   further	   drugs	   and	   other	  
therapeutic	   approaches,	   and	   making	   the	   modulation	   of	   gene	   expression	   a	  
promising	  strategy	  for	  potential	  CML	  treatment.	  
This	  project	  aims	  to	  develop	  an	  alternative	  therapeutic	  approach	  for	  CML	  
by	  the	  use	  of	  shRNA	  that	  target	  and	  down	  regulate	  the	  expression	  of	  the	  two	  
BCR-­‐ABL	  variants	  accounting	  for	  95%	  of	  CML	  cases.	  	  
	  
	  
5.1.1 Development	   and	   Expression	   of	   shRNA	   constructs	  
targeting	  the	  BCR-­‐ABL	  variants	  
	  
K562	  and	  KCL-­‐22	  cell	  lines	  were	  selected	  for	  the	  purpose	  of	  this	  study.	  The	  
K562	  cell	  line	  is	  a	  CML	  cell	  line	  with	  the	  β3α2	  variant	  (Lozzio	  and	  Lozzio,	  1975),	  
whereas	   the	   β2α2	   variant	   is	   present	   in	   the	   KCL-­‐22	   cell	   line	   (Kubinishi	   and	  
Miyoshi,	   1983).	   shRNA	  molecules	  were	   designed	   based	   on	   the	   sequences	   of	  
these	   fusion	   points,	   and	   delivered	   endogenously	   along	  with	   a	   reporter	   gene	  
system.	  The	  first	  attempt	  to	  construct	  a	  reporter	  gene	  system	  used	  the	  pEGFP-­‐
N1	   vector.	   This	   vector	   has	   an	   eGFP	   and	   a	   CMV	   promoter.	   The	   eGFP	   is	   a	  
mutated	  form	  of	  GFP	  that	  is	  found	  to	  be	  thermostable	  at	  37°C	  in	  mammalian	  
cultured	  cells.	  Hence,	  it	  has	  greater	  and	  improved	  levels	  of	  fluorescence	  when	  
compared	   the	   wild	   type	   protein	   (Siemering	   et	   al.,	   1996),	   making	   its	   use	  
advantageous	   in	   the	   current	   study.	   Also,	   the	   CMV	   promoter	   was	   to	   be	  
removed	   from	   the	   vector	   and	   the	   shRNA	   molecules	   placed	   under	   the	  
regulation	   of	   the	   human	   U6	   and	   H1	   promoters.	   This	   was	   because	   these	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promoters	   are	  members	   of	   the	   RNA	   Polymerase	   III	   (Pol	   III)	   promoter	   family,	  
and	   transcribe	   successfully	   any	   sequence	   no	   more	   than	   400	   bases	   (Tuschl,	  
2002)	  without	  addition	  of	  extra	  bases	  flanking	  sequences	  of	  interest.	  Previous	  
studies	  have	  shown	  that	  chemically	  and	  T7-­‐synthesized	  shRNAs	  exhibit	  3’	  or	  5’	  
overhang	   extensions,	   which	   tend	   to	   reduce	   the	   efficacy	   of	   the	   synthesized	  
shRNA	   (Paddison	   et	   al.,	   2002).	   In	   addition,	   transcription	   with	   U6	   and	   H1	  
promoters	  is	  easily	  terminated	  by	  a	  stretch	  of	  6	  ‘T’	  residues,	  making	  them	  ideal	  
for	   the	   expression	   of	   siRNAs	   and	   shRNAs	   (Tuschl,	   2002).	   Furthermore,	   these	  
promoters	   can	   transcribe	   small	   RNA	   transcripts	   that	   lack	   the	   5’	   cap	   and	  
3’polyadenosine	  (Wu	  et	  al.,	  2005).	  
Attempts	   to	   remove	   part	   of	   the	   CMV	   promoter	   and	   re-­‐circularize	   the	  
double	   digested	   pEGFP-­‐N1	   vector	   were	   undertaken	   and	   were	   successful	  
(previously	   shown	   in	   chapter	   3,	   sections	   3.2.2.1	   and	   3.2.2.2).	   However,	   it	  
proved	  difficult	  to	  transform	  E.coli	  with	  the	  altered	  pEGFP-­‐N1	  plasmid.	  In	  every	  
attempt,	  colony	  screening	  showed	  that	  E.coli	  were	  transformed	  with	  only	  the	  
wild	   type	  vector.	  This	  may	  be	  due	   to	   the	   fact	   that	  not	  all	   the	  CMV	  promoter	  
was	  removed	  and	  the	  part	  still	  intact	  within	  the	  vector	  was	  toxic	  for	  the	  growth	  
of	   E.coli	   bacterial	   cells.	   This	   explanation	  was	   considered	  due	   to	   the	   fact	   that	  
the	  wild	   type	  vector	  always	  got	  cloned,	   rather	   then	  the	  altered	  one.	   In	  cases	  
where	   attempts	   to	   eliminate	   the	   presence	   of	   the	   wild	   type	   vector	   in	   the	  
sample	  was	  undertaken,	  none	  of	  the	  vectors	  were	  cloned.	  In	  future	  studies,	  it	  
would	   be	   interesting	   to	   see	  which	   part	   of	   the	   CMV	  promoter	   is	   toxic	   to	   the	  
cells.	  A	  previous	  study	  done	  by	  Trudel	  et	  al.	   in	  1996	  found	  that	  a	  part	  of	   the	  
GATA-­‐1	   eukaryotic	   transcription	   factor	  was	   toxic	   to	   bacterial	   cells.	   This	   toxic	  
peptide	   was	   then	   used	   to	   develop	   a	   positive	   selection	   vector	   called	   pGATA	  
(ClonesureTM),	  where	   inserts	   caused	   a	   disturbance	   to	   the	   gene	   encoding	   the	  
peptide.	  Something	  similar	  may	  be	  done	  after	  identifying	  the	  toxic	  part	  of	  the	  
CMV	  promoter.	  	  
Because	  of	  the	  above	  difficulties,	  another	  plasmid	  was	  considered	  in	  order	  
to	   construct	   the	   reporter	   gene	   system.	   This	  was	   the	  pB12mcs-­‐eGFP	  plasmid,	  
which	  has	  an	  eGFP	  as	  a	  reporter	  gene,	  and	  lacks	  a	  promoter.	  	  Therefore,	  it	  was	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a	  suitable	  choice	  because	  the	  human	  U6	  or	  the	  H1	  promoter	  could	  be	  inserted	  
into	  it.	  	  
The	  shRNA	  expression	  cassettes,	  containing	  both	  the	  promoter	  and	  shRNA	  
molecules,	   were	   synthesised	   by	   PCR,	   and	   inserted	   into	   the	   pB12mcs-­‐eGFP	  
plasmid.	  The	  shRNA	  molecules	  designed	   in	  this	  study	  were	  designed	  to	  be	  as	  
symmetrical	  as	  possible	  to	  aid	  the	  binding	  to	  their	  target	  site	  and	  cleavage	  of	  
the	  correct	  gene.	  All	   constructs	  were	   sequenced	  before	   testing	   in	  expression	  
studies.	   To	   conduct	   expression	   studies,	   the	   pB12mcs-­‐U6-­‐shRNA-­‐eGFP	  
constructs	  were	  delivered	  into	  K562	  and	  KCL-­‐22,	  suspension	  cell	  lines.	  Because	  
primary	  cells	  and	  cells	   in	  suspension	  are	  hard	  to	  transfect	  (Ovcharenko	  et	  al.,	  
2005,	  Oliveira	  and	  Goodell,	  2003	  and	  Merkerova	  et	  al.,	  2007),	  several	  chemical	  
transfection	   agents	   were	   tested,	   none	   was	   found	   to	   give	   good	   transfection	  
efficiency	   (45-­‐50%	   for	   both	   cell	   lines).	   Consequently,	   other	   methods	   of	  
transfection	   were	   used.	   It	   was	   found	   that	   nucleofection,	   a	   form	   of	  
electroporation,	   where	   the	   DNA	  molecules	   of	   interest	   are	   directly	   delivered	  
into	   the	   target	   cell’s	   nucleus	   gave	   acceptable	   transfection	   efficiencies,	   a	  
maximum	   of	   72%	   for	   K562	   and	   a	   maximum	   of	   67%	   for	   KCL-­‐22.	   In	   addition	  
nucleofection	  gave	  a	  good	  percentage	  of	  cell	  viability,	  an	  average	  of	  89.3%	  for	  
K562	   and	   90.8%	   for	   KCL-­‐22.	   The	   `negative’	   control	   (pB12mcs-­‐eGFP	   with	   no	  
promoter)	   showed	   auto-­‐fluorescence;	   therefore,	   the	   transfection	   efficiencies	  
with	  regards	  to	  the	  `negative’	  control,	  as	  well	  as	  the	  non-­‐transfected	  cells	  were	  
calculated.	  However,	   the	   transfection	  efficiencies	   shown	   in	   the	  current	   study	  
are	  those	  with	  regards	  to	  the	  non-­‐transfected	  cell	  lines.	  The	  auto-­‐fluorescence	  
observed	   on	   the	   `negative’	   control	   maybe	   due	   to	   cell	   damage	   or	   due	   to	  
intrinsic	   levels	   of	   fluorescence	   due	   to	   mitochondria,	   lysosomes,	   aromatic	  
amino	  acids,	  and	  other	  endogenous	  fluorophores	  such	  as	  NADPH	  (Srivastava	  et	  
al.,	  2011	  and	  Mosiman	  et	  al.,	  1997).	  	  Cell	  damage	  might	  have	  occurred	  due	  to	  
the	  physical	  nature	  of	  nucleofection.	  Thus,	   suggesting	   that	  other	  methods	  of	  
transfection	   avoiding	   cell	   damage	   and	   at	   the	   same	   time	   giving	   high	  
transfection	   efficiencies	   are	   required	   for	   CML	   cell	   lines.	   In	   future	  
developments,	   attempts	   to	   quench	   auto-­‐fluorescence	   through	   staining	   with	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trypan	   blue	   before	   FACS	   analysis	   can	   be	   applied	   (Srivastava	  et	   al.,	   2011	   and	  
Mosiman	  et	  al.,	  1997).	  	  
Merkerova	   et	   al.,	   2007,	   examined	   two	   physical	   transfection	   methods	  
including	  nucleofection	  on	  CML	  primary	  cells	  and	   three	  chemical	  methods	   to	  
transfect	   leukemic	  cell	   lines	  and	  primary	  CML	  cells.	  Their	  study	  reported	  that	  
two	   chemical	   methods	   gave	   35-­‐40%	   efficiency	   while	   the	   third	   one	   gave	   no	  
satisfactory	  transfection	  in	   leukaemic	  cell	   lines;	  the	  efficiency	  for	  the	  last	  was	  
not	  reported	  nor	  the	  type	  of	  the	  cell	  lines	  used	  in	  the	  study.	  The	  efficiency	  of	  
nucleofection	   using	   the	   program	   T-­‐16	   on	   primary	   CML	   cells	   was	   25-­‐29%.	  
Another	   study	   done	   by	   Mahmodabady	   et	   al.,	   2010,	   also	   compared	  
nucleofection	   to	  other	  chemical	  methods	   in	  K562	  cells.	  The	  study	   found	   that	  
nucleofection	   gave	   higher	   transfection	   efficiencies,	   50%,	   when	   compared	   to	  
lipofectamine	   and	   CaCl2	  methods,	   <50%	   and	   <20%	   respectively;	   cell	   viability	  
was	  not	  mentioned.	  Nevertheless,	  both	   studies	   give	  evidence	   supporting	   the	  
results	  in	  the	  current	  study	  on	  the	  difficulty	  of	  transfecting	  leukaemic	  cell	  lines	  
and	  that	  nucleofection	  is	  a	  more	  efficient	  method	  of	  transfection	  in	  regards	  to	  
CML	  cell	  lines.	  	  
The	  reason	  behind	  the	  K562	  and	  KCL-­‐22	  cell	  lines	  being	  difficult	  to	  transfect	  
maybe	   due	   to	   the	   fact	   that	   these	   cells	   are	   morphologically	   spherical	   cells	  
(Bártová	  et	  al.,	  2005)	  that	  float	  within	  the	  media,	  in	  contrast	  to	  adherent	  cells	  
that	   become	   immobilized	   and	   adhere	   to	   the	   bottom	   of	   the	   culture	   flask.	  
Adherent	   cells	   become	   flatted	   and	   spread,	   gaining	   more	   surface	   area	   in	  
comparison	   to	   the	   spherical	   K562	   and	   KCL-­‐22	   cell	   lines.	   This	  would	   result	   in	  
easier,	  more	  abundant	  take	  up	  of	  the	  chemically	  manipulated	  DNA	  complexes	  
used	   in	   transfection.	  No	  program,	  or	   a	   transfection	   kit,	  was	  available	   for	   the	  
KCL-­‐22	  cell	  line,	  therefore	  the	  same	  program	  and	  Kit	  used	  for	  the	  K562	  cell	  line	  
were	  tested	  and	  were	  found	  to	  give	  satisfactory	  results,	  average	  of	  61.3%	  for	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5.1.2 Efficiency	  of	  shRNA	  constructs	  targeting	  the	  β3α2	  fusion	  
point	  
	  	  
Two	   shRNA	  constructs,	   shRNA1β3α2	  and	   shRNA3β3α2,	  under	   the	   regulation	  
of	  the	  U6	  promoter	  were	  tested	  against	  the	  β3α2	  and	  β2α2	  variants.	  The	  β3α2	  
and	   β2α2	   BCR-­‐ABL	   mRNA	   expression	   levels	   were	   examined	   24	   hr	   after	  
transfection,	  and	  were	  quantified	  by	   the	  use	  of	   real	   time	  PCR.	  The	   results	  of	  
this	  reaction	  demonstrated	  a	  decrease	  in	  the	  levels	  of	  only	  β3α2.	  	  The	  results	  
show	  that	  the	  mRNA	  expression	   levels	  of	  β3α2	  fusion	  product	  were	  depleted	  
by	  66.4%	  with	  shRNA1β3α2and	  38%	  with	  shRNA3β3α2.	  Further	  studies	  showed	  
that	   the	  constructs	  were	  specific	   for	   the	  β3α2	   fusion	  point	  and	  that	   they	  did	  
not	  target	  the	  β2α2	  fusion	  point.	  The	  different	  efficiencies	  of	  shRNA1β3α2	  and	  
shRNA3β3α2	   could	   be	   due	   to	   the	   fact	   that	   the	   U6	   promoter	   expressing	   the	  
shRNA3β3α2	  molecule	  had	  3	  mismatches	  compared	  to	  2	  mismatches	  in	  the	  U6	  
promoter	  regulating	  the	  expression	  of	   the	  shRNA1β3α2	  molecule.	  Mismatches	  
occurred	  in	  the	  U6	  promoter	  even	  though	  a	  high	  fidelity	  Taq	  polymerase	  was	  
used	   (Fast	   Start	   High	   Fidelity	   PCR	   system,	   Roche,	   UK).	   For	   future	   studies,	   it	  
would	  be	  interesting	  to	  examine	  what	  effect	  the	  mismatches	   in	  U6	  may	  have	  
on	   the	   effectiveness	   of	   the	   promoter.	   Another	   reason	   could	   be	   due	   to	   the	  
difference	  in	  sequences	  of	  the	  shRNA	  molecules,	  or	  how	  the	  molecules	  bind	  to	  
their	   targets	   in	   the	   cells	   in	   regards	   to	   the	   target’s	   secondary	   structure;	   the	  
shRNA1β3α2	  sequence	  may	  give	  the	  molecule	  a	  better	  efficiency	  to	  induce	  RNAi	  
based	  silencing	  than	  shRNA3β3α2.	  	  
Western	  blot	  results	  supported	  the	  real	  time	  PCR	  results	  and	  demonstrated	  
a	  reduction	   in	  the	  protein	   levels	  and	  confirmed	  the	  specificity	  of	  the	  shRNAs.	  
This	   reduction	   was	   40%	   and	   33.5%	   for	   shRNA1β3α2	   and	   shRNA3β3α2,	  
respectively,	  in	  relation	  to	  the	  positive	  control.	  These	  results	  demonstrate	  that	  
the	  shRNA	  molecules	  tested	  had	  an	  effect	  on	  both	  mRNA	  and	  protein	  levels	  of	  
the	  BCR-­‐ABL	  fusion	  gene.	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5.1.2.1 Delivery	  and	  production	  of	  the	  shRNAβ3α2	  Constructs	  
	  
Mahmodabady	  et	  al.,	  2010,	  used	  shRNA	  targeting	  the	  β3α2	  variant	  in	  K562	  
cell	   lines.	   Their	   publication	   reported	   that	   they	   have	   established	   50%	  
transfection	   efficiency	   with	   the	   use	   of	   electroporation,	   however,	  
LipofectamineTM	  2000	  that	  gave	   lower	  transfection	  efficacy	  was	  used	  to	  carry	  
out	   their	   transfection	   experiments	   (the	   actual	   percentage	   of	   transfection	  
efficiency	   was	   not	   reported	   but	   only	   a	   bar	   chart	   represented	   the	   results).	  
Arthanari	   et	   al.,	   2010,	   also	   transfected	   K562	   cells	   with	   shRNA	   constructs;	  
transfection	  was	  done	  through	  chemical	  methods	  that	   involved	  lipofectamine	  
showing	  transfection	  efficiencies	  between	  20-­‐50%.	  In	  the	  current	  study,	  K562	  
cells	  were	  transfected	  by	  nucleofection	  and	  a	  maximum	  transfection	  efficiency	  
of	  72%	  was	  established	  when	  using	  non-­‐viral	  vectors	  for	  shRNA	  delivery.	  Other	  
studies	   have	   achieved	   higher	   transfection	   efficiencies	   for	   shRNA	   delivery	  
including	   those	   using	   a	   lentiviral	   system.	   Examples	   include	   studies	   done	   by	  
Myssina	   et	   al.,	   2008	   and	   Li	   et	   al.,	   2003.	   In	   general	   lentiviral	   vectors,	   have	  
higher	   transfection	   efficiencies	   than	   other	   non-­‐viral	   systems,	   and	   the	  
advantage	  of	   long	   stable	  expression.	  However,	   these	   vectors	   are	  highly	   toxic	  
(Wang	  et	  al.,	  2008).	  
Different	  promoters	  can	  be	  used	  to	  produce	  shRNA	  molecules,	  however,	  as	  
discussed	  earlier,	   the	   small	  nuclear	  RNA	  Pol	   III	  promoters	  have	  been	  used	   to	  
develop	  transcripts	  to	  induce	  RNAi,	  especially	  the	  U6	  and	  H1	  promoters	  (Wu	  et	  
al.,	  2005).	  Mahmodabady	  et	  al.,	  2010,	  used	  the	  H1	  promoter	  to	  express	  shRNA	  
molecules	  used	   in	  their	  study.	  Myssina	  et	  al.,	  2009,	  used	  a	  CMV	  promoter	  to	  
produce	  their	  shRNA	  molecules.	  The	  CMV	  promoter	  is	  a	  Pol	  II	  promoter;	  these	  
promoters	  have	  also	  been	  shown	  to	  produce	  shRNA	  molecules	  (Rossi,	  2008).	  A	  
study	   done	   by	   Li	   and	  Mahato,	   2009,	   to	   see	   the	   effects	   of	   H1,	   U6,	   and	   CMV	  
promoters	   on	   shRNA	   mediated	   gene	   silencing,	   found	   that	   when	   the	   same	  
shRNA	  molecule	  was	  produced	  from	  the	  three	  different	  promoters,	  there	  was	  
no	   significant	   difference	   in	   gene	   silencing	   between	   the	   U6	   and	   CMV	  
promoters.	  However,	  H1	  had	  less	  effect	  than	  CMV	  and	  U6.	  Other	  studies	  have	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also	   reported	   that	   the	  U6	  promoter	   is	  more	  potent	   than	  H1	   (An	  et	  al.,	   2006	  
and	  Snyder	  et	  al.,	  2009).	   In	   the	  present	   study,	   the	  U6	  promoter	  was	  used	   to	  
produce	  shRNA	  molecules.	  	  
	  
	  
5.1.2.2 Effects	  of	   the	   shRNAβ3α2	  Constructs	  on	  β3α2	  mRNA	  and	  
protein	  levels	  
	  	  
Mahmodabady	   et	   al.,	   2010,	   showed	   significant	   reduction	   in	   the	   BCR-­‐ABL	  
mRNA	  levels,	  up	  to	  42%,	  24hr	  after	  shRNA	  transfection.	  However,	  to	  measure	  
the	  mRNA	  levels,	  RT-­‐PCR	  was	  performed	  and	  PCR	  was	  used	  to	  amplify	  the	  RT-­‐
PCR	  products.	  A	  more	  accurate	  way	  of	  measuring	  β3α2	  mRNA	  levels	  is	  through	  
qPCR	   as	   attempted	   in	   this	   study.	   Myssina	   et	   al.,	   2009,	   showed	   that	   their	  
designed	  shRNA	  against	  the	  β3α2	  variant	  had	  an	  effect	  on	  mRNA	  and	  protein	  
levels,	  where	  a	  75%	  and	  95%	  reduction,	  respectively	  were	  reported.	  However,	  
this	   was	   measured	   48hr	   after	   transfection	   on	   a	   100%	   transfected	   cell	  
population	  (FACS	  was	  used	  to	  select	  GFP+	  cells)	  that	  was	  transfected	  with	  high	  
concentrations	  of	  shRNA	  (5μg/106	  cells),	  which	  was	  expressed	  from	  a	  lentiviral	  
system.	   These	   can	   be	   the	   reasons	   for	   achieving	   the	   high	   levels	   of	   reduction.	  
This	  was	  also	  the	  case	  in	  the	  study	  conducted	  by	  Li	  et	  al.,	  in	  2003	  that	  used	  a	  
lentiviral	  vector	  to	  express	  shRNAs,	  under	  the	  regulation	  of	  the	  U6	  promoter.	  
The	   latter,	  as	  discussed	  previously,	  also	  yields	  high	   levels	  of	  gene	  expression,	  
hence	   the	   observation	   of	   >90%	   depletion	   in	   both	  mRNA	   and	   protein	   levels.	  
Nevertheless,	   in	   the	   current	   study	   a	   non-­‐viral	   system	   has	   demonstrated	  
successful	   depletion	   of	   both	   mRNA	   (66.4%)	   and	   protein	   levels	   (40%)	   when	  
under	  regulation	  of	  the	  U6	  promoter,	  and	  a	  shRNA	  concentration	  of	  2μg/2.5	  x	  
106	  cells.	  The	  effects	  of	  the	  shRNA	  constructs	  used	  in	  the	  current	  work	  might	  
have	  greater	  effects	  if	  a	  lentiviral	  system	  were	  used.	  	  
Arthanari	  et	  al.,	  2010,	  have	  shown	  that	  an	  shRNA	  expressed	  in	  the	  K562	  cell	  
line	  leads	  to	  a	  decrease	  in	  β3α2	  mRNA	  levels	  of	  70%	  and	  protein	  of	  75%.	  mRNA	  
levels	  were	  measured	  after	  48hr	  and	  protein	  levels	  after	  96hr,	  when	  cells	  were	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treated	  with	  10μg	  of	  shRNA.	  A	  further	  decease	  of	  mRNA	  to	  85%	  and	  protein	  to	  
90%	  was	  observed	  at	  30μg	  of	  shRNA.	  The	  depletion	  levels	  were	  measured	  after	  
48	  and	  96hr	  in	  comparison	  to	  only	  24hr	  in	  the	  present	  work.	  These	  high	  levels	  
of	   depletion	  might	   be	   due	   to	   this	   reason.	   Another	   explanation	   for	   achieving	  
such	   high	   depletion	   levels	   could	   be	   due	   to	   the	   high	   shRNA	   vector	  
concentrations	  used	  by	  Arthanari	  et	  al.,	   2010.	  As	   they	  have	  used	  10-­‐30μg	  of	  
shRNA	   vector	   per	   1.5	   x	   106	   cells,	   which	   is	   5-­‐15x	  more	   the	   concentration	   of	  
shRNA,	  used	   in	   the	  present	  study	   (2μg/2.5	  x	  106).	  Greater	   levels	  of	  depletion	  
might	  have	  been	  accomplished	   in	   the	  current	  project,	   if	  higher	  shRNA	  vector	  
concentrations	  had	  been	  used.	  	  	  	  
In	  the	  current	  work,	  the	  shRNAβ3α2	  constructs	  demonstrated	  high	  specificity	  
to	   their	   target	   site	   because	   these	   molecules	   induced	   RNAi	   mediated	   gene	  
silencing	   only	   to	   their	   target	   sites	   and	   not	   to	   other	   genes	   such	   as	   BCR-­‐ABL	  
fusion	  point	  (β2α2),	  the	  normal	  ABL,	  and	  BCR	  genes,	  in	  which	  48-­‐50%	  similarity	  
in	   sequence	   exist.	   Other	   studies	   testing	   shRNA	   molecules	   against	   the	   β3α2	  
either	   considered	   their	   molecules	   specific	   on	   the	   basis	   that	   the	   levels	   of	  
GAPDH	  housekeeping	  were	  not	  affected,	  or	  by	  having	  a	  scramble	  sequence	  of	  
the	  same	  shRNA	  used	  that	  did	  not	  target	  any	  human	  gene	  (Mahmodabady	  et	  
al.,	  2010).	  Myssina	  et	  al.,	  2009	  and	  Li	  et	  al.,	  2003,	  demonstrated	  specificity	  of	  
their	  shRNA	  molecules	  in	  regards	  to	  the	  β2α2	  variant	  and	  did	  not	  consider	  the	  




In	  conclusion,	  the	  shRNA	  molecules	  targeting	  the	  β3α2	  fusion	  gene	  showed	  
specific	  reduction	  of	  their	   target	  site	  mRNA	  (66.4%)	  and	  protein	   levels	   (40%),	  
which	  were	   achieved	   24hr	   after	   transfection	  with	   the	   shRNA	   constructs	   and	  
with	  a	  relatively	  low	  concentration	  of	  shRNA	  (2μg/2.5	  x	  106	  cells).	  The	  BCR-­‐ABL	  
protein	   has	   been	   reported	   to	   have	   a	   long	   half-­‐life	   (Myssina	  et	   al.,	   2008	   and	  
Wilda	   et	   al.,	   2002)	   that	   is	   estimated	   to	   be	   >48hr	   (Spiller	   et	   al.,	   1998).	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Therefore,	  higher	  levels	  of	  reduction	  at	  protein	  levels	  can	  be	  expected	  for	  the	  
shRNAs	  used	  in	  the	  current	  study	  over	  a	  longer	  period	  of	  time.	  	  
	  	  
	  
5.1.3 Efficiency	  of	  shRNA	  constructs	  targeting	  the	  β2α2	  fusion	  
point	  
	  
The	  β2α2	  BCR-­‐ABL	  mRNA	  expression	   levels	  were	  examined	  24	  hours	  after	  
transfection,	   and	   were	   quantified	   by	   the	   use	   of	   real	   time	   PCR.	   The	   results	  
demonstrated	  a	  decrease	  in	  the	  level	  of	  the	  β2α2	  BCR-­‐ABL	  variant.	  One	  shRNA	  
constructs,	  shRNA1β2α2,	  under	  the	  regulation	  of	  the	  U6	  promoter	  was	  tested.	  
The	  results	  show	  that	  the	  mRNA	  expression	  levels	  of	  the	  β2α2	  fusion	  product,	  
and	   not	   β3α2	  were	   depleted	   by	   66%	  with	   shRNA1β3α2.	  Western	   blot	   results	  
demonstrated	   a	   reduction	   in	   the	   protein	   levels	   of	   45%,	   in	   relation	   to	   the	  
`positive’	  control.	  These	  results	  show	  that	  the	  shRNA	  molecules	  tested	  had	  an	  
effect	  on	  both	  mRNA	  and	  protein	  levels	  of	  the	  BCR-­‐ABL	  fusion	  gene.	  	  
	  
	  
5.1.3.1 Delivery	  and	  production	  of	  the	  shRNAβ2α2	  Construct	  
	  
The	  current	  study	  demonstrated	  that	  KCL-­‐22	  cell	  lines	  can	  be	  transfected	  by	  
means	   of	   nucleofection,	   and	   the	   shRNA1β2α2	   construct	   achieved	   a	   relatively	  
high	  transfection	  efficiency	  of	  67%	  by	  this	  method.	  shRNA1β2α2	  was	  cloned	  in	  a	  
non-­‐viral	  vector,	  pB12mcs-­‐eGFP	  plasmid,	  and	  was	  under	  the	  regulation	  of	  the	  
snRNA	  Pol	  III	  U6	  promoter.	  Li	  et	  al.,	  2003,	  constructed	  a	  β2α2	  shRNA	  molecule	  
under	  the	  regulation	  of	  the	  U6	  promoter,	  however,	  the	  construct	  was	  inserted	  
into	   a	   lentiviral	   system,	   and	   the	   transduction	   efficiency	   reached	   ~100%	   in	  
Meg01	   leukaemic	   cell	   line.	  Meg01	   is	  a	  CML	  cell	   line	   that	  expresses	   the	  β2α2	  
variant,	  and	  was	  developed	  by	  Ogura	  et	  al.,	  in	  1985.	  This	  is	  a	  differentiated	  cell	  
line	   where	   mostly	   large	   immature	   megakaryocytes	   predominate,	   unlike	   the	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KCL-­‐22	   cell	   line,	   used	   in	   the	   current	   study,	   that	   is	   an	   undifferentiated	  
haematopoietic	  cell	   line	   (Kamamoto	  et	  al,	  1986).	   In	   summary,	  Li	  et	  al.,	  2003,	  
used	  a	  different	  cell	   line	  and	  a	  viral	  system	  to	  express	  their	  shRNA	  constructs	  
that	  can	  both	  explain	  the	  high	  transduction	  efficiency	  achieved	  in	  their	  study,	  
in	  comparison	  to	  the	  non-­‐viral	  vectors	  used	  in	  the	  current	  study.	  
	  	  
	  
5.1.3.2 Effects	  of	   the	   shRNAβ2α2	  Constructs	  on	  β2α2	  mRNA	  and	  
protein	  levels	  
	  
In	   the	   present	   study	   a	   reduction	   in	   the	   β2α2	   mRNA	   levels	   of	   66%	   and	  
protein	  levels	  of	  45%	  was	  observed	  24hr	  after	  transfection	  with	  shRNA1β2α2.	  In	  
contrast	   Li	  et	   al.,	   2003,	   showed	  no	   significant	   reduction	   in	   the	  β2α2	   variant.	  
This	  maybe	  the	  result	  of	  differences	  in	  the	  shRNA	  structure	  and	  sequence	  used	  
in	  their	  study.	  The	  current	  study	  used	  an	  shRNA	  molecule	  of	  21	  nt	  long	  and	  an	  
open	  stem	  loop	  of	  8	  nt.	  Li	  et	  al.,	  used	  the	  same	  shRNA	  sequence	  but	  with	  a	  9	  nt	  
loop	   and	   a	   G	   overhang	   at	   the	   5’	   end	   on	   the	   antisense	   strand.	   It	   has	   been	  
reported	  that	  the	  loop	  size,	  structure,	  and	  its	  sequence,	  affects	  the	  knockdown	  
efficiencies	  of	  shRNA	  molecules	  (Brummelkamp	  et	  al.,	  2002	  and	  Schopman	  et	  
al.,	   2010).	   Schopman	   and	   colleges,	   2010,	   have	   found	   that	   improvements	   on	  
the	   9	   nt	   long	   stem	   loop	   used	   in	   Brummelkamp	   et	   al.,	   2002,	   studies	   are	  
achievable	   by	   using	   different	   structures	   of	   the	   stem	   loop.	   Schopman	   et	   al.,	  
2010,	   demonstrated	   that	   even	   weak	   shRNA	   inhibitors	   could	   be	   turned	   into	  
strong	   gene	   silencers	   by	   simply	   differing	   the	   loop	   length,	   sequence,	   or	  
structure.	  	  Consequently,	  these	  could	  be	  the	  reasons	  why	  the	  shRNA	  molecules	  
used	   in	   Li	   et	   al.,	   2003,	   study	   demonstrated	   lack	   of	   β2α2	   gene	   silencing	   in	  
comparison	  to	  current	  work.	  	  
In	   the	   current	   study,	   qPCR	   results	   also	   demonstrate	   that	   the	   shRNA1β2α2	  
construct	  was	   specific	   to	   its	   target	   sequence	  and	  no	   significant	   reductions	   in	  
the	  mRNA	  expression	   levels	  were	  observed	   in	  related	  and	  non-­‐related	  genes,	  
including	  normal	  ABL,	  normal	  BCR,	  GAPDH	  (when	  transfected	  into	  KCL-­‐22	  cells)	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and	  the	  β3α2	  fusion	  gene.	  The	  protein	  analysis	  confirmed	  that	  the	  shRNA1β2α2	  





In	   conclusion,	   the	   current	   study	   demonstrates	   successful	   and	   specific	  
targeting	   of	   the	   β2α2	   variant	   by	   a	   non-­‐viral	   system	   expressing	   shRNA	  
molecules	  under	  the	  regulation	  of	  the	  U6	  promoter.	  The	  effects	  of	  the	  shRNA	  
used	  in	  the	  present	  work	  might	  have	  greater	  effects	  if	  a	  lentiviral	  system	  was	  
used.	   Lentiviral	   systems	   have	   higher	   transfection	   efficiencies	   than	   non-­‐viral	  
systems;	   this	   is	  mainly	   because	   lentiviruses	   have	   the	   ability	   to	   integrate	   into	  
the	  host’s	  genome,	  establishing	  long-­‐term	  stable	  expression	  of	  the	  integrated	  
DNA	   sequence.	   However,	   drawbacks	   exist	   for	   these	   types	   of	   system,	   which	  
include	  toxicity	  and	  oncogenesis	   (Hacein-­‐Bey-­‐Abina	  et	  al.,	  2008	  and	  Davidson	  
and	  McCary,	  2011).	  	  
	  
5.1.4 siRNA	  against	  the	  BCR-­‐ABL	  Variants	  
	  
Other	   studies	   have	   targeted	   the	   BCR-­‐ABL	   fusion	   genes	   through	   siRNA	  
technology	   have	   for	   example	   Scherr	   et	   al.,	   2003,	   Koldehoff	   et	   al.,	   2010,	  
Wohlbold	  et	  al.,	  2003,	  Bártová	  et	  al.,	  2005,	  and	  Withey	  et	  al.,	  2005	  using	  siRNA	  
targeting	  the	  β3α2	  variant,	  and	  Rapozzi	  and	  Xodo,	  2004	  for	  targeting	  the	  β2α2	  
variant.	  Findings	  from	  Scherr	  et	  al.,	  2003,	  demonstrated	  that	  the	  siRNA	  tested	  
had	   reduced	   the	  mRNA	   levels	  up	   to	  87%	  after	  24hr.	  However,	   this	  efficiency	  
was	   obtained	   from	   a	   co-­‐transfection	   of	   both	   a	   BCR-­‐ABL	   expressing	   vector,	  
which	  was	  fluorescently	  labelled,	  and	  chemically	  synthesised	  siRNA	  molecules	  
in	  Hela	  cells.	   It	  was	   further	   reported,	   in	   the	  same	  publication,	   that	  when	   the	  
same	  siRNA	  was	  transfected	  into	  K562	  cell	   lines,	  the	  mRNA	  levels	  of	  the	  BCR-­‐
ABL	   fusion	   gene	  were	   reduced	   up	   to	   24.8%	   after	   24hr.	  Withey	   et	   al.,	   2005,	  
reported	   a	   84%	   reduction	   of	   mRNA	   levels	   in	   K562	   cell	   line.	   However,	   these	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results	  were	  obtained	   from	  PCR	  amplification	  of	   the	  cDNA	  of	   the	  transfected	  
cell	  lines.	  A	  more	  precise	  method	  to	  measure	  the	  mRNA	  levels	  would	  be	  to	  use	  
qPCR,	  which	  was	  used	  in	  the	  current	  study.	  The	  shRNA	  molecules	  used	  in	  the	  
current	  study	  have	  higher	  potency,	  sustainable	  effects	  using	  low	  copy	  number,	  
and	  less	  off-­‐target	  effects	  in	  comparison	  with	  siRNAs	  (Rao	  et	  al.,	  2009).	  	  	  
Studies	   have	   also	   been	   conducted	   where	   antisense	   technology	   and	   drug	  
treatment	   have	   been	   combined	   to	   try	   and	   reduce	   CML	   effect.	   For	   example	  
Koldehoff	  et	  al.,	  2010	  and	  Wohlbold	  et	  al.,	  2003	  showed	  that	  siRNA	  targeting	  
the	   BCR-­‐ABL	   fusion	   point	   had	   additive	   effects	  with	  Nilotinib	   and	   Imatinib.	   In	  
addition,	  the	  study	  done	  by	  Wohlbold	  et	  al.,	  2003,	  suggested	  that	  targeting	  the	  
mRNA	  by	   the	  process	  of	  RNAi	   sensitizes	   the	  drug	   resistant	   leukaemic	  cells	   to	  
TKI.	   The	   findings	   of	   these	   studies	   suggest	   future	   strategies	   combining	   both	  
molecular	  targeting	  of	  the	  BCR-­‐ABL	  fusion	  gene	  at	  the	  mRNA	  level	  by	  the	  use	  
of	  RNAi	  and	  using	  TKI	  on	  the	  protein	  level.	  	  
Bártová	  et	   al.,	   2005,	   demonstrated	   the	   use	   of	   siRNA	   against	   the	  BCR-­‐ABL	  
fusion	  gene.	  However,	  the	  siRNA	  designed	  in	  this	  study	  targeted	  the	  BCR-­‐ABL	  
downstream	   of	   the	   fusion	   point,	   thus	   also	   targeting	   the	   normal	   c-­‐ABL.	   In	  
addition,	   the	   transfection	   levels	   of	   the	   siRNA	   only	   ranged	   between	   25-­‐30%	  
which	  is	  considered	  to	  be	  quite	  low.	  	  
A	   study	   done	   by	   Rapozzi	   and	   Xodo,	   in	   2004,	   showed	   that	   significant	  
reductions	   in	  mRNA	  and	  protein	   levels	  of	   the	  β2α2	  BCR-­‐ABL	  variant	  could	  be	  
achieved	  with	  single	  stranded	  (40%	  for	  mRNA	  and	  28%	  for	  protein)	  and	  double	  
stranded	  siRNA	  (20-­‐40%	  for	  mRNA	  and	  83%	  for	  protein)	  within	  24hr.	  Analysis	  
was	  carried	  out	  24	  and	  48hr	  after	  two	  electroporation	  treatments.	  Thus,	  high	  
doses	  of	  siRNA	  were	  required	  to	  achieve	  these	  results.	  In	  addition,	  the	  effects	  
of	   the	   siRNA	   molecules	   only	   lasted	   for	   72hr	   after	   treatment,	   indicating	   the	  
transient	  effect	  of	  siRNA	  molecules.	  	  
In	   conclusion,	   RNAi	   technology	   is	   a	   powerful	   tool	   for	   down	   regulation	   of	  
genes	   of	   interest.	   In	   the	   current	   project,	   this	   technology	   was	   used	   to	   down	  
regulate	  the	  expression	  of	  the	  abnormal	  BCR-­‐ABL	  gene,	  more	  precisely	  the	  up-­‐
regulated	   tyrosine	   kinase	   activity	   of	   the	   ABL	   part	   of	   the	   fusion	   gene.	   The	  
constructed	   shRNA	   molecules,	   targeting	   both	   BCR-­‐ABL	   variants,	   show	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specificity	  to	  their	  target	  sites	  and	  caused	  depletion	  in	  both	  mRNA	  and	  protein	  
levels.	  The	  U6	  promoter	  showed	  ease	  of	  production	  and	  construction	  of	  shRNA	  
expression	  cassettes.	  The	  promoter	  also	  displayed	  efficient	  synthesis	  of	  shRNA	  
molecules.	  In	  this	  context,	  shRNA	  constructs	  demonstrated	  in	  the	  current	  work	  
can	  be	  promising	  tools	  for	  CML	  therapy	  when	  used	  alone	  or	  coupled	  with	  TKI’s.	  	  	  	  	  	  	  	  	  	  	  	  	  	  
	  
	  	  	  	  	  	  	  	  
5.1.5 Future	  developments	  
	  
Future	  developments	  to	  be	  considered	  in	  this	  project	  include	  the	  testing	  of	  
the	  other	  constructs	  that	  have	  been	  synthesised	  and	  sequenced;	  transfection	  
for	   longer	   periods	   of	   time,	   such	   as	   48	   and	   72	   hours;	   and	   a	   comparison	   the	  
effects	  of	  different	  concentration	  of	  the	  shRNA	  molecules	  on	  their	  target	  sites.	  
Once	   an	   appropriate	   time	   period	   and	   concentration	   has	   been	   achieved,	   it	  
would	  also	  be	  appealing	  to	  compare	  the	  effects	  of	  the	  same	  shRNA	  molecules	  
but	  under	   the	   regulation	  of	   the	   two	  different	  human	  promoters,	   the	  U6	  and	  
H1,	  as	  only	  the	  U6	  promoter	  was	  tested	  in	  the	  current	  project.	  The	  effects	  of	  
the	  shRNA	  on	  growth	  inhibition,	  cell	  proliferation,	  and	  differentiation	  could	  be	  
also	  investigated.	  	  
It	  would	   also	   be	   intriguing	   to	   examine	   the	   tested	   shRNA	   constructs	   in	   an	  
animal	  model.	  To	  do	  so,	   first,	  a	   suitable	  delivery	  system	  needs	   to	  be	  chosen.	  
These	  systems	  can	  be	  either	  viral	  or	  non-­‐viral	  systems,	  with	  each	  option	  having	  
its	  own	  pro	  and	   cons.	  Non-­‐viral	   vectors	  avoid	   issues	   such	  as	   immunogenicity	  
and	   insertional	   mutagenesis;	   however,	   these	   vectors	   suffer	   from	   low	  
transduction	   efficiency,	   and	  non-­‐permanent	   expression.	   Viral	   vectors,	   on	   the	  
other	   hand,	   overcome	   the	   disadvantages	   of	   non-­‐viral	   vectors,	   in	   terms	   of	  
efficiency	   and	   provide	   stable	   expression,	   but,	   give	   rise	   to	   issues	   relating	   to	  
toxicity,	   safety,	   immunogenicity,	   and	   specificity	   of	   delivery.	   Other	   vectors	   to	  
consider	  are	  the	  new	  hybrid	  vectors,	  engineered	  to	  have	  qualities	  of	  more	  than	  
one	  vector	  (Wang	  et	  al.,	  2008).	  Rumpold	  et	  al.,	  2005,	  constructed	  a	  non-­‐viral	  
transposon-­‐based	  vector	  that	  demonstrated	  stable	  expression	  of	  siRNAs,	  that	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caused	  knockdown	  to	  their	  target	  genes.	  However,	  the	  system	  was	  described	  
to	  have	  a	  laborious	  production,	  systematic	  instability	  and	  had	  a	  pathogenicity	  
issue.	  Therefore,	  great	  care	  should	  be	  taken	  when	  deciding	  what	  type	  of	  vector	  
system	  is	  chosen	  to	  express	  the	  shRNA	  molecules	  in	  vivo.	  	  
Secondly,	   once	   the	   appropriate	   vector	   system	   has	   been	   chosen,	   another	  
concern	  is	  the	  method	  and	  specificity	  of	  delivery	  to	  the	  target	  cells.	  The	  target	  
cells	   in	   CML	   will	   not	   only	   be	   the	   cancerous	   cells	   but	   also	   the	   abnormal	  
hematopoietic	   stem	   cells	   that	   are	   hard	   to	   identify.	   Recently,	   researchers	   at	  
Lund	  University	  have	  shown	  that	  CML	  stem	  cells	  might	  be	   isolated	  through	  a	  
cell	  surface	  marker	  called	  IL-­‐1	  receptor	  accessory	  protein	  (Luo,	  2010).	  This	  can	  
be	   advantageous,	   as	   it	   can	   help	   the	   identification	   of	   stem	   cells	   with	   the	  
Philadelphia	  chromosome.	  These	  stem	  cells	  can	  be	  therefore	  isolated	  and	  used	  
for	   the	   conduction	   of	   ex	   vivo	   studies,	   providing	   a	   way	   to	   achieve	   specific	  
targeting	  of	  the	  abnormal	  cells	  of	   interest.	  Another	  aspect	  to	  consider	   is	  cell-­‐
penetrating	  peptides.	  This	   technology	  has	  been	  successfully	  considered	  as	  an	  
application	  for	  in	  vivo	  delivery	  of	  various	  molecules	  including	  shRNAs	  (Wang	  et	  
al.,	  2008).	  A	   study	  done	  by	  Arthanari	  el	  al.,	  2010,	   showed	   that	  by	  combining	  
the	   cell	   penetrating	   peptide	  HIV-­‐Tat	  with	   the	  membrane	   lytic	   peptide	   LK-­‐15,	  
higher	   transfections	   efficiencies	   could	   be	   achieved	   for	   delivery	   of	   shRNA	  
targeting	   the	  BCR-­‐ABL	   fusion	  gene	   in	  K562	  cell	   lines.	   These	   finding	  make	   the	  
technology	   of	   cell-­‐penetrating	   peptides	   an	   appealing	   area	   to	   explore	   when	  
considering	  in	  vivo	  studies.	  	  
The	  next	  stage	  would	  be	  to	  choose	  the	  appropriate	  animal	  model.	  This	  is	  of	  
great	   importance.	   It	   would	   be	   highly	   interesting	   to	   see	   how	   the	   shRNA	  
molecules	   react	   in	   vivo	   and	   how	   the	   animal	   reacts	   to	   such	   treatment.	   The	  
Severe	  Combined	  Immunodeficiency	  (SCID)	  mouse	  or	  murine	  CML-­‐like	  models	  
could	  be	  considered.	  The	  SCID	  mouse	  results	  from	  a	  mutation	  that	  impairs	  the	  
cell	  development	  in	  the	  lymphoid	  lineage	  making	  the	  animal	  severely	  immune-­‐
deficient.	   This	   leads	   to	   the	   animal	   accepting	   human	   exogenic	   engraftments	  
without	   initiating	  an	  immune	  response.	  A	  study	  done	  by	  Wang	  et	  al.,	   in	  1998	  
showed	   the	   establishment	   of	   high	   levels	   of	   engraftments	   by	   SCID	  mice	  with	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haematopoietic	  cells	   from	  patients	  with	  CML.	  Thus,	  making	  this	  model	  highly	  
considerable	  for	  future	  studies.	  	  
Other	   murine	   CML-­‐like	   models	   have	   also	   been	   developed	   to	   study	   CML	  
through	   in	   vivo	   studies.	   These	   include	   mice	   where	   both	   transgenic	   and	  
retroviral	   transduction	   approaches	   have	  been	   employed,	   the	   latter	   seems	   to	  
be	  more	  promising	  in	  regards	  to	  establishing	  a	  realistic	  murine	  CML-­‐like	  model	  
(Van	   Etten,	   2002).	   A	   study	   done	   by	   Wertheim	   et	   al.,	   in	   2002	   has	   shown	   a	  
successful	   attempt	   to	   generate	   a	   CML-­‐like	   murine	   model.	   Scientists	   in	   this	  
study	   developed	   a	   protocol	   to	   transfuse	   high	   titre	   retroviral	   vectors	   into	  
murine	   bone	   marrow	   causing	   the	   haematopoietic	   stem	   cells	   to	   have	   an	  
increased	  expression	  of	   the	  BCR-­‐ABL	  protein.	  Furthermore,	   lethally	   irradiated	  
mice	  were	  transplanted	  with	  the	  transfused	  bone	  marrow	  cells	  leading	  to	  the	  
development	   of	   fatal	   myeloproliferative	   disorders	   in	   100%	   of	   the	   mice.	  
Therefore,	   this	  model	   can	   also	   be	   considered.	   However,	  more	   research	   into	  
this	   area	   should	  be	   conducted	   in	  order	   to	   select	   the	  best	  CML	  model	  before	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Appendix	   1:	   The	  Molecular	  Weight	  Markers	  Used	   in	   The	  
Current	  Project	  
	  
Five	  types	  of	  molecular	  weight	  markers	  were	  used	  to	  determine	  band	  sizes.	  
The	   λ/EcoRI/HindIII	  marker,	   and	   the	  GeneRulerTM	   1Kb	  marker	  were	   used	   for	  
determination	   of	   large	   band	   sizes	   and	   on	   a	   1%	   agarose	   gel.	   The	   pBluescript	  
Hpa	   II	   marker,	   the	   100bp	   DNA	   Ladder,	   and	   the	   GeneRulerTM	   100bp	   marker	  
were	  used	  for	  smaller	  size	  bands	  ranging	  from	  1000bp	  to	  as	  small	  as	  100bp	  in	  




Figure	  67	  The	  λ/EcoRI/HindIII	  Marker.	  Taken	  from	  the	  Promega	  website	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Figure	  68	  The	  GeneRulerTM	  1Kb	  marker.	  Taken	  from	  the	  Thermo	  Scientific	  website	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Figure	  70	  The	  100bp	  DNA	  Ladder.	  Taken	  from	  the	  NEB	  website	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Appendix	  2:	  The	  Secondary	  shRNA	  Structures	  
	  	  	  
	  
The	   following	   figures	   are	   the	   secondary	   structures	   predictions	   of	   the	  
designed	   shRNA	  molecules.	   The	   program	   “mfold”	  was	   used	   to	   predict	   these	  




Figure	  72	  The	  Secondary	  structure	  prediction	  of	  shRNA2
β3α2
	  by	  “mfold”	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Figure	  73	  The	  Secondary	  structure	  prediction	  of	  shRNA3
β3α2
	  by	  “mfold”	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Figure	  74	  The	  Secondary	  structure	  prediction	  of	  shRNA1
β2α2
	  by	  “mfold”	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Figure	  75	  The	  Secondary	  structure	  prediction	  of	  shRNA2
β2α2
	  by	  “mfold”	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Figure	  76	  The	  Secondary	  structure	  prediction	  of	  shRNA3
β2α2
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Appendix	   3:	   The	   Protein	  Molecular	  Weight	  Marker	   used	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Appendix	  4:	  The	  β3α2	  and	  β2α2	  Sequences	  
	  
• The	  β3α2	  fusion	  point	  sequence	  from	  the	  EMBL	  website	  (Accession	  number	  
AJ131466).	  	  
	  
1   gcgaacaagg gcagcaaagc tacggagagg ctgaagaaga agctgtcgga gcaggagtca        
61  ctgctgctgc ttatgtctcc cagcatggcc ttcagggtgc acagccgcaa cggcaagagt       
121 tacacgttcc tgatctcctc tgactatgag cgtgcagagt ggagggagaa catccgggag       
181 cagcagaaga agtgtttcag aagcttctcc ctgacatccg tggagctgca gatgctgacc       
241 aactcgtgtg tgaaactcca gactgtccac agcattccgc tgaccatcaa taaggaagat       
301 gatgagtctc cggggctcta tgggtttctg aatgtcatcg tccactcagc cactggattt       
361 aagcagagtt caaaagccct tcagcggcca gtagcatctg actttgagcc tcagggtctg       
421 agtgaagccg ctcgttggaa ctccaaggaa aaccttctcg ctggacccag tgaaaatgac       
481 cccaaccttt tcgttgcact gtatgatttt gtggccagtg gagataacac tctaagcata       
541 actaaaggtg aaaagctccg ggtcttaggc tataatcaca atggggaatg gtgtgaagcc       
601 caaaccaaaa atggccaagg ctgggtccca agcaactaca tcacgccagt caacagtctg       
661 gagaaacact cctggtacca tgggcctgtg tcccgcaatg ccgctgagta tctgctgagc       
721 agcgggatca atggcagctt cttggtgcgt gagagtgaga gcagtcctgg ccagaggtcc       
781 atctcgctga gatacgaagg gagggtgtac cattacagga tcaacactgc ttctgatggc       
841 aagctctacg tctcctccga gagccgcttc aacaccctgg ccgagttggt tcatcatcat       
901 tcaacggtgg ccgacgggct catcaccacg ctccattatc cagccccaaa gcgcaacaag       
961 cccactgtct  atggtgtgtc ccctaactac gacaagt	  
	  
	   The	  fusion	  point	  is	  underlined	  and	  highlighted	  in	  yellow.	  The	  forward	  (in	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• The	  β2α2	  fusion	  point	  sequence	  from	  the	  EMBL	  website	  (Accession	  number	  
AJ131467).	  
	  
 1  gcgaacaagg gcagcaaggc tacggagagg ctgaagaaga agctgtcgga gcaggagtca        
61  ctgctgctgc ttatgtctcc cagcatggcc ttcagggtgc acagccgcaa cggcaagagt       
121 tacacgttcc tgatctcctc tgactatgag cgtgcagagt ggagggagaa catccgggag       
181 cagcagaaga agtgtttcag aagcttctcc ctgacatccg tggagctgca gatgctgacc       
241 aactcgtgtg tgaaactcca gactgtccac agcattccgc tgaccatcaa taaggaagaa       
301 gcccttcagc ggccagtagc atctgacttt gagcctcagg gtctgagtga agccgctcgt       
361 tggaactcca aggaaaacct tctcgctgga cccagtgaaa atgaccccaa ccttttcgtt       
421 gcactgtatg attttgtggc cagtggagat aacactctaa gcataactaa aggtgaaaag       
481 ctccgggtct taggctataa tcacaatggg gaatggtgtg aagcccaaac caaaaatggc       
541 caaggctggg tcccaagcaa ctacatcacg ccagtcaaca gtctggagaa acactcctgg       
601 taccatgggc ctgtgtcccg caatgccgct gagtatctgc tgagcagcgg gatcaatggc       
661 agcttcttgg tgcgtgagag tgagagcagt cctggccaga ggtccatctc gctgagatac       
721 gaagggaggg tgtaccatta caggatcaac actgcttctg atggcaagct ctacgtctcc       
781 tccgagagcc gcttcaacac cctggccgag ttggttcatc atcattcaac ggtggccgac       
841 gggctcatca ccacgctcca ttatccagcc ccaaagcgca acaagcccac tgtctatggt       
901 gtgtccccca actacgacaa gt 
	  
	   The	   fusion	   point	   is	   underlined	   and	   highlighted	   in	   yellow.	   The	   forward	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Appendix	   5:	   The	   Raw	   Sequencing	   Data	   of	   the	   β3α2	   and	  
β2α2	  Fusion	  Point	  Sequences	  in	  the	  pGEM®-­‐T	  Easy	  Vector	  
	  
• 3	   colonies	   were	   sequenced,	   and	   all	   showed	   similar	   results.	   The	   β3α2	   fusion	  
point	   sequence	   for	   a	   representative	   colony	   is	   shown	   bellow,	   colony	   A5.	   The	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• 3	   colonies	   were	   sequenced,	   and	   all	   showed	   similar	   results.	   The	   β2α2	   fusion	  
point	  sequence	  for	  a	  representative	  colony	  is	  shown	  bellow,	  colony	  KCL-­‐22	  `1’.	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Appendix	  6:	  The	  Human	  U6	  and	  H1	  Promoter	  Sequences	  
	  
• The	  Human	  snRNA	  U6	  Pol	  III	  promoter	  sequence	  from	  the	  EMBL	  Website	  
(Accession	  number	  M14486).	  
	  
 1  ccccagtgga aagacgcgca ggcaaaacgc accacgtgac ggagcgtgac cgcgcgccga        
61  gcccaaggtc gggcaggaag agggcctatt tcccatgatt ccttcatatt tgcatatacg       
121 atacaaggct gttagagaga taattagaat taatttgact gtaaacacaa agatattagt       
181 acaaaatacg tgacgtagaa agtaataatt tcttgggtag tttgcagttt taaaattatg       
241 ttttaaaatg gactatcata tgcttaccgt aacttgaaag tatttcgatt tcttggcttt       
301 atatatcttg tggaaaggac gaaacaccgt gctcgcttcg gcagcacata tactaaaatt       
361 ggaacgatac agagaagatt agcatggccc ctgcgcaagg atgacacgca aattcgtgaa       
421 gcgttccata tttttacatc aggttgtttt tctgttttta catcaggttg tttttctgtt       
481 tggttttttt tttacaccac gtttatacgc cggtgcacgg tttacca 
	  
The	   forward	   and	   reverse	   primers	   to	   amplify	   the	   U6	   promoter	   are	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• The	   Human	   RNA	   H1	   Pol	   III	   promoter	   sequence	   from	   the	   EMBL	  Website	  
(Accession	  number	  X16612).	  
	  
1   ttatagggag ctgaagggaa gggggtcaca gtaggtggca tcgttccttt ctgactgccc        
61  gccccccgca tgccgtcccg cgatattgag ctccgaacct ctcgccctgc cgccgccggt       
121 gctccgtcgc cgccgcgccg ccatggaatt cgaacgctga cgtcatcaac ccgctccaag       
181 gaatcgcggg cccagtgtca ctaggcggga acacccagcg cgcgtgcgcc ctggcaggaa       
241 gatggctgtg agggacaggg gagtggcgcc ctgcaatatt tgcatgtcgc tatgtgttct       
301 gggaaatcac cataaacgtg aaatgtcttt ggatttggga atcttataag ttctgtatga       
361 gaccactctt tcccataggg cggagggaag ctcatcagtg gggccacgag ctgagtgcgt       
421 cctgtcactc cactcccatg tcccttggga aggtctgaga ctagggccag aggcggccct       
481 aacagggctc tccctgagct tcggggaggt gagttcccag agaacggggc tccgcgcgag       
541 gtcagactgg gcaggagatg ccgtggaccc cgcccttcgg ggaggggccc ggcggatgcc       
601 tcctttgccg gagcttggaa cagactcacg gccagcgaag tgagttcaat ggctgaggtg       
661 aggtaccccg caggggacct cataacccaa ttcagactac tctcctccgc ccatttttgg       
721 aaaaaaaaaa aaaaaaaaaa aacaaaacga aaccgggccg ggcgcggtgg ttcacgccta       
781 taatcccagc actttgggag gccgaggcgg gcggatcaca aggtcaggag gtcgagacca       
841 tccaggctaa cacggtgaaa ccccccccca tctctactaa aaaaaaaaaa tacaaaaaat       
901 tagccattag ccgggcgtgg tggcgggcgc ctataatccc agctacttgg gaggctgaag       
961 cagaatggcg tgaacccggg aggcggacgt tgcagtgagc cgagatcgcg ccgactgcat      
1021 tccagcctgg gcgacagagc gagtctcaaa aaaaaaa 
	  
	  
The	   forward	   (in	   yellow)	   and	   reverse	   (in	   green)	   primers	   to	   amplify	   the	  H1	  












	  	   212	  
Appendix	   7:	   Electrophoretic	   Analysis	   of	   Representative	  
Colony	   Screens	   PCR	   Products	   of	   the	   U6	   shRNA	   and	   H1	  
shRNA	  	  Construct	  
	  




Gel	   (A):	   PCR	   products	   of	   the	  U6	   shRNA1β3α2	   constrcut	   using	   the	   T7	   forward	   and	   T3	   reverse	  
primers	  
Lane	  1:	  Gene	  RulerTM	  1KB	  DNA	  Ladder	  
Lane	  2:	  PCR	  pruduct	  of	  wild	  type	  pB12mcs-­‐eGFP	  vector	  (~1050bp)	  
Lanes	  3-­‐7:	  PCR	  products	  of	  the	  colony	  screen	  	  
Lanes	  3,	  6,	  and	  7:	  positive	  colonies	  (~1390bp)	  
Gel	  (B):	  PCR	  products	  of	  pB12mcs-­‐U6-­‐shRNA1β3α2-­‐eGFP	  extracted	  plasmids	  	  
Lane	  1:	  Gene	  RulerTM	  1KB	  DNA	  Ladder	  
Lane	  2:	  PCR	  pruduct	  of	  wild	  type	  pB12mcs-­‐eGFP	  vector	  (~1050bp)	  
Lanes	  3	  and	  6:	  PCR	  product	  of	  the	  primer	  set	  T7	  forward	  and	  T3	  Reverse	  (~1390bp)	  
Lanes	   4	   and	   7:	   PCR	   products	   of	   the	   primer	   set	   T7	   forward	   with	   U6	   shRNA1β3α2	   reverse	  
(~380bp)	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Gel	   (A):	   PCR	   products	   of	   the	  U6	   shRNA2β3α2	   constrcut	   using	   the	   T7	   forward	   and	   T3	   reverse	  
primers	  
Lane	  1:	  Gene	  RulerTM	  1KB	  DNA	  Ladder	  
Lane	  2:	  PCR	  pruduct	  of	  wild	  type	  pB12mcs-­‐eGFP	  vector	  (~1050bp)	  
Lanes	  3-­‐12:	  PCR	  products	  of	  the	  colony	  screen	  	  
Lanes	  11	  and	  12:	  positive	  colonies	  (~1390bp)	  
	  
Gel	  (B):	  PCR	  products	  of	  pB12mcs-­‐U6-­‐shRNA2	  β3α2-­‐eGFP	  extracted	  plasmids	  	  
Lane	  1:	  Gene	  RulerTM	  1KB	  DNA	  Ladder	  
Lane	  2:	  PCR	  pruduct	  of	  wild	  type	  pB12mcs-­‐eGFP	  vector	  (~1050bp)	  
Lanes	  3	  and	  6:	  PCR	  product	  of	  the	  primer	  set	  T7	  forward	  and	  T3	  Reverse	  (~1390bp)	  
Lanes	   4	   and	   7:	   PCR	   products	   of	   the	   primer	   set	   T7	   forward	   with	   U6	   shRNA2β3α2	   reverse	  
(~380bp)	  
Lanes	  5	  and	  8:	  PCR	  products	  of	  the	  primer	  set	  U6	  forward	  and	  T3	  reverse	  (~1420bp)	  
Lane	  9:	  Gene	  RulerTM	  100bp	  DNA	  Ladder	  
(A)	  
(B)	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Gel	   (A):	   PCR	   products	   of	   the	  U6	   shRNA3β3α2	   constrcut	   using	   the	   T7	   forward	   and	   T3	   reverse	  
primers	  
Lane	  1:	  Gene	  RulerTM	  1KB	  DNA	  Ladder	  
Lane	  2:	  PCR	  pruduct	  of	  wild	  type	  pB12mcs-­‐eGFP	  vector	  (~1050bp)	  
Lanes	  3-­‐9:	  PCR	  products	  of	  the	  colony	  screen	  	  
Lanes	  3,	  6,	  and	  9:	  positive	  colonies	  (~1390bp)	  
	  
Gel	  (B):	  PCR	  products	  of	  pB12mcs-­‐U6-­‐shRNA3	  β3α2-­‐eGFP	  extracted	  plasmids	  	  
Lane	  1:	  Gene	  RulerTM	  1KB	  DNA	  Ladder	  
Lane	  2:	  PCR	  pruduct	  of	  wild	  type	  pB12mcs-­‐eGFP	  vector	  (~1050bp)	  
Lanes	  3,	  6,	  and	  9:	  PCR	  product	  of	  the	  primer	  set	  T7	  forward	  and	  T3	  Reverse	  (~1390bp)	  
Lanes	   4,	   7,	   and	  10:	   PCR	  products	   of	   the	  primer	   set	   T7	   forward	  with	  U6	   shRNA3β3α2	   reverse	  
(~380bp)	  
Lanes	  5,	  8,	  and	  11:	  PCR	  products	  of	  the	  primer	  set	  U6	  forward	  and	  T3	  reverse	  (~1420bp)	  
Lane	  12:	  Gene	  RulerTM	  100bp	  DNA	  Ladder	  
	  
(A)	  
(B)	   	  	  	  	  	  1	  	  	  	  	  2	  	  	  	  3	  	  	  	  4	  	  	  	  	  5	  	  	  	  	  6	  	  	  	  	  7	  	  	  	  	  8	  	  	  	  	  9	  	  	  	  	  10	  	  	  11	  	  	  	  12	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Gel	   (A):	   PCR	   products	   of	   the	  H1	   shRNA1β2α2	   constrcut	   using	   the	   T7	   forward	   and	   T3	   reverse	  
primers	  
Lanes	  1	  and	  15:	  Gene	  RulerTM	  1KB	  DNA	  Ladder	  
Lane	  2:	  PCR	  pruduct	  of	  wild	  type	  pB12mcs-­‐eGFP	  vector	  (~1050bp)	  
Lanes	  3-­‐14:	  PCR	  products	  of	  the	  colony	  screen	  	  
Lanes	  3-­‐14:	  positive	  colonies	  (~1340bp)	  
	  
Gel	  (B):	  PCR	  products	  of	  pB12mcs-­‐H1-­‐shRNA1	  β2α2-­‐eGFP	  extracted	  plasmid	  	  
Lane	  1:	  Gene	  RulerTM	  1KB	  DNA	  Ladder	  
Lane	  2:	  PCR	  pruduct	  of	  wild	  type	  pB12mcs-­‐eGFP	  vector	  (~1050bp)	  
Lane	  3:	  PCR	  product	  of	  the	  primer	  set	  T7	  forward	  and	  T3	  Reverse	  (~1340bp)	  
Lane	  4:	  PCR	  products	  of	  the	  primer	  set	  T7	  forward	  with	  U6	  shRNA1β3α2	  reverse	  (~330bp)	  
Lane	  5:	  PCR	  products	  of	  the	  primer	  set	  H1	  forward	  and	  T3	  reverse	  (~1370bp)	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Gel	   (A):	   PCR	   products	   of	   the	  H1	   shRNA2β2α2	   constrcut	   using	   the	   T7	   forward	   and	   T3	   reverse	  
primers	  
Lane	  1:	  Gene	  RulerTM	  1KB	  DNA	  Ladder	  
Lane	  2:	  PCR	  pruduct	  of	  wild	  type	  pB12mcs-­‐eGFP	  vector	  (~1050bp)	  
Lanes	  3-­‐15:	  PCR	  products	  of	  the	  colony	  screen	  	  
Lanes	  9-­‐10,	  and	  15:	  positive	  colonies	  (~1340bp)	  
	  
Gel	  (B):	  PCR	  products	  of	  pB12mcs-­‐H1-­‐shRNA2	  β2α2-­‐eGFP	  extracted	  plasmid	  
Lane	  1:	  Gene	  RulerTM	  1KB	  DNA	  Ladder	  
Lane	  2:	  PCR	  pruduct	  of	  wild	  type	  pB12mcs-­‐eGFP	  vector	  (~1050bp)	  
Lane	  3:	  PCR	  product	  of	  the	  primer	  set	  T7	  forward	  and	  T3	  Reverse	  (~1340bp)	  
Lane	  4:	  PCR	  products	  of	  the	  primer	  set	  T7	  forward	  with	  H1	  shRNA2β3α2	  reverse	  (~330bp)	  
Lane	  5:	  PCR	  products	  of	  the	  primer	  set	  H1	  forward	  and	  T3	  reverse	  (~1370bp)	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Gel	   (A):	   PCR	   products	   of	   the	  H1	   shRNA3β2α2	   constrcut	   using	   the	   T7	   forward	   and	   T3	   reverse	  
primers	  
Lane	  1:	  Gene	  RulerTM	  1KB	  DNA	  Ladder	  
Lane	  2:	  PCR	  pruduct	  of	  wild	  type	  pB12mcs-­‐eGFP	  vector	  (~1050bp)	  
Lanes	  3-­‐8:	  PCR	  products	  of	  the	  colony	  screen	  	  
Lanes	  3,	  5,	  and	  6:	  positive	  colonies	  (~1340bp)	  
	  
Gel	  (B):	  PCR	  products	  of	  pB12mcs-­‐H1-­‐shRNA3β2α2-­‐eGFP	  extracted	  plasmid	  
Lane	  1:	  Gene	  RulerTM	  1KB	  DNA	  Ladder	  
Lane	  2:	  PCR	  pruduct	  of	  wild	  type	  pB12mcs-­‐eGFP	  vector	  (~1050bp)	  
Lanes	  3	  and	  6:	  PCR	  product	  of	  the	  primer	  set	  T7	  forward	  and	  T3	  Reverse	  (~1340bp)	  
Lanes	   4	   and	   7:	   PCR	   products	   of	   the	   primer	   set	   T7	   forward	   with	   H1	   shRNA2β3α2	   reverse	  
(~330bp)	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Appendix	  8:	  The	  Raw	  Sequencing	  Data	  of	   the	  U6	  and	  H1	  
Promoters	  Inserted	  into	  the	  pB12mcs-­‐eGFP	  Plasmid	  
	  
• Sequencing	  of	  the	  U6	  promoter	  inserted	  into	  the	  pB12mcs-­‐eGFP	  
	  
1. Colony	  number	  5.	  The	  following	  U6	  sequence	  is	  given	  as	  the	  forward	  sequence	  
5’	  	  3’	  and	  is	  highlighted	  in	  yellow.	  The	  U6	  sequence	  shows	  no	  mismatches	  to	  






















The	   following	   is	   the	   same	   U6	   sequence,	   however,	   it	   is	   given	   as	   the	   reverse	  
























2. Colony	   number	   11.	   The	   following	   U6	   sequence	   is	   given	   as	   the	   forward	  
sequence	   5’	  	   3’	   and	   is	   highlighted	   in	   yellow.	   The	   U6	   sequence	   shows	   no	  
mismatches	  to	  the	  U6	  sequence	  found	  in	  the	  EMBL	  website	  (accession	  number	  






















The	   following	   is	   the	   same	   U6	   sequence,	   however,	   it	   is	   given	   as	   the	   reverse	  






















Another	   6	   colonies	   were	   also	   sequenced	   and	   were	   found	   to	   have	  
mismatches	  (raw	  sequences	  are	  not	  shown).	  
	  
• Sequencing	  of	  the	  H1	  promoter	  inserted	  into	  the	  pB12mcs-­‐eGFP	  
	  
1. Colony	  number	  8.	  The	  following	  U6	  sequence	  is	  given	  as	  the	  forward	  sequence	  
5’	  	  3’	  and	  is	  highlighted	  in	  yellow.	  The	  U6	  sequence	  shows	  no	  mismatches	  to	  




















	  	   221	  
 
 
The	   following	   is	   the	   same	   H1	   sequence,	   however,	   it	   is	   given	   as	   the	   reverse	  





















Another	   4	   colonies	   were	   also	   sequenced	   and	   were	   found	   to	   have	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Appendix	   9:	   Raw	   Data	   of	   Sequencing	   of	   the	   shRNA	  
Constructs	  	  
	  
• The	   followings	   are	   the	   raw	   sequence	   data	   of	   all	   colonies	   sequenced	   for	   the	  
shRNA	  constructs	  targeting	  the	  β3α2	  fusion	  point	  and	  under	  the	  regulation	  of	  
the	  U6	  promoter.	  
	  
1. The	  following	  are	  sequences	  from	  colonies	  with	  the	  pB12mcs-­‐U6-­‐shRNA1β3α2-­‐
eGFP	  plasmid	  
	  










































































































































1. The	  following	  are	  sequences	  from	  colonies	  with	  the	  pB12mcs-­‐U6-­‐shRNA2β3α2-­‐
eGFP	  plasmid.	  The	  sequencing	  results	  were	  inconclusive.	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2. The	  following	  are	  sequences	  from	  colonies	  with	  the	  pB12mcs-­‐U6-­‐shRNA3β3α2-­‐
eGFP	  plasmid.	  
	  
-­‐	  Colony	  3,	  the	  forward	  sequence	  is	  given	  from	  5’	  	  3’	  	  

























































































-­‐	  Colony	  9,	  the	  forward	  sequence	  is	  given	  from	  5’	  	  3’	  	  














































• The	   followings	   are	   the	   raw	   sequence	   data	   of	   all	   colonies	   sequenced	   for	   the	  
shRNA	  constructs	  targeting	  the	  β2α2	  fusion	  point	  and	  under	  the	  regulation	  of	  
the	  U6	  promoter.	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• The	   followings	   are	   the	   raw	   sequence	   data	   of	   all	   colonies	   sequenced	   for	   the	  
shRNA	  constructs	  targeting	  the	  β2α2	  fusion	  point	  and	  under	  the	  regulation	  of	  
the	  H1	  promoter.	  
	  
1. The	  following	  are	  sequences	  from	  colonies	  with	  the	  pB12mcs-­‐H1-­‐shRNA1β2α2-­‐
eGFP	  plasmid.	  All	  sequences	  were	  missing	  the	  shRNA	  sequence.	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The	  following	  sequences	  were	  inconclusive:	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2. The	  following	  are	  sequences	  from	  colonies	  with	  the	  pB12mcs-­‐H1-­‐shRNA2β2α2-­‐
eGFP	  plasmid.	  All	  sequences	  were	  missing	  the	  shRNA	  sequence.	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The	  following	  sequence	  was	  inconclusive:	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3. The	  following	  are	  sequences	  from	  colonies	  with	  the	  pB12mcs-­‐H1-­‐shRNA3β2α2-­‐
eGFP	  plasmid.	  All	  sequences	  were	  missing	  the	  shRNA	  sequence.	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The	  following	  sequences	  was	  inconclusive:	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Appendix	   10:	   FACS	   Generated	   Data	   of	   Transfection	   of	  
K562	  and	  KCL-­‐22	  cell	  lines	  	  	  	  
	  




Figure	   84	   FACS	   histogram	   showing	   the	   transfection	   efficiency	   in	   K562	   cells,	   transfection	  




Sample	   Transfection	  efficiency	  with	  
regards	  to	  non-­‐transfected	  	  
cells	  
(35.95%)	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  -­‐Purple	  
Transfection	  efficiency	  with	  
regards	  to	  negative	  control	  
	  
(47.40%)	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  -­‐Green	  
Positive	  control	  	  	  -­‐Blue	   	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  28.06%	   28%	  
shRNA1β3α2	  	  	  	  	  	  	  	  	  -­‐	  Pink	   26.04%	   26.07%	  
shRNA3β3α2	  	  	  	  	  	  -­‐Orange	   14.01%	   2.53%	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Figure	   85	   FACS	   histogram	   showing	   the	   transfection	   efficiency	   in	   K562	   cells,	   transfection	  








Sample	   Transfection	   efficiency	   with	  
regards	  to	  non-­‐transfected	  
	  cells	  
(23.05%)	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  -­‐Purple	  
Transfection	   efficiency	   with	  
regards	  to	  negative	  control	  
	  
(68.33%)	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  -­‐Green	  
Positive	  control	  	  	  -­‐Pink	   72.15%	   27.17%	  
shRNA1β3α2	  	  	  	  	  	  	  	  	  -­‐	  Blue	   54.18%	   8.9%	  
shRNA3β3α2	  	  	  	  	  	  -­‐Orange	   47.72%	   2.44%	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Figure	   86	   FACS	   histogram	   showing	   the	   transfection	   efficiency	   in	   K562	   cells,	   using	  
shRNA1
β2α2



















Sample	   Transfection	   efficiency	   with	  
regards	  to	  non-­‐transfected	  	  
cells	  
(21.70%)	  –Purple	  
Positive	  control	  	  	  -­‐Green	   	  	  	  	  	  	  	  	  	  43.18%	  
shRNA1β2α2	  	  	  	  	  	  	  	  	  -­‐	  Pink	   	  	  	  	  	  	  	  	  	  	  	  5.77%	  
shRNA1β2α2	  	  	  	  	  	  	  	  	  -­‐	  Blue	   	  	  	  	  	  	  	  	  	  	  	  9.86%	  
shRNA1β2α2	  	  	  	  	  	  	  	  -­‐	  Orange	   	  	  	  	  	  	  	  	  	  	  	  6.77%	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Figure	   87	   FACS	   histogram	   showing	   the	   transfection	   efficiency	   in	   KCL-­‐22	   cells,	   transfection	  






Sample	   Transfection	   efficiency	   with	  
regards	  to	  non-­‐transfected	  
	  cells	  
	  
(32.29%)	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  -­‐Purple	  
Transfection	   efficiency	   with	  
regards	  to	  negative	  control	  
	  
	  
(58.69%)	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  -­‐Green	  
Positive	  control	  	  	  -­‐Pink	   53.14%	   26.74%	  
shRNA1β2α2	  	  	  	  	  	  	  	  	  -­‐	  Bue	   28.33%	   1.93%	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Figure	   88	   FACS	   histogram	   showing	   the	   transfection	   efficiency	   in	   KCL-­‐22	   cells,	   transfection	  




Sample	   Transfection	   efficiency	   with	  
regards	  to	  non-­‐transfected	  
	  cells	  
	  
(26.06%)	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  -­‐Purple	  
Transfection	   efficiency	   with	  
regards	  to	  negative	  control	  
	  
	  
(61.66%)	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  -­‐Green	  
Positive	  control	  	  	  -­‐Pink	   67%	   31.35%	  
shRNA1β3α2	  	  	  	  	  	  	  	  	  -­‐	  Blue	   36.94%	   1.34%	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Figure	   89	   FACS	   histogram	   showing	   the	   transfection	   efficiency	   in	   KCL-­‐22	   cells,	   using	  
shRNA1
β3α2










Sample	   Transfection	   efficiency	   with	  
regards	  to	  non-­‐transfected	  
	  cells	  
(18.87%)	  	  	  	  	  	  	  	  	  –	  Purple	  
Positive	  control	  	  -­‐Green	   79.27%	  
shRNA1β3α2	  	  	  	  	  	  	  	  	  -­‐	  Pink	   50.36%	  
shRNA1β3α2	  	  	  	  	  	  	  	  	  -­‐	  Blue	   51.35%	  
shRNA1β3α2	  	  	  	  	  	  	  	  	  -­‐	  Yellow	   44.29%	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Figure	   90	   FACS	   histogram	   showing	   the	   transfection	   efficiency	   in	   KCL-­‐22	   cells,	   using	  
shRNA3
β3α2
.	  The	  results	  as	  shown	  below:	  
	  
Sample	   Transfection	  efficiency	  with	  	  
regards	  to	  non-­‐transfected	  cells	  
(15.44%)	  	  	  	  	  	  	  –	  	  Purple	  
	  Positive	  control	  	  -­‐Green	   	  77.49%	  
	  shRNA3β3α2	  	  	  	  	  	  	  	  	  -­‐	  Pink	   	  53.67%	  
	  shRNA3β3α2	  	  	  	  	  	  	  	  	  -­‐	  Yellow	   	  51.81%	  
	  shRNA3β3α2	  	  	  	  	  	  	  	  	  -­‐	  Blue	   	  54.88%	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